NO_RELATION	<e2> Tricuspid valve regurgitation </e2> and <e1> lithium carbonate </e1> toxicity in a newborn infant .
NO_RELATION	Tricuspid valve regurgitation and <e1> lithium carbonate </e1> <e2> toxicity </e2> in a newborn infant .
NO_RELATION	A newborn with massive <e2> tricuspid regurgitation </e2> , atrial flutter , congestive heart failure , and a high serum <e1> lithium </e1> level is described .
NO_RELATION	A newborn with massive tricuspid regurgitation , <e2> atrial flutter </e2> , congestive heart failure , and a high serum <e1> lithium </e1> level is described .
NO_RELATION	A newborn with massive tricuspid regurgitation , atrial flutter , <e2> congestive heart failure </e2> , and a high serum <e1> lithium </e1> level is described .
NO_RELATION	This is the first patient to initially manifest <e2> tricuspid regurgitation </e2> and atrial flutter , and the 11th described patient with cardiac disease among infants exposed to <e1> lithium </e1> compounds in the first trimester of pregnancy .
NO_RELATION	This is the first patient to initially manifest tricuspid regurgitation and <e2> atrial flutter </e2> , and the 11th described patient with cardiac disease among infants exposed to <e1> lithium </e1> compounds in the first trimester of pregnancy .
NO_RELATION	This is the first patient to initially manifest tricuspid regurgitation and atrial flutter , and the 11th described patient with <e2> cardiac disease </e2> among infants exposed to <e1> lithium </e1> compounds in the first trimester of pregnancy .
NO_RELATION	<e1> Lithium carbonate </e1> may be a factor in the increasing incidence of <e2> congenital heart disease </e2> when taken during early pregnancy .
CID	<e1> Phenobarbital </e1> - induced <e2> dyskinesia </e2> in a neurologically - impaired child .
NO_RELATION	<e1> Phenobarbital </e1> - induced dyskinesia in a <e2> neurologically - impaired </e2> child .
NO_RELATION	A 2 - year - old child with known <e2> neurologic impairment </e2> developed a dyskinesia soon after starting <e1> phenobarbital </e1> therapy for seizures .
CID	A 2 - year - old child with known neurologic impairment developed a <e2> dyskinesia </e2> soon after starting <e1> phenobarbital </e1> therapy for seizures .
NO_RELATION	A 2 - year - old child with known neurologic impairment developed a dyskinesia soon after starting <e1> phenobarbital </e1> therapy for <e2> seizures </e2> .
CID	On repeat challenge with <e1> phenobarbital </e1> , the <e2> dyskinesia </e2> recurred .
NO_RELATION	<e1> Phenobarbital </e1> should be added to the list of anticonvulsant drugs that can cause <e2> movement disorders </e2> .
NO_RELATION	<e1> Valproic acid </e1> ( VPA ) was given to 24 <e2> epileptic </e2> patients who were already being treated with other antiepileptic drugs .
NO_RELATION	Valproic acid ( <e1> VPA </e1> ) was given to 24 <e2> epileptic </e2> patients who were already being treated with other antiepileptic drugs .
CID	<e1> Ammonia </e1> ( NH3 ) was higher in patients who , during continuous therapy , complained of <e2> drowsiness </e2> ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .
CID	Ammonia ( <e1> NH3 </e1> ) was higher in patients who , during continuous therapy , complained of <e2> drowsiness </e2> ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .
CID	Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of <e2> drowsiness </e2> ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although <e1> VPA </e1> plasma levels were similar in both groups .
CID	Calcitonin injection resulted in a potentiation of <e1> haloperidol </e1> - induced <e2> catalepsy </e2> and a partial prevention of apomorphine - induced hyperactivity .
NO_RELATION	Calcitonin injection resulted in a potentiation of <e1> haloperidol </e1> - induced catalepsy and a partial prevention of apomorphine - induced <e2> hyperactivity </e2> .
NO_RELATION	Calcitonin injection resulted in a potentiation of haloperidol - induced <e2> catalepsy </e2> and a partial prevention of <e1> apomorphine </e1> - induced hyperactivity .
CID	Calcitonin injection resulted in a potentiation of haloperidol - induced catalepsy and a partial prevention of <e1> apomorphine </e1> - induced <e2> hyperactivity </e2> .
CID	Development of <e1> isoproterenol </e1> - induced <e2> cardiac hypertrophy </e2> .
CID	The development of <e2> cardiac hypertrophy </e2> was studied in adult female Wistar rats following daily subcutaneous injections of <e1> isoproterenol </e1> ( ISO ) ( 0 . 3 mg / kg body weight ) .
CID	The development of <e2> cardiac hypertrophy </e2> was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( <e1> ISO </e1> ) ( 0 . 3 mg / kg body weight ) .
NO_RELATION	These data indicate that the adaptive response to <e1> ISO </e1> shows an early <e2> hypertrophic </e2> phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .
NO_RELATION	Co - <e2> carcinogenic </e2> effect of <e1> retinyl acetate </e1> on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole .
NO_RELATION	Co - carcinogenic effect of <e1> retinyl acetate </e1> on <e2> forestomach carcinogenesis </e2> of male F344 rats induced with butylated hydroxyanisole .
NO_RELATION	Co - <e2> carcinogenic </e2> effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with <e1> butylated hydroxyanisole </e1> .
CID	Co - carcinogenic effect of retinyl acetate on <e2> forestomach carcinogenesis </e2> of male F344 rats induced with <e1> butylated hydroxyanisole </e1> .
NO_RELATION	The potential modifying effect of <e1> retinyl acetate </e1> ( RA ) on butylated hydroxyanisole ( BHA ) - induced rat <e2> forestomach tumorigenesis </e2> was examined .
NO_RELATION	The potential modifying effect of retinyl acetate ( <e1> RA </e1> ) on butylated hydroxyanisole ( BHA ) - induced rat <e2> forestomach tumorigenesis </e2> was examined .
CID	The potential modifying effect of retinyl acetate ( RA ) on <e1> butylated hydroxyanisole </e1> ( BHA ) - induced rat <e2> forestomach tumorigenesis </e2> was examined .
CID	The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole ( <e1> BHA </e1> ) - induced rat <e2> forestomach tumorigenesis </e2> was examined .
CID	In groups given 2 % <e1> BHA </e1> , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of <e2> forestomach tumors </e2> ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
NO_RELATION	In groups given 2 % <e1> BHA </e1> , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( <e2> squamous cell papilloma </e2> and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
NO_RELATION	In groups given 2 % <e1> BHA </e1> , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and <e2> carcinoma </e2> ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
NO_RELATION	In groups given 2 % <e1> BHA </e1> , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with <e2> carcinoma </e2> ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
NO_RELATION	In groups given 2 % <e1> BHA </e1> , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with <e2> carcinoma </e2> ) in the group given RA - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % <e1> RA </e1> significantly ( P less than 0 . 05 ) increased the incidence of <e2> forestomach tumors </e2> ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % <e1> RA </e1> significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( <e2> squamous cell papilloma </e2> and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % <e1> RA </e1> significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and <e2> carcinoma </e2> ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % <e1> RA </e1> significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with <e2> carcinoma </e2> ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % <e1> RA </e1> significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with <e2> carcinoma </e2> ) in the group given RA - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of <e2> forestomach tumors </e2> ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given <e1> RA </e1> - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( <e2> squamous cell papilloma </e2> and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given <e1> RA </e1> - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and <e2> carcinoma </e2> ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given <e1> RA </e1> - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with <e2> carcinoma </e2> ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given <e1> RA </e1> - free water .
NO_RELATION	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with <e2> carcinoma </e2> ) in the group given <e1> RA </e1> - free water .
NO_RELATION	In rats given 1 % <e1> BHA </e1> , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced <e2> epithelial hyperplasia </e2> .
NO_RELATION	In rats given 1 % BHA , <e1> RA </e1> co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced <e2> epithelial hyperplasia </e2> .
NO_RELATION	In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the <e1> BHA </e1> - induced <e2> epithelial hyperplasia </e2> .
NO_RELATION	<e2> Tumors </e2> , all papillomas , were induced in 3 rats ( 17 % ) with 0 . 25 % <e1> RA </e1> and in one rat ( 10 % ) with 0 . 05 % RA co - administration .
NO_RELATION	Tumors , all <e2> papillomas </e2> , were induced in 3 rats ( 17 % ) with 0 . 25 % <e1> RA </e1> and in one rat ( 10 % ) with 0 . 05 % RA co - administration .
NO_RELATION	<e2> Tumors </e2> , all papillomas , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % <e1> RA </e1> co - administration .
NO_RELATION	Tumors , all <e2> papillomas </e2> , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % <e1> RA </e1> co - administration .
NO_RELATION	These findings indicate that <e1> RA </e1> acted as a co - carcinogen in the BHA <e2> forestomach carcinogenesis </e2> of the rat .
CID	These findings indicate that RA acted as a co - carcinogen in the <e1> BHA </e1> <e2> forestomach carcinogenesis </e2> of the rat .
NO_RELATION	<e1> Ketanserin </e1> pretreatment reverses alfentanil - induced <e2> muscle rigidity </e2> .
CID	Ketanserin pretreatment reverses <e1> alfentanil </e1> - induced <e2> muscle rigidity </e2> .
NO_RELATION	Systemic pretreatment with <e1> ketanserin </e1> , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the <e2> muscle rigidity </e2> produced in rats by the potent short - acting opiate agonist alfentanil .
NO_RELATION	Systemic pretreatment with ketanserin , a relatively specific type - 2 <e1> serotonin </e1> receptor antagonist , significantly attenuated the <e2> muscle rigidity </e2> produced in rats by the potent short - acting opiate agonist alfentanil .
CID	Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the <e2> muscle rigidity </e2> produced in rats by the potent short - acting opiate agonist <e1> alfentanil </e1> .
NO_RELATION	<e1> Chlordiazepoxide </e1> at doses up to 10 mg / kg failed to significantly influence the <e2> rigidity </e2> produced by alfentanil .
CID	Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the <e2> rigidity </e2> produced by <e1> alfentanil </e1> .
NO_RELATION	Despite the absence of <e2> rigidity </e2> , animals that received <e1> ketanserin </e1> ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .
CID	Despite the absence of <e2> rigidity </e2> , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by <e1> alfentanil </e1> were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .
CID	Despite the absence of <e2> rigidity </e2> , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving <e1> alfentanil </e1> alone .
NO_RELATION	Pretreatment with type - 2 <e1> serotonin </e1> antagonists may be clinically useful in attenuating opiate - induced <e2> rigidity </e2> , although further studies will be necessary to assess the interaction of possibly enhanced CNS , cardiovascular , and respiratory depression .
NO_RELATION	Pretreatment with type - 2 <e1> serotonin </e1> antagonists may be clinically useful in attenuating opiate - induced rigidity , although further studies will be necessary to assess the interaction of possibly enhanced CNS , <e2> cardiovascular , and respiratory depression </e2> .
NO_RELATION	Use of <e1> glycopyrronium </e1> 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , edrophonium - induced <e2> bradycardias </e2> .
CID	Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the <e1> edrophonium </e1> , was sufficient to minimize early , edrophonium - induced <e2> bradycardias </e2> .
CID	Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , <e1> edrophonium </e1> - induced <e2> bradycardias </e2> .
CID	Involvement of locus coeruleus and noradrenergic neurotransmission in <e1> fentanyl </e1> - induced <e2> muscular rigidity </e2> in the rat .
CID	Whereas <e2> muscular rigidity </e2> is a well - known side effect that is associated with high - dose <e1> fentanyl </e1> anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .
NO_RELATION	Such an induced <e2> muscular rigidity </e2> by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , <e1> prazosin </e1> .
CID	It is speculated that the induction of <e2> muscular rigidity </e2> by <e1> fentanyl </e1> may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .
NO_RELATION	We describe a 42 - year - old woman who developed superior <e2> sagittal and left transverse sinus thrombosis </e2> associated with prolonged <e1> epsilon - aminocaproic acid </e1> therapy for menorrhagia .
NO_RELATION	We describe a 42 - year - old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged <e1> epsilon - aminocaproic acid </e1> therapy for <e2> menorrhagia </e2> .
NO_RELATION	Although increased risk of <e2> thromboembolic disease </e2> has been reported during treatment with <e1> epsilon - aminocaproic acid </e1> , cerebral sinus thrombosis has not been previously described .
NO_RELATION	Although increased risk of thromboembolic disease has been reported during treatment with <e1> epsilon - aminocaproic acid </e1> , <e2> cerebral sinus thrombosis </e2> has not been previously described .
NO_RELATION	<e2> Hemorrhagic cystitis </e2> is a potentially serious complication of high - dose <e1> cyclophosphamide </e1> therapy administered before bone marrow transplantation .
NO_RELATION	In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with <e1> mesna </e1> , which neutralizes the hepatic metabolite of cyclophosphamide that causes <e2> hemorrhagic cystitis </e2> .
NO_RELATION	In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of <e1> cyclophosphamide </e1> that causes <e2> hemorrhagic cystitis </e2> .
NO_RELATION	In contrast , two of four consecutive patients who received <e1> mesna </e1> uroprophylaxis before allogeneic bone marrow transplantation had severe <e2> hemorrhagic cystitis </e2> for at least 2 weeks .
CID	The most common adverse effects were <e2> nausea </e2> and vomiting in the <e1> flumazenil </e1> group and nausea and injection - site pain in the placebo group .
CID	The most common adverse effects were nausea and <e2> vomiting </e2> in the <e1> flumazenil </e1> group and nausea and injection - site pain in the placebo group .
CID	The most common adverse effects were nausea and vomiting in the <e1> flumazenil </e1> group and <e2> nausea </e2> and injection - site pain in the placebo group .
NO_RELATION	The most common adverse effects were nausea and vomiting in the <e1> flumazenil </e1> group and nausea and injection - site <e2> pain </e2> in the placebo group .
CID	Hepatic <e2> adenomas </e2> and focal nodular hyperplasia of the liver in young women on <e1> oral contraceptives </e1> : case reports .
CID	Hepatic adenomas and <e2> focal nodular hyperplasia </e2> of the liver in young women on <e1> oral contraceptives </e1> : case reports .
CID	Two cases of hepatic <e2> adenoma </e2> and one of focal nodular hyperplasia presumably associated with the use of <e1> oral contraceptives </e1> , are reported .
CID	Two cases of hepatic adenoma and one of <e2> focal nodular hyperplasia </e2> presumably associated with the use of <e1> oral contraceptives </e1> , are reported .
NO_RELATION	Arterial <e2> thromboembolism </e2> in patients receiving systemic <e1> heparin </e1> therapy : a complication associated with heparin - induced thrombocytopenia .
CID	Arterial thromboembolism in patients receiving systemic <e1> heparin </e1> therapy : a complication associated with heparin - induced <e2> thrombocytopenia </e2> .
NO_RELATION	Arterial <e2> thromboembolism </e2> in patients receiving systemic heparin therapy : a complication associated with <e1> heparin </e1> - induced thrombocytopenia .
CID	Arterial thromboembolism in patients receiving systemic heparin therapy : a complication associated with <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> .
NO_RELATION	Arterial <e2> thromboembolism </e2> is a recognized complication of systemic <e1> heparin </e1> therapy .
CID	Characteristic of the entity is <e2> arterial occlusion </e2> by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of <e1> heparin </e1> therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .
NO_RELATION	Characteristic of the entity is arterial occlusion by platelet - fibrin <e2> thrombi </e2> with distal ischemia occurring four to twenty days after the initiation of <e1> heparin </e1> therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .
NO_RELATION	Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal <e2> ischemia </e2> occurring four to twenty days after the initiation of <e1> heparin </e1> therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .
CID	Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of <e1> heparin </e1> therapy , preceded by profound <e2> thrombocytopenia </e2> with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .
NO_RELATION	The common factor relating <e2> thromboembolism </e2> and thrombocytopenia is <e1> heparin </e1> - induced platelet aggregation .
CID	The common factor relating thromboembolism and <e2> thrombocytopenia </e2> is <e1> heparin </e1> - induced platelet aggregation .
NO_RELATION	The common factor relating thromboembolism and thrombocytopenia is <e1> heparin </e1> - induced <e2> platelet aggregation </e2> .
CID	Long - term prognosis for transplant - free survivors of <e1> paracetamol </e1> - induced <e2> acute liver failure </e2> .
CID	BACKGROUND : The prognosis for transplant - free survivors of <e1> paracetamol </e1> - induced <e2> acute liver failure </e2> remains unknown .
CID	AIM : To examine whether <e1> paracetamol </e1> - induced <e2> acute liver failure </e2> increases long - term mortality .
NO_RELATION	METHODS : We followed up all transplant - free survivors of <e1> paracetamol </e1> - induced <e2> acute liver injury </e2> , hospitalized in a Danish national referral centre during 1984 - 2004 .
NO_RELATION	On average , age - specific mortality rates were slightly higher for the 101 patients whose <e1> paracetamol </e1> - induced <e2> liver injury </e2> had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .
CID	On average , age - specific mortality rates were slightly higher for the 101 patients whose <e1> paracetamol </e1> - induced liver injury had caused an <e2> acute liver failure </e2> ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .
CID	On average , age - specific mortality rates were slightly higher for the 101 patients whose <e1> paracetamol </e1> - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of <e2> acute liver failure </e2> died of liver disease , whereas suicides were frequent in both groups .
NO_RELATION	On average , age - specific mortality rates were slightly higher for the 101 patients whose <e1> paracetamol </e1> - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of <e2> liver disease </e2> , whereas suicides were frequent in both groups .
CID	CONCLUSIONS : <e1> Paracetamol </e1> - induced <e2> acute liver failure </e2> did not affect long - term mortality .
NO_RELATION	<e1> Serotonin </e1> 6 receptor gene is associated with methamphetamine - induced <e2> psychosis </e2> in a Japanese population .
CID	Serotonin 6 receptor gene is associated with <e1> methamphetamine </e1> - induced <e2> psychosis </e2> in a Japanese population .
NO_RELATION	The <e1> serotonin </e1> 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .
NO_RELATION	The serotonin 6 ( <e1> 5 - HT6 </e1> ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .
NO_RELATION	The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as <e1> clozapine </e1> and olanzapine , and d - amphetamine - induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .
NO_RELATION	The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and <e1> olanzapine </e1> , and d - amphetamine - induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .
NO_RELATION	The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and <e1> d - amphetamine </e1> - induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .
NO_RELATION	The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced <e2> hyperactivity </e2> in rats is corrected with the use of a selective <e1> 5 - HT6 </e1> receptor antagonist .
NO_RELATION	These animal models were considered to reflect the positive symptoms of <e2> schizophrenia </e2> , and the above evidence suggests that altered <e1> 5 - HT6 </e1> receptors are involved in the pathophysiology of psychotic disorders .
NO_RELATION	These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered <e1> 5 - HT6 </e1> receptors are involved in the pathophysiology of <e2> psychotic disorders </e2> .
CID	The symptoms of <e1> methamphetamine </e1> ( METH ) - induced <e2> psychosis </e2> are similar to those of paranoid type schizophrenia .
NO_RELATION	The symptoms of <e1> methamphetamine </e1> ( METH ) - induced psychosis are similar to those of <e2> paranoid type schizophrenia </e2> .
CID	The symptoms of methamphetamine ( <e1> METH </e1> ) - induced <e2> psychosis </e2> are similar to those of paranoid type schizophrenia .
NO_RELATION	The symptoms of methamphetamine ( <e1> METH </e1> ) - induced psychosis are similar to those of <e2> paranoid type schizophrenia </e2> .
NO_RELATION	Therefore , we conducted an analysis of the association of the <e1> 5 - HT6 </e1> gene ( HTR6 ) with METH - induced <e2> psychosis </e2> .
CID	Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with <e1> METH </e1> - induced <e2> psychosis </e2> .
CID	METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 <e1> METH </e1> - induced <e2> psychosis </e2> patients and 337 controls ) in the Japanese population .
CID	RESULTS : rs6693503 was associated with <e1> METH </e1> - induced <e2> psychosis </e2> patients in the allele / genotype - wise analysis .
CID	In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and <e1> METH </e1> - induced <e2> psychosis </e2> patients , respectively .
CID	CONCLUSION : HTR6 may play an important role in the pathophysiology of <e1> METH </e1> - induced <e2> psychosis </e2> in the Japanese population .
CID	Effect of increasing intraperitoneal infusion rates on <e1> bupropion hydrochloride </e1> - induced <e2> seizures </e2> in mice .
CID	BACKGROUND : It is not known if there is a relationship between input rate and incidence of <e1> bupropion </e1> - induced <e2> seizures </e2> .
CID	METHODS : We investigated the effect of varying the intraperitoneal infusion rates of <e1> bupropion HCl </e1> 120 mg / kg , a known <e2> convulsive </e2> dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .
CID	METHODS : We investigated the effect of varying the intraperitoneal infusion rates of <e1> bupropion HCl </e1> 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced <e2> convulsions </e2> in the Swiss albino mice .
CID	METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known <e2> convulsive </e2> dose 50 ( CD50 ) , on the incidence and severity of <e1> bupropion </e1> - induced convulsions in the Swiss albino mice .
CID	METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of <e1> bupropion </e1> - induced <e2> convulsions </e2> in the Swiss albino mice .
CID	RESULTS : The results showed that IP administration of <e1> bupropion HCl </e1> 120 mg / kg by bolus injection induced <e2> convulsions </e2> in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .
CID	Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of <e1> bupropion HCl </e1> 120 mg / kg was associated with a 91 % reduced odds of <e2> convulsions </e2> at infusion times of 15 to 90 min compared to bolus injection .
CID	CONCLUSION : In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and <e2> convulsive </e2> dose of <e1> bupropion </e1> and the risk of convulsions in a prospective study is novel .
CID	CONCLUSION : In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of <e1> bupropion </e1> and the risk of <e2> convulsions </e2> in a prospective study is novel .
NO_RELATION	Detailed spectral profile analysis of <e1> penicillin </e1> - induced <e2> epileptiform activity </e2> in anesthetized rats .
NO_RELATION	<e1> Penicillin </e1> model is a widely used experimental model for <e2> epilepsy </e2> research .
NO_RELATION	In the present study we aimed to portray a detailed spectral analysis of <e1> penicillin </e1> - induced <e2> epileptiform activity </e2> in comparison with basal brain activity in anesthetized Wistar rats .
CID	After a short period of basal activity recording , <e2> epileptic </e2> focus was induced by injecting 400IU / 2 microl <e1> penicillin - G potassium </e1> into the left lateral ventricle while the cortical activity was continuously recorded .
NO_RELATION	Basal activity , latent period and the <e1> penicillin </e1> - induced <e2> epileptiform activity </e2> periods were then analyzed using both conventional methods and spectral analysis .
CID	Although <e1> dexmedetomidine </e1> sedation was associated with a 16 % incidence of <e2> bradycardia </e2> , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .
NO_RELATION	Although dexmedetomidine sedation was associated with a 16 % incidence of <e2> bradycardia </e2> , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and <e1> oxygen </e1> saturations were 95 % or higher .
CID	<e1> Methamphetamine </e1> causes alterations in the MAP kinase - related pathways in the brains of mice that display increased <e2> aggressiveness </e2> .
CID	<e2> Aggressive behaviors </e2> have been reported in patients who suffer from some psychiatric disorders , and are common in <e1> methamphetamine </e1> ( METH ) abusers .
CID	Aggressive behaviors have been reported in patients who suffer from some <e2> psychiatric disorders </e2> , and are common in <e1> methamphetamine </e1> ( METH ) abusers .
CID	<e2> Aggressive behaviors </e2> have been reported in patients who suffer from some psychiatric disorders , and are common in methamphetamine ( <e1> METH </e1> ) abusers .
CID	Aggressive behaviors have been reported in patients who suffer from some <e2> psychiatric disorders </e2> , and are common in methamphetamine ( <e1> METH </e1> ) abusers .
CID	Herein , we report that multiple ( but not single ) injections of <e1> METH </e1> significantly increased <e2> aggressiveness </e2> in male CD - 1 mice .
CID	This increase in <e2> aggressiveness </e2> was not secondary to <e1> METH </e1> - induced hyperactivity .
NO_RELATION	This increase in aggressiveness was not secondary to <e1> METH </e1> - induced <e2> hyperactivity </e2> .
CID	<e1> Lamotrigine </e1> associated with exacerbation or de novo <e2> myoclonus </e2> in idiopathic generalized epilepsies .
NO_RELATION	<e1> Lamotrigine </e1> associated with exacerbation or de novo myoclonus in <e2> idiopathic generalized epilepsies </e2> .
NO_RELATION	Five patients with <e2> idiopathic generalized epilepsies </e2> ( IGE ) treated with <e1> lamotrigine </e1> ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .
NO_RELATION	Five patients with idiopathic generalized epilepsies ( <e2> IGE </e2> ) treated with <e1> lamotrigine </e1> ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .
CID	Five patients with idiopathic generalized epilepsies ( IGE ) treated with <e1> lamotrigine </e1> ( LTG ) experienced exacerbation or de novo appearance of <e2> myoclonic jerks </e2> ( MJ ) .
CID	Five patients with idiopathic generalized epilepsies ( IGE ) treated with <e1> lamotrigine </e1> ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( <e2> MJ </e2> ) .
NO_RELATION	Five patients with <e2> idiopathic generalized epilepsies </e2> ( IGE ) treated with lamotrigine ( <e1> LTG </e1> ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .
NO_RELATION	Five patients with idiopathic generalized epilepsies ( <e2> IGE </e2> ) treated with lamotrigine ( <e1> LTG </e1> ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .
CID	Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( <e1> LTG </e1> ) experienced exacerbation or de novo appearance of <e2> myoclonic jerks </e2> ( MJ ) .
CID	Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( <e1> LTG </e1> ) experienced exacerbation or de novo appearance of myoclonic jerks ( <e2> MJ </e2> ) .
CID	In three patients , <e1> LTG </e1> exacerbated <e2> MJ </e2> in a dose - dependent manner with early aggravation during titration .
CID	<e2> MJ </e2> disappeared when <e1> LTG </e1> dose was decreased by 25 to 50 % .
CID	In two patients , <e1> LTG </e1> exacerbated <e2> MJ </e2> in a delayed but more severe manner , with myoclonic status that only ceased after LTG withdrawal .
CID	In two patients , <e1> LTG </e1> exacerbated MJ in a delayed but more severe manner , with <e2> myoclonic status </e2> that only ceased after LTG withdrawal .
CID	In two patients , LTG exacerbated <e2> MJ </e2> in a delayed but more severe manner , with myoclonic status that only ceased after <e1> LTG </e1> withdrawal .
CID	In two patients , LTG exacerbated MJ in a delayed but more severe manner , with <e2> myoclonic status </e2> that only ceased after <e1> LTG </e1> withdrawal .
CID	The neural mechanisms and circuitry involved in <e1> levodopa </e1> - induced <e2> dyskinesia </e2> are unclear .
NO_RELATION	Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced <e2> Parkinson disease </e2> , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous <e1> apomorphine </e1> infusion .
NO_RELATION	Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a <e2> dyskinetic </e2> state induced by continuous <e1> apomorphine </e1> infusion .
CID	Assessment of the onset and persistence of <e2> amnesia </e2> during procedural sedation with <e1> propofol </e1> .
CID	Assessment was done on the following : prenatal screening for <e2> hepatitis B </e2> and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .
NO_RELATION	Assessment was done on the following : prenatal screening for hepatitis B and <e2> rubella </e2> , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .
CID	Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the <e2> hepatitis B </e2> vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .
CID	Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of <e2> hepatitis B </e2> immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .
NO_RELATION	Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> - positive mothers , <e2> rubella </e2> immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .
NO_RELATION	Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> - positive mothers , rubella immunity , and administration of in - hospital postpartum <e2> rubella </e2> vaccine to rubella nonimmune women .
NO_RELATION	Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to <e1> hepatitis B surface antigen </e1> - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to <e2> rubella </e2> nonimmune women .
CID	All infants who were born to <e1> hepatitis B surface antigen </e1> - positive mothers also received <e2> hepatitis B </e2> immune globulin .
NO_RELATION	<e1> Doxorubicin </e1> is an anti - <e2> tumor </e2> agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .
CID	These findings demonstrate that overexpression of p300 protects cardiac myocytes from <e1> doxorubicin </e1> - induced apoptosis and reduces the extent of acute <e2> heart failure </e2> in adult mice in vivo .
CID	Mitochondrial DNA and its respiratory chain products are defective in <e1> doxorubicin </e1> <e2> nephrosis </e2> .
NO_RELATION	BACKGROUND : <e1> Doxorubicin </e1> induces a self - perpetuating <e2> nephropathy </e2> characterized by early glomerular and late - onset tubular lesions in rats .
NO_RELATION	BACKGROUND : <e1> Doxorubicin </e1> induces a self - perpetuating nephropathy characterized by early <e2> glomerular and late - onset tubular lesions </e2> in rats .
NO_RELATION	RESULTS : The ' long - term ' group had significant <e2> glomerular and tubular lesions </e2> , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased <e1> citrate </e1> synthase activity .
NO_RELATION	CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of <e1> superoxide </e1> in doxorubicin - induced <e2> renal lesions </e2> .
NO_RELATION	CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in <e1> doxorubicin </e1> - induced <e2> renal lesions </e2> .
CID	<e1> Amphotericin B </e1> - induced <e2> seizures </e2> in a patient with AIDS .
NO_RELATION	<e1> Amphotericin B </e1> - induced seizures in a patient with <e2> AIDS </e2> .
CID	OBJECTIVE : To report a case of multiple episodes of <e2> seizure </e2> activity in an AIDS patent following <e1> amphotericin B </e1> infusion .
NO_RELATION	OBJECTIVE : To report a case of multiple episodes of seizure activity in an <e2> AIDS </e2> patent following <e1> amphotericin B </e1> infusion .
NO_RELATION	CASE SUMMARY : A 46 - year - old African - American man experienced recurrent <e2> grand mal seizures </e2> during intravenous infusion of <e1> amphotericin B </e1> , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .
CID	CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of <e1> amphotericin B </e1> , then petit mal <e2> seizures </e2> as the infusion was stopped and the drug concentrations decreased with time .
NO_RELATION	Despite administration of <e1> phenytoin </e1> and lorazepam , the <e2> seizures </e2> persisted and occurred only during amphotercin B administration .
NO_RELATION	Despite administration of phenytoin and <e1> lorazepam </e1> , the <e2> seizures </e2> persisted and occurred only during amphotercin B administration .
CID	Despite administration of phenytoin and lorazepam , the <e2> seizures </e2> persisted and occurred only during <e1> amphotercin B </e1> administration .
NO_RELATION	The patient had a history of <e2> alcohol abuse </e2> ; <e1> alcohol </e1> intake as well as withdrawal can also cause seizures .
NO_RELATION	The patient had a history of alcohol abuse ; <e1> alcohol </e1> intake as well as withdrawal can also cause <e2> seizures </e2> .
NO_RELATION	<e1> Didanosine </e1> also has a potential for inducing <e2> seizures </e2> .
CID	The time course of events suggested that <e1> amphotericin B </e1> was the cause of the <e2> seizures </e2> in this AIDS patient .
NO_RELATION	The time course of events suggested that <e1> amphotericin B </e1> was the cause of the seizures in this <e2> AIDS </e2> patient .
CID	CONCLUSIONS : <e1> Amphotericin B </e1> seems to be the probable cause of the <e2> seizures </e2> .
CID	To date , only three cases of <e2> seizures </e2> associated with <e1> amphotericin B </e1> have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .
NO_RELATION	twice - daily ) of <e1> tobramicyn </e1> on steady - state serum concentrations and <e2> toxicity </e2> .
NO_RELATION	Increased serum <e1> creatinine </e1> was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of <e2> nephrotoxicity </e2> .
NO_RELATION	Chronic effects of a novel synthetic <e1> anthracycline </e1> derivative ( SM - 5887 ) on normal heart and doxorubicin - induced <e2> cardiomyopathy </e2> in beagle dogs .
NO_RELATION	Chronic effects of a novel synthetic anthracycline derivative ( <e1> SM - 5887 </e1> ) on normal heart and doxorubicin - induced <e2> cardiomyopathy </e2> in beagle dogs .
CID	Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and <e1> doxorubicin </e1> - induced <e2> cardiomyopathy </e2> in beagle dogs .
NO_RELATION	This study was designed to investigate the chronic <e2> cardiotoxic </e2> potential of <e1> SM - 5887 </e1> and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .
NO_RELATION	This study was designed to investigate the chronic cardiotoxic potential of <e1> SM - 5887 </e1> and a possible deteriorating effect of SM - 5887 on low - grade <e2> cardiotoxicity </e2> pre - induced by doxorubicin in beagle dogs .
NO_RELATION	This study was designed to investigate the chronic <e2> cardiotoxic </e2> potential of SM - 5887 and a possible deteriorating effect of <e1> SM - 5887 </e1> on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .
NO_RELATION	This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of <e1> SM - 5887 </e1> on low - grade <e2> cardiotoxicity </e2> pre - induced by doxorubicin in beagle dogs .
NO_RELATION	This study was designed to investigate the chronic <e2> cardiotoxic </e2> potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by <e1> doxorubicin </e1> in beagle dogs .
NO_RELATION	This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade <e2> cardiotoxicity </e2> pre - induced by <e1> doxorubicin </e1> in beagle dogs .
CID	Animals which received over six courses of <e1> doxorubicin </e1> demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological <e2> cardiomyopathy </e2> , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .
NO_RELATION	Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological <e2> cardiomyopathy </e2> , while animals which were terminally sacrificed after the <e1> SM - 5887 </e1> administration did not show any changes in ECG , blood pressure and histopathological examinations .
NO_RELATION	To examine a possibly deteriorating <e2> cardiotoxic </e2> effect of <e1> SM - 5887 </e1> , low - grade cardiomyopathy was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .
NO_RELATION	To examine a possibly deteriorating cardiotoxic effect of <e1> SM - 5887 </e1> , low - grade <e2> cardiomyopathy </e2> was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .
NO_RELATION	To examine a possibly deteriorating <e2> cardiotoxic </e2> effect of SM - 5887 , low - grade cardiomyopathy was induced in dogs by four courses of <e1> doxorubicin </e1> ( 1 . 5 mg / kg ) .
CID	To examine a possibly deteriorating cardiotoxic effect of SM - 5887 , low - grade <e2> cardiomyopathy </e2> was induced in dogs by four courses of <e1> doxorubicin </e1> ( 1 . 5 mg / kg ) .
NO_RELATION	The low - grade <e2> cardiotoxic </e2> changes were enhanced by the additional <e1> doxorubicin </e1> treatment .
NO_RELATION	On the contrary , the <e1> SM - 5887 </e1> treatment did not progress the grade of <e2> cardiomyopathy </e2> .
NO_RELATION	In conclusion , <e1> SM - 5887 </e1> does not have any potential of chronic <e2> cardiotoxicity </e2> and deteriorating effect on doxorubicin - induced cardiotoxicity in dogs .
NO_RELATION	In conclusion , <e1> SM - 5887 </e1> does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin - induced <e2> cardiotoxicity </e2> in dogs .
NO_RELATION	In conclusion , SM - 5887 does not have any potential of chronic <e2> cardiotoxicity </e2> and deteriorating effect on <e1> doxorubicin </e1> - induced cardiotoxicity in dogs .
NO_RELATION	In conclusion , SM - 5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on <e1> doxorubicin </e1> - induced <e2> cardiotoxicity </e2> in dogs .
NO_RELATION	CONCLUSIONS : In late - stage <e2> Parkinson ' s disease </e2> , pallidotomy significantly reduces <e1> levodopa </e1> - induced dyskinesias and off - period disability .
CID	CONCLUSIONS : In late - stage Parkinson ' s disease , pallidotomy significantly reduces <e1> levodopa </e1> - induced <e2> dyskinesias </e2> and off - period disability .
CID	Neuropeptide - Y immunoreactivity in the <e1> pilocarpine </e1> model of <e2> temporal lobe epilepsy </e2> .
NO_RELATION	The <e1> pilocarpine </e1> ( PILO ) model of <e2> epilepsy </e2> is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .
NO_RELATION	The <e1> pilocarpine </e1> ( PILO ) model of epilepsy is characterized by an acute period of <e2> status epilepticus </e2> followed by spontaneous recurrent seizures and related brain damage .
NO_RELATION	The <e1> pilocarpine </e1> ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent <e2> seizures </e2> and related brain damage .
NO_RELATION	The <e1> pilocarpine </e1> ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related <e2> brain damage </e2> .
NO_RELATION	The pilocarpine ( <e1> PILO </e1> ) model of <e2> epilepsy </e2> is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .
NO_RELATION	The pilocarpine ( <e1> PILO </e1> ) model of epilepsy is characterized by an acute period of <e2> status epilepticus </e2> followed by spontaneous recurrent seizures and related brain damage .
NO_RELATION	The pilocarpine ( <e1> PILO </e1> ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent <e2> seizures </e2> and related brain damage .
NO_RELATION	The pilocarpine ( <e1> PILO </e1> ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related <e2> brain damage </e2> .
CID	The results demonstrate that changes in NPY expression , including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons , are present in the <e1> PILO </e1> model of <e2> TLE </e2> .
NO_RELATION	During the follow - up , 3 patients ( 12 % ) developed <e1> steroid </e1> - induced <e2> elevated intraocular pressure </e2> ( IOP ) that resolved after corticosteroid therapy was discontinued .
CID	During the follow - up , 3 patients ( 12 % ) developed steroid - induced <e2> elevated intraocular pressure </e2> ( IOP ) that resolved after <e1> corticosteroid </e1> therapy was discontinued .
NO_RELATION	The transient <e1> steroid </e1> - induced <e2> IOP rise </e2> did not seem to cause functional impairment .
NO_RELATION	Liposomal <e1> daunorubicin </e1> in advanced <e2> Kaposi ' s sarcoma </e2> : a phase II study .
NO_RELATION	We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal <e1> daunorubicin </e1> ( DaunoXome ) in the treatment of <e2> AIDS </e2> related Kaposi ' s sarcoma .
NO_RELATION	We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal <e1> daunorubicin </e1> ( DaunoXome ) in the treatment of AIDS related <e2> Kaposi ' s sarcoma </e2> .
NO_RELATION	In this small patient sample , liposomal <e1> daunorubicin </e1> was an effective and well tolerated agent in the treatment of <e2> Kaposi ' s sarcoma </e2> .
CID	Failure of ancrod in the treatment of <e1> heparin </e1> - induced arterial <e2> thrombosis </e2> .
CID	The morbidity and mortality associated with <e1> heparin </e1> - induced <e2> thrombosis </e2> remain high despite numerous empirical therapies .
CID	Ancrod has been used successfully for prophylaxis against development of <e2> thrombosis </e2> in patients with <e1> heparin </e1> induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .
NO_RELATION	Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with <e1> heparin </e1> induced <e2> platelet aggregation </e2> who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .
CID	Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with <e1> heparin </e1> induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the <e2> thrombosis </e2> syndrome is not well defined .
CID	Ancrod has been used successfully for prophylaxis against development of <e2> thrombosis </e2> in patients with heparin induced platelet aggregation who require brief reexposure to <e1> heparin </e1> , but its success in patients who have developed the thrombosis syndrome is not well defined .
NO_RELATION	Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced <e2> platelet aggregation </e2> who require brief reexposure to <e1> heparin </e1> , but its success in patients who have developed the thrombosis syndrome is not well defined .
CID	Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to <e1> heparin </e1> , but its success in patients who have developed the <e2> thrombosis </e2> syndrome is not well defined .
CID	The authors present a case of failure of ancrod treatment in a patient with <e1> heparin </e1> - induced <e2> thrombosis </e2> .
CID	<e2> Seizure </e2> after <e1> flumazenil </e1> administration in a pediatric patient .
NO_RELATION	<e1> Flumazenil </e1> is a benzodiazepine receptor antagonist used to reverse sedation and <e2> respiratory depression </e2> induced by benzodiazepines .
NO_RELATION	Flumazenil is a <e1> benzodiazepine </e1> receptor antagonist used to reverse sedation and <e2> respiratory depression </e2> induced by benzodiazepines .
NO_RELATION	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and <e2> respiratory depression </e2> induced by <e1> benzodiazepines </e1> .
CID	We report the occurrence of a generalized <e2> tonic - clonic seizure </e2> in a pediatric patient following the administration of <e1> flumazenil </e1> .
CID	Remodelling of nerve structure in experimental <e1> isoniazid </e1> <e2> neuropathy </e2> in the rat .
CID	The <e2> neuropathy </e2> caused by a single dose of <e1> isoniazid </e1> in rats was studied with a computer - assisted morphometric method .
NO_RELATION	Frequencies of <e2> ventricular fibrillation </e2> were significantly lower ( p less than 0 . 05 ) after <e1> iopentol </e1> ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .
NO_RELATION	Frequencies of <e2> ventricular fibrillation </e2> were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and <e1> iohexol </e1> ( 3 % ) than after metrizoate ( 22 % ) .
CID	Frequencies of <e2> ventricular fibrillation </e2> were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after <e1> metrizoate </e1> ( 22 % ) .
NO_RELATION	Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of <e2> coronary stenosis </e2> : correlation with <e1> thallium </e1> - 201 single - photon emission tomography .
CID	During <e1> dipyridamole </e1> - induced <e2> hyperemia </e2> , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography .
NO_RELATION	During <e1> dipyridamole </e1> - induced hyperemia , 12 of the 16 dogs with a partial <e2> coronary stenosis </e2> had a visible area of hypoperfusion by contrast echocardiography .
CID	The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in <e1> dipyridamole </e1> - induced <e2> hyperemia </e2> .
NO_RELATION	<e1> Thallium </e1> - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced <e2> hyperemia </e2> ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .
CID	Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during <e1> dipyridamole </e1> - induced <e2> hyperemia </e2> ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .
NO_RELATION	Potential deleterious effect of <e1> furosemide </e1> in radiocontrast <e2> nephropathy </e2> .
NO_RELATION	The purpose of the study was to determine the efficacy of <e1> furosemide </e1> in addition to intravenous fluids in the prevention of radiocontrast <e2> nephropathy </e2> .
CID	<e2> Renal function significantly deteriorated </e2> in the group pretreated with <e1> furosemide </e1> ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .
NO_RELATION	<e2> Renal function significantly deteriorated </e2> in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum <e1> creatinine </e1> from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .
NO_RELATION	<e2> Renal failure </e2> was associated with weight loss in the <e1> furosemide </e1> - treated group .
NO_RELATION	Renal failure was associated with <e2> weight loss </e2> in the <e1> furosemide </e1> - treated group .
NO_RELATION	<e1> Furosemide </e1> may be deleterious in the prevention of radiocontrast <e2> nephropathy </e2> .
CID	The renal pathology in a case of <e1> lithium </e1> - induced <e2> diabetes insipidus </e2> .
CID	A case of <e1> lithium </e1> - induced <e2> diabetes insipidus </e2> is reported .
CID	Etiologic factors in the pathogenesis of <e2> liver tumors </e2> associated with <e1> oral contraceptives </e1> .
CID	Within the last several years , previously rare <e2> liver tumors </e2> have been seen in young women using <e1> oral contraceptive </e1> steroids .
NO_RELATION	Within the last several years , previously rare <e2> liver tumors </e2> have been seen in young women using oral contraceptive <e1> steroids </e1> .
CID	The Registry for <e2> Liver Tumors </e2> Associated with <e1> Oral Contraceptives </e1> at the University of California , Irvine , has clearly identified 27 cases .
NO_RELATION	<e2> Graft - versus - host disease </e2> prophylaxis with <e1> everolimus </e1> and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .
CID	Graft - versus - host disease prophylaxis with <e1> everolimus </e1> and tacrolimus is associated with a high incidence of <e2> sinusoidal obstruction syndrome </e2> and microangiopathy : results of the EVTAC trial .
CID	Graft - versus - host disease prophylaxis with <e1> everolimus </e1> and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and <e2> microangiopathy </e2> : results of the EVTAC trial .
NO_RELATION	<e2> Graft - versus - host disease </e2> prophylaxis with everolimus and <e1> tacrolimus </e1> is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .
CID	Graft - versus - host disease prophylaxis with everolimus and <e1> tacrolimus </e1> is associated with a high incidence of <e2> sinusoidal obstruction syndrome </e2> and microangiopathy : results of the EVTAC trial .
CID	Graft - versus - host disease prophylaxis with everolimus and <e1> tacrolimus </e1> is associated with a high incidence of sinusoidal obstruction syndrome and <e2> microangiopathy </e2> : results of the EVTAC trial .
NO_RELATION	A calcineurin inhibitor combined with <e1> methotrexate </e1> is the standard prophylaxis for <e2> graft - versus - host disease </e2> ( GVHD ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .
NO_RELATION	A calcineurin inhibitor combined with <e1> methotrexate </e1> is the standard prophylaxis for graft - versus - host disease ( <e2> GVHD </e2> ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .
NO_RELATION	We report on a combination of <e1> everolimus </e1> and tacrolimus in 24 patients ( median age , 62 years ) with either <e2> myelodysplastic syndrome </e2> ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
NO_RELATION	We report on a combination of <e1> everolimus </e1> and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( <e2> MDS </e2> ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
NO_RELATION	We report on a combination of <e1> everolimus </e1> and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or <e2> acute myeloid leukemia </e2> ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
NO_RELATION	We report on a combination of <e1> everolimus </e1> and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( <e2> AML </e2> ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
NO_RELATION	We report on a combination of everolimus and <e1> tacrolimus </e1> in 24 patients ( median age , 62 years ) with either <e2> myelodysplastic syndrome </e2> ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
NO_RELATION	We report on a combination of everolimus and <e1> tacrolimus </e1> in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( <e2> MDS </e2> ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
NO_RELATION	We report on a combination of everolimus and <e1> tacrolimus </e1> in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or <e2> acute myeloid leukemia </e2> ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
NO_RELATION	We report on a combination of everolimus and <e1> tacrolimus </e1> in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( <e2> AML </e2> ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
NO_RELATION	<e1> Loreclezole </e1> ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both <e2> seizure </e2> and afterdischarge durations .
CID	<e2> Acute liver failure </e2> with concurrent <e1> bupropion </e1> and carbimazole therapy .
CID	<e2> Acute liver failure </e2> with concurrent bupropion and <e1> carbimazole </e1> therapy .
NO_RELATION	OBJECTIVE : To report a case of fatal <e2> liver failure </e2> possibly associated with concurrent use of <e1> bupropion </e1> and carbimazole .
NO_RELATION	OBJECTIVE : To report a case of fatal <e2> liver failure </e2> possibly associated with concurrent use of bupropion and <e1> carbimazole </e1> .
NO_RELATION	CASE SUMMARY : A 41 - year - old Chinese man with a history of <e2> hyperthyroidism </e2> had been treated with <e1> carbimazole </e1> and propranolol for the past 5 years .
NO_RELATION	CASE SUMMARY : A 41 - year - old Chinese man with a history of <e2> hyperthyroidism </e2> had been treated with carbimazole and <e1> propranolol </e1> for the past 5 years .
CID	The likelihood that <e1> bupropion </e1> induced <e2> hepatotoxicity </e2> in our patient was possible , based on the Naranjo probability scale .
CID	DISCUSSION : Although there is increasing evidence of <e2> hepatotoxicity </e2> induced by <e1> bupropion </e1> , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole .
CID	DISCUSSION : Although there is increasing evidence of hepatotoxicity induced by <e1> bupropion </e1> , this is the first case of fatality that could have resulted from <e2> acute liver failure </e2> in a patient receiving bupropion while on concomitant treatment with carbimazole .
CID	DISCUSSION : Although there is increasing evidence of <e2> hepatotoxicity </e2> induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving <e1> bupropion </e1> while on concomitant treatment with carbimazole .
CID	DISCUSSION : Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from <e2> acute liver failure </e2> in a patient receiving <e1> bupropion </e1> while on concomitant treatment with carbimazole .
CID	DISCUSSION : Although there is increasing evidence of <e2> hepatotoxicity </e2> induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with <e1> carbimazole </e1> .
CID	DISCUSSION : Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from <e2> acute liver failure </e2> in a patient receiving bupropion while on concomitant treatment with <e1> carbimazole </e1> .
CID	CONCLUSIONS : Clinicians should be aware of the possibility of <e2> acute liver insult </e2> induced by <e1> bupropion </e1> given concurrently with other hepatotoxic drugs .
CID	CONCLUSIONS : Clinicians should be aware of the possibility of acute liver insult induced by <e1> bupropion </e1> given concurrently with other <e2> hepatotoxic </e2> drugs .
CID	Long - term <e1> oestrogen </e1> - only HT significantly increased the risk of <e2> venous thrombo - embolism </e2> , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .
CID	Long - term <e1> oestrogen </e1> - only HT significantly increased the risk of venous thrombo - embolism , <e2> stroke </e2> and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .
CID	Long - term <e1> oestrogen </e1> - only HT significantly increased the risk of venous thrombo - embolism , stroke and <e2> gallbladder disease </e2> ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .
NO_RELATION	Long - term <e1> oestrogen </e1> - only HT significantly increased the risk of venous thrombo - embolism , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of <e2> breast cancer </e2> .
NO_RELATION	Among women with <e2> cardiovascular disease </e2> , long - term use of combined continuous HT significantly increased the risk of venous thrombo - embolism . One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking <e1> oestrogen </e1> - only HT , versus similar - sized placebo groups .
CID	Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of <e2> venous thrombo - embolism </e2> . One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking <e1> oestrogen </e1> - only HT , versus similar - sized placebo groups .
NO_RELATION	Passage of <e1> mannitol </e1> into the brain around <e2> gliomas </e2> : a potential cause of rebound phenomenon .
NO_RELATION	AIM : Widespread use of <e1> mannitol </e1> to reduce <e2> brain edema </e2> and lower elevated ICP in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .
CID	AIM : Widespread use of <e1> mannitol </e1> to reduce brain edema and lower <e2> elevated ICP </e2> in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .
NO_RELATION	AIM : Widespread use of <e1> mannitol </e1> to reduce brain edema and lower elevated ICP in <e2> brain tumor </e2> patients continues to be afflicted by the so - called rebound phenomenon .
NO_RELATION	As a contribution to this issue we decided to research the possible passage of <e1> mannitol </e1> into the brain after administration to 21 <e2> brain tumor </e2> patients .
NO_RELATION	METHODS : <e1> Mannitol </e1> ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had <e2> malignant glioma </e2> , seven brain metastases and four meningioma ) about 30 minutes before craniotomy .
NO_RELATION	METHODS : <e1> Mannitol </e1> ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain <e2> metastases </e2> and four meningioma ) about 30 minutes before craniotomy .
NO_RELATION	METHODS : <e1> Mannitol </e1> ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain metastases and four <e2> meningioma </e2> ) about 30 minutes before craniotomy .
NO_RELATION	RESULTS : In most <e2> glioma </e2> patients , <e1> mannitol </e1> concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .
NO_RELATION	In <e2> meningioma </e2> and metastases patients plasma concentrations of <e1> mannitol </e1> were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .
NO_RELATION	In meningioma and <e2> metastases </e2> patients plasma concentrations of <e1> mannitol </e1> were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .
NO_RELATION	CONCLUSIONS : The results of our study show that even after a single bolus , <e1> mannitol </e1> may leak through the altered BBB near <e2> gliomas </e2> , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .
NO_RELATION	CONCLUSIONS : The results of our study show that even after a single bolus , <e1> mannitol </e1> may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral <e2> edema </e2> and promoting rebound of ICP .
NO_RELATION	Can <e1> lidocaine </e1> reduce succinylcholine induced <e2> postoperative myalgia </e2> ?
CID	Can lidocaine reduce <e1> succinylcholine </e1> induced <e2> postoperative myalgia </e2> ?
NO_RELATION	This study was undertaken to determine the effect of <e1> lidocaine </e1> pretreatment on reduction of succinylcholine - induced <e2> myalgia </e2> in patients undergoing general anesthesia for gynecological surgery .
NO_RELATION	This study was undertaken to determine the effect of lidocaine pretreatment on reduction of <e1> succinylcholine </e1> - induced <e2> myalgia </e2> in patients undergoing general anesthesia for gynecological surgery .
CID	In conclusion , where <e1> succinylcholine </e1> is used , lidocaine is proven to be the useful pretreatment agent for the reduction of <e2> postoperative myalgia </e2> .
NO_RELATION	In conclusion , where succinylcholine is used , <e1> lidocaine </e1> is proven to be the useful pretreatment agent for the reduction of <e2> postoperative myalgia </e2> .
NO_RELATION	Open - label assessment of <e1> levofloxacin </e1> for the treatment of acute bacterial <e2> sinusitis </e2> in adults .
NO_RELATION	PURPOSE : To evaluate the efficacy and safety of <e1> levofloxacin </e1> ( 500 mg orally once daily for 10 to 14 days ) in treating adult outpatients with acute bacterial <e2> sinusitis </e2> .
NO_RELATION	CONCLUSION : The results of this study indicate that <e1> levofloxacin </e1> 500 mg once daily is an effective and safe treatment for acute bacterial <e2> sinusitis </e2> .
NO_RELATION	At various time intervals , physical examination and blood collection for ex vivo <e2> platelet aggregation </e2> and determination of intraplatelet <e1> cAMP </e1> were performed .
CID	Seven out of 12 subjects experienced <e2> headache </e2> of a short duration accompanying facial flush in one and nausea in one , especially after ingestion of <e1> CLZ </e1> .
CID	Seven out of 12 subjects experienced headache of a short duration accompanying <e2> facial flush </e2> in one and nausea in one , especially after ingestion of <e1> CLZ </e1> .
CID	Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and <e2> nausea </e2> in one , especially after ingestion of <e1> CLZ </e1> .
NO_RELATION	Gastrointestinal tolerability of <e1> etoricoxib </e1> in <e2> rheumatoid arthritis </e2> patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .
NO_RELATION	Gastrointestinal tolerability of etoricoxib in <e2> rheumatoid arthritis </e2> patients : results of the <e1> etoricoxib </e1> vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .
NO_RELATION	Gastrointestinal tolerability of etoricoxib in <e2> rheumatoid arthritis </e2> patients : results of the etoricoxib vs <e1> diclofenac sodium </e1> gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .
NO_RELATION	OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of <e1> etoricoxib </e1> and diclofenac in patients with <e2> rheumatoid arthritis </e2> ( RA ) .
NO_RELATION	OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of <e1> etoricoxib </e1> and diclofenac in patients with rheumatoid arthritis ( <e2> RA </e2> ) .
NO_RELATION	OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and <e1> diclofenac </e1> in patients with <e2> rheumatoid arthritis </e2> ( RA ) .
NO_RELATION	OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and <e1> diclofenac </e1> in patients with rheumatoid arthritis ( <e2> RA </e2> ) .
NO_RELATION	PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with <e2> RA </e2> were enrolled and received <e1> etoricoxib </e1> 90 mg daily ( n = 2032 ) or diclofenac 75 mg twice daily ( n = 2054 ) .
NO_RELATION	PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with <e2> RA </e2> were enrolled and received etoricoxib 90 mg daily ( n = 2032 ) or <e1> diclofenac </e1> 75 mg twice daily ( n = 2054 ) .
NO_RELATION	The cumulative discontinuation rate due to <e2> GI AEs </e2> was significantly lower with <e1> etoricoxib </e1> than diclofenac ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .
CID	The cumulative discontinuation rate due to <e2> GI AEs </e2> was significantly lower with etoricoxib than <e1> diclofenac </e1> ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .
CID	The incidence of discontinuations for <e2> hypertension </e2> - related and oedema - related AEs were significantly higher with <e1> etoricoxib </e1> ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .
CID	The incidence of discontinuations for hypertension - related and <e2> oedema </e2> - related AEs were significantly higher with <e1> etoricoxib </e1> ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .
CID	The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with <e1> etoricoxib </e1> ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for <e2> hypertension </e2> and p < 0 . 01 for oedema ) .
CID	The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with <e1> etoricoxib </e1> ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for <e2> oedema </e2> ) .
NO_RELATION	The incidence of discontinuations for <e2> hypertension </e2> - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with <e1> diclofenac </e1> ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .
NO_RELATION	The incidence of discontinuations for hypertension - related and <e2> oedema </e2> - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with <e1> diclofenac </e1> ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .
NO_RELATION	The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with <e1> diclofenac </e1> ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for <e2> hypertension </e2> and p < 0 . 01 for oedema ) .
NO_RELATION	The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with <e1> diclofenac </e1> ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for <e2> oedema </e2> ) .
NO_RELATION	CONCLUSIONS : <e1> Etoricoxib </e1> 90 mg demonstrated a significantly lower risk for discontinuing treatment due to <e2> GI AEs </e2> compared with diclofenac 150 mg .
CID	CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to <e2> GI AEs </e2> compared with <e1> diclofenac </e1> 150 mg .
NO_RELATION	Discontinuations from renovascular AEs , although less common than discontinuations from <e2> GI AEs </e2> , were significantly higher with <e1> etoricoxib </e1> .
NO_RELATION	Placebo - level incidence of <e2> extrapyramidal symptoms </e2> ( EPS ) with <e1> quetiapine </e1> in controlled studies of patients with bipolar mania .
NO_RELATION	Placebo - level incidence of extrapyramidal symptoms ( <e2> EPS </e2> ) with <e1> quetiapine </e1> in controlled studies of patients with bipolar mania .
NO_RELATION	Placebo - level incidence of extrapyramidal symptoms ( EPS ) with <e1> quetiapine </e1> in controlled studies of patients with <e2> bipolar mania </e2> .
NO_RELATION	OBJECTIVES : To evaluate <e2> extrapyramidal symptoms </e2> ( EPS ) , including akathisia , with <e1> quetiapine </e1> in patients with bipolar mania .
NO_RELATION	OBJECTIVES : To evaluate extrapyramidal symptoms ( <e2> EPS </e2> ) , including akathisia , with <e1> quetiapine </e1> in patients with bipolar mania .
NO_RELATION	OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including <e2> akathisia </e2> , with <e1> quetiapine </e1> in patients with bipolar mania .
NO_RELATION	OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with <e1> quetiapine </e1> in patients with <e2> bipolar mania </e2> .
NO_RELATION	RESULTS : The incidence of <e2> EPS </e2> - related adverse events , including akathisia , was no different with <e1> quetiapine </e1> monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .
NO_RELATION	RESULTS : The incidence of EPS - related adverse events , including <e2> akathisia </e2> , was no different with <e1> quetiapine </e1> monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .
NO_RELATION	Similarly , <e2> EPS </e2> - related adverse events with <e1> QTP </e1> + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .
CID	Similarly , <e2> EPS </e2> - related adverse events with QTP + <e1> Li </e1> / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .
NO_RELATION	Similarly , <e2> EPS </e2> - related adverse events with QTP + Li / <e1> DVP </e1> ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .
CID	Similarly , <e2> EPS </e2> - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + <e1> Li </e1> / DVP ( 19 . 2 % ) .
NO_RELATION	Similarly , <e2> EPS </e2> - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / <e1> DVP </e1> ( 19 . 2 % ) .
CID	Adverse events related to <e2> EPS </e2> occurred in 59 . 6 % of patients treated with <e1> haloperidol </e1> ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .
CID	Adverse events related to EPS occurred in 59 . 6 % of patients treated with <e1> haloperidol </e1> ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to <e2> EPS </e2> .
CID	Adverse events related to <e2> EPS </e2> occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with <e1> lithium </e1> ( n = 98 ) monotherapy experienced adverse events related to EPS .
CID	Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with <e1> lithium </e1> ( n = 98 ) monotherapy experienced adverse events related to <e2> EPS </e2> .
NO_RELATION	The incidence of <e2> akathisia </e2> was low and similar with <e1> quetiapine </e1> monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .
NO_RELATION	The incidence of <e2> akathisia </e2> was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with <e1> QTP </e1> + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .
NO_RELATION	The incidence of <e2> akathisia </e2> was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + <e1> Li </e1> / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .
NO_RELATION	The incidence of <e2> akathisia </e2> was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / <e1> DVP </e1> ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .
NO_RELATION	The incidence of <e2> akathisia </e2> was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + <e1> Li </e1> / DVP ( 4 . 9 % ) .
NO_RELATION	The incidence of <e2> akathisia </e2> was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / <e1> DVP </e1> ( 4 . 9 % ) .
CID	<e1> Lithium </e1> was associated with a significantly higher incidence ( p < 0 . 05 ) of <e2> tremor </e2> ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .
CID	<e1> Lithium </e1> was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar <e2> tremor </e2> , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .
CID	<e1> Lithium </e1> was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of <e2> tremor </e2> in patients receiving lithium therapy .
NO_RELATION	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of <e2> tremor </e2> ( 18 . 4 % ) than <e1> quetiapine </e1> ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .
NO_RELATION	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than <e1> quetiapine </e1> ( 5 . 6 % ) ; cerebellar <e2> tremor </e2> , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .
NO_RELATION	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than <e1> quetiapine </e1> ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of <e2> tremor </e2> in patients receiving lithium therapy .
CID	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of <e2> tremor </e2> ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of <e1> lithium </e1> , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .
CID	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar <e2> tremor </e2> , which is a known adverse effect of <e1> lithium </e1> , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .
CID	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of <e1> lithium </e1> , may have contributed to the elevated rate of <e2> tremor </e2> in patients receiving lithium therapy .
CID	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of <e2> tremor </e2> ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving <e1> lithium </e1> therapy .
CID	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar <e2> tremor </e2> , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving <e1> lithium </e1> therapy .
CID	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of <e2> tremor </e2> in patients receiving <e1> lithium </e1> therapy .
CID	<e1> Haloperidol </e1> induced a significantly higher incidence ( p < 0 . 001 ) of <e2> akathisia </e2> ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .
CID	<e1> Haloperidol </e1> induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , <e2> tremor </e2> ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .
CID	<e1> Haloperidol </e1> induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and <e2> extrapyramidal syndrome </e2> ( 35 . 4 % versus 5 . 9 % ) than quetiapine .
NO_RELATION	Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of <e2> akathisia </e2> ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than <e1> quetiapine </e1> .
NO_RELATION	Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , <e2> tremor </e2> ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than <e1> quetiapine </e1> .
NO_RELATION	Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and <e2> extrapyramidal syndrome </e2> ( 35 . 4 % versus 5 . 9 % ) than <e1> quetiapine </e1> .
NO_RELATION	CONCLUSIONS : In <e2> bipolar mania </e2> , the incidence of EPS , including akathisia , with <e1> quetiapine </e1> therapy is similar to that with placebo .
NO_RELATION	CONCLUSIONS : In bipolar mania , the incidence of <e2> EPS </e2> , including akathisia , with <e1> quetiapine </e1> therapy is similar to that with placebo .
NO_RELATION	CONCLUSIONS : In bipolar mania , the incidence of EPS , including <e2> akathisia </e2> , with <e1> quetiapine </e1> therapy is similar to that with placebo .
NO_RELATION	Contribution of the sympathetic nervous system to salt - sensitivity in lifetime <e1> captopril </e1> - treated spontaneously <e2> hypertensive </e2> rats .
NO_RELATION	OBJECTIVE : To test the hypothesis that , in lifetime <e1> captopril </e1> - treated spontaneously <e2> hypertensive </e2> rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation .
NO_RELATION	OBJECTIVE : To test the hypothesis that , in lifetime <e1> captopril </e1> - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the <e2> hypertensive </e2> effect of dietary sodium chloride supplementation .
CID	OBJECTIVE : To test the hypothesis that , in lifetime captopril - treated spontaneously <e2> hypertensive </e2> rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of <e1> dietary sodium chloride </e1> supplementation .
CID	OBJECTIVE : To test the hypothesis that , in lifetime captopril - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the <e2> hypertensive </e2> effect of <e1> dietary sodium chloride </e1> supplementation .
NO_RELATION	Intravenous infusion of the ganglionic blocker <e1> hexamethonium </e1> resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced <e2> increase in MAP </e2> in both groups .
CID	Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the <e1> dietary sodium chloride </e1> - induced <e2> increase in MAP </e2> in both groups .
NO_RELATION	Dose - related beneficial and adverse effects of dietary <e1> corticosterone </e1> on organophosphorus - induced delayed <e2> neuropathy </e2> in chickens .
NO_RELATION	Dose - related beneficial and adverse effects of dietary corticosterone on <e1> organophosphorus </e1> - induced delayed <e2> neuropathy </e2> in chickens .
NO_RELATION	Although low concentrations ( less than or equal to 50 ppm ) of <e1> corticosterone </e1> had beneficial effects on TOTP - induced <e2> neuropathy </e2> , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .
CID	Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on <e1> TOTP </e1> - induced <e2> neuropathy </e2> , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .
CID	Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced <e2> neuropathy </e2> , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either <e1> TOTP </e1> or DFP .
CID	Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced <e2> neuropathy </e2> , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or <e1> DFP </e1> .
NO_RELATION	<e2> Neurotoxic </e2> esterase activities 24 hr after <e1> TOTP </e1> or DFP were less than 20 % of values measured in chickens not given organophosphorous compounds .
NO_RELATION	<e2> Neurotoxic </e2> esterase activities 24 hr after TOTP or <e1> DFP </e1> were less than 20 % of values measured in chickens not given organophosphorous compounds .
NO_RELATION	<e2> Neurotoxic </e2> esterase activities 24 hr after TOTP or DFP were less than 20 % of values measured in chickens not given <e1> organophosphorous </e1> compounds .
CID	<e2> Degenerating myelinated fibers </e2> were also evident in distal levels of the peripheral nerves of chickens given <e1> TOTP </e1> or DFP .
CID	<e2> Degenerating myelinated fibers </e2> were also evident in distal levels of the peripheral nerves of chickens given TOTP or <e1> DFP </e1> .
NO_RELATION	In vivo characterization of a dual <e1> adenosine A2A / A1 receptor antagonist </e1> in animal models of <e2> Parkinson ' s disease </e2> .
NO_RELATION	The in vivo characterization of a dual <e1> adenosine A ( 2A ) / A ( 1 ) receptor antagonist </e1> in several animal models of <e2> Parkinson ' s disease </e2> is described .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of <e2> Parkinson ' s disease </e2> including mouse and rat models of <e1> haloperidol </e1> - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
CID	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of <e1> haloperidol </e1> - induced <e2> catalepsy </e2> , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of <e1> haloperidol </e1> - induced catalepsy , mouse model of reserpine - induced <e2> akinesia </e2> , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of <e2> Parkinson ' s disease </e2> including mouse and rat models of haloperidol - induced catalepsy , mouse model of <e1> reserpine </e1> - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced <e2> catalepsy </e2> , mouse model of <e1> reserpine </e1> - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
CID	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of <e1> reserpine </e1> - induced <e2> akinesia </e2> , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of <e2> Parkinson ' s disease </e2> including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat <e1> 6 - hydroxydopamine </e1> ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced <e2> catalepsy </e2> , mouse model of reserpine - induced akinesia , rat <e1> 6 - hydroxydopamine </e1> ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced <e2> akinesia </e2> , rat <e1> 6 - hydroxydopamine </e1> ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of <e2> Parkinson ' s disease </e2> including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( <e1> 6 - OHDA </e1> ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced <e2> catalepsy </e2> , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( <e1> 6 - OHDA </e1> ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced <e2> akinesia </e2> , rat 6 - hydroxydopamine ( <e1> 6 - OHDA </e1> ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of <e2> Parkinson ' s disease </e2> including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and <e1> MPTP </e1> - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced <e2> catalepsy </e2> , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and <e1> MPTP </e1> - treated non - human primate model .
NO_RELATION	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced <e2> akinesia </e2> , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and <e1> MPTP </e1> - treated non - human primate model .
CID	An extremely rare case of <e2> delusional parasitosis </e2> in a chronic hepatitis C patient during <e1> pegylated interferon alpha - 2b </e1> and ribavirin treatment .
NO_RELATION	An extremely rare case of delusional parasitosis in a <e2> chronic hepatitis C </e2> patient during <e1> pegylated interferon alpha - 2b </e1> and ribavirin treatment .
CID	An extremely rare case of <e2> delusional parasitosis </e2> in a chronic hepatitis C patient during pegylated interferon alpha - 2b and <e1> ribavirin </e1> treatment .
NO_RELATION	An extremely rare case of delusional parasitosis in a <e2> chronic hepatitis C </e2> patient during pegylated interferon alpha - 2b and <e1> ribavirin </e1> treatment .
NO_RELATION	During treatment of <e2> chronic hepatitis C </e2> patients with interferon and <e1> ribavirin </e1> , a lot of side effects are described .
CID	We present a 49 - year - old woman who developed a <e2> delusional parasitosis </e2> during treatment with <e1> pegylated interferon alpha - 2b </e1> weekly and ribavirin .
CID	We present a 49 - year - old woman who developed a <e2> delusional parasitosis </e2> during treatment with pegylated interferon alpha - 2b weekly and <e1> ribavirin </e1> .
CID	Possible <e2> neuroleptic malignant syndrome </e2> related to concomitant treatment with <e1> paroxetine </e1> and alprazolam .
CID	Possible <e2> neuroleptic malignant syndrome </e2> related to concomitant treatment with paroxetine and <e1> alprazolam </e1> .
NO_RELATION	On the 10th day of <e1> paroxetine </e1> and alprazolam treatment , the patient exhibited marked <e2> psychomotor retardation </e2> , disorientation , and severe muscle rigidity with tremors .
NO_RELATION	On the 10th day of <e1> paroxetine </e1> and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe <e2> muscle rigidity </e2> with tremors .
NO_RELATION	On the 10th day of <e1> paroxetine </e1> and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with <e2> tremors </e2> .
NO_RELATION	On the 10th day of paroxetine and <e1> alprazolam </e1> treatment , the patient exhibited marked <e2> psychomotor retardation </e2> , disorientation , and severe muscle rigidity with tremors .
NO_RELATION	On the 10th day of paroxetine and <e1> alprazolam </e1> treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe <e2> muscle rigidity </e2> with tremors .
NO_RELATION	On the 10th day of paroxetine and <e1> alprazolam </e1> treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with <e2> tremors </e2> .
CID	This patient presented with symptoms of <e2> neuroleptic malignant syndrome </e2> ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined <e1> paroxetine </e1> and alprazolam treatment .
CID	This patient presented with symptoms of neuroleptic malignant syndrome ( <e2> NMS </e2> ) , thus demonstrating that NMS - like symptoms can occur after combined <e1> paroxetine </e1> and alprazolam treatment .
CID	This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that <e2> NMS </e2> - like symptoms can occur after combined <e1> paroxetine </e1> and alprazolam treatment .
CID	This patient presented with symptoms of <e2> neuroleptic malignant syndrome </e2> ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and <e1> alprazolam </e1> treatment .
CID	This patient presented with symptoms of neuroleptic malignant syndrome ( <e2> NMS </e2> ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and <e1> alprazolam </e1> treatment .
CID	This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that <e2> NMS </e2> - like symptoms can occur after combined paroxetine and <e1> alprazolam </e1> treatment .
NO_RELATION	<e1> Pilocarpine </e1> <e2> seizures </e2> cause age - dependent impairment in auditory location discrimination .
CID	<e1> Pilocarpine </e1> seizures cause age - dependent <e2> impairment in auditory location discrimination </e2> .
CID	<e1> Pilocarpine </e1> on either day induced <e2> status epilepticus </e2> ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .
CID	<e1> Pilocarpine </e1> on either day induced status epilepticus ; <e2> status epilepticus </e2> at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .
NO_RELATION	<e1> Pilocarpine </e1> on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous <e2> seizures </e2> , whereas P20 rats had no cell loss or spontaneous seizures .
NO_RELATION	<e1> Pilocarpine </e1> on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous <e2> seizures </e2> .
CID	Randomised clinical trials and observational studies have shown an increased risk of <e2> myocardial infarction </e2> , stroke , hypertension and heart failure during treatment with <e1> cyclooxygenase inhibitors </e1> .
CID	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , <e2> stroke </e2> , hypertension and heart failure during treatment with <e1> cyclooxygenase inhibitors </e1> .
CID	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , <e2> hypertension </e2> and heart failure during treatment with <e1> cyclooxygenase inhibitors </e1> .
CID	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , hypertension and <e2> heart failure </e2> during treatment with <e1> cyclooxygenase inhibitors </e1> .
NO_RELATION	Diagnostic markers such as <e1> N - terminal pro brain natriuretic peptide </e1> ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious <e2> cardiovascular toxicity </e2> .
NO_RELATION	Diagnostic markers such as N - terminal pro brain natriuretic peptide ( <e1> NT - proBNP </e1> ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious <e2> cardiovascular toxicity </e2> .
NO_RELATION	Predictors of <e2> decreased renal function </e2> in patients with heart failure during <e1> angiotensin </e1> - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with <e2> heart failure </e2> during <e1> angiotensin </e1> - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with heart failure during <e1> angiotensin </e1> - converting enzyme inhibitor therapy : results from the studies of <e2> left ventricular dysfunction </e2> ( SOLVD ) BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with heart failure during <e1> angiotensin </e1> - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with <e2> congestive heart failure </e2> ( CHF ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with heart failure during <e1> angiotensin </e1> - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( <e2> CHF </e2> ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with heart failure during <e1> angiotensin </e1> - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause <e2> decreased renal function </e2> .
NO_RELATION	Predictors of <e2> decreased renal function </e2> in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although <e1> angiotensin </e1> - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with <e2> heart failure </e2> during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although <e1> angiotensin </e1> - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of <e2> left ventricular dysfunction </e2> ( SOLVD ) BACKGROUND : Although <e1> angiotensin </e1> - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although <e1> angiotensin </e1> - converting enzyme inhibitor therapy reduces mortality rates in patients with <e2> congestive heart failure </e2> ( CHF ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although <e1> angiotensin </e1> - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( <e2> CHF </e2> ) , it may also cause decreased renal function .
NO_RELATION	Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ) BACKGROUND : Although <e1> angiotensin </e1> - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause <e2> decreased renal function </e2> .
NO_RELATION	OBJECTIVE : To quantify specific clinical predictors of <e2> reduction in renal function </e2> in patients with CHF who are prescribed <e1> angiotensin </e1> - converting enzyme inhibitor therapy .
NO_RELATION	OBJECTIVE : To quantify specific clinical predictors of reduction in renal function in patients with <e2> CHF </e2> who are prescribed <e1> angiotensin </e1> - converting enzyme inhibitor therapy .
NO_RELATION	METHOD : We analyzed data from the Studies of <e2> Left Ventricular Dysfunction </e2> ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of <e1> enalapril </e1> for the treatment of CHF .
NO_RELATION	METHOD : We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of <e1> enalapril </e1> for the treatment of <e2> CHF </e2> .
NO_RELATION	<e2> Decreased renal function </e2> was defined as a rise in serum <e1> creatinine </e1> > / = 0 . 5 mg / dL ( 44 micromol / L ) from baseline .
NO_RELATION	We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline <e1> creatinine </e1> , low systolic blood pressure ( < 100 mm Hg ) , history of <e2> hypertension </e2> , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .
NO_RELATION	We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline <e1> creatinine </e1> , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , <e2> diabetes </e2> , and use of antiplatelet , diuretic , and beta - blocker therapy .
NO_RELATION	We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of <e2> hypertension </e2> , diabetes , and use of antiplatelet , <e1> diuretic </e1> , and beta - blocker therapy .
NO_RELATION	We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , <e2> diabetes </e2> , and use of antiplatelet , <e1> diuretic </e1> , and beta - blocker therapy .
CID	RESULTS : Patients randomly assigned to <e1> enalapril </e1> had a 33 % greater likelihood of <e2> decreased renal function </e2> than controls ( P = . 003 ) .
NO_RELATION	By multivariate analysis , in both the placebo and <e1> enalapril </e1> groups older age , diuretic therapy , and <e2> diabetes </e2> were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .
CID	By multivariate analysis , in both the placebo and <e1> enalapril </e1> groups older age , diuretic therapy , and diabetes were associated with <e2> decreased renal function </e2> , whereas beta - blocker therapy and higher ejection fraction were renoprotective .
NO_RELATION	By multivariate analysis , in both the placebo and enalapril groups older age , <e1> diuretic </e1> therapy , and <e2> diabetes </e2> were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .
CID	By multivariate analysis , in both the placebo and enalapril groups older age , <e1> diuretic </e1> therapy , and diabetes were associated with <e2> decreased renal function </e2> , whereas beta - blocker therapy and higher ejection fraction were renoprotective .
CID	Older age was associated with a greater risk of developing <e2> decreased renal function </e2> in both groups , but significantly more so in the <e1> enalapril </e1> group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .
CID	Older age was associated with a greater risk of developing <e2> decreased renal function </e2> in both groups , but significantly more so in the enalapril group ( <e1> enalapril </e1> : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .
CID	Older age was associated with a greater risk of developing <e2> decreased renal function </e2> in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with <e1> enalapril </e1> ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .
CID	<e1> Diuretic </e1> therapy was likewise associated with a greater risk of <e2> decreased renal function </e2> in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .
CID	Diuretic therapy was likewise associated with a greater risk of <e2> decreased renal function </e2> in the <e1> enalapril </e1> group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .
NO_RELATION	Conversely , <e1> enalapril </e1> had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with <e2> diabetes </e2> .
CID	CONCLUSIONS : <e1> Enalapril </e1> use caused a 33 % increase in the risk of <e2> decreased renal function </e2> in patients with CHF .
NO_RELATION	CONCLUSIONS : <e1> Enalapril </e1> use caused a 33 % increase in the risk of decreased renal function in patients with <e2> CHF </e2> .
NO_RELATION	<e2> Diabetes </e2> was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the <e1> enalapril </e1> group compared with the placebo group .
CID	Diabetes was associated with an increased risk of <e2> renal impairment </e2> in all patients with CHF , but this risk was reduced in the <e1> enalapril </e1> group compared with the placebo group .
NO_RELATION	Diabetes was associated with an increased risk of renal impairment in all patients with <e2> CHF </e2> , but this risk was reduced in the <e1> enalapril </e1> group compared with the placebo group .
NO_RELATION	<e1> Pemoline </e1> induced acute <e2> choreoathetosis </e2> : case report and review of the literature .
NO_RELATION	BACKGROUND : <e1> Pemoline </e1> is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of <e2> attention deficit disorder </e2> .
NO_RELATION	BACKGROUND : Pemoline is an <e1> oxazolidine </e1> derivative that is structurally different from amphetamines and used in the treatment of <e2> attention deficit disorder </e2> .
NO_RELATION	BACKGROUND : Pemoline is an oxazolidine derivative that is structurally different from <e1> amphetamines </e1> and used in the treatment of <e2> attention deficit disorder </e2> .
NO_RELATION	<e1> Pemoline </e1> has not been commonly associated in the literature as a cause of acute <e2> movement disorders </e2> .
NO_RELATION	The following case describes two children acutely poisoned with <e1> pemoline </e1> who experienced profound <e2> choreoathetosis </e2> .
NO_RELATION	The children had a medical history significant for <e2> attention deficit disorder </e2> previously treated with <e1> methylphenidate </e1> without success .
NO_RELATION	The children received gastrointestinal decontamination and high doses of intravenous <e1> benzodiazepines </e1> in an attempt to control the <e2> choreoathetoid </e2> movements .
NO_RELATION	CONCLUSION : <e1> Pemoline </e1> associated <e2> movement disorder </e2> has been rarely reported in the acute toxicology literature .
NO_RELATION	The possibility of <e2> choreoathetoid </e2> movements should be considered in patients presenting after <e1> pemoline </e1> overdose .
CID	The possibility of choreoathetoid movements should be considered in patients presenting after <e1> pemoline </e1> <e2> overdose </e2> .
NO_RELATION	Continuous subcutaneous administration of <e1> mesna </e1> to prevent ifosfamide - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	Continuous subcutaneous administration of mesna to prevent <e1> ifosfamide </e1> - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	<e2> Hemorrhagic cystitis </e2> is a major potential toxicity of <e1> ifosfamide </e1> that can be prevented by administering mesna along with the cytotoxic agent .
NO_RELATION	Hemorrhagic cystitis is a major potential <e2> toxicity </e2> of <e1> ifosfamide </e1> that can be prevented by administering mesna along with the cytotoxic agent .
NO_RELATION	<e2> Hemorrhagic cystitis </e2> is a major potential toxicity of ifosfamide that can be prevented by administering <e1> mesna </e1> along with the cytotoxic agent .
NO_RELATION	Hemorrhagic cystitis is a major potential <e2> toxicity </e2> of ifosfamide that can be prevented by administering <e1> mesna </e1> along with the cytotoxic agent .
NO_RELATION	In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary <e1> mesna </e1> concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced <e2> emesis </e2> and is unable to absorb the drug .
NO_RELATION	In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral <e1> mesna </e1> who experiences severe ifosfamide - induced <e2> emesis </e2> and is unable to absorb the drug .
NO_RELATION	In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe <e1> ifosfamide </e1> - induced <e2> emesis </e2> and is unable to absorb the drug .
CID	Pretreatment with <e1> ammonium acetate </e1> ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular <e2> incoordination </e2> by diazepam , but NH4Ac treatment alone had no effect .
CID	Pretreatment with ammonium acetate ( <e1> NH4Ac </e1> ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular <e2> incoordination </e2> by diazepam , but NH4Ac treatment alone had no effect .
NO_RELATION	Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time <e1> morphine </e1> - treated mice remained on a hot surface and similarly increased muscular <e2> incoordination </e2> by diazepam , but NH4Ac treatment alone had no effect .
CID	Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular <e2> incoordination </e2> by <e1> diazepam </e1> , but NH4Ac treatment alone had no effect .
CID	Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular <e2> incoordination </e2> by diazepam , but <e1> NH4Ac </e1> treatment alone had no effect .
NO_RELATION	Addition of excess <e1> calcium </e1> reversed the <e2> depression </e2> in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .
NO_RELATION	Addition of excess calcium reversed the <e2> depression </e2> in both tissues , but <e1> calcium </e1> - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .
NO_RELATION	Addition of excess calcium reversed the <e2> depression </e2> in both tissues , but calcium - independent <e1> catecholamine </e1> release by acetaldehyde was not blocked by NH4Ac .
NO_RELATION	Addition of excess calcium reversed the <e2> depression </e2> in both tissues , but calcium - independent catecholamine release by <e1> acetaldehyde </e1> was not blocked by NH4Ac .
NO_RELATION	Addition of excess calcium reversed the <e2> depression </e2> in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by <e1> NH4Ac </e1> .
NO_RELATION	Both <e1> verapamil </e1> ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine <e2> analgesia </e2> - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both <e1> verapamil </e1> ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular <e2> incoordination </e2> and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and <e1> NH4Ac </e1> pretreatment enhanced morphine <e2> analgesia </e2> - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
CID	Both verapamil ( 10 mg / kg i . p . ) and <e1> NH4Ac </e1> pretreatment enhanced morphine analgesia - and diazepam - induced muscular <e2> incoordination </e2> and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced <e1> morphine </e1> <e2> analgesia </e2> - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced <e1> morphine </e1> analgesia - and diazepam - induced muscular <e2> incoordination </e2> and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine <e2> analgesia </e2> - and <e1> diazepam </e1> - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
CID	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and <e1> diazepam </e1> - induced muscular <e2> incoordination </e2> and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine <e2> analgesia </e2> - and diazepam - induced muscular incoordination and antagonized <e1> amphetamine </e1> - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular <e2> incoordination </e2> and antagonized <e1> amphetamine </e1> - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine <e2> analgesia </e2> - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither <e1> verapamil </e1> nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular <e2> incoordination </e2> and antagonized amphetamine - induced motor activity , and neither <e1> verapamil </e1> nor NH4Ac affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine <e2> analgesia </e2> - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor <e1> NH4Ac </e1> affected the convulsant action of metrazol .
CID	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular <e2> incoordination </e2> and antagonized amphetamine - induced motor activity , and neither verapamil nor <e1> NH4Ac </e1> affected the convulsant action of metrazol .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine <e2> analgesia </e2> - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of <e1> metrazol </e1> .
NO_RELATION	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular <e2> incoordination </e2> and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of <e1> metrazol </e1> .
NO_RELATION	The data suggest that <e2> hyperammonemia </e2> exerts a <e1> calcium </e1> channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .
CID	Risk of <e2> nephropathy </e2> after consumption of nonionic <e1> contrast media </e1> by children undergoing cardiac angiography : a prospective study .
CID	Despite increasing reports on nonionic <e1> contrast media </e1> - induced <e2> nephropathy </e2> ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .
CID	Despite increasing reports on nonionic <e1> contrast media </e1> - induced nephropathy ( <e2> CIN </e2> ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .
CID	This prospective study determined the incidence of <e2> CIN </e2> for two nonionic <e1> contrast media </e1> ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .
NO_RELATION	This prospective study determined the incidence of CIN for two nonionic <e1> contrast media </e1> ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2> cyanosis </e2> .
CID	This prospective study determined the incidence of <e2> CIN </e2> for two nonionic contrast media ( <e1> CM </e1> ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .
NO_RELATION	This prospective study determined the incidence of CIN for two nonionic contrast media ( <e1> CM </e1> ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2> cyanosis </e2> .
CID	This prospective study determined the incidence of <e2> CIN </e2> for two nonionic contrast media ( CM ) , <e1> iopromide </e1> and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .
NO_RELATION	This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , <e1> iopromide </e1> and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2> cyanosis </e2> .
CID	This prospective study determined the incidence of <e2> CIN </e2> for two nonionic contrast media ( CM ) , iopromide and <e1> iohexol </e1> , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .
NO_RELATION	This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and <e1> iohexol </e1> , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of <e2> cyanosis </e2> .
CID	This prospective study determined the incidence of <e2> CIN </e2> for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of <e1> CM </e1> and the presence of cyanosis .
NO_RELATION	This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of <e1> CM </e1> and the presence of <e2> cyanosis </e2> .
CID	Whereas 33 . 3 % of the patients with <e2> CIN </e2> were among those who received the proper dosage of <e1> CM </e1> , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of CM ( p = 0 . 014 ) .
CID	Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of <e1> CM </e1> , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of <e2> CIN </e2> related to the different dosages of CM ( p = 0 . 014 ) .
CID	Whereas 33 . 3 % of the patients with <e2> CIN </e2> were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of <e1> CM </e1> ( p = 0 . 014 ) .
CID	Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of <e2> CIN </e2> related to the different dosages of <e1> CM </e1> ( p = 0 . 014 ) .
NO_RELATION	The incidence depends on dosage but not on the type of consumed nonionic <e1> CM </e1> , nor on the presence of <e2> cyanosis </e2> , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .
CID	The incidence depends on dosage but not on the type of consumed nonionic <e1> CM </e1> , nor on the presence of cyanosis , and although <e2> CIN </e2> usually is reversible , more concern is needed for the prevention of such a complication in children .
CID	A case of <e2> ventricular tachycardia </e2> related to <e1> caffeine </e1> pretreatment .
CID	Intravenous <e1> caffeine </e1> is commonly used to improve <e2> seizure </e2> duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy .
CID	Intravenous <e1> caffeine </e1> is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign <e2> ventricular ectopy </e2> .
NO_RELATION	We describe a patient with no previous history of <e2> cardiac disease </e2> or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after <e1> caffeine </e1> administration .
NO_RELATION	We describe a patient with no previous history of cardiac disease or <e2> arrhythmia </e2> who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after <e1> caffeine </e1> administration .
CID	We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of <e2> ventricular tachycardia </e2> after <e1> caffeine </e1> administration .
NO_RELATION	Although intravenous <e1> caffeine </e1> is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious <e2> ventricular arrhythmias </e2> .
CID	Optical coherence tomography can measure axonal loss in patients with <e1> ethambutol </e1> - induced <e2> optic neuropathy </e2> .
NO_RELATION	PURPOSE : To map and identify the pattern , in vivo , of <e2> axonal degeneration </e2> in <e1> ethambutol </e1> - induced optic neuropathy using optical coherence tomography ( OCT ) .
CID	PURPOSE : To map and identify the pattern , in vivo , of axonal degeneration in <e1> ethambutol </e1> - induced <e2> optic neuropathy </e2> using optical coherence tomography ( OCT ) .
NO_RELATION	<e1> Ethambutol </e1> is an antimycobacterial agent often used to treat <e2> tuberculosis </e2> .
CID	A serious complication of <e1> ethambutol </e1> is an <e2> optic neuropathy </e2> that impairs visual acuity , contrast sensitivity , and color vision .
CID	METHODS : Three subjects with a history of <e1> ethambutol </e1> ( EMB ) - induced <e2> optic neuropathy </e2> of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .
CID	METHODS : Three subjects with a history of <e1> ethambutol </e1> ( EMB ) - induced optic neuropathy of short - , intermediate - , and long - term <e2> visual deficits </e2> were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .
CID	METHODS : Three subjects with a history of ethambutol ( <e1> EMB </e1> ) - induced <e2> optic neuropathy </e2> of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .
CID	METHODS : Three subjects with a history of ethambutol ( <e1> EMB </e1> ) - induced optic neuropathy of short - , intermediate - , and long - term <e2> visual deficits </e2> were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .
CID	In all subjects with history of <e1> EMB </e1> - induced <e2> optic neuropathy </e2> , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .
CID	In all subjects with history of <e1> EMB </e1> - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate <e2> visual deficits </e2> , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .
CID	In all subjects with history of <e1> EMB </e1> - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic <e2> visual deficits </e2> , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .
CID	CONCLUSIONS : The OCT results in these patients with <e1> EMB </e1> - induced <e2> optic neuropathy </e2> show considerable loss especially of the temporal fibers .
CID	Additionally , in terms of management of <e1> EMB </e1> - induced <e2> optic neuropathy </e2> , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .
NO_RELATION	Additionally , in terms of management of <e1> EMB </e1> - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with <e2> renal impairment </e2> and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .
CID	Additionally , in terms of management of EMB - induced <e2> optic neuropathy </e2> , it is important to properly manage <e1> ethambutol </e1> dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .
NO_RELATION	Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage <e1> ethambutol </e1> dosing in patients with <e2> renal impairment </e2> and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .
NO_RELATION	Effects of the cyclooxygenase - 2 specific inhibitor <e1> valdecoxib </e1> versus nonsteroidal antiinflammatory agents and placebo on cardiovascular <e2> thrombotic </e2> events in patients with arthritis .
NO_RELATION	Effects of the cyclooxygenase - 2 specific inhibitor <e1> valdecoxib </e1> versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with <e2> arthritis </e2> .
NO_RELATION	We evaluated cardiovascular event data for <e1> valdecoxib </e1> , a new COX - 2 - specific inhibitor in approximately 8000 patients with <e2> osteoarthritis </e2> and rheumatoid arthritis treated with this agent in randomized clinical trials .
NO_RELATION	We evaluated cardiovascular event data for <e1> valdecoxib </e1> , a new COX - 2 - specific inhibitor in approximately 8000 patients with osteoarthritis and <e2> rheumatoid arthritis </e2> treated with this agent in randomized clinical trials .
NO_RELATION	The incidence of cardiovascular <e2> thrombotic </e2> events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled <e1> valdecoxib </e1> ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial <e2> thrombotic </e2> ) was determined by analyzing pooled <e1> valdecoxib </e1> ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled <e1> valdecoxib </e1> ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized <e2> osteoarthritis </e2> and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled <e1> valdecoxib </e1> ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and <e2> rheumatoid arthritis </e2> trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular <e2> thrombotic </e2> events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( <e1> diclofenac </e1> 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial <e2> thrombotic </e2> ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( <e1> diclofenac </e1> 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( <e1> diclofenac </e1> 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized <e2> osteoarthritis </e2> and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( <e1> diclofenac </e1> 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and <e2> rheumatoid arthritis </e2> trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular <e2> thrombotic </e2> events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , <e1> ibuprofen </e1> 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial <e2> thrombotic </e2> ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , <e1> ibuprofen </e1> 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , <e1> ibuprofen </e1> 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized <e2> osteoarthritis </e2> and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , <e1> ibuprofen </e1> 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and <e2> rheumatoid arthritis </e2> trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular <e2> thrombotic </e2> events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or <e1> naproxen </e1> 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial <e2> thrombotic </e2> ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or <e1> naproxen </e1> 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or <e1> naproxen </e1> 500 mg bid ) and placebo data from 10 randomized <e2> osteoarthritis </e2> and rheumatoid arthritis trials that were 6 - 52 weeks in duration .
NO_RELATION	The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or <e1> naproxen </e1> 500 mg bid ) and placebo data from 10 randomized osteoarthritis and <e2> rheumatoid arthritis </e2> trials that were 6 - 52 weeks in duration .
NO_RELATION	Crude and exposure - adjusted incidences of <e2> thrombotic </e2> events were similar for <e1> valdecoxib </e1> , NSAIDs , and placebo .
NO_RELATION	The risk of serious <e2> thrombotic </e2> events was also similar for each <e1> valdecoxib </e1> dose .
CID	<e2> Thrombotic </e2> risk was consistently higher for users of <e1> aspirin </e1> users than nonusers of aspirin ( placebo , 1 . 4 % vs .
CID	<e2> Thrombotic </e2> risk was consistently higher for users of aspirin users than nonusers of <e1> aspirin </e1> ( placebo , 1 . 4 % vs .
NO_RELATION	Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) <e1> valdecoxib </e1> doses was not associated with an increased incidence of <e2> thrombotic </e2> events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .
NO_RELATION	Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) <e1> valdecoxib </e1> doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in <e2> osteoarthritis </e2> and rheumatoid arthritis patients in controlled clinical trials .
NO_RELATION	Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) <e1> valdecoxib </e1> doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and <e2> rheumatoid arthritis </e2> patients in controlled clinical trials .
NO_RELATION	A randomized , placebo - controlled , crossover study of <e1> ephedrine </e1> for SSRI - induced female <e2> sexual dysfunction </e2> .
NO_RELATION	The objective of this study was to determine whether <e1> ephedrine </e1> , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced <e2> sexual dysfunction </e2> .
CID	Nineteen <e2> sexually dysfunctional </e2> women receiving either <e1> fluoxetine </e1> , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .
CID	Nineteen <e2> sexually dysfunctional </e2> women receiving either fluoxetine , <e1> sertraline </e1> , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .
CID	Nineteen <e2> sexually dysfunctional </e2> women receiving either fluoxetine , sertraline , or <e1> paroxetine </e1> participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .
NO_RELATION	Nineteen <e2> sexually dysfunctional </e2> women receiving either fluoxetine , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of <e1> ephedrine </e1> ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .
NO_RELATION	Potential therapeutic use of the selective <e1> dopamine </e1> D1 receptor agonist , A - 86929 : an acute study in <e2> parkinsonian </e2> levodopa - primed monkeys .
NO_RELATION	Potential therapeutic use of the selective dopamine D1 receptor agonist , <e1> A - 86929 </e1> : an acute study in <e2> parkinsonian </e2> levodopa - primed monkeys .
NO_RELATION	Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in <e2> parkinsonian </e2> <e1> levodopa </e1> - primed monkeys .
NO_RELATION	The clinical utility of <e1> dopamine </e1> ( DA ) D1 receptor agonists in the treatment of <e2> Parkinson ' s disease </e2> ( PD ) is still unclear .
NO_RELATION	The clinical utility of <e1> dopamine </e1> ( DA ) D1 receptor agonists in the treatment of Parkinson ' s disease ( <e2> PD </e2> ) is still unclear .
NO_RELATION	The clinical utility of dopamine ( <e1> DA </e1> ) D1 receptor agonists in the treatment of <e2> Parkinson ' s disease </e2> ( PD ) is still unclear .
NO_RELATION	The clinical utility of dopamine ( <e1> DA </e1> ) D1 receptor agonists in the treatment of Parkinson ' s disease ( <e2> PD </e2> ) is still unclear .
NO_RELATION	We therefore conducted the present acute dose - response study in four <e1> 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine </e1> ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four <e1> 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine </e1> ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( <e1> MPTP </e1> ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( <e1> MPTP </e1> ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
CID	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit <e1> levodopa </e1> - induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
CID	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit <e1> levodopa </e1> - induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of <e1> A - 86929 </e1> ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of <e1> A - 86929 </e1> ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( <e1> [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol </e1> ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( <e1> [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol </e1> ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced <e2> dyskinesias </e2> to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full <e1> DA </e1> D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and <e2> dyskinetic </e2> effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full <e1> DA </e1> D1 - like receptor agonist with an intermediate duration of action .
NO_RELATION	Acute administration of <e1> A - 86929 </e1> was as efficacious in alleviating MPTP - induced <e2> parkinsonism </e2> as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .
NO_RELATION	Acute administration of <e1> A - 86929 </e1> was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced <e2> dyskinesias </e2> in these animals than with either LY - 171555 or subsequent challenge of levodopa .
CID	Acute administration of A - 86929 was as efficacious in alleviating <e1> MPTP </e1> - induced <e2> parkinsonism </e2> as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .
NO_RELATION	Acute administration of A - 86929 was as efficacious in alleviating <e1> MPTP </e1> - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced <e2> dyskinesias </e2> in these animals than with either LY - 171555 or subsequent challenge of levodopa .
NO_RELATION	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced <e2> parkinsonism </e2> as <e1> levodopa </e1> and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .
CID	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as <e1> levodopa </e1> and LY - 171555 , but was less likely to reproduce the levodopa - induced <e2> dyskinesias </e2> in these animals than with either LY - 171555 or subsequent challenge of levodopa .
NO_RELATION	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced <e2> parkinsonism </e2> as levodopa and <e1> LY - 171555 </e1> , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .
NO_RELATION	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and <e1> LY - 171555 </e1> , but was less likely to reproduce the levodopa - induced <e2> dyskinesias </e2> in these animals than with either LY - 171555 or subsequent challenge of levodopa .
NO_RELATION	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced <e2> parkinsonism </e2> as levodopa and LY - 171555 , but was less likely to reproduce the <e1> levodopa </e1> - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .
CID	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the <e1> levodopa </e1> - induced <e2> dyskinesias </e2> in these animals than with either LY - 171555 or subsequent challenge of levodopa .
NO_RELATION	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced <e2> parkinsonism </e2> as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either <e1> LY - 171555 </e1> or subsequent challenge of levodopa .
NO_RELATION	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced <e2> dyskinesias </e2> in these animals than with either <e1> LY - 171555 </e1> or subsequent challenge of levodopa .
NO_RELATION	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced <e2> parkinsonism </e2> as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of <e1> levodopa </e1> .
CID	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced <e2> dyskinesias </e2> in these animals than with either LY - 171555 or subsequent challenge of <e1> levodopa </e1> .
NO_RELATION	Potent <e1> DA </e1> D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in <e2> PD </e2> and merit further attention .
NO_RELATION	Potent DA D1 receptor agents with an intermediate duration of efficacy such as <e1> A - 86929 </e1> ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in <e2> PD </e2> and merit further attention .
CID	A CD50 dose of local anesthetic ( causing <e2> convulsions </e2> in 50 % of mice ) was fatal in 90 % of <e1> bupivacaine </e1> - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .
CID	A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of <e1> bupivacaine </e1> - induced <e2> seizures </e2> , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .
CID	A CD50 dose of local anesthetic ( causing <e2> convulsions </e2> in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the <e1> chloroprocaine </e1> group , and in 6 % of the lidocaine group .
CID	A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced <e2> seizures </e2> , in 57 % of the <e1> chloroprocaine </e1> group , and in 6 % of the lidocaine group .
CID	A CD50 dose of local anesthetic ( causing <e2> convulsions </e2> in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the <e1> lidocaine </e1> group .
CID	A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced <e2> seizures </e2> , in 57 % of the chloroprocaine group , and in 6 % of the <e1> lidocaine </e1> group .
NO_RELATION	<e2> Myoclonic , atonic , and absence seizures </e2> following institution of <e1> carbamazepine </e1> therapy in children .
NO_RELATION	Five children , aged 3 to 11 years , treated with <e1> carbamazepine </e1> for <e2> epilepsy </e2> , had an acute aberrant reaction characterized by the onset of myoclonic , atypical absence and / or atonic ( minor motor ) seizures within a few days .
NO_RELATION	Five children , aged 3 to 11 years , treated with <e1> carbamazepine </e1> for epilepsy , had an acute aberrant reaction characterized by the onset of <e2> myoclonic , atypical absence and / or atonic ( minor motor ) seizures </e2> within a few days .
NO_RELATION	When the <e1> carbamazepine </e1> was discontinued , two of the children returned to their former state very quickly , two had the minor motor <e2> seizures </e2> resolve in 3 and 6 months , and one had the seizures persist .
NO_RELATION	When the <e1> carbamazepine </e1> was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the <e2> seizures </e2> persist .
NO_RELATION	<e1> Naloxone </e1> reversal of <e2> hypotension </e2> due to captopril overdose .
NO_RELATION	<e1> Naloxone </e1> reversal of hypotension due to captopril <e2> overdose </e2> .
NO_RELATION	Naloxone reversal of <e2> hypotension </e2> due to <e1> captopril </e1> overdose .
NO_RELATION	Naloxone reversal of hypotension due to <e1> captopril </e1> <e2> overdose </e2> .
NO_RELATION	The opioid antagonist <e1> naloxone </e1> has been shown to block or reverse the <e2> hypotensive </e2> actions of captopril .
NO_RELATION	The opioid antagonist naloxone has been shown to block or reverse the <e2> hypotensive </e2> actions of <e1> captopril </e1> .
NO_RELATION	We report a case of an intentional <e1> captopril </e1> <e2> overdose </e2> , manifested by marked hypotension , that resolved promptly with the administration of naloxone .
NO_RELATION	We report a case of an intentional <e1> captopril </e1> overdose , manifested by marked <e2> hypotension </e2> , that resolved promptly with the administration of naloxone .
NO_RELATION	We report a case of an intentional captopril <e2> overdose </e2> , manifested by marked hypotension , that resolved promptly with the administration of <e1> naloxone </e1> .
NO_RELATION	We report a case of an intentional captopril overdose , manifested by marked <e2> hypotension </e2> , that resolved promptly with the administration of <e1> naloxone </e1> .
NO_RELATION	To our knowledge , this is the first reported case of <e1> captopril </e1> - induced <e2> hypotension </e2> treated with naloxone .
NO_RELATION	To our knowledge , this is the first reported case of captopril - induced <e2> hypotension </e2> treated with <e1> naloxone </e1> .
NO_RELATION	Our experience demonstrates a possible role of <e1> naloxone </e1> in the reversal of <e2> hypotension </e2> resulting from captopril .
NO_RELATION	Our experience demonstrates a possible role of naloxone in the reversal of <e2> hypotension </e2> resulting from <e1> captopril </e1> .
NO_RELATION	<e1> Carbamazepine </e1> - induced <e2> cardiac dysfunction </e2> .
CID	A patient with sinus <e2> bradycardia </e2> and atrioventricular block , induced by <e1> carbamazepine </e1> , prompted an extensive literature review of all previously reported cases .
CID	A patient with sinus bradycardia and <e2> atrioventricular block </e2> , induced by <e1> carbamazepine </e1> , prompted an extensive literature review of all previously reported cases .
NO_RELATION	From the analysis of these cases , two distinct forms of <e1> carbamazepine </e1> - associated <e2> cardiac dysfunction </e2> emerged .
CID	One patient group developed <e2> sinus tachycardias </e2> in the setting of a massive <e1> carbamazepine </e1> overdose .
NO_RELATION	One patient group developed sinus tachycardias in the setting of a massive <e1> carbamazepine </e1> <e2> overdose </e2> .
CID	The second group consisted almost exclusively of elderly women who developed potentially life - threatening <e2> bradyarrhythmias </e2> or atrioventricular conduction delay , associated with either therapeutic or modestly elevated <e1> carbamazepine </e1> serum levels .
CID	The second group consisted almost exclusively of elderly women who developed potentially life - threatening bradyarrhythmias or <e2> atrioventricular conduction delay </e2> , associated with either therapeutic or modestly elevated <e1> carbamazepine </e1> serum levels .
NO_RELATION	Because <e1> carbamazepine </e1> is widely used in the treatment of many neurologic and <e2> psychiatric </e2> conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .
NO_RELATION	Glutamatergic neurotransmission mediated by <e1> NMDA </e1> receptors in the inferior colliculus can modulate haloperidol - induced <e2> catalepsy </e2> .
CID	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate <e1> haloperidol </e1> - induced <e2> catalepsy </e2> .
NO_RELATION	The present study examined the influence of excitatory <e1> amino acid </e1> - mediated mechanisms in the IC on the <e2> catalepsy </e2> induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .
NO_RELATION	The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the <e2> catalepsy </e2> induced by the <e1> dopamine </e1> receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .
CID	The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the <e2> catalepsy </e2> induced by the dopamine receptor blocker <e1> haloperidol </e1> administered systemically ( 1 or 0 . 5 mg / kg ) in rats .
CID	<e1> Haloperidol </e1> - induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
NO_RELATION	Haloperidol - induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of <e1> glutamate </e1> NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
NO_RELATION	Haloperidol - induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate <e1> NMDA </e1> receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
NO_RELATION	Haloperidol - induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , <e1> MK - 801 </e1> ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
NO_RELATION	Haloperidol - induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and <e1> AP7 </e1> ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
NO_RELATION	Haloperidol - induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the <e1> NMDA </e1> receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
NO_RELATION	Haloperidol - induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist <e1> N - methyl - d - aspartate </e1> ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
NO_RELATION	Haloperidol - induced <e2> catalepsy </e2> was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( <e1> NMDA </e1> , 20 or 30 nmol / 0 . 5 microl ) .
NO_RELATION	The results showed that intracollicular microinjection of <e1> MK - 801 </e1> and AP7 previous to systemic injections of haloperidol significantly attenuated the <e2> catalepsy </e2> , as indicated by a reduced latency to step down from a horizontal bar .
NO_RELATION	The results showed that intracollicular microinjection of MK - 801 and <e1> AP7 </e1> previous to systemic injections of haloperidol significantly attenuated the <e2> catalepsy </e2> , as indicated by a reduced latency to step down from a horizontal bar .
CID	The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of <e1> haloperidol </e1> significantly attenuated the <e2> catalepsy </e2> , as indicated by a reduced latency to step down from a horizontal bar .
NO_RELATION	These findings suggest that <e1> glutamate </e1> - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced <e2> catalepsy </e2> and participate in the regulation of motor activity .
CID	These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence <e1> haloperidol </e1> - induced <e2> catalepsy </e2> and participate in the regulation of motor activity .
NO_RELATION	Metabotropic <e1> glutamate </e1> 7 receptor subtype modulates motor symptoms in rodent models of <e2> Parkinson ' s disease </e2> .
NO_RELATION	Metabotropic <e1> glutamate </e1> ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of <e2> Parkinson ' s disease </e2> ( PD ) .
NO_RELATION	Metabotropic <e1> glutamate </e1> ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson ' s disease ( <e2> PD </e2> ) .
NO_RELATION	The effects of <e1> N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride </e1> ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of <e2> PD </e2> .
NO_RELATION	The effects of N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( <e1> AMN082 </e1> ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of <e2> PD </e2> .
NO_RELATION	Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of <e1> AMN082 </e1> reverses haloperidol - induced <e2> catalepsy </e2> in rats .
CID	Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses <e1> haloperidol </e1> - induced <e2> catalepsy </e2> in rats .
NO_RELATION	In a more complex task commonly used to evaluate major <e2> akinetic </e2> symptoms of PD patients , 5 mg / kg <e1> AMN082 </e1> reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .
NO_RELATION	In a more complex task commonly used to evaluate major akinetic symptoms of <e2> PD </e2> patients , 5 mg / kg <e1> AMN082 </e1> reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .
NO_RELATION	In a more complex task commonly used to evaluate major <e2> akinetic </e2> symptoms of PD patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral <e1> 6 - OHDA </e1> - lesioned rats .
NO_RELATION	In a more complex task commonly used to evaluate major akinetic symptoms of <e2> PD </e2> patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral <e1> 6 - OHDA </e1> - lesioned rats .
NO_RELATION	In addition , <e1> AMN082 </e1> reduces the duration of haloperidol - induced <e2> catalepsy </e2> in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .
CID	In addition , AMN082 reduces the duration of <e1> haloperidol </e1> - induced <e2> catalepsy </e2> in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .
NO_RELATION	Higher doses of <e1> AMN082 </e1> ( 10 and 20 mg / kg p . o . ) have no effect on the same models of <e2> PD </e2> .
NO_RELATION	<e1> Nimodipine </e1> prevents <e2> memory impairment </e2> caused by nitroglycerin - induced hypotension in adult mice .
NO_RELATION	<e1> Nimodipine </e1> prevents memory impairment caused by nitroglycerin - induced <e2> hypotension </e2> in adult mice .
CID	Nimodipine prevents <e2> memory impairment </e2> caused by <e1> nitroglycerin </e1> - induced hypotension in adult mice .
CID	Nimodipine prevents memory impairment caused by <e1> nitroglycerin </e1> - induced <e2> hypotension </e2> in adult mice .
NO_RELATION	We tested the hypothesis that <e1> nimodipine </e1> ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced <e2> hypotension </e2> would preserve long - term associative memory .
NO_RELATION	We tested the hypothesis that nimodipine ( <e1> NIMO </e1> ) administered at the onset of nitroglycerin ( NTG ) - induced <e2> hypotension </e2> would preserve long - term associative memory .
CID	We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of <e1> nitroglycerin </e1> ( NTG ) - induced <e2> hypotension </e2> would preserve long - term associative memory .
CID	We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( <e1> NTG </e1> ) - induced <e2> hypotension </e2> would preserve long - term associative memory .
CID	Mice subjected to <e2> hypotensive </e2> episodes showed a significant decrease in latency time ( 178 + / - 156 s ) compared with those injected with saline , <e1> NTG </e1> + NIMO , or delayed NTG ( 580 + / - 81 s , 557 + / - 67 s , and 493 + / - 146 s , respectively ) .
NO_RELATION	Mice subjected to <e2> hypotensive </e2> episodes showed a significant decrease in latency time ( 178 + / - 156 s ) compared with those injected with saline , NTG + <e1> NIMO </e1> , or delayed NTG ( 580 + / - 81 s , 557 + / - 67 s , and 493 + / - 146 s , respectively ) .
CID	Mice subjected to <e2> hypotensive </e2> episodes showed a significant decrease in latency time ( 178 + / - 156 s ) compared with those injected with saline , NTG + NIMO , or delayed <e1> NTG </e1> ( 580 + / - 81 s , 557 + / - 67 s , and 493 + / - 146 s , respectively ) .
CID	CONCLUSION : In a PA retention paradigm , the injection of <e1> NTG </e1> immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced <e2> hypotension </e2> had no effect .
NO_RELATION	<e1> NIMO </e1> attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of <e2> hypotension </e2> .
CID	NIMO attenuated the disruption in consolidation of long - term memory caused by <e1> NTG </e1> but did not improve latency in the absence of <e2> hypotension </e2> .
NO_RELATION	The observed effect of <e1> NIMO </e1> may have been attributable to the preservation of calcium homeostasis during <e2> hypotension </e2> , because there were no differences in the PbtO ( 2 ) indices among groups .
NO_RELATION	The observed effect of NIMO may have been attributable to the preservation of <e1> calcium </e1> homeostasis during <e2> hypotension </e2> , because there were no differences in the PbtO ( 2 ) indices among groups .
NO_RELATION	Fatal <e2> haemopericardium </e2> and gastrointestinal haemorrhage due to possible interaction of cranberry juice with <e1> warfarin </e1> .
CID	Fatal haemopericardium and <e2> gastrointestinal haemorrhage </e2> due to possible interaction of cranberry juice with <e1> warfarin </e1> .
NO_RELATION	We report a case of fatal internal <e2> haemorrhage </e2> in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of <e1> warfarin </e1> .
CID	<e1> Isoproterenol </e1> induces primary loss of dystrophin in rat hearts : correlation with <e2> myocardial injury </e2> .
CID	The mechanism of <e1> isoproterenol </e1> - induced <e2> myocardial damage </e2> is unknown , but a mismatch of oxygen supply vs .
NO_RELATION	The mechanism of isoproterenol - induced <e2> myocardial damage </e2> is unknown , but a mismatch of <e1> oxygen </e1> supply vs .
CID	These changes , related to <e2> ischaemic injury </e2> , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by <e1> isoproterenol </e1> .
CID	High <e1> fat </e1> diet - fed <e2> obese </e2> rats are highly sensitive to doxorubicin - induced cardiotoxicity .
NO_RELATION	High <e1> fat </e1> diet - fed obese rats are highly sensitive to doxorubicin - induced <e2> cardiotoxicity </e2> .
NO_RELATION	High fat diet - fed <e2> obese </e2> rats are highly sensitive to <e1> doxorubicin </e1> - induced cardiotoxicity .
NO_RELATION	High fat diet - fed obese rats are highly sensitive to <e1> doxorubicin </e1> - induced <e2> cardiotoxicity </e2> .
NO_RELATION	Often , chemotherapy by <e1> doxorubicin </e1> ( Adriamycin ) is limited due to life threatening <e2> cardiotoxicity </e2> in patients during and posttherapy .
NO_RELATION	Often , chemotherapy by doxorubicin ( <e1> Adriamycin </e1> ) is limited due to life threatening <e2> cardiotoxicity </e2> in patients during and posttherapy .
NO_RELATION	Recently , we have shown that moderate diet restriction remarkably protects against <e1> doxorubicin </e1> - induced <e2> cardiotoxicity </e2> .
CID	In the current study , we investigated whether a physiological intervention by feeding 40 % high <e1> fat </e1> diet ( HFD ) , which induces <e2> obesity </e2> in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced cardiotoxicity .
NO_RELATION	In the current study , we investigated whether a physiological intervention by feeding 40 % high <e1> fat </e1> diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced <e2> cardiotoxicity </e2> .
NO_RELATION	In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces <e2> obesity </e2> in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to <e1> doxorubicin </e1> - induced cardiotoxicity .
NO_RELATION	In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to <e1> doxorubicin </e1> - induced <e2> cardiotoxicity </e2> .
NO_RELATION	A LD ( 10 ) dose ( 8 mg <e1> doxorubicin </e1> / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher <e2> cardiotoxicity </e2> , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .
CID	A LD ( 10 ) dose ( 8 mg <e1> doxorubicin </e1> / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , <e2> cardiac dysfunction </e2> , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .
NO_RELATION	A LD ( 10 ) dose ( 8 mg <e1> doxorubicin </e1> / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the <e2> obese </e2> ( OB ) rats in the absence of any significant renal or hepatic toxicity .
NO_RELATION	A LD ( 10 ) dose ( 8 mg <e1> doxorubicin </e1> / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( <e2> OB </e2> ) rats in the absence of any significant renal or hepatic toxicity .
NO_RELATION	A LD ( 10 ) dose ( 8 mg <e1> doxorubicin </e1> / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant <e2> renal or hepatic toxicity </e2> .
NO_RELATION	<e1> Doxorubicin </e1> toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and <e2> OB </e2> hearts .
NO_RELATION	Doxorubicin toxicokinetics studies revealed no change in accumulation of <e1> doxorubicin </e1> and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and <e2> OB </e2> hearts .
NO_RELATION	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and <e1> doxorubicinol </e1> ( toxic metabolite ) in the normal diet - fed ( ND ) and <e2> OB </e2> hearts .
NO_RELATION	Mechanistic studies revealed that <e2> OB </e2> rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial <e1> AMP </e1> - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .
NO_RELATION	Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in <e2> OB </e2> ) , ( 5 ) decreased mitochondrial <e1> AMP </e1> - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .
NO_RELATION	Mechanistic studies revealed that <e2> OB </e2> rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac <e1> ATP </e1> levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .
NO_RELATION	Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in <e2> OB </e2> ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac <e1> ATP </e1> levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .
NO_RELATION	Mechanistic studies revealed that <e2> OB </e2> rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased <e1> ATP </e1> / ADP ratio after doxorubicin administration .
NO_RELATION	Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in <e2> OB </e2> ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased <e1> ATP </e1> / ADP ratio after doxorubicin administration .
NO_RELATION	Mechanistic studies revealed that <e2> OB </e2> rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / <e1> ADP </e1> ratio after doxorubicin administration .
NO_RELATION	Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in <e2> OB </e2> ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / <e1> ADP </e1> ratio after doxorubicin administration .
NO_RELATION	Mechanistic studies revealed that <e2> OB </e2> rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after <e1> doxorubicin </e1> administration .
NO_RELATION	Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in <e2> OB </e2> ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after <e1> doxorubicin </e1> administration .
NO_RELATION	In conclusion , HFD - induced <e2> obese </e2> rats are highly sensitized to <e1> doxorubicin </e1> - induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .
NO_RELATION	In conclusion , HFD - induced obese rats are highly sensitized to <e1> doxorubicin </e1> - induced <e2> cardiotoxicity </e2> by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .
NO_RELATION	In conclusion , HFD - induced <e2> obese </e2> rats are highly sensitized to doxorubicin - induced cardiotoxicity by substantially downregulating cardiac mitochondrial <e1> ATP </e1> generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .
NO_RELATION	In conclusion , HFD - induced obese rats are highly sensitized to doxorubicin - induced <e2> cardiotoxicity </e2> by substantially downregulating cardiac mitochondrial <e1> ATP </e1> generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .
CID	Complete <e2> atrioventricular block </e2> secondary to <e1> lithium </e1> therapy .
CID	<e2> Sinus node dysfunction </e2> has been reported most frequently among the adverse cardiovascular effects of <e1> lithium </e1> .
CID	In the present case , complete <e2> atrioventricular ( AV ) block </e2> with syncopal attacks developed secondary to <e1> lithium </e1> therapy , necessitating permanent pacemaker implantation .
NO_RELATION	In the present case , complete atrioventricular ( AV ) block with <e2> syncopal attacks </e2> developed secondary to <e1> lithium </e1> therapy , necessitating permanent pacemaker implantation .
NO_RELATION	Serum <e1> lithium </e1> levels remained under or within the therapeutic range during the <e2> syncopal attacks </e2> .
CID	<e2> Neuroleptic malignant syndrome </e2> induced by <e1> ziprasidone </e1> on the second day of treatment .
CID	We describe a case of <e2> neuroleptic malignant syndrome </e2> ( NMS ) associated with the use of <e1> ziprasidone </e1> .
CID	We describe a case of neuroleptic malignant syndrome ( <e2> NMS </e2> ) associated with the use of <e1> ziprasidone </e1> .
CID	Although conventional neuroleptics are more frequently associated with <e2> NMS </e2> , atypical antipsychotic drugs like <e1> ziprasidone </e1> may also be a cause .
NO_RELATION	The patient is a 24 - year - old male with a history of <e2> schizophrenia </e2> who developed signs and symptoms of NMS after 2 days of treatment with an 80 - mg / day dose of orally administrated <e1> ziprasidone </e1> .
CID	The patient is a 24 - year - old male with a history of schizophrenia who developed signs and symptoms of <e2> NMS </e2> after 2 days of treatment with an 80 - mg / day dose of orally administrated <e1> ziprasidone </e1> .
CID	This case is the earliest ( second day of treatment ) <e2> NMS </e2> due to <e1> ziprasidone </e1> reported in the literature .
NO_RELATION	Role of <e1> mangiferin </e1> on biochemical alterations and antioxidant status in isoproterenol - induced <e2> myocardial infarction </e2> in rats .
CID	Role of mangiferin on biochemical alterations and antioxidant status in <e1> isoproterenol </e1> - induced <e2> myocardial infarction </e2> in rats .
CID	( Anacardiaceae ) , on <e1> isoproterenol </e1> ( ISPH ) - induced <e2> myocardial infarction </e2> ( MI ) in rats through its antioxidative mechanism .
CID	( Anacardiaceae ) , on <e1> isoproterenol </e1> ( ISPH ) - induced myocardial infarction ( <e2> MI </e2> ) in rats through its antioxidative mechanism .
CID	( Anacardiaceae ) , on isoproterenol ( <e1> ISPH </e1> ) - induced <e2> myocardial infarction </e2> ( MI ) in rats through its antioxidative mechanism .
CID	( Anacardiaceae ) , on isoproterenol ( <e1> ISPH </e1> ) - induced myocardial infarction ( <e2> MI </e2> ) in rats through its antioxidative mechanism .
NO_RELATION	Subcutaneous injection of <e1> ISPH </e1> ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused <e2> myocardial damage </e2> in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .
NO_RELATION	Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused <e2> myocardial damage </e2> in rat heart , which was determined by the increased activity of serum <e1> lactate </e1> dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .
NO_RELATION	Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused <e2> myocardial damage </e2> in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and <e1> creatine </e1> phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .
NO_RELATION	Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused <e2> myocardial damage </e2> in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased <e1> uric acid </e1> level and reduced plasma iron binding capacity .
NO_RELATION	Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused <e2> myocardial damage </e2> in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma <e1> iron </e1> binding capacity .
NO_RELATION	The protective role of <e1> mangiferin </e1> was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the <e2> ischemic myocardium </e2> .
NO_RELATION	The protective role of mangiferin was analyzed by <e1> triphenyl tetrazolium chloride </e1> ( TTC ) test used for macroscopic enzyme mapping assay of the <e2> ischemic myocardium </e2> .
NO_RELATION	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( <e1> TTC </e1> ) test used for macroscopic enzyme mapping assay of the <e2> ischemic myocardium </e2> .
NO_RELATION	The heart tissue antioxidant enzymes such as <e1> superoxide </e1> dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in <e2> MI </e2> rats .
NO_RELATION	The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , <e1> glutathione </e1> peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in <e2> MI </e2> rats .
NO_RELATION	The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , <e1> glutathione </e1> transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in <e2> MI </e2> rats .
NO_RELATION	The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and <e1> glutathione </e1> reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in <e2> MI </e2> rats .
NO_RELATION	The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , <e1> Vitamin C </e1> , Vitamin E and glutathione levels were altered in <e2> MI </e2> rats .
NO_RELATION	The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , <e1> Vitamin E </e1> and glutathione levels were altered in <e2> MI </e2> rats .
NO_RELATION	The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and <e1> glutathione </e1> levels were altered in <e2> MI </e2> rats .
NO_RELATION	Upon pretreatment with <e1> mangiferin </e1> ( 100 mg / kg body weight suspended in 2 ml of dimethyl sulphoxide ) given intraperitoneally for 28 days to <e2> MI </e2> rats protected the above - mentioned parameters to fall from the normal levels .
NO_RELATION	Upon pretreatment with mangiferin ( 100 mg / kg body weight suspended in 2 ml of <e1> dimethyl sulphoxide </e1> ) given intraperitoneally for 28 days to <e2> MI </e2> rats protected the above - mentioned parameters to fall from the normal levels .
NO_RELATION	Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon <e1> mangiferin </e1> administration as compared to ISPH - induced <e2> MI </e2> rats .
CID	Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon mangiferin administration as compared to <e1> ISPH </e1> - induced <e2> MI </e2> rats .
NO_RELATION	From the present study it is concluded that <e1> mangiferin </e1> exerts a beneficial effect against ISPH - induced <e2> MI </e2> due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .
NO_RELATION	From the present study it is concluded that <e1> mangiferin </e1> exerts a beneficial effect against ISPH - induced MI due to its antioxidant potential , which regulated the tissues defense system against <e2> cardiac damage </e2> .
CID	From the present study it is concluded that mangiferin exerts a beneficial effect against <e1> ISPH </e1> - induced <e2> MI </e2> due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .
NO_RELATION	From the present study it is concluded that mangiferin exerts a beneficial effect against <e1> ISPH </e1> - induced MI due to its antioxidant potential , which regulated the tissues defense system against <e2> cardiac damage </e2> .
NO_RELATION	<e1> Remifentanil </e1> pretreatment reduces <e2> myoclonus </e2> after etomidate .
CID	Remifentanil pretreatment reduces <e2> myoclonus </e2> after <e1> etomidate </e1> .
NO_RELATION	STUDY OBJECTIVE : The aim of the study was to compare the effect of pretreatment with <e1> remifentanil </e1> 1 microg / kg and the effect of gender on the incidence of <e2> myoclonus </e2> after anesthesia induction with etomidate .
CID	STUDY OBJECTIVE : The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of <e2> myoclonus </e2> after anesthesia induction with <e1> etomidate </e1> .
NO_RELATION	MAIN RESULTS : The incidence of <e2> myoclonus </e2> was significantly lower in the <e1> remifentanil </e1> group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .
CID	In the placebo group , male patients were associated with significantly increased incidence of <e2> myoclonus </e2> after <e1> etomidate </e1> administration .
NO_RELATION	CONCLUSION : Pretreatment with <e1> remifentanil </e1> 1 microg / kg reduced <e2> myoclonus </e2> after etomidate induction without side effects such as sedation , apnea , nausea , or pruritus .
NO_RELATION	CONCLUSION : Pretreatment with <e1> remifentanil </e1> 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , <e2> apnea </e2> , nausea , or pruritus .
NO_RELATION	CONCLUSION : Pretreatment with <e1> remifentanil </e1> 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , <e2> nausea </e2> , or pruritus .
NO_RELATION	CONCLUSION : Pretreatment with <e1> remifentanil </e1> 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , nausea , or <e2> pruritus </e2> .
CID	CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced <e2> myoclonus </e2> after <e1> etomidate </e1> induction without side effects such as sedation , apnea , nausea , or pruritus .
NO_RELATION	CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced myoclonus after <e1> etomidate </e1> induction without side effects such as sedation , <e2> apnea </e2> , nausea , or pruritus .
NO_RELATION	CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced myoclonus after <e1> etomidate </e1> induction without side effects such as sedation , apnea , <e2> nausea </e2> , or pruritus .
NO_RELATION	CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced myoclonus after <e1> etomidate </e1> induction without side effects such as sedation , apnea , nausea , or <e2> pruritus </e2> .
CID	Men experience increased incidence of <e2> myoclonus </e2> than women after <e1> etomidate </e1> administration .
NO_RELATION	<e1> Daidzein </e1> activates choline acetyltransferase from MC - IXC cells and improves drug - induced <e2> amnesia </e2> .
NO_RELATION	Daidzein activates <e1> choline </e1> acetyltransferase from MC - IXC cells and improves drug - induced <e2> amnesia </e2> .
NO_RELATION	The <e1> choline </e1> acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of <e2> Alzheimer ' s disease </e2> ( AD ) .
NO_RELATION	The <e1> choline </e1> acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer ' s disease ( <e2> AD </e2> ) .
NO_RELATION	The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of <e1> acetylcholine </e1> ( ACh ) , is an important factor in the treatment of <e2> Alzheimer ' s disease </e2> ( AD ) .
NO_RELATION	The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of <e1> acetylcholine </e1> ( ACh ) , is an important factor in the treatment of Alzheimer ' s disease ( <e2> AD </e2> ) .
NO_RELATION	The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( <e1> ACh </e1> ) , is an important factor in the treatment of <e2> Alzheimer ' s disease </e2> ( AD ) .
NO_RELATION	The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( <e1> ACh </e1> ) , is an important factor in the treatment of Alzheimer ' s disease ( <e2> AD </e2> ) .
NO_RELATION	In order to investigate the effects of <e1> daidzein </e1> from Pueraria thunbergiana on scopolamine - induced <e2> impairments of learning and memory </e2> , we conducted a series of in vivo tests .
NO_RELATION	In order to investigate the effects of daidzein from Pueraria thunbergiana on <e1> scopolamine </e1> - induced <e2> impairments of learning and memory </e2> , we conducted a series of in vivo tests .
NO_RELATION	Administration of <e1> daidzein </e1> ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced <e2> amnesia </e2> , according to the results of a Y - maze test .
CID	Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse <e1> scopolamine </e1> - induced <e2> amnesia </e2> , according to the results of a Y - maze test .
NO_RELATION	These results indicate that <e1> daidzein </e1> might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced <e2> amnesia </e2> .
NO_RELATION	These results indicate that daidzein might play a role in <e1> acetylcholine </e1> biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced <e2> amnesia </e2> .
CID	These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates <e1> scopolamine </e1> - induced <e2> amnesia </e2> .
CID	Possible <e1> azithromycin </e1> - associated <e2> hiccups </e2> .
CID	OBJECTIVE : To report a case of persistent <e2> hiccups </e2> associated by <e1> azithromycin </e1> therapy .
CID	CASE SUMMARY : A 76 - year - old man presented with persistent <e2> hiccups </e2> after beginning <e1> azithromycin </e1> for the treatment of pharyngitis .
NO_RELATION	CASE SUMMARY : A 76 - year - old man presented with persistent hiccups after beginning <e1> azithromycin </e1> for the treatment of <e2> pharyngitis </e2> .
CID	Discontinuation of <e1> azithromycin </e1> and therapy with baclofen finally resolved <e2> hiccups </e2> .
CID	Discontinuation of azithromycin and therapy with <e1> baclofen </e1> finally resolved <e2> hiccups </e2> .
NO_RELATION	Corticosteroids ( <e1> dexamethasone </e1> and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <e2> hiccups </e2> .
NO_RELATION	Corticosteroids ( dexamethasone and <e1> methylprednisolone </e1> ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <e2> hiccups </e2> .
NO_RELATION	Corticosteroids ( dexamethasone and methylprednisolone ) , <e1> benzodiazepines </e1> ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <e2> hiccups </e2> .
NO_RELATION	Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( <e1> midazolam </e1> ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <e2> hiccups </e2> .
NO_RELATION	Few cases of drug - induced <e2> hiccups </e2> have been reported related to <e1> macrolide </e1> antimicrobials .
NO_RELATION	Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other <e1> macrolides </e1> and the absence of any alternative explanation for <e2> hiccups </e2> .
CID	Our hypothesis is that a vagal mechanism mediated by <e1> azithromycin </e1> could be the pathogenesis of <e2> hiccups </e2> in our patient .
NO_RELATION	However , <e1> macrolide </e1> antimicrobials have been reported to be associated with <e2> hiccups </e2> and vagal mechanism could explain the development of this side - effect .
CID	Time trends in <e1> warfarin </e1> - associated <e2> hemorrhage </e2> .
CID	The annual incidence of <e1> warfarin </e1> - related <e2> bleeding </e2> at Brigham and Women ' s Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .
NO_RELATION	Fatal <e2> haemorrhagic myocarditis </e2> secondary to <e1> cyclophosphamide </e1> therapy .
NO_RELATION	<e2> Haemorrhagic myocarditis </e2> is a rare but important complication of <e1> cyclophosphamide </e1> therapy .
CID	<e1> Glyceryl trinitrate </e1> induces attacks of <e2> migraine without aura </e2> in sufferers of migraine with aura .
NO_RELATION	<e1> Glyceryl trinitrate </e1> induces attacks of migraine without aura in sufferers of <e2> migraine with aura </e2> .
NO_RELATION	In recent years , increasing evidence has suggested that the messenger molecule <e1> nitric oxide </e1> ( NO ) is involved in <e2> pain </e2> mechanisms of migraine without aura .
CID	In recent years , increasing evidence has suggested that the messenger molecule <e1> nitric oxide </e1> ( NO ) is involved in pain mechanisms of <e2> migraine without aura </e2> .
NO_RELATION	In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( <e1> NO </e1> ) is involved in <e2> pain </e2> mechanisms of migraine without aura .
CID	In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( <e1> NO </e1> ) is involved in pain mechanisms of <e2> migraine without aura </e2> .
NO_RELATION	In order to clarify whether the same is true for <e2> migraine with aura </e2> , in the present study we examined the headache response to intravenous infusion of <e1> glyceryl trinitrate </e1> ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .
NO_RELATION	In order to clarify whether the same is true for migraine with aura , in the present study we examined the <e2> headache </e2> response to intravenous infusion of <e1> glyceryl trinitrate </e1> ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .
NO_RELATION	In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of <e1> glyceryl trinitrate </e1> ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of <e2> migraine with aura </e2> .
NO_RELATION	In order to clarify whether the same is true for <e2> migraine with aura </e2> , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( <e1> GTN </e1> ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .
NO_RELATION	In order to clarify whether the same is true for migraine with aura , in the present study we examined the <e2> headache </e2> response to intravenous infusion of glyceryl trinitrate ( <e1> GTN </e1> ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .
NO_RELATION	In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( <e1> GTN </e1> ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of <e2> migraine with aura </e2> .
NO_RELATION	<e2> Headache </e2> was more severe in migraineurs than in the controls during and immediately after <e1> GTN </e1> infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .
NO_RELATION	Headache was more severe in <e2> migraineurs </e2> than in the controls during and immediately after <e1> GTN </e1> infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .
NO_RELATION	In the controls , the <e1> GTN </e1> - induced <e2> headache </e2> gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .
NO_RELATION	In the controls , the <e1> GTN </e1> - induced headache gradually disappeared , whereas in <e2> migraineurs </e2> peak headache intensity occurred at a mean time of 240 min post - infusion .
NO_RELATION	In the controls , the <e1> GTN </e1> - induced headache gradually disappeared , whereas in migraineurs peak <e2> headache </e2> intensity occurred at a mean time of 240 min post - infusion .
NO_RELATION	The results therefore suggest that <e1> NO </e1> is involved in the <e2> pain </e2> mechanisms of migraine with aura .
NO_RELATION	The results therefore suggest that <e1> NO </e1> is involved in the pain mechanisms of <e2> migraine with aura </e2> .
NO_RELATION	Since cortical spreading <e2> depression </e2> has been shown to liberate <e1> NO </e1> in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .
NO_RELATION	Since cortical spreading depression has been shown to liberate <e1> NO </e1> in animals , this finding may help our understanding of the coupling between cortical spreading <e2> depression </e2> and headache in migraine with aura .
NO_RELATION	Since cortical spreading depression has been shown to liberate <e1> NO </e1> in animals , this finding may help our understanding of the coupling between cortical spreading depression and <e2> headache </e2> in migraine with aura .
NO_RELATION	Since cortical spreading depression has been shown to liberate <e1> NO </e1> in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in <e2> migraine with aura </e2> .
CID	<e2> Stroke </e2> and <e1> cocaine </e1> or amphetamine use .
CID	<e2> Stroke </e2> and cocaine or <e1> amphetamine </e1> use .
NO_RELATION	The association of <e1> cocaine </e1> and amphetamine use with hemorrhagic and <e2> ischemic </e2> stroke is based almost solely on data from case series .
CID	The association of <e1> cocaine </e1> and amphetamine use with hemorrhagic and ischemic <e2> stroke </e2> is based almost solely on data from case series .
NO_RELATION	The association of cocaine and <e1> amphetamine </e1> use with hemorrhagic and <e2> ischemic </e2> stroke is based almost solely on data from case series .
CID	The association of cocaine and <e1> amphetamine </e1> use with hemorrhagic and ischemic <e2> stroke </e2> is based almost solely on data from case series .
CID	The limited number of epidemiologic studies of <e2> stroke </e2> and use of <e1> cocaine </e1> and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .
CID	The limited number of epidemiologic studies of <e2> stroke </e2> and use of cocaine and / or <e1> amphetamine </e1> have been done in settings that serve mostly the poor and / or minorities .
CID	The univariate matched odds ratio for <e2> stroke </e2> in women who admitted to using <e1> cocaine </e1> and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .
CID	The univariate matched odds ratio for <e2> stroke </e2> in women who admitted to using cocaine and / or <e1> amphetamine </e1> was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .
CID	The use of <e1> cocaine </e1> and / or amphetamine is a strong risk factor for <e2> stroke </e2> in this socioeconomically heterogeneous , insured urban population .
CID	The use of cocaine and / or <e1> amphetamine </e1> is a strong risk factor for <e2> stroke </e2> in this socioeconomically heterogeneous , insured urban population .
NO_RELATION	Prevention of <e2> breast cancer </e2> with <e1> tamoxifen </e1> : preliminary findings from the Italian randomised trial among hysterectomised women .
NO_RELATION	BACKGROUND : <e1> Tamoxifen </e1> is a candidate chemopreventive agent in <e2> breast cancer </e2> , although the drug may be associated with the development of endometrial cancer .
NO_RELATION	BACKGROUND : <e1> Tamoxifen </e1> is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of <e2> endometrial cancer </e2> .
NO_RELATION	METHODS : In October , 1992 , we started a double - blind placebo - controlled , randomised trial of <e1> tamoxifen </e1> in women ( mainly in Italy ) who did not have <e2> breast cancer </e2> and who had had a hysterectomy .
NO_RELATION	There is no difference in <e2> breast - cancer </e2> frequency between the placebo ( 22 cases ) and <e1> tamoxifen </e1> ( 19 ) arms .
NO_RELATION	There is a statistically significant reduction of <e2> breast cancer </e2> among women receiving <e1> tamoxifen </e1> who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .
NO_RELATION	There is a statistically significant reduction of breast cancer among women receiving <e1> tamoxifen </e1> who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of <e2> breast cancer </e2> compared with one case among 362 women allocated to tamoxifen .
NO_RELATION	There is a statistically significant reduction of <e2> breast cancer </e2> among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to <e1> tamoxifen </e1> .
NO_RELATION	There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of <e2> breast cancer </e2> compared with one case among 362 women allocated to <e1> tamoxifen </e1> .
CID	Compared with the placebo group , there was a significantly increased risk of <e2> vascular events </e2> and hypertriglyceridaemia among women on <e1> tamoxifen </e1> .
CID	Compared with the placebo group , there was a significantly increased risk of vascular events and <e2> hypertriglyceridaemia </e2> among women on <e1> tamoxifen </e1> .
NO_RELATION	INTERPRETATION : Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of <e2> breast cancer </e2> , the postulated protective effects of <e1> tamoxifen </e1> are not yet apparent .
CID	A measure of <e2> pupillary oscillation </e2> as a marker of <e1> cocaine </e1> - induced paranoia .
CID	A measure of pupillary oscillation as a marker of <e1> cocaine </e1> - induced <e2> paranoia </e2> .
CID	<e1> Cocaine </e1> - induced <e2> paranoia </e2> ( CIP ) remains an important drug - induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged .
CID	<e1> Cocaine </e1> - induced paranoia ( <e2> CIP </e2> ) remains an important drug - induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged .
CID	<e1> Cocaine </e1> - induced paranoia ( CIP ) remains an important drug - induced model of idiopathic <e2> paranoia </e2> for which no psychophysiologic marker has yet emerged .
NO_RELATION	Measures of <e2> pupillary oscillation </e2> were able to significantly distinguish a group of abstinent <e1> crack cocaine </e1> abusers endorsing past CIP ( n = 32 ) from another group of crack addicts who denied past CIP ( n = 29 ) .
NO_RELATION	Measures of pupillary oscillation were able to significantly distinguish a group of abstinent <e1> crack cocaine </e1> abusers endorsing past <e2> CIP </e2> ( n = 32 ) from another group of crack addicts who denied past CIP ( n = 29 ) .
NO_RELATION	Measures of pupillary oscillation were able to significantly distinguish a group of abstinent <e1> crack cocaine </e1> abusers endorsing past CIP ( n = 32 ) from another group of crack addicts who denied past <e2> CIP </e2> ( n = 29 ) .
NO_RELATION	Measures of <e2> pupillary oscillation </e2> were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP ( n = 32 ) from another group of <e1> crack </e1> addicts who denied past CIP ( n = 29 ) .
NO_RELATION	Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past <e2> CIP </e2> ( n = 32 ) from another group of <e1> crack </e1> addicts who denied past CIP ( n = 29 ) .
NO_RELATION	Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP ( n = 32 ) from another group of <e1> crack </e1> addicts who denied past <e2> CIP </e2> ( n = 29 ) .
CID	<e2> Seizures </e2> induced by combined <e1> levomepromazine </e1> - fluvoxamine treatment .
CID	<e2> Seizures </e2> induced by combined levomepromazine - <e1> fluvoxamine </e1> treatment .
CID	We report a case of combined <e1> levomepromazine </e1> - fluvoxamine treatment - induced <e2> seizures </e2> .
CID	We report a case of combined levomepromazine - <e1> fluvoxamine </e1> treatment - induced <e2> seizures </e2> .
CID	Why may <e1> epsilon - aminocaproic acid </e1> ( EACA ) induce <e2> myopathy </e2> in man ?
CID	Why may epsilon - aminocaproic acid ( <e1> EACA </e1> ) induce <e2> myopathy </e2> in man ?
NO_RELATION	A case of <e2> necrotizing myopathy </e2> due to a short <e1> epsilon - aminocaproic acid </e1> ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .
NO_RELATION	A case of necrotizing myopathy due to a short <e1> epsilon - aminocaproic acid </e1> ( EACA ) treatment in a 72 year - old patient with <e2> subarachnoid haemorrhage </e2> ( SAH ) is described .
NO_RELATION	A case of necrotizing myopathy due to a short <e1> epsilon - aminocaproic acid </e1> ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( <e2> SAH </e2> ) is described .
NO_RELATION	A case of <e2> necrotizing myopathy </e2> due to a short epsilon - aminocaproic acid ( <e1> EACA </e1> ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .
NO_RELATION	A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( <e1> EACA </e1> ) treatment in a 72 year - old patient with <e2> subarachnoid haemorrhage </e2> ( SAH ) is described .
NO_RELATION	A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( <e1> EACA </e1> ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( <e2> SAH </e2> ) is described .
CID	Sixty percent of the males developed breast changes or <e2> impotence </e2> while taking <e1> cimetidine </e1> and in all cases these changes disappeared when cimetidine was replaced by ranitidine .
CID	Sixty percent of the males developed breast changes or <e2> impotence </e2> while taking cimetidine and in all cases these changes disappeared when <e1> cimetidine </e1> was replaced by ranitidine .
NO_RELATION	Sixty percent of the males developed breast changes or <e2> impotence </e2> while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by <e1> ranitidine </e1> .
NO_RELATION	Treatment with high doses of <e1> cimetidine </e1> ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with <e2> hepatic or hematologic toxicity </e2> or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .
NO_RELATION	Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or <e1> ranitidine </e1> ( two to 31 months ; median , 14 months ) was not associated with <e2> hepatic or hematologic toxicity </e2> or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .
NO_RELATION	Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with <e2> hepatic or hematologic toxicity </e2> or alterations of serum gastrin concentrations , but <e1> ranitidine </e1> therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .
NO_RELATION	Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with <e2> hepatic or hematologic toxicity </e2> or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum <e1> creatinine </e1> level than seen with cimetidine therapy .
NO_RELATION	Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with <e2> hepatic or hematologic toxicity </e2> or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with <e1> cimetidine </e1> therapy .
NO_RELATION	<e2> Reye syndrome </e2> may be disappearing from Australia despite a total lack of association with <e1> salicylates </e1> or aspirin ingestion , since there were no cases found at The Children ' s Hospital in 1983 , 1984 , or 1985 .
CID	<e2> Reye syndrome </e2> may be disappearing from Australia despite a total lack of association with salicylates or <e1> aspirin </e1> ingestion , since there were no cases found at The Children ' s Hospital in 1983 , 1984 , or 1985 .
CID	A rare case of morbid <e2> vasospasm </e2> , together with striking angiographic findings , is described secondary to the ingestion of <e1> methysergide </e1> by a 48 - year - old woman .
NO_RELATION	A discussion of the history of <e1> ergot </e1> includes its original discovery , the epidemics of <e2> gangrene </e2> that it has caused through the ages and its past and present role in the management of migraine headache .
CID	A discussion of the history of <e1> ergot </e1> includes its original discovery , the epidemics of gangrene that it has caused through the ages and its past and present role in the management of <e2> migraine headache </e2> .
NO_RELATION	Despite the advent of <e1> calcium </e1> channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in <e2> migraine </e2> therapy , so that the danger of St .
CID	Despite the advent of calcium channel blockers and beta - adrenergic antagonists , <e1> ergot </e1> preparations continue to play a major role in <e2> migraine </e2> therapy , so that the danger of St .
NO_RELATION	Beta - 2 - adrenoceptor - mediated <e2> hypokalemia </e2> and its abolishment by <e1> oxprenolol </e1> .
CID	The time course and concentration - effect relationship of <e1> terbutaline </e1> - induced <e2> hypokalemia </e2> was studied , using computer - aided pharmacokinetic - dynamic modeling .
NO_RELATION	Subsequently we investigated the efficacy of <e1> oxprenolol </e1> in antagonizing such <e2> hypokalemia </e2> , together with the pharmacokinetic interaction between both drugs .
CID	In spite of higher <e1> terbutaline </e1> concentrations after oxprenolol pretreatment , the <e2> hypokalemia </e2> was almost completely antagonized by the beta 2 - blocking action .
NO_RELATION	In spite of higher terbutaline concentrations after <e1> oxprenolol </e1> pretreatment , the <e2> hypokalemia </e2> was almost completely antagonized by the beta 2 - blocking action .
NO_RELATION	Midline B3 <e1> serotonin </e1> nerves in rat medulla are involved in <e2> hypotensive </e2> effect of methyldopa .
CID	Midline B3 serotonin nerves in rat medulla are involved in <e2> hypotensive </e2> effect of <e1> methyldopa </e1> .
CID	Previous experiments in this laboratory have shown that microinjection of <e1> methyldopa </e1> onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a <e2> hypotensive </e2> response mediated by a projection descending into the spinal cord .
NO_RELATION	Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 <e1> serotonin </e1> neurons in the medulla elicits a <e2> hypotensive </e2> response mediated by a projection descending into the spinal cord .
NO_RELATION	In spontaneously <e2> hypertensive </e2> , stroke - prone rats , microinjection of <e1> methyldopa </e1> into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , <e2> stroke </e2> - prone rats , microinjection of <e1> methyldopa </e1> into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
CID	In spontaneously hypertensive , stroke - prone rats , microinjection of <e1> methyldopa </e1> into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent <e2> hypotension </e2> of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously <e2> hypertensive </e2> , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 <e1> serotonin </e1> cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , <e2> stroke </e2> - prone rats , microinjection of methyldopa into the area of the midline B3 <e1> serotonin </e1> cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 <e1> serotonin </e1> cell group in the ventral medulla caused a potent <e2> hypotension </e2> of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously <e2> hypertensive </e2> , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the <e1> serotonin </e1> neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , <e2> stroke </e2> - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the <e1> serotonin </e1> neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent <e2> hypotension </e2> of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the <e1> serotonin </e1> neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously <e2> hypertensive </e2> , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin <e1> 5 , 7 - dihydroxytryptamine </e1> ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , <e2> stroke </e2> - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin <e1> 5 , 7 - dihydroxytryptamine </e1> ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent <e2> hypotension </e2> of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin <e1> 5 , 7 - dihydroxytryptamine </e1> ( 5 , 7 - DHT ) injected intracerebroventricularly .
NO_RELATION	In spontaneously <e2> hypertensive </e2> , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( <e1> 5 , 7 - DHT </e1> ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , <e2> stroke </e2> - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( <e1> 5 , 7 - DHT </e1> ) injected intracerebroventricularly .
NO_RELATION	In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent <e2> hypotension </e2> of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( <e1> 5 , 7 - DHT </e1> ) injected intracerebroventricularly .
NO_RELATION	However , intraspinal injection of <e1> 5 , 7 - DHT </e1> to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this <e2> hypotension </e2> .
NO_RELATION	However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending <e1> serotonin </e1> projections in the spinal cord did not affect this <e2> hypotension </e2> .
CID	It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a <e1> methyldopa </e1> - induced <e2> hypotension </e2> via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
CID	It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a <e1> methyldopa </e1> - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the <e2> hypotensive </e2> action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
NO_RELATION	It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced <e2> hypotension </e2> via descending projections , the midline <e1> serotonin </e1> B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
NO_RELATION	It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline <e1> serotonin </e1> B3 cells in the medulla contribute to the <e2> hypotensive </e2> action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
CID	It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced <e2> hypotension </e2> via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of <e1> methyldopa </e1> , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
CID	It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the <e2> hypotensive </e2> action of <e1> methyldopa </e1> , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
NO_RELATION	<e1> Yohimbine </e1> treatment of <e2> sexual side effects </e2> induced by serotonin reuptake blockers .
NO_RELATION	Yohimbine treatment of <e2> sexual side effects </e2> induced by <e1> serotonin </e1> reuptake blockers .
NO_RELATION	BACKGROUND : Preclinical and clinical studies suggest that <e1> yohimbine </e1> facilitates sexual behavior and may be helpful in the treatment of <e2> male impotence </e2> .
NO_RELATION	A single case report suggests that <e1> yohimbine </e1> may be used to treat the <e2> sexual side effects </e2> of clomipramine .
CID	A single case report suggests that yohimbine may be used to treat the <e2> sexual side effects </e2> of <e1> clomipramine </e1> .
NO_RELATION	This study evaluated <e1> yohimbine </e1> as a treatment for the <e2> sexual side effects </e2> caused by serotonin reuptake blockers .
NO_RELATION	This study evaluated yohimbine as a treatment for the <e2> sexual side effects </e2> caused by <e1> serotonin </e1> reuptake blockers .
NO_RELATION	METHOD : Six patients with either <e2> obsessive compulsive disorder </e2> , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with <e1> serotonin </e1> reuptake blockers were given yohimbine on a p . r . n .
NO_RELATION	METHOD : Six patients with either obsessive compulsive disorder , <e2> trichotillomania </e2> , anxiety , or affective disorders who suffered sexual side effects after treatment with <e1> serotonin </e1> reuptake blockers were given yohimbine on a p . r . n .
NO_RELATION	METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , <e2> anxiety </e2> , or affective disorders who suffered sexual side effects after treatment with <e1> serotonin </e1> reuptake blockers were given yohimbine on a p . r . n .
NO_RELATION	METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or <e2> affective disorders </e2> who suffered sexual side effects after treatment with <e1> serotonin </e1> reuptake blockers were given yohimbine on a p . r . n .
NO_RELATION	METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered <e2> sexual side effects </e2> after treatment with <e1> serotonin </e1> reuptake blockers were given yohimbine on a p . r . n .
NO_RELATION	METHOD : Six patients with either <e2> obsessive compulsive disorder </e2> , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> on a p . r . n .
NO_RELATION	METHOD : Six patients with either obsessive compulsive disorder , <e2> trichotillomania </e2> , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> on a p . r . n .
NO_RELATION	METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , <e2> anxiety </e2> , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> on a p . r . n .
NO_RELATION	METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or <e2> affective disorders </e2> who suffered sexual side effects after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> on a p . r . n .
NO_RELATION	METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered <e2> sexual side effects </e2> after treatment with serotonin reuptake blockers were given <e1> yohimbine </e1> on a p . r . n .
NO_RELATION	Side effects of <e1> yohimbine </e1> included excessive sweating , increased <e2> anxiety </e2> , and a wound - up feeling in some patients .
NO_RELATION	CONCLUSION : The results of this study indicate that <e1> yohimbine </e1> may be an effective treatment for the <e2> sexual side effects </e2> caused by serotonin reuptake blockers .
NO_RELATION	CONCLUSION : The results of this study indicate that yohimbine may be an effective treatment for the <e2> sexual side effects </e2> caused by <e1> serotonin </e1> reuptake blockers .
CID	<e2> Hypersensitivity </e2> immune reaction as a mechanism for <e1> dilevalol </e1> - associated hepatitis .
CID	Hypersensitivity immune reaction as a mechanism for <e1> dilevalol </e1> - associated <e2> hepatitis </e2> .
CID	OBJECTIVE : To assess lymphocyte reactivity to <e1> dilevalol </e1> and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced <e2> liver injury </e2> .
CID	OBJECTIVE : To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo <e1> dilevalol </e1> antigens or metabolites in a case of dilevalol - induced <e2> liver injury </e2> .
CID	OBJECTIVE : To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of <e1> dilevalol </e1> - induced <e2> liver injury </e2> .
CID	PATIENT : A 58 - year - old woman with a clinical diagnosis of <e1> dilevalol </e1> - induced <e2> liver injury </e2> .
CID	CONCLUSIONS : The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared <e1> dilevalol </e1> antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced <e2> liver injury </e2> .
CID	CONCLUSIONS : The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in <e1> dilevalol </e1> - induced <e2> liver injury </e2> .
CID	Reversible <e2> myocardial hypertrophy </e2> induced by <e1> tacrolimus </e1> in a pediatric heart transplant recipient : case report .
CID	Herein we describe transient <e2> myocardial hypertrophy </e2> induced by <e1> tacrolimus </e1> after heart transplantation .
CID	<e2> Myocardial hypertrophy </e2> completely resolved upon reducing the target concentration of <e1> tacrolimus </e1> and did not recur , as confirmed at echocardiography and myocardial biopsy .
CID	Thus , we conclude that <e1> tacrolimus </e1> induces reversible <e2> myocardial hypertrophy </e2> .
CID	Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and <e1> levodopa </e1> - induced <e2> dyskinesias </e2> were selected .
NO_RELATION	Complications were observed in two patients : one had a left <e2> homonymous hemianopsia </e2> after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with <e1> Valproate </e1> 1000 mg / day .
CID	Protective effects of antithrombin on <e1> puromycin aminonucleoside </e1> <e2> nephrosis </e2> in rats .
CID	We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with <e1> puromycin aminonucleoside </e1> - induced <e2> nephrosis </e2> , which is an experimental model of human nephrotic syndrome .
NO_RELATION	We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with <e1> puromycin aminonucleoside </e1> - induced nephrosis , which is an experimental model of human <e2> nephrotic syndrome </e2> .
NO_RELATION	Treatment with antithrombin attenuated the <e1> puromycin aminonucleoside </e1> - induced <e2> hematological abnormalities </e2> .
NO_RELATION	<e1> Puromycin aminonucleoside </e1> - induced <e2> renal dysfunction </e2> and hyperlipidemia were also suppressed .
NO_RELATION	<e1> Puromycin aminonucleoside </e1> - induced renal dysfunction and <e2> hyperlipidemia </e2> were also suppressed .
NO_RELATION	These findings suggest that thrombin plays an important role in the pathogenesis of <e1> puromycin aminonucleoside </e1> - induced <e2> nephrotic syndrome </e2> .
CID	Reverse or inverted <e2> left ventricular apical ballooning syndrome </e2> ( reverse Takotsubo cardiomyopathy ) in a young woman in the setting of <e1> amphetamine </e1> use .
CID	Reverse or inverted left ventricular apical ballooning syndrome ( reverse <e2> Takotsubo cardiomyopathy </e2> ) in a young woman in the setting of <e1> amphetamine </e1> use .
CID	In this article , we report an interesting case of a young woman who presented with this rare type of reverse <e2> apical ballooning syndrome </e2> occurring after <e1> amphetamine </e1> use .
CID	<e1> Amphetamine </e1> - induced <e2> locomotor hyperactivity </e2> was similar in all groups .
CID	Peripheral <e1> iron dextran </e1> induced <e2> degeneration of dopaminergic neurons </e2> in rat substantia nigra .
NO_RELATION	<e1> Iron </e1> accumulation is considered to be involved in the pathogenesis of <e2> Parkinson ' s disease </e2> .
NO_RELATION	To demonstrate the relationship between peripheral <e1> iron </e1> overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the <e2> degeneration of dopaminergic neurons </e2> and increased iron content in the SN of iron dextran overloaded animals .
NO_RELATION	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , <e1> tyrosine </e1> hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the <e2> degeneration of dopaminergic neurons </e2> and increased iron content in the SN of iron dextran overloaded animals .
NO_RELATION	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' <e1> iron </e1> staining , and high performance liquid chromatography - electrochemical detection to study the <e2> degeneration of dopaminergic neurons </e2> and increased iron content in the SN of iron dextran overloaded animals .
NO_RELATION	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the <e2> degeneration of dopaminergic neurons </e2> and increased <e1> iron </e1> content in the SN of iron dextran overloaded animals .
CID	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the <e2> degeneration of dopaminergic neurons </e2> and increased iron content in the SN of <e1> iron dextran </e1> overloaded animals .
CID	These results suggest that peripheral <e1> iron dextran </e1> can increase the iron level in the SN , where excessive iron causes the <e2> degeneration of dopaminergic neurons </e2> .
NO_RELATION	These results suggest that peripheral iron dextran can increase the <e1> iron </e1> level in the SN , where excessive iron causes the <e2> degeneration of dopaminergic neurons </e2> .
NO_RELATION	These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive <e1> iron </e1> causes the <e2> degeneration of dopaminergic neurons </e2> .
NO_RELATION	<e1> Warfarin </e1> - induced <e2> leukocytoclastic vasculitis </e2> .
NO_RELATION	We report 4 patients with late - onset <e2> LV </e2> probably due to <e1> warfarin </e1> .
NO_RELATION	All 4 patients presented with <e2> skin eruptions </e2> that developed after receiving <e1> warfarin </e1> for several years .
NO_RELATION	The results of <e2> skin lesion </e2> biopsies were available in 3 patients , confirming LV Cutaneous lesions resolved in all patients after <e1> warfarin </e1> was discontinued .
CID	The results of skin lesion biopsies were available in 3 patients , confirming <e2> LV Cutaneous lesions </e2> resolved in all patients after <e1> warfarin </e1> was discontinued .
NO_RELATION	<e2> LV </e2> may be a late - onset adverse reaction associated with <e1> warfarin </e1> therapy .
NO_RELATION	The activation of spinal <e1> N - methyl - D - aspartate </e1> receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of <e2> spinal cord ischemia </e2> .
NO_RELATION	The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial <e1> morphine </e1> after a noninjurious interval of <e2> spinal cord ischemia </e2> .
NO_RELATION	We investigated the relationship between the degeneration of spinal motor neurons and activation of <e1> N - methyl - d - aspartate </e1> ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of <e2> aortic occlusion </e2> in rats .
NO_RELATION	We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( <e1> NMDA </e1> ) receptors after neuraxial morphine following a noninjurious interval of <e2> aortic occlusion </e2> in rats .
NO_RELATION	We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial <e1> morphine </e1> following a noninjurious interval of <e2> aortic occlusion </e2> in rats .
NO_RELATION	Second , we investigated the effect of IT <e1> MK - 801 </e1> ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced <e2> spastic paraparesis </e2> .
CID	Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after <e1> morphine </e1> - induced <e2> spastic paraparesis </e2> .
NO_RELATION	IT <e1> MK - 801 </e1> significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced <e2> spastic paraparesis </e2> compared with the saline group .
CID	IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after <e1> morphine </e1> - induced <e2> spastic paraparesis </e2> compared with the saline group .
CID	These data indicate that IT <e1> morphine </e1> induces <e2> spastic paraparesis </e2> with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .
NO_RELATION	These data indicate that IT morphine induces <e2> spastic paraparesis </e2> with a concomitant increase in CSF <e1> glutamate </e1> , which is involved in NMDA receptor activation .
NO_RELATION	These data indicate that IT morphine induces <e2> spastic paraparesis </e2> with a concomitant increase in CSF glutamate , which is involved in <e1> NMDA </e1> receptor activation .
NO_RELATION	We suggest that opioids may be <e2> neurotoxic </e2> in the setting of spinal cord ischemia via <e1> NMDA </e1> receptor activation .
NO_RELATION	We suggest that opioids may be neurotoxic in the setting of <e2> spinal cord ischemia </e2> via <e1> NMDA </e1> receptor activation .
NO_RELATION	Reduced <e1> sodium </e1> channel density , altered voltage dependence of inactivation , and increased susceptibility to <e2> seizures </e2> in mice lacking sodium channel beta 2 - subunits .
NO_RELATION	Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to <e2> seizures </e2> in mice lacking <e1> sodium </e1> channel beta 2 - subunits .
CID	beta2 ( - / - ) mice displayed increased susceptibility to <e2> seizures </e2> , as indicated by reduced latency and threshold for <e1> pilocarpine </e1> - induced seizures , but seemed normal in other neurological tests .
CID	beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for <e1> pilocarpine </e1> - induced <e2> seizures </e2> , but seemed normal in other neurological tests .
NO_RELATION	OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for <e1> cocaine </e1> or amphetamine in adult emergency department <e2> seizure </e2> patients .
NO_RELATION	OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or <e1> amphetamine </e1> in adult emergency department <e2> seizure </e2> patients .
NO_RELATION	Patient demographics , history of underlying drug or <e1> alcohol </e1> - related <e2> seizure </e2> disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .
NO_RELATION	Patient demographics , history of underlying drug or <e1> alcohol </e1> - related seizure disorder , estimated time from <e2> seizure </e2> to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .
NO_RELATION	Patient demographics , history of underlying drug or <e1> alcohol </e1> - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of <e2> cocaine or amphetamine abuse </e2> , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .
NO_RELATION	CONCLUSIONS : During this study period , routine plasma screening for <e1> cocaine </e1> and amphetamines in adult <e2> seizure </e2> patients had a low yield .
NO_RELATION	CONCLUSIONS : During this study period , routine plasma screening for cocaine and <e1> amphetamines </e1> in adult <e2> seizure </e2> patients had a low yield .
NO_RELATION	The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on <e2> parkinsonian </e2> ' off ' signs and <e1> levodopa </e1> - induced dyskinesias ( LID ) .
CID	The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and <e1> levodopa </e1> - induced <e2> dyskinesias </e2> ( LID ) .
CID	The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and <e1> levodopa </e1> - induced dyskinesias ( <e2> LID </e2> ) .
CID	We found significant positive correlations between the preoperative <e1> levodopa </e1> responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in <e2> LID </e2> .
CID	We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the <e1> levodopa </e1> responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in <e2> LID </e2> .
NO_RELATION	The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of <e2> parkinsonian </e2> ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .
CID	The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian ' off ' signs and <e2> LID </e2> and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .
CID	The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with <e2> dyskinesias </e2> and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .
NO_RELATION	The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and <e2> parkinsonian </e2> ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .
NO_RELATION	The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of <e2> parkinsonian </e2> ' off ' signs and dyskinesias .
CID	The differential predictive value of <e1> levodopa </e1> responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and <e2> dyskinesias </e2> .
NO_RELATION	<e2> Pain </e2> responses in <e1> methadone </e1> - maintained opioid abusers .
NO_RELATION	This study was designed to describe <e2> pain </e2> tolerance and analgesic response in a sample of opioid addicts stabilized in <e1> methadone </e1> - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .
NO_RELATION	This study was designed to describe pain tolerance and analgesic response in a sample of <e2> opioid addicts </e2> stabilized in <e1> methadone </e1> - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .
NO_RELATION	By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) <e2> pain </e2> was examined , both before and after oral administration of therapeutic doses of common opioid ( <e1> hydromorphone </e1> 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .
NO_RELATION	By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) <e2> pain </e2> was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( <e1> ketorolac </e1> 10 mg ) analgesic agents .
CID	METHODS : <e1> Puromycin aminonucleoside </e1> ( PAN ) was administered to Sprague Dawley rats to induce <e2> proteinuria </e2> .
CID	METHODS : Puromycin aminonucleoside ( <e1> PAN </e1> ) was administered to Sprague Dawley rats to induce <e2> proteinuria </e2> .
NO_RELATION	Over expression of vascular endothelial growth factor and its receptor during the development of <e1> estrogen </e1> - induced rat <e2> pituitary tumors </e2> may mediate estrogen - initiated tumor angiogenesis .
NO_RELATION	Over expression of vascular endothelial growth factor and its receptor during the development of <e1> estrogen </e1> - induced rat pituitary tumors may mediate estrogen - initiated <e2> tumor </e2> angiogenesis .
NO_RELATION	Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat <e2> pituitary tumors </e2> may mediate <e1> estrogen </e1> - initiated tumor angiogenesis .
NO_RELATION	Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate <e1> estrogen </e1> - initiated <e2> tumor </e2> angiogenesis .
NO_RELATION	<e1> Estrogens </e1> , which have been associated with several types of human and animal <e2> cancers </e2> , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .
NO_RELATION	<e1> Estrogens </e1> , which have been associated with several types of human and animal cancers , can induce <e2> tumor </e2> angiogenesis in the pituitary of Fischer 344 rats .
NO_RELATION	The mechanistic details of <e2> tumor </e2> angiogenesis induction , during <e1> estrogen </e1> carcinogenesis , are still unknown .
NO_RELATION	The mechanistic details of tumor angiogenesis induction , during <e1> estrogen </e1> <e2> carcinogenesis </e2> , are still unknown .
NO_RELATION	To elucidate the role of <e1> estrogen </e1> in the regulation of <e2> tumor </e2> angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .
NO_RELATION	The high <e2> tumor </e2> angiogenic potential was associated with an elevated VEGF / VPF protein expression in the <e1> E2 </e1> exposed pituitary of ovariectomized ( OVEX ) rats .
NO_RELATION	These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of <e1> estrogen </e1> induced <e2> tumor </e2> angiogenesis in the rat pituitary .
NO_RELATION	<e1> Pravastatin </e1> - associated <e2> myopathy </e2> .
CID	A case of acute <e2> inflammatory myopathy </e2> associated with the use of <e1> pravastatin </e1> , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .
NO_RELATION	He assumed <e1> pravastatin </e1> ( 20 mg / day ) because of <e2> hypercholesterolemia </e2> .
NO_RELATION	He was admitted with acute <e2> myopathy </e2> of the lower limbs which resolved in a few days after <e1> pravastatin </e1> discontinuation .
NO_RELATION	While <e1> lovastatin </e1> and simvastatin have been associated with toxic <e2> myopathy </e2> , pravastatin - associated myopathy could represent a distinct , inflammatory entity .
NO_RELATION	While <e1> lovastatin </e1> and simvastatin have been associated with toxic myopathy , pravastatin - associated <e2> myopathy </e2> could represent a distinct , inflammatory entity .
NO_RELATION	While lovastatin and <e1> simvastatin </e1> have been associated with toxic <e2> myopathy </e2> , pravastatin - associated myopathy could represent a distinct , inflammatory entity .
NO_RELATION	While lovastatin and <e1> simvastatin </e1> have been associated with toxic myopathy , pravastatin - associated <e2> myopathy </e2> could represent a distinct , inflammatory entity .
NO_RELATION	While lovastatin and simvastatin have been associated with toxic <e2> myopathy </e2> , <e1> pravastatin </e1> - associated myopathy could represent a distinct , inflammatory entity .
NO_RELATION	While lovastatin and simvastatin have been associated with toxic myopathy , <e1> pravastatin </e1> - associated <e2> myopathy </e2> could represent a distinct , inflammatory entity .
CID	Dose - effect and structure - function relationships in <e1> doxorubicin </e1> <e2> cardiomyopathy </e2> .
CID	The <e2> cardiomyopathy </e2> ( CM ) produced by the anticancer drug <e1> doxorubicin </e1> ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .
CID	The cardiomyopathy ( <e2> CM </e2> ) produced by the anticancer drug <e1> doxorubicin </e1> ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .
CID	The cardiomyopathy ( CM ) produced by the anticancer drug <e1> doxorubicin </e1> ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of <e2> myocardial disease </e2> .
CID	The <e2> cardiomyopathy </e2> ( CM ) produced by the anticancer drug doxorubicin ( <e1> DXR </e1> ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .
CID	The cardiomyopathy ( <e2> CM </e2> ) produced by the anticancer drug doxorubicin ( <e1> DXR </e1> ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .
CID	The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( <e1> DXR </e1> ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of <e2> myocardial disease </e2> .
CID	The <e2> cardiomyopathy </e2> ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( <e1> Adriamycin </e1> ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .
CID	The cardiomyopathy ( <e2> CM </e2> ) produced by the anticancer drug doxorubicin ( DXR ) ( <e1> Adriamycin </e1> ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .
CID	The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( <e1> Adriamycin </e1> ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of <e2> myocardial disease </e2> .
CID	In <e1> DXR </e1> - <e2> CM </e2> myocardial damage is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .
CID	In <e1> DXR </e1> - CM <e2> myocardial damage </e2> is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .
CID	In DXR - <e2> CM </e2> myocardial damage is proportional to the degree of cytotoxic insult ( <e1> DXR </e1> dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .
CID	In DXR - CM <e2> myocardial damage </e2> is proportional to the degree of cytotoxic insult ( <e1> DXR </e1> dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .
CID	Fatal <e2> aplastic anemia </e2> following topical administration of ophthalmic <e1> chloramphenicol </e1> .
CID	A 73 - year - old woman died of <e2> aplastic anemia </e2> less than two months after undergoing cataract extraction and beginning topical therapy with <e1> chloramphenicol </e1> .
NO_RELATION	A 73 - year - old woman died of aplastic anemia less than two months after undergoing <e2> cataract </e2> extraction and beginning topical therapy with <e1> chloramphenicol </e1> .
CID	The pattern of the <e2> aplastic anemia </e2> was associated with an idiosyncratic response to <e1> chloramphenicol </e1> .
CID	This was the second report of fatal <e2> aplastic anemia </e2> after topical treatment with <e1> chloramphenicol </e1> for ocular conditions , although two cases of reversible bone marrow hypoplasia have also been reported .
NO_RELATION	This was the second report of fatal aplastic anemia after topical treatment with <e1> chloramphenicol </e1> for ocular conditions , although two cases of reversible <e2> bone marrow hypoplasia </e2> have also been reported .
NO_RELATION	Any other suspected cases of <e2> ocular toxicity </e2> associated with topically applied <e1> chloramphenicol </e1> should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .
CID	<e2> Bradycardia </e2> due to <e1> trihexyphenidyl hydrochloride </e1> .
NO_RELATION	A chronic <e2> schizophrenic </e2> patient was treated with an anticholinergic drug , <e1> trihexyphenidyl hydrochloride </e1> .
CID	Experimental <e1> cyclosporine </e1> <e2> nephrotoxicity </e2> : risk of concomitant chemotherapy .
CID	The role of <e1> cyclosporine </e1> ( CSA ) alone or in combination with various chemotherapeutics in the development of <e2> renal toxicity </e2> was evaluated in rats .
CID	The role of cyclosporine ( <e1> CSA </e1> ) alone or in combination with various chemotherapeutics in the development of <e2> renal toxicity </e2> was evaluated in rats .
CID	The combined administration of <e1> CSA </e1> and various chemotherapeutic drugs with a <e2> nephrotoxic </e2> potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .
NO_RELATION	The combined administration of <e1> CSA </e1> and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced <e2> toxicity </e2> in the rat model .
NO_RELATION	The combined administration of CSA and various chemotherapeutic drugs with a <e2> nephrotoxic </e2> potential , such as <e1> gentamicin </e1> ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .
NO_RELATION	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as <e1> gentamicin </e1> ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced <e2> toxicity </e2> in the rat model .
NO_RELATION	The combined administration of CSA and various chemotherapeutic drugs with a <e2> nephrotoxic </e2> potential , such as gentamicin ( at therapeutic doses ) , <e1> amphothericin B </e1> and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .
NO_RELATION	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , <e1> amphothericin B </e1> and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced <e2> toxicity </e2> in the rat model .
NO_RELATION	The combined administration of CSA and various chemotherapeutic drugs with a <e2> nephrotoxic </e2> potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and <e1> ketoconazole </e1> , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .
NO_RELATION	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and <e1> ketoconazole </e1> , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced <e2> toxicity </e2> in the rat model .
CID	The combined administration of CSA and various chemotherapeutic drugs with a <e2> nephrotoxic </e2> potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the <e1> CSA </e1> induced toxicity in the rat model .
NO_RELATION	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the <e1> CSA </e1> induced <e2> toxicity </e2> in the rat model .
NO_RELATION	<e1> Gentamicin </e1> at toxic doses , however , increased CSA <e2> nephrotoxicity </e2> .
CID	Gentamicin at toxic doses , however , increased <e1> CSA </e1> <e2> nephrotoxicity </e2> .
CID	Thus , the <e2> nephrotoxicity </e2> induced by <e1> CSA </e1> has a different pathogenetic mechanism .
CID	Receptor mechanisms of <e1> nicotine </e1> - induced <e2> locomotor hyperactivity </e2> in chronic nicotine - treated rats .
CID	Receptor mechanisms of nicotine - induced <e2> locomotor hyperactivity </e2> in chronic <e1> nicotine </e1> - treated rats .
CID	These results suggest that chronic <e1> nicotine </e1> - treated rats develop <e2> locomotor hyperactivity </e2> in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .
CID	These results suggest that chronic nicotine - treated rats develop <e2> locomotor hyperactivity </e2> in response to <e1> nicotine </e1> initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .
NO_RELATION	These results suggest that chronic nicotine - treated rats develop <e2> locomotor hyperactivity </e2> in response to nicotine initially due to increases of both the density of nicotinic receptors and <e1> DA </e1> concentration , followed by inducing DA receptor supersensitivity in the striatum .
NO_RELATION	These results suggest that chronic nicotine - treated rats develop <e2> locomotor hyperactivity </e2> in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing <e1> DA </e1> receptor supersensitivity in the striatum .
CID	<e1> Hydrocortisone </e1> - induced <e2> hypertension </e2> in humans : pressor responsiveness and sympathetic function .
CID	The <e2> rise in resting blood pressure </e2> with <e1> hydrocortisone </e1> is associated with an increased cardiac output ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	The rise in resting blood pressure with <e1> hydrocortisone </e1> is associated with an <e2> increased cardiac output </e2> ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
CID	Although <e1> suprofen </e1> has been associated with the development of <e2> acute renal failure </e2> in greater than 100 subjects , the mechanism of damage remains unclear .
NO_RELATION	The direct <e2> nephrotoxic </e2> effects of a single dose of 15 mg of <e1> suprofen </e1> were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .
NO_RELATION	The direct <e2> nephrotoxic </e2> effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of <e1> uric acid </e1> .
CID	In summary , <e1> suprofen </e1> causes <e2> acute declines in renal function </e2> , most likely by directly altering the intrarenal distribution of uric acid .
NO_RELATION	In summary , suprofen causes <e2> acute declines in renal function </e2> , most likely by directly altering the intrarenal distribution of <e1> uric acid </e1> .
CID	<e1> Cocaine </e1> - induced brainstem <e2> seizures </e2> and behavior .
NO_RELATION	Increased sulfation and decreased 7alpha - hydroxylation of <e1> deoxycholic acid </e1> in ethinyl estradiol - induced <e2> cholestasis </e2> in rats .
CID	Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in <e1> ethinyl estradiol </e1> - induced <e2> cholestasis </e2> in rats .
NO_RELATION	Effects of <e1> ouabain </e1> on myocardial oxygen supply and demand in patients with chronic <e2> coronary artery disease </e2> .
NO_RELATION	Effects of ouabain on myocardial <e1> oxygen </e1> supply and demand in patients with chronic <e2> coronary artery disease </e2> .
NO_RELATION	The effects of <e1> digitalis glycosides </e1> on myocardial oxygen supply and demand are of particular interest in the presence of obstructive <e2> coronary artery disease </e2> , but have not been measured previously in man .
NO_RELATION	The effects of digitalis glycosides on myocardial <e1> oxygen </e1> supply and demand are of particular interest in the presence of obstructive <e2> coronary artery disease </e2> , but have not been measured previously in man .
NO_RELATION	We assessed the effects of <e1> ouabain </e1> ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic <e2> coronary artery disease </e2> without clinical congestive heart failure .
NO_RELATION	We assessed the effects of <e1> ouabain </e1> ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical <e2> congestive heart failure </e2> .
NO_RELATION	We conclude that in patients with chronic <e2> coronary artery disease </e2> who are not in clinical congestive heart failure left ventricular end - diastolic volume falls after <e1> ouabain </e1> administration even when it is initially normal .
NO_RELATION	We conclude that in patients with chronic coronary artery disease who are not in clinical <e2> congestive heart failure </e2> left ventricular end - diastolic volume falls after <e1> ouabain </e1> administration even when it is initially normal .
CID	We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure <e2> left ventricular end - diastolic volume falls </e2> after <e1> ouabain </e1> administration even when it is initially normal .
CID	<e2> Prolongation of the QT interval </e2> related to <e1> cisapride </e1> - diltiazem interaction .
CID	<e2> Prolongation of the QT interval </e2> related to cisapride - <e1> diltiazem </e1> interaction .
NO_RELATION	<e1> Cisapride </e1> , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of <e2> gastrointestinal motility disorders </e2> .
CID	<e2> Prolongation of QT interval </e2> , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with <e1> erythromycin </e1> or azole antifungal agents , but not with other CYP3A4 inhibitors .
CID	Prolongation of QT interval , <e2> torsades de pointes </e2> , and sudden cardiac death have been reported after concomitant administration with <e1> erythromycin </e1> or azole antifungal agents , but not with other CYP3A4 inhibitors .
CID	Prolongation of QT interval , torsades de pointes , and <e2> sudden cardiac death </e2> have been reported after concomitant administration with <e1> erythromycin </e1> or azole antifungal agents , but not with other CYP3A4 inhibitors .
CID	<e2> Prolongation of QT interval </e2> , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with erythromycin or <e1> azole </e1> antifungal agents , but not with other CYP3A4 inhibitors .
CID	Prolongation of QT interval , <e2> torsades de pointes </e2> , and sudden cardiac death have been reported after concomitant administration with erythromycin or <e1> azole </e1> antifungal agents , but not with other CYP3A4 inhibitors .
CID	Prolongation of QT interval , torsades de pointes , and <e2> sudden cardiac death </e2> have been reported after concomitant administration with erythromycin or <e1> azole </e1> antifungal agents , but not with other CYP3A4 inhibitors .
NO_RELATION	A possible drug interaction occurred in a 45 - year - old woman who was taking <e1> cisapride </e1> for <e2> gastroesophageal reflux disorder </e2> and diltiazem , an agent that has inhibitory effect on CYP3A4 , for hypertension .
NO_RELATION	A possible drug interaction occurred in a 45 - year - old woman who was taking <e1> cisapride </e1> for gastroesophageal reflux disorder and diltiazem , an agent that has inhibitory effect on CYP3A4 , for <e2> hypertension </e2> .
NO_RELATION	A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for <e2> gastroesophageal reflux disorder </e2> and <e1> diltiazem </e1> , an agent that has inhibitory effect on CYP3A4 , for hypertension .
NO_RELATION	A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for gastroesophageal reflux disorder and <e1> diltiazem </e1> , an agent that has inhibitory effect on CYP3A4 , for <e2> hypertension </e2> .
NO_RELATION	<e1> Paclitaxel </e1> combined with carboplatin in the first - line treatment of advanced <e2> ovarian cancer </e2> .
NO_RELATION	Paclitaxel combined with <e1> carboplatin </e1> in the first - line treatment of advanced <e2> ovarian cancer </e2> .
NO_RELATION	In a phase I study to determine the maximum tolerated dose of <e1> paclitaxel </e1> ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced <e2> ovarian cancer </e2> , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .
NO_RELATION	In a phase I study to determine the maximum tolerated dose of paclitaxel ( <e1> Taxol </e1> ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced <e2> ovarian cancer </e2> , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .
NO_RELATION	In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with <e1> carboplatin </e1> administered every 21 days to women with advanced <e2> ovarian cancer </e2> , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .
NO_RELATION	In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced <e2> ovarian cancer </e2> , <e1> paclitaxel </e1> doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .
NO_RELATION	Relative efficacy and <e2> toxicity </e2> of <e1> netilmicin </e1> and tobramycin in oncology patients .
NO_RELATION	Relative efficacy and <e2> toxicity </e2> of netilmicin and <e1> tobramycin </e1> in oncology patients .
NO_RELATION	We prospectively compared the efficacy and safety of <e1> netilmicin sulfate </e1> or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe <e2> infections </e2> .
NO_RELATION	We prospectively compared the efficacy and safety of netilmicin sulfate or <e1> tobramycin sulfate </e1> in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe <e2> infections </e2> .
NO_RELATION	We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with <e1> piperacillin sodium </e1> in 118 immunocompromised patients with presumed severe <e2> infections </e2> .
CID	<e2> Nephrotoxicity </e2> occurred in a similar proportion in patients treated with <e1> netilmicin </e1> and tobramycin ( 17 % vs 11 % ) .
CID	<e2> Nephrotoxicity </e2> occurred in a similar proportion in patients treated with netilmicin and <e1> tobramycin </e1> ( 17 % vs 11 % ) .
CID	<e2> Ototoxicity </e2> occurred in four ( 9 . 5 % ) of 42 <e1> netilmicin </e1> and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .
CID	<e2> Ototoxicity </e2> occurred in four ( 9 . 5 % ) of 42 netilmicin and <e1> piperacillin </e1> and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .
CID	<e2> Ototoxicity </e2> occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 <e1> tobramycin </e1> and piperacillin - treated patients .
CID	<e2> Ototoxicity </e2> occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and <e1> piperacillin </e1> - treated patients .
NO_RELATION	We conclude that <e1> aminoglycoside </e1> - associated <e2> ototoxicity </e2> was less severe and more often reversible with netilmicin than with tobramycin .
CID	We conclude that aminoglycoside - associated <e2> ototoxicity </e2> was less severe and more often reversible with <e1> netilmicin </e1> than with tobramycin .
CID	We conclude that aminoglycoside - associated <e2> ototoxicity </e2> was less severe and more often reversible with netilmicin than with <e1> tobramycin </e1> .
NO_RELATION	Effect of <e1> prostaglandin </e1> synthetase inhibitors on experimentally induced <e2> convulsions </e2> in rats .
NO_RELATION	To investigate the relationship of <e1> prostaglandins </e1> ( PGs ) to <e2> seizure </e2> induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
NO_RELATION	To investigate the relationship of <e1> prostaglandins </e1> ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
NO_RELATION	To investigate the relationship of prostaglandins ( <e1> PGs </e1> ) to <e2> seizure </e2> induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
NO_RELATION	To investigate the relationship of prostaglandins ( <e1> PGs </e1> ) to seizure induction , the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to <e2> seizure </e2> induction , the effects of six PG synthetase inhibitors on convulsions induced by <e1> flurothyl </e1> , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by <e1> flurothyl </e1> , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to <e2> seizure </e2> induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , <e1> picrotoxin </e1> , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by flurothyl , <e1> picrotoxin </e1> , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to <e2> seizure </e2> induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , <e1> pentetrazol </e1> ( PTZ ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by flurothyl , picrotoxin , <e1> pentetrazol </e1> ( PTZ ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to <e2> seizure </e2> induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( <e1> PTZ </e1> ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by flurothyl , picrotoxin , pentetrazol ( <e1> PTZ </e1> ) , electroshock or bicuculline were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to <e2> seizure </e2> induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or <e1> bicuculline </e1> were evaluated .
CID	To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on <e2> convulsions </e2> induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or <e1> bicuculline </e1> were evaluated .
NO_RELATION	These results suggest that <e1> PGs </e1> are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced <e2> convulsions </e2> , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .
NO_RELATION	These results suggest that <e1> PGs </e1> are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced <e2> convulsions </e2> .
CID	These results suggest that PGs are involved in the mechanism ( s ) underlying <e1> fluorthyl </e1> - and PTZ - induced <e2> convulsions </e2> , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .
CID	These results suggest that PGs are involved in the mechanism ( s ) underlying <e1> fluorthyl </e1> - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced <e2> convulsions </e2> .
CID	These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and <e1> PTZ </e1> - induced <e2> convulsions </e2> , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .
CID	These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and <e1> PTZ </e1> - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced <e2> convulsions </e2> .
CID	These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced <e2> convulsions </e2> , but not <e1> picrotoxin </e1> - , electroshock - , or bicuculline - induced convulsions .
CID	These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not <e1> picrotoxin </e1> - , electroshock - , or bicuculline - induced <e2> convulsions </e2> .
CID	These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced <e2> convulsions </e2> , but not picrotoxin - , electroshock - , or <e1> bicuculline </e1> - induced convulsions .
CID	These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or <e1> bicuculline </e1> - induced <e2> convulsions </e2> .
NO_RELATION	This is a case report on a 45 - year old African - American female with newly diagnosed <e2> hypertension </e2> , who was started on a combination pill of <e1> amlodipine </e1> / benazapril 10 / 5 mg .
NO_RELATION	This is a case report on a 45 - year old African - American female with newly diagnosed <e2> hypertension </e2> , who was started on a combination pill of amlodipine / <e1> benazapril </e1> 10 / 5 mg .
NO_RELATION	The recognition of <e1> angiotensin </e1> - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) <e2> intestinal angioedema </e2> constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .
NO_RELATION	The recognition of angiotensin - converting enzyme ( ACE ) and <e1> angiotensin </e1> receptor blocker ( ARB ) <e2> intestinal angioedema </e2> constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .
CID	<e1> Valproic acid </e1> I : time course of lipid peroxidation biomarkers , <e2> liver toxicity </e2> , and valproic acid metabolite levels in rats .
CID	Valproic acid I : time course of lipid peroxidation biomarkers , <e2> liver toxicity </e2> , and <e1> valproic acid </e1> metabolite levels in rats .
CID	To determine whether there was a temporal relationship between <e1> VPA </e1> - associated oxidative stress and <e2> hepatotoxicity </e2> , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .
CID	To determine whether there was a temporal relationship between VPA - associated oxidative stress and <e2> hepatotoxicity </e2> , adult male Sprague - Dawley rats were treated ip with <e1> VPA </e1> ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .
NO_RELATION	<e2> Liver toxicity </e2> was evaluated based on serum levels of alpha - <e1> glutathione </e1> S - transferase ( alpha - GST ) and by histology .
CID	Overall , these findings indicate that <e1> VPA </e1> treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of <e2> necrosis </e2> , steatosis , and elevated levels of serum alpha - GST .
CID	Overall , these findings indicate that <e1> VPA </e1> treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of necrosis , <e2> steatosis </e2> , and elevated levels of serum alpha - GST .
NO_RELATION	Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of <e1> 15 - F ( 2t ) - IsoP </e1> , which precedes the onset of <e2> necrosis </e2> , steatosis , and elevated levels of serum alpha - GST .
NO_RELATION	Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of <e1> 15 - F ( 2t ) - IsoP </e1> , which precedes the onset of necrosis , <e2> steatosis </e2> , and elevated levels of serum alpha - GST .
NO_RELATION	<e2> Pheochromocytoma </e2> unmasked by <e1> amisulpride </e1> and tiapride .
NO_RELATION	<e2> Pheochromocytoma </e2> unmasked by amisulpride and <e1> tiapride </e1> .
NO_RELATION	OBJECTIVE : To describe the unmasking of <e2> pheochromocytoma </e2> in a patient treated with <e1> amisulpride </e1> and tiapride .
NO_RELATION	OBJECTIVE : To describe the unmasking of <e2> pheochromocytoma </e2> in a patient treated with amisulpride and <e1> tiapride </e1> .
CID	CASE SUMMARY : A 42 - year - old white man developed acute <e2> hypertension </e2> with severe headache and vomiting 2 hours after the first doses of <e1> amisulpride </e1> 100 mg and tiapride 100 mg .
CID	CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe <e2> headache </e2> and vomiting 2 hours after the first doses of <e1> amisulpride </e1> 100 mg and tiapride 100 mg .
CID	CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe headache and <e2> vomiting </e2> 2 hours after the first doses of <e1> amisulpride </e1> 100 mg and tiapride 100 mg .
CID	CASE SUMMARY : A 42 - year - old white man developed acute <e2> hypertension </e2> with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and <e1> tiapride </e1> 100 mg .
CID	CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe <e2> headache </e2> and vomiting 2 hours after the first doses of amisulpride 100 mg and <e1> tiapride </e1> 100 mg .
CID	CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe headache and <e2> vomiting </e2> 2 hours after the first doses of amisulpride 100 mg and <e1> tiapride </e1> 100 mg .
NO_RELATION	DISCUSSION : Drug - induced symptoms of <e2> pheochromocytoma </e2> are often associated with the use of substituted <e1> benzamide </e1> drugs , but the underlying mechanism is unknown .
CID	In our case , use of the Naranjo probability scale indicated a possible relationship between the <e2> hypertensive </e2> crisis and <e1> amisulpride </e1> and tiapride therapy .
CID	In our case , use of the Naranjo probability scale indicated a possible relationship between the <e2> hypertensive </e2> crisis and amisulpride and <e1> tiapride </e1> therapy .
CID	CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of <e1> amisulpride </e1> - and tiapride - induced <e2> hypertensive </e2> crisis in a patient with pheochromocytoma .
NO_RELATION	CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of <e1> amisulpride </e1> - and tiapride - induced hypertensive crisis in a patient with <e2> pheochromocytoma </e2> .
CID	CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and <e1> tiapride </e1> - induced <e2> hypertensive </e2> crisis in a patient with pheochromocytoma .
NO_RELATION	CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and <e1> tiapride </e1> - induced hypertensive crisis in a patient with <e2> pheochromocytoma </e2> .
NO_RELATION	Quantitative drug levels in stimulant <e2> psychosis </e2> : relationship to symptom severity , <e1> catecholamines </e1> and hyperkinesia .
NO_RELATION	Quantitative drug levels in stimulant psychosis : relationship to symptom severity , <e1> catecholamines </e1> and <e2> hyperkinesia </e2> .
NO_RELATION	To examine the relationship between quantitative stimulant drug levels , <e1> catecholamines </e1> , and <e2> psychotic symptoms </e2> , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
NO_RELATION	To examine the relationship between quantitative stimulant drug levels , <e1> catecholamines </e1> , and psychotic symptoms , nineteen patients in a <e2> psychiatric </e2> emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
NO_RELATION	To examine the relationship between quantitative stimulant drug levels , <e1> catecholamines </e1> , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced <e2> psychosis </e2> were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
CID	To examine the relationship between quantitative stimulant drug levels , catecholamines , and <e2> psychotic symptoms </e2> , nineteen patients in a psychiatric emergency service with a diagnosis of <e1> amphetamine </e1> - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
NO_RELATION	To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a <e2> psychiatric </e2> emergency service with a diagnosis of <e1> amphetamine </e1> - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
CID	To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of <e1> amphetamine </e1> - or cocaine - induced <e2> psychosis </e2> were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
CID	To examine the relationship between quantitative stimulant drug levels , catecholamines , and <e2> psychotic symptoms </e2> , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or <e1> cocaine </e1> - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
NO_RELATION	To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a <e2> psychiatric </e2> emergency service with a diagnosis of amphetamine - or <e1> cocaine </e1> - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
CID	To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or <e1> cocaine </e1> - induced <e2> psychosis </e2> were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
NO_RELATION	To examine the relationship between quantitative stimulant drug levels , catecholamines , and <e2> psychotic symptoms </e2> , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and <e1> catecholamine </e1> metabolite levels .
NO_RELATION	To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a <e2> psychiatric </e2> emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and <e1> catecholamine </e1> metabolite levels .
NO_RELATION	To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced <e2> psychosis </e2> were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and <e1> catecholamine </e1> metabolite levels .
CID	<e1> Methamphetamine </e1> or amphetamine levels were related to several psychopathology scores and the global <e2> hyperkinesia </e2> rating .
CID	Methamphetamine or <e1> amphetamine </e1> levels were related to several psychopathology scores and the global <e2> hyperkinesia </e2> rating .
CID	Delayed <e2> asystolic </e2> cardiac arrest after <e1> diltiazem </e1> overdose ; resuscitation with high dose intravenous calcium .
CID	Delayed asystolic <e2> cardiac arrest </e2> after <e1> diltiazem </e1> overdose ; resuscitation with high dose intravenous calcium .
CID	Delayed asystolic cardiac arrest after <e1> diltiazem </e1> <e2> overdose </e2> ; resuscitation with high dose intravenous calcium .
NO_RELATION	Delayed <e2> asystolic </e2> cardiac arrest after diltiazem overdose ; resuscitation with high dose intravenous <e1> calcium </e1> .
NO_RELATION	Delayed asystolic <e2> cardiac arrest </e2> after diltiazem overdose ; resuscitation with high dose intravenous <e1> calcium </e1> .
NO_RELATION	Delayed asystolic cardiac arrest after diltiazem <e2> overdose </e2> ; resuscitation with high dose intravenous <e1> calcium </e1> .
CID	A 51 year old man took a mixed <e2> overdose </e2> including 1 . 8 - 3 . 6 g of <e1> diltiazem </e1> , paracetamol , aspirin , isosorbide nitrate , and alcohol .
NO_RELATION	A 51 year old man took a mixed <e2> overdose </e2> including 1 . 8 - 3 . 6 g of diltiazem , <e1> paracetamol </e1> , aspirin , isosorbide nitrate , and alcohol .
NO_RELATION	A 51 year old man took a mixed <e2> overdose </e2> including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , <e1> aspirin </e1> , isosorbide nitrate , and alcohol .
NO_RELATION	A 51 year old man took a mixed <e2> overdose </e2> including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , <e1> isosorbide </e1> nitrate , and alcohol .
NO_RELATION	A 51 year old man took a mixed <e2> overdose </e2> including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide <e1> nitrate </e1> , and alcohol .
NO_RELATION	A 51 year old man took a mixed <e2> overdose </e2> including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and <e1> alcohol </e1> .
NO_RELATION	This case suggests there is a role for aggressive high dose intravenous <e1> calcium </e1> therapy in severe diltiazem <e2> overdose </e2> , particularly with the onset of asystole .
NO_RELATION	This case suggests there is a role for aggressive high dose intravenous <e1> calcium </e1> therapy in severe diltiazem overdose , particularly with the onset of <e2> asystole </e2> .
CID	This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe <e1> diltiazem </e1> <e2> overdose </e2> , particularly with the onset of asystole .
CID	This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe <e1> diltiazem </e1> overdose , particularly with the onset of <e2> asystole </e2> .
CID	It should be considered early in cases of <e2> cardiac arrest </e2> after <e1> diltiazem </e1> overdose .
CID	It should be considered early in cases of cardiac arrest after <e1> diltiazem </e1> <e2> overdose </e2> .
CID	<e2> Renal papillary necrosis </e2> due to <e1> naproxen </e1> .
NO_RELATION	A 31 - year - old man with <e2> rheumatoid arthritis </e2> , who had previously been treated with <e1> sulindac </e1> , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with <e1> sulindac </e1> , fenoprofen calcium , high dose salicylates and gold salts , developed <e2> renal papillary necrosis </e2> ( RPN ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with <e1> sulindac </e1> , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( <e2> RPN </e2> ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with <e2> rheumatoid arthritis </e2> , who had previously been treated with sulindac , <e1> fenoprofen calcium </e1> , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , <e1> fenoprofen calcium </e1> , high dose salicylates and gold salts , developed <e2> renal papillary necrosis </e2> ( RPN ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , <e1> fenoprofen calcium </e1> , high dose salicylates and gold salts , developed renal papillary necrosis ( <e2> RPN </e2> ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with <e2> rheumatoid arthritis </e2> , who had previously been treated with sulindac , fenoprofen calcium , high dose <e1> salicylates </e1> and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose <e1> salicylates </e1> and gold salts , developed <e2> renal papillary necrosis </e2> ( RPN ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose <e1> salicylates </e1> and gold salts , developed renal papillary necrosis ( <e2> RPN </e2> ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with <e2> rheumatoid arthritis </e2> , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and <e1> gold </e1> salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and <e1> gold </e1> salts , developed <e2> renal papillary necrosis </e2> ( RPN ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and <e1> gold </e1> salts , developed renal papillary necrosis ( <e2> RPN </e2> ) 4 months after institution of naproxen therapy .
NO_RELATION	A 31 - year - old man with <e2> rheumatoid arthritis </e2> , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of <e1> naproxen </e1> therapy .
CID	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed <e2> renal papillary necrosis </e2> ( RPN ) 4 months after institution of <e1> naproxen </e1> therapy .
CID	A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( <e2> RPN </e2> ) 4 months after institution of <e1> naproxen </e1> therapy .
NO_RELATION	We review previous reports linking <e2> RPN </e2> to antiinflammatory drug use and discuss possible advantages of <e1> sulindac </e1> in patients who have experienced renal toxicity from other antiinflammatory agents .
NO_RELATION	We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of <e1> sulindac </e1> in patients who have experienced <e2> renal toxicity </e2> from other antiinflammatory agents .
NO_RELATION	Three patients with <e2> ischaemic heart disease </e2> developed profound cardiac failure , hypotension and bradycardia during combined therapy with <e1> verapamil </e1> and beta - adrenergic blocking drugs .
CID	Three patients with ischaemic heart disease developed profound <e2> cardiac failure </e2> , hypotension and bradycardia during combined therapy with <e1> verapamil </e1> and beta - adrenergic blocking drugs .
CID	Three patients with ischaemic heart disease developed profound cardiac failure , <e2> hypotension </e2> and bradycardia during combined therapy with <e1> verapamil </e1> and beta - adrenergic blocking drugs .
CID	Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and <e2> bradycardia </e2> during combined therapy with <e1> verapamil </e1> and beta - adrenergic blocking drugs .
NO_RELATION	Three patients with <e2> ischaemic heart disease </e2> developed profound cardiac failure , hypotension and bradycardia during combined therapy with verapamil and <e1> beta - adrenergic blocking drugs </e1> .
CID	Three patients with ischaemic heart disease developed profound <e2> cardiac failure </e2> , hypotension and bradycardia during combined therapy with verapamil and <e1> beta - adrenergic blocking drugs </e1> .
CID	Three patients with ischaemic heart disease developed profound cardiac failure , <e2> hypotension </e2> and bradycardia during combined therapy with verapamil and <e1> beta - adrenergic blocking drugs </e1> .
CID	Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and <e2> bradycardia </e2> during combined therapy with verapamil and <e1> beta - adrenergic blocking drugs </e1> .
NO_RELATION	Adverse reactions to <e1> bendrofluazide </e1> and propranolol for the treatment of mild <e2> hypertension </e2> .
NO_RELATION	Adverse reactions to bendrofluazide and <e1> propranolol </e1> for the treatment of mild <e2> hypertension </e2> .
NO_RELATION	Participants in the Medical Research Council treatment trial for mild <e2> hypertension </e2> are randomly allocated to one of four treatment groups : <e1> bendrofluazide </e1> , propranolol , or a placebo for either of these drugs .
NO_RELATION	Participants in the Medical Research Council treatment trial for mild <e2> hypertension </e2> are randomly allocated to one of four treatment groups : bendrofluazide , <e1> propranolol </e1> , or a placebo for either of these drugs .
CID	The results show an association between <e1> bendrofluazide </e1> treatment and <e2> impotence </e2> , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos .
CID	The results show an association between <e1> bendrofluazide </e1> treatment and impotence , and <e2> impotence </e2> also occurred more frequently in patients taking propranolol than in those taking placebos .
CID	The results show an association between bendrofluazide treatment and <e2> impotence </e2> , and impotence also occurred more frequently in patients taking <e1> propranolol </e1> than in those taking placebos .
CID	The results show an association between bendrofluazide treatment and impotence , and <e2> impotence </e2> also occurred more frequently in patients taking <e1> propranolol </e1> than in those taking placebos .
CID	Other adverse reactions significantly linked with active drugs include <e2> impaired glucose tolerance </e2> in men and women and gout in men , associated with <e1> bendrofluazide </e1> treatment , and Raynaud ' s phenomenon and dyspnoea in men and women taking propranolol .
CID	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and <e2> gout </e2> in men , associated with <e1> bendrofluazide </e1> treatment , and Raynaud ' s phenomenon and dyspnoea in men and women taking propranolol .
NO_RELATION	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with <e1> bendrofluazide </e1> treatment , and <e2> Raynaud ' s phenomenon </e2> and dyspnoea in men and women taking propranolol .
NO_RELATION	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with <e1> bendrofluazide </e1> treatment , and Raynaud ' s phenomenon and <e2> dyspnoea </e2> in men and women taking propranolol .
NO_RELATION	Other adverse reactions significantly linked with active drugs include <e2> impaired glucose tolerance </e2> in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud ' s phenomenon and dyspnoea in men and women taking <e1> propranolol </e1> .
NO_RELATION	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and <e2> gout </e2> in men , associated with bendrofluazide treatment , and Raynaud ' s phenomenon and dyspnoea in men and women taking <e1> propranolol </e1> .
CID	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and <e2> Raynaud ' s phenomenon </e2> and dyspnoea in men and women taking <e1> propranolol </e1> .
CID	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud ' s phenomenon and <e2> dyspnoea </e2> in men and women taking <e1> propranolol </e1> .
NO_RELATION	No <e2> corneal disease </e2> is known to have occurred in the <e1> propranolol </e1> group .
NO_RELATION	<e1> Dexmedetomidine </e1> was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal <e2> myocardial infarction </e2> ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and myocardial ischaemia ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .
NO_RELATION	<e1> Dexmedetomidine </e1> was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal myocardial infarction ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and <e2> myocardial ischaemia </e2> ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .
NO_RELATION	Differential diagnosis of high serum <e1> creatine </e1> kinase levels in <e2> systemic lupus erythematosus </e2> .
NO_RELATION	We report the clinical and bioptic findings for a 57 - year - old woman with severe <e1> chloroquine </e1> - induced <e2> myopathy </e2> .
NO_RELATION	Since 1989 , she had been suffering from <e2> systemic lupus erythematosus </e2> ( SLE ) with renal involvement and undergone periods of treatment with <e1> azathioprine </e1> and cyclophosphamide .
NO_RELATION	Since 1989 , she had been suffering from systemic lupus erythematosus ( <e2> SLE </e2> ) with renal involvement and undergone periods of treatment with <e1> azathioprine </e1> and cyclophosphamide .
NO_RELATION	Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with <e2> renal involvement </e2> and undergone periods of treatment with <e1> azathioprine </e1> and cyclophosphamide .
NO_RELATION	Since 1989 , she had been suffering from <e2> systemic lupus erythematosus </e2> ( SLE ) with renal involvement and undergone periods of treatment with azathioprine and <e1> cyclophosphamide </e1> .
NO_RELATION	Since 1989 , she had been suffering from systemic lupus erythematosus ( <e2> SLE </e2> ) with renal involvement and undergone periods of treatment with azathioprine and <e1> cyclophosphamide </e1> .
NO_RELATION	Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with <e2> renal involvement </e2> and undergone periods of treatment with azathioprine and <e1> cyclophosphamide </e1> .
NO_RELATION	Additional therapy with <e1> chloroquine </e1> ( CQ ) was started because of <e2> arthralgia </e2> .
NO_RELATION	Additional therapy with chloroquine ( <e1> CQ </e1> ) was started because of <e2> arthralgia </e2> .
NO_RELATION	<e2> Myositis </e2> was suspected , and the patient was treated with <e1> steroids </e1> .
NO_RELATION	As it revealed <e1> chloroquine </e1> - induced <e2> myopathy </e2> , medication was stopped .
NO_RELATION	Intravenous <e1> ribavirin </e1> treatment for severe <e2> adenovirus disease </e2> in immunocompromised children .
NO_RELATION	<e1> Ribavirin </e1> is licensed in aerosol form for the treatment of <e2> respiratory syncytial virus infection </e2> , and orally in combination with interferon to treat hepatitis C .
NO_RELATION	<e1> Ribavirin </e1> is licensed in aerosol form for the treatment of respiratory syncytial virus infection , and orally in combination with interferon to treat <e2> hepatitis C </e2> .
NO_RELATION	Intravenous <e1> ribavirin </e1> is the treatment of choice for <e2> infection with hemorrhagic fever viruses </e2> .
NO_RELATION	The most common adverse effect of intravenous <e1> ribavirin </e1> is reversible mild <e2> anemia </e2> .
NO_RELATION	The use of <e1> cidofovir </e1> in severe <e2> adenovirus infection </e2> has been limited by adverse effects , the most significant of which is nephrotoxicity .
NO_RELATION	The use of <e1> cidofovir </e1> in severe adenovirus infection has been limited by adverse effects , the most significant of which is <e2> nephrotoxicity </e2> .
NO_RELATION	OBJECTIVE : We report our experience with intravenous <e1> ribavirin </e1> therapy for severe <e2> adenovirus disease </e2> in a series of immunocompromised children and review the literature .
NO_RELATION	DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous <e1> ribavirin </e1> for documented severe <e2> adenovirus disease </e2> .
CID	Use of <e1> cidofovir </e1> in 1 child was associated with <e2> progressive renal failure </e2> and neutropenia .
CID	Use of <e1> cidofovir </e1> in 1 child was associated with progressive renal failure and <e2> neutropenia </e2> .
NO_RELATION	Although intravenous <e1> ribavirin </e1> was not effective for all children with severe <e2> adenovirus disease </e2> in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .
NO_RELATION	Although intravenous <e1> ribavirin </e1> was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the <e2> infection </e2> .
NO_RELATION	CONCLUSIONS : Two of 5 children with severe <e2> adenovirus disease </e2> treated with intravenous <e1> ribavirin </e1> recovered .
NO_RELATION	Given the seriousness and increasing prevalence of <e2> adenovirus disease </e2> in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous <e1> ribavirin </e1> , is clearly required to demonstrate the most effective and least toxic therapy .
CID	<e2> Hepatotoxicity </e2> of <e1> amiodarone </e1> .
NO_RELATION	<e1> Amiodarone </e1> has proved very effective in the treatment of otherwise resistant cardiac <e2> tachyarrhythmias </e2> .
NO_RELATION	A patient with <e2> cholestatic hepatitis </e2> due to <e1> amiodarone </e1> treatment is presented below and a review of the hepatotoxicity of amiodarone is given .
CID	A patient with cholestatic hepatitis due to <e1> amiodarone </e1> treatment is presented below and a review of the <e2> hepatotoxicity </e2> of amiodarone is given .
NO_RELATION	A patient with <e2> cholestatic hepatitis </e2> due to amiodarone treatment is presented below and a review of the hepatotoxicity of <e1> amiodarone </e1> is given .
CID	A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the <e2> hepatotoxicity </e2> of <e1> amiodarone </e1> is given .
CID	It is concluded that solid evidence exists of <e2> hepatic injury </e2> due to <e1> amiodarone </e1> treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .
CID	It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> treatment , including <e2> steatosis </e2> , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .
NO_RELATION	It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> treatment , including steatosis , alterations resembling <e2> alcoholic hepatitis </e2> , cholestatic hepatitis and micronodular cirrhosis of the liver .
NO_RELATION	It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> treatment , including steatosis , alterations resembling alcoholic hepatitis , <e2> cholestatic hepatitis </e2> and micronodular cirrhosis of the liver .
CID	It is concluded that solid evidence exists of hepatic injury due to <e1> amiodarone </e1> treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular <e2> cirrhosis of the liver </e2> .
CID	<e2> Catalepsy </e2> induced by combinations of <e1> ketamine </e1> and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .
CID	<e2> Catalepsy </e2> induced by combinations of ketamine and <e1> morphine </e1> : potentiation , antagonism , tolerance and cross - tolerance in the rat .
NO_RELATION	Previous studies demonstrated that both <e1> ketamine </e1> and morphine induced <e2> analgesia </e2> and catalepsy in the rat .
CID	Previous studies demonstrated that both <e1> ketamine </e1> and morphine induced analgesia and <e2> catalepsy </e2> in the rat .
NO_RELATION	Previous studies demonstrated that both ketamine and <e1> morphine </e1> induced <e2> analgesia </e2> and catalepsy in the rat .
CID	Previous studies demonstrated that both ketamine and <e1> morphine </e1> induced analgesia and <e2> catalepsy </e2> in the rat .
CID	Pre - treatment with <e1> ketamine </e1> produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the <e2> cataleptic </e2> response ; this augmentation was attributed to residual morphine in the brain .
CID	Pre - treatment with ketamine produced cross - tolerance to <e1> morphine </e1> , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the <e2> cataleptic </e2> response ; this augmentation was attributed to residual morphine in the brain .
CID	Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with <e1> morphine </e1> did not induce cross - tolerance to ketamine but rather augmented the <e2> cataleptic </e2> response ; this augmentation was attributed to residual morphine in the brain .
CID	Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to <e1> ketamine </e1> but rather augmented the <e2> cataleptic </e2> response ; this augmentation was attributed to residual morphine in the brain .
CID	Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the <e2> cataleptic </e2> response ; this augmentation was attributed to residual <e1> morphine </e1> in the brain .
NO_RELATION	Latency to the loss of righting reflex , <e2> rigidity </e2> and behavior on recovery , reflected the relative predominance of <e1> ketamine </e1> or morphine in each combination .
NO_RELATION	Latency to the loss of righting reflex , <e2> rigidity </e2> and behavior on recovery , reflected the relative predominance of ketamine or <e1> morphine </e1> in each combination .
NO_RELATION	<e1> Naloxone </e1> inhibited the induced <e2> cataleptic </e2> effects .
NO_RELATION	While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced <e2> catalepsy </e2> , differences in latency , rigidity and behavior , asymmetry of cross - tolerance and a widely - different ID50 for <e1> naloxone </e1> would argue against an action at a single opioid site .
NO_RELATION	While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced catalepsy , differences in latency , <e2> rigidity </e2> and behavior , asymmetry of cross - tolerance and a widely - different ID50 for <e1> naloxone </e1> would argue against an action at a single opioid site .
NO_RELATION	<e2> Acute renal failure </e2> in patients with AIDS on <e1> tenofovir </e1> while receiving prolonged vancomycin course for osteomyelitis .
NO_RELATION	Acute renal failure in patients with <e2> AIDS </e2> on <e1> tenofovir </e1> while receiving prolonged vancomycin course for osteomyelitis .
NO_RELATION	Acute renal failure in patients with AIDS on <e1> tenofovir </e1> while receiving prolonged vancomycin course for <e2> osteomyelitis </e2> .
CID	<e2> Acute renal failure </e2> in patients with AIDS on tenofovir while receiving prolonged <e1> vancomycin </e1> course for osteomyelitis .
NO_RELATION	Acute renal failure in patients with <e2> AIDS </e2> on tenofovir while receiving prolonged <e1> vancomycin </e1> course for osteomyelitis .
NO_RELATION	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged <e1> vancomycin </e1> course for <e2> osteomyelitis </e2> .
NO_RELATION	<e2> Renal failure </e2> developed after a prolonged course of <e1> vancomycin </e1> therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .
NO_RELATION	<e2> Renal failure </e2> developed after a prolonged course of vancomycin therapy in 2 patients who were receiving <e1> tenofovir disoproxil fumarate </e1> as part of an antiretroviral regimen .
NO_RELATION	<e1> Tenofovir </e1> has been implicated in the development of <e2> Fanconi syndrome </e2> and renal insufficiency because of its effects on the proximal renal tubule .
NO_RELATION	<e1> Tenofovir </e1> has been implicated in the development of Fanconi syndrome and <e2> renal insufficiency </e2> because of its effects on the proximal renal tubule .
NO_RELATION	<e1> Vancomycin </e1> <e2> nephrotoxicity </e2> is infrequent but may result from coadministration with a nephrotoxic agent .
NO_RELATION	<e1> Vancomycin </e1> nephrotoxicity is infrequent but may result from coadministration with a <e2> nephrotoxic </e2> agent .
NO_RELATION	Clinicians should be aware that <e1> tenofovir </e1> may raise the risk of <e2> renal failure </e2> during prolonged administration of vancomycin .
NO_RELATION	Clinicians should be aware that tenofovir may raise the risk of <e2> renal failure </e2> during prolonged administration of <e1> vancomycin </e1> .
CID	BACKGROUND : A transient <e2> leukoencephalopathy </e2> mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal <e1> methotrexate </e1> for childhood leukaemia .
NO_RELATION	BACKGROUND : A transient leukoencephalopathy mimicking <e2> cerebrovascular accident </e2> has been described as a complication of chemotherapy , most commonly in recipients of intrathecal <e1> methotrexate </e1> for childhood leukaemia .
NO_RELATION	BACKGROUND : A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal <e1> methotrexate </e1> for childhood <e2> leukaemia </e2> .
CID	RESULTS : We identified 27 reports of toxic <e2> leukoencephalopathy </e2> in patients treated with <e1> methotrexate </e1> ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .
CID	RESULTS : We identified 27 reports of toxic <e2> leukoencephalopathy </e2> in patients treated with methotrexate ( intrathecal , systemic ) , <e1> 5 - fluorouracil </e1> and its derivative carmofur , and capecitabine .
CID	RESULTS : We identified 27 reports of toxic <e2> leukoencephalopathy </e2> in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative <e1> carmofur </e1> , and capecitabine .
CID	RESULTS : We identified 27 reports of toxic <e2> leukoencephalopathy </e2> in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and <e1> capecitabine </e1> .
NO_RELATION	Down - regulation of <e1> norepinephrine </e1> transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced <e2> convulsions </e2> and the counteraction by co - administration with local anesthetics .
NO_RELATION	Down - regulation of norepinephrine transporter function induced by chronic administration of <e1> desipramine </e1> linking to the alteration of sensitivity of local - anesthetics - induced <e2> convulsions </e2> and the counteraction by co - administration with local anesthetics .
NO_RELATION	Alterations of <e1> norepinephrine </e1> transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to <e2> seizures </e2> induce by cocaine and local anesthetics were studied in mice .
CID	Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to <e2> seizures </e2> induce by <e1> cocaine </e1> and local anesthetics were studied in mice .
NO_RELATION	Daily administration of <e1> desipramine </e1> increased the incidence of appearance of lidocaine - induced <e2> convulsions </e2> and decreased that of cocaine - induced convulsions .
NO_RELATION	Daily administration of <e1> desipramine </e1> increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced <e2> convulsions </e2> .
CID	Daily administration of desipramine increased the incidence of appearance of <e1> lidocaine </e1> - induced <e2> convulsions </e2> and decreased that of cocaine - induced convulsions .
CID	Daily administration of desipramine increased the incidence of appearance of <e1> lidocaine </e1> - induced convulsions and decreased that of cocaine - induced <e2> convulsions </e2> .
CID	Daily administration of desipramine increased the incidence of appearance of lidocaine - induced <e2> convulsions </e2> and decreased that of <e1> cocaine </e1> - induced convulsions .
CID	Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of <e1> cocaine </e1> - induced <e2> convulsions </e2> .
CID	Co - administration of <e1> lidocaine </e1> with desipramine reversed the changes of <e2> convulsive </e2> activity of lidocaine and cocaine induced by repeated administration of desipramine .
NO_RELATION	Co - administration of lidocaine with <e1> desipramine </e1> reversed the changes of <e2> convulsive </e2> activity of lidocaine and cocaine induced by repeated administration of desipramine .
CID	Co - administration of lidocaine with desipramine reversed the changes of <e2> convulsive </e2> activity of <e1> lidocaine </e1> and cocaine induced by repeated administration of desipramine .
CID	Co - administration of lidocaine with desipramine reversed the changes of <e2> convulsive </e2> activity of lidocaine and <e1> cocaine </e1> induced by repeated administration of desipramine .
NO_RELATION	Co - administration of lidocaine with desipramine reversed the changes of <e2> convulsive </e2> activity of lidocaine and cocaine induced by repeated administration of <e1> desipramine </e1> .
NO_RELATION	These results suggest that down - regulation of hippocampal NET induced by chronic administration of <e1> desipramine </e1> may be relevant to desipramine - induced sensitization of lidocaine <e2> convulsions </e2> .
NO_RELATION	These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to <e1> desipramine </e1> - induced sensitization of lidocaine <e2> convulsions </e2> .
CID	These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of <e1> lidocaine </e1> <e2> convulsions </e2> .
NO_RELATION	<e1> Desipramine </e1> - induced sensitization of lidocaine <e2> seizures </e2> may have a mechanism distinct from kindling resulting from repeated administration of cocaine .
CID	Desipramine - induced sensitization of <e1> lidocaine </e1> <e2> seizures </e2> may have a mechanism distinct from kindling resulting from repeated administration of cocaine .
CID	Desipramine - induced sensitization of lidocaine <e2> seizures </e2> may have a mechanism distinct from kindling resulting from repeated administration of <e1> cocaine </e1> .
NO_RELATION	The current best treatment for <e2> HCV infection </e2> is combination therapy with pegylated <e1> interferon </e1> and ribavirin .
NO_RELATION	The current best treatment for <e2> HCV infection </e2> is combination therapy with pegylated interferon and <e1> ribavirin </e1> .
NO_RELATION	Hemoglobin concentrations decrease mainly as a result of <e1> ribavirin </e1> - induced <e2> hemolysis </e2> , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .
NO_RELATION	Hemoglobin concentrations decrease mainly as a result of <e1> ribavirin </e1> - induced hemolysis , and this <e2> anemia </e2> can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .
NO_RELATION	Hemoglobin concentrations decrease mainly as a result of <e1> ribavirin </e1> - induced hemolysis , and this anemia can be problematic in patients with <e2> HCV infection </e2> , especially those who have comorbid renal or cardiovascular disorders .
NO_RELATION	Hemoglobin concentrations decrease mainly as a result of <e1> ribavirin </e1> - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid <e2> renal or cardiovascular disorders </e2> .
NO_RELATION	Although <e1> ribavirin </e1> - associated <e2> anemia </e2> can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .
NO_RELATION	Recombinant human erythropoietin has been used to manage <e1> ribavirin </e1> - associated <e2> anemia </e2> but has other potential disadvantages .
NO_RELATION	<e1> Viramidine </e1> , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2> hemolytic anemia </e2> in patients with chronic hepatitis C .
NO_RELATION	<e1> Viramidine </e1> , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2> chronic hepatitis C </e2> .
CID	Viramidine , a liver - targeting prodrug of <e1> ribavirin </e1> , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of <e2> hemolytic anemia </e2> in patients with chronic hepatitis C .
NO_RELATION	Viramidine , a liver - targeting prodrug of <e1> ribavirin </e1> , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with <e2> chronic hepatitis C </e2> .
CID	Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of <e1> ribavirin </e1> while decreasing the risk of <e2> hemolytic anemia </e2> in patients with chronic hepatitis C .
NO_RELATION	Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of <e1> ribavirin </e1> while decreasing the risk of hemolytic anemia in patients with <e2> chronic hepatitis C </e2> .
NO_RELATION	<e1> Calcium carbonate </e1> <e2> toxicity </e2> : the updated milk - alkali syndrome ; report of 3 cases and review of the literature .
CID	<e1> Calcium carbonate </e1> toxicity : the updated <e2> milk - alkali syndrome </e2> ; report of 3 cases and review of the literature .
CID	OBJECTIVE : To describe 3 patients with <e1> calcium carbonate </e1> - induced <e2> hypercalcemia </e2> and gain insights into the cause and management of the milk - alkali syndrome .
CID	OBJECTIVE : To describe 3 patients with <e1> calcium carbonate </e1> - induced hypercalcemia and gain insights into the cause and management of the <e2> milk - alkali syndrome </e2> .
NO_RELATION	METHODS : We report the clinical and laboratory data in 3 patients who presented with severe <e2> hypercalcemia </e2> ( corrected serum <e1> calcium </e1> > or = 14 mg / dL ) and review the pertinent literature on milk - alkali syndrome .
NO_RELATION	METHODS : We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia ( corrected serum <e1> calcium </e1> > or = 14 mg / dL ) and review the pertinent literature on <e2> milk - alkali syndrome </e2> .
NO_RELATION	RESULTS : The 3 patients had <e2> acute renal insufficiency </e2> , relative metabolic alkalosis , and low parathyroid hormone ( PTH ) , PTH - related peptide , and <e1> 1 , 25 - dihydroxyvitamin D </e1> concentrations .
NO_RELATION	RESULTS : The 3 patients had acute renal insufficiency , relative <e2> metabolic alkalosis </e2> , and low parathyroid hormone ( PTH ) , PTH - related peptide , and <e1> 1 , 25 - dihydroxyvitamin D </e1> concentrations .
NO_RELATION	The 2 patients with the higher serum <e1> calcium </e1> concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe <e2> hypocalcemia </e2> .
CID	The 2 patients with the higher serum calcium concentrations received <e1> pamidronate </e1> intravenously ( 60 and 30 mg , respectively ) , which caused severe <e2> hypocalcemia </e2> .
CID	CONCLUSION : <e2> Milk - alkali syndrome </e2> may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested <e1> calcium carbonate </e1> in susceptible persons .
CID	CONCLUSION : Milk - alkali syndrome may be a common cause of unexplained <e2> hypercalcemia </e2> and can be precipitated by small amounts of orally ingested <e1> calcium carbonate </e1> in susceptible persons .
CID	<e1> Pamidronate </e1> treatment is associated with considerable risk for <e2> hypocalcemia </e2> , even in cases of initially severe hypercalcemia .
NO_RELATION	<e1> Pamidronate </e1> treatment is associated with considerable risk for hypocalcemia , even in cases of initially severe <e2> hypercalcemia </e2> .
CID	Management strategies for <e1> ribavirin </e1> - induced <e2> hemolytic anemia </e2> in the treatment of hepatitis C : clinical and economic implications .
NO_RELATION	Management strategies for <e1> ribavirin </e1> - induced hemolytic anemia in the treatment of <e2> hepatitis C </e2> : clinical and economic implications .
NO_RELATION	OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / <e1> ribavirin </e1> compared with interferon - alpha monotherapy in the treatment of <e2> chronic hepatitis C </e2> ( CHC ) .
NO_RELATION	OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / <e1> ribavirin </e1> compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( <e2> CHC </e2> ) .
NO_RELATION	OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with <e1> interferon - alpha </e1> monotherapy in the treatment of <e2> chronic hepatitis C </e2> ( CHC ) .
NO_RELATION	OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with <e1> interferon - alpha </e1> monotherapy in the treatment of chronic hepatitis C ( <e2> CHC </e2> ) .
CID	Combination therapy is associated with a clinically important adverse effect : <e1> ribavirin </e1> - induced <e2> hemolytic anemia </e2> ( RIHA ) .
CID	Combination therapy is associated with a clinically important adverse effect : <e1> ribavirin </e1> - induced hemolytic anemia ( <e2> RIHA </e2> ) .
CID	The standard of care for management of <e2> RIHA </e2> is reduction or discontinuation of the <e1> ribavirin </e1> dosage .
CID	Questions remain about the optimal dose of <e1> ribavirin </e1> and the incidence of <e2> RIHA </e2> in a real - world population .
NO_RELATION	Effects of <e1> amine </e1> pretreatment on ketamine <e2> catatonia </e2> in pinealectomized or hypophysectomized animals .
CID	Effects of amine pretreatment on <e1> ketamine </e1> <e2> catatonia </e2> in pinealectomized or hypophysectomized animals .
NO_RELATION	The present studies were designed to clarify the role of <e1> catecholamines </e1> and pineal idolamines on ketamine - induced <e2> catatonia </e2> in the intact , pinealectomized or hypophysectomized chick and rat .
CID	The present studies were designed to clarify the role of catecholamines and pineal idolamines on <e1> ketamine </e1> - induced <e2> catatonia </e2> in the intact , pinealectomized or hypophysectomized chick and rat .
CID	In the pinealectomized chick , pretreatment with <e1> dopamine </e1> increased the duration of <e2> catatonia </e2> ( DOC ) after ketamine , but pretreatment with norepinephrine did not .
CID	In the pinealectomized chick , pretreatment with dopamine increased the duration of <e2> catatonia </e2> ( DOC ) after <e1> ketamine </e1> , but pretreatment with norepinephrine did not .
NO_RELATION	In the pinealectomized chick , pretreatment with dopamine increased the duration of <e2> catatonia </e2> ( DOC ) after ketamine , but pretreatment with <e1> norepinephrine </e1> did not .
CID	Furthermore , <e1> dopamine </e1> appeared to act on systems more closely involved with the induction of ketamine <e2> catatonia </e2> rather than directly on the pituitary .
CID	Furthermore , dopamine appeared to act on systems more closely involved with the induction of <e1> ketamine </e1> <e2> catatonia </e2> rather than directly on the pituitary .
NO_RELATION	Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of <e1> azelastine </e1> , chlorpheniramine , and placebo in the treatment of <e2> spring allergic rhinitis </e2> .
NO_RELATION	Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , <e1> chlorpheniramine </e1> , and placebo in the treatment of <e2> spring allergic rhinitis </e2> .
NO_RELATION	<e1> Azelastine </e1> , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of <e2> spring allergic rhinitis </e2> in a multicenter , double - blind , multiple - dose , parallel - groups study .
NO_RELATION	Azelastine , a novel antiallergic medication , was compared with <e1> chlorpheniramine maleate </e1> and placebo for efficacy and safety in the treatment of <e2> spring allergic rhinitis </e2> in a multicenter , double - blind , multiple - dose , parallel - groups study .
CID	<e2> Drowsiness </e2> and altered taste perception were increased significantly over placebo only in the high - dose <e1> azelastine </e1> group .
CID	Drowsiness and <e2> altered taste perception </e2> were increased significantly over placebo only in the high - dose <e1> azelastine </e1> group .
NO_RELATION	<e1> Azelastine </e1> appears to be a safe , efficacious medication for <e2> seasonal allergic rhinitis </e2> .
CID	One case of acute <e2> hypercalcaemia </e2> and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of <e1> calcium carbon - ate </e1> - sodium bicarbonate powders for more than 20 years .
CID	One case of acute hypercalcaemia and two of recurrent <e2> nephrolithiasis </e2> are reported in patients who had regularly consumed large amounts of <e1> calcium carbon - ate </e1> - sodium bicarbonate powders for more than 20 years .
CID	One case of acute <e2> hypercalcaemia </e2> and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon - ate - <e1> sodium bicarbonate </e1> powders for more than 20 years .
CID	One case of acute hypercalcaemia and two of recurrent <e2> nephrolithiasis </e2> are reported in patients who had regularly consumed large amounts of calcium carbon - ate - <e1> sodium bicarbonate </e1> powders for more than 20 years .
NO_RELATION	Prolonged <e2> paralysis </e2> due to <e1> nondepolarizing neuromuscular blocking agents </e1> and corticosteroids .
NO_RELATION	Prolonged <e2> paralysis </e2> due to nondepolarizing neuromuscular blocking agents and <e1> corticosteroids </e1> .
CID	The long - term use of <e1> nondepolarizing neuromuscular blocking agents </e1> ( ND - NMBA ) has recently been implicated as a cause of prolonged <e2> muscle weakness </e2> , although the site of the lesion and the predisposing factors have been unclear .
CID	The long - term use of nondepolarizing neuromuscular blocking agents ( <e1> ND - NMBA </e1> ) has recently been implicated as a cause of prolonged <e2> muscle weakness </e2> , although the site of the lesion and the predisposing factors have been unclear .
NO_RELATION	We report 3 patients ( age 37 - 52 years ) with acute <e2> respiratory insufficiency </e2> who developed prolonged weakness following the discontinuation of <e1> ND - NMBAs </e1> .
CID	We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged <e2> weakness </e2> following the discontinuation of <e1> ND - NMBAs </e1> .
CID	The <e2> weakness </e2> in these patients is due to pathology at both the neuromuscular junction ( most likely due to <e1> ND - NMBA </e1> ) and muscle ( most likely due to corticosteroids ) .
CID	The weakness in these patients is due to <e2> pathology at both the neuromuscular junction </e2> ( most likely due to <e1> ND - NMBA </e1> ) and muscle ( most likely due to corticosteroids ) .
NO_RELATION	The <e2> weakness </e2> in these patients is due to pathology at both the neuromuscular junction ( most likely due to ND - NMBA ) and muscle ( most likely due to <e1> corticosteroids </e1> ) .
NO_RELATION	The weakness in these patients is due to <e2> pathology at both the neuromuscular junction </e2> ( most likely due to ND - NMBA ) and muscle ( most likely due to <e1> corticosteroids </e1> ) .
CID	<e1> Prostaglandin E2 </e1> - induced <e2> bladder hyperactivity </e2> in normal , conscious rats : involvement of tachykinins ?
NO_RELATION	Prostaglandin E2 - induced <e2> bladder hyperactivity </e2> in normal , conscious rats : involvement of <e1> tachykinins </e1> ?
NO_RELATION	<e1> Prostanoids </e1> may , via release of tachykinins , contribute to both urge and <e2> bladder hyperactivity </e2> seen in inflammatory conditions of the lower urinary tract .
NO_RELATION	Prostanoids may , via release of <e1> tachykinins </e1> , contribute to both urge and <e2> bladder hyperactivity </e2> seen in inflammatory conditions of the lower urinary tract .
NO_RELATION	<e1> Thiazide </e1> diuretics , <e2> hypokalemia </e2> and cardiac arrhythmias .
NO_RELATION	<e1> Thiazide </e1> diuretics , hypokalemia and <e2> cardiac arrhythmias </e2> .
NO_RELATION	<e2> Hypokalemia </e2> is a commonly encountered metabolic consequence of chronic <e1> thiazide </e1> therapy .
NO_RELATION	We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate <e2> diastolic hypertension </e2> with <e1> hydrochlorothiazide </e1> ( HCTC ) administered on a twice daily schedule .
NO_RELATION	We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate <e2> diastolic hypertension </e2> with hydrochlorothiazide ( <e1> HCTC </e1> ) administered on a twice daily schedule .
NO_RELATION	In conclusion we found that <e1> thiazide </e1> diuretics cause <e2> hypokalemia </e2> and depletion of body potassium .
NO_RELATION	In conclusion we found that thiazide diuretics cause <e2> hypokalemia </e2> and depletion of body <e1> potassium </e1> .
NO_RELATION	Diuretics , <e1> potassium </e1> and <e2> arrhythmias </e2> in hypertensive coronary disease .
NO_RELATION	Diuretics , <e1> potassium </e1> and arrhythmias in <e2> hypertensive </e2> coronary disease .
NO_RELATION	Diuretics , <e1> potassium </e1> and arrhythmias in hypertensive <e2> coronary disease </e2> .
NO_RELATION	It has been proposed that modest changes in plasma <e1> potassium </e1> can alter the tendency towards <e2> cardiac arrhythmias </e2> .
NO_RELATION	Thus , myocardial electrical excitability was measured in patients with mild essential <e2> hypertension </e2> and known coronary artery disease after 8 weeks of treatment with a <e1> potassium </e1> - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .
NO_RELATION	Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known <e2> coronary artery disease </e2> after 8 weeks of treatment with a <e1> potassium </e1> - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .
NO_RELATION	Thus , myocardial electrical excitability was measured in patients with mild essential <e2> hypertension </e2> and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( <e1> amiloride </e1> ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .
NO_RELATION	Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known <e2> coronary artery disease </e2> after 8 weeks of treatment with a potassium - conserving diuretic ( <e1> amiloride </e1> ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .
NO_RELATION	Thus , myocardial electrical excitability was measured in patients with mild essential <e2> hypertension </e2> and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a <e1> potassium </e1> - losing diuretic ( chlorthalidone ) in a randomised study .
NO_RELATION	Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known <e2> coronary artery disease </e2> after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a <e1> potassium </e1> - losing diuretic ( chlorthalidone ) in a randomised study .
NO_RELATION	Thus , myocardial electrical excitability was measured in patients with mild essential <e2> hypertension </e2> and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( <e1> chlorthalidone </e1> ) in a randomised study .
NO_RELATION	Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known <e2> coronary artery disease </e2> after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( <e1> chlorthalidone </e1> ) in a randomised study .
NO_RELATION	Compared to <e1> amiloride </e1> treatment , the chlorthalidone phase was associated with an increased frequency of <e2> ventricular ectopic beats </e2> ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .
CID	Compared to amiloride treatment , the <e1> chlorthalidone </e1> phase was associated with an increased frequency of <e2> ventricular ectopic beats </e2> ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .
NO_RELATION	The above results indicate that because <e1> potassium </e1> - losing diuretic therapy can increase myocardial electrical excitability in patients with <e2> ischaemic heart disease </e2> , even minor falls in plasma potassium concentrations are probably best avoided in such patients .
NO_RELATION	The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with <e2> ischaemic heart disease </e2> , even minor falls in plasma <e1> potassium </e1> concentrations are probably best avoided in such patients .
NO_RELATION	<e1> GABA </e1> involvement in naloxone induced reversal of <e2> respiratory paralysis </e2> produced by thiopental .
NO_RELATION	GABA involvement in <e1> naloxone </e1> induced reversal of <e2> respiratory paralysis </e2> produced by thiopental .
CID	GABA involvement in naloxone induced reversal of <e2> respiratory paralysis </e2> produced by <e1> thiopental </e1> .
NO_RELATION	In this study <e1> naloxone </e1> reversed <e2> respiratory paralysis </e2> induced by thiopental in rats .
CID	In this study naloxone reversed <e2> respiratory paralysis </e2> induced by <e1> thiopental </e1> in rats .
NO_RELATION	<e1> thiopental </e1> produced <e2> respiratory arrest </e2> with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .
NO_RELATION	thiopental produced <e2> respiratory arrest </e2> with further increase in <e1> GABA </e1> and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .
NO_RELATION	thiopental produced <e2> respiratory arrest </e2> with further increase in GABA and decrease in <e1> glutamate </e1> again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .
NO_RELATION	thiopental produced <e2> respiratory arrest </e2> with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the <e1> amino acids </e1> studied in four regions of rat brain .
NO_RELATION	<e1> Naloxone </e1> ( 2 . 5 mg / kg , i . v . ) reversed <e2> respiratory paralysis </e2> , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .
NO_RELATION	Naloxone ( 2 . 5 mg / kg , i . v . ) reversed <e2> respiratory paralysis </e2> , <e1> glutamate </e1> and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .
NO_RELATION	Naloxone ( 2 . 5 mg / kg , i . v . ) reversed <e2> respiratory paralysis </e2> , glutamate and <e1> GABA </e1> levels to control values in brain stem and cortex with no changes in caudate or cerebellum .
NO_RELATION	These data suggest <e1> naloxone </e1> reverses <e2> respiratory paralysis </e2> produced by thiopental and involves GABA in its action .
CID	These data suggest naloxone reverses <e2> respiratory paralysis </e2> produced by <e1> thiopental </e1> and involves GABA in its action .
NO_RELATION	These data suggest naloxone reverses <e2> respiratory paralysis </e2> produced by thiopental and involves <e1> GABA </e1> in its action .
NO_RELATION	These infants are treated with two injections of <e2> hepatitis B </e2> immune globulin ( HBIG ) and at least three injections of plasma derived <e1> hepatitis B vaccine </e1> .
NO_RELATION	The effects of intrathecal administration of <e1> prostaglandins </e1> on <e2> pain </e2> responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .
NO_RELATION	The effects of intrathecal administration of prostaglandins on <e2> pain </e2> responses in conscious mice were evaluated by using hot plate and <e1> acetic acid </e1> writhing tests .
CID	<e1> Prostaglandin D2 </e1> ( 0 . 5 - 3 ng / mouse ) had a <e2> hyperalgesic </e2> action on the response to a hot plate during a 3 - 60 min period after injection .
CID	<e1> Prostaglandin E2 </e1> showed a <e2> hyperalgesic </e2> effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .
NO_RELATION	Prostaglandin E2 showed a <e2> hyperalgesic </e2> effect at doses of 1 <e1> pg </e1> to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .
CID	Prostaglandin E2 showed a <e2> hyperalgesic </e2> effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of <e1> prostaglandin D2 </e1> .
CID	The <e2> hyperalgesic </e2> effect of <e1> prostaglandin D2 </e1> was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by AH6809 , a prostanoid EP1 - receptor antagonist .
NO_RELATION	The <e2> hyperalgesic </e2> effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by <e1> AH6809 </e1> , a prostanoid EP1 - receptor antagonist .
CID	Conversely , <e1> prostaglandin E2 </e1> - induced <e2> hyperalgesia </e2> was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .
NO_RELATION	Conversely , prostaglandin E2 - induced <e2> hyperalgesia </e2> was blocked by <e1> AH6809 </e1> ( greater than or equal to 500 ng ) but not by the substance P antagonist .
NO_RELATION	<e1> Prostaglandin F2 alpha </e1> had little effect on <e2> pain </e2> responses .
CID	These results demonstrate that both <e1> prostaglandin D2 </e1> and prostaglandin E2 exert <e2> hyperalgesia </e2> in the spinal cord , but in different ways .
CID	These results demonstrate that both prostaglandin D2 and <e1> prostaglandin E2 </e1> exert <e2> hyperalgesia </e2> in the spinal cord , but in different ways .
CID	Swallowing - induced <e2> atrial tachyarrhythmia </e2> triggered by <e1> salbutamol </e1> : case report and review of the literature .
NO_RELATION	The <e2> arrhythmia </e2> resolved after therapy with <e1> atenolol </e1> , but recurred a year later .
NO_RELATION	After stopping the beta - agonist , and after a week with the <e1> atenolol </e1> , the <e2> arrhythmia </e2> disappeared .
CID	CONCLUSION : <e1> Salbutamol </e1> is presented here as a possible trigger for <e2> SIAT </e2> .
NO_RELATION	Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like <e1> salbutamol </e1> ( known to induce <e2> tachycardia </e2> ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .
NO_RELATION	Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce <e2> tachycardia </e2> ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as <e1> atenolol </e1> ( that blocks the adrenergic activity ) may relieve it .
NO_RELATION	<e1> Coenzyme Q10 </e1> treatment ameliorates acute cisplatin <e2> nephrotoxicity </e2> in mice .
NO_RELATION	Coenzyme Q10 treatment ameliorates acute <e1> cisplatin </e1> <e2> nephrotoxicity </e2> in mice .
NO_RELATION	The nephroprotective effect of <e1> coenzyme Q10 </e1> was investigated in mice with <e2> acute renal injury </e2> induced by a single i . p .
NO_RELATION	<e1> Coenzyme Q10 </e1> significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of <e2> tumor </e2> necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	<e1> Coenzyme Q10 </e1> significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor <e2> necrosis </e2> factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( <e1> reduced glutathione </e1> level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of <e2> tumor </e2> necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( <e1> reduced glutathione </e1> level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor <e2> necrosis </e2> factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and <e1> superoxide </e1> dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of <e2> tumor </e2> necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and <e1> superoxide </e1> dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor <e2> necrosis </e2> factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of <e2> tumor </e2> necrosis factor - alpha , <e1> nitric oxide </e1> and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor <e2> necrosis </e2> factor - alpha , <e1> nitric oxide </e1> and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of <e2> tumor </e2> necrosis factor - alpha , nitric oxide and <e1> platinum </e1> ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor <e2> necrosis </e2> factor - alpha , nitric oxide and <e1> platinum </e1> ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of <e2> tumor </e2> necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of <e1> selenium </e1> and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor <e2> necrosis </e2> factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of <e1> selenium </e1> and zinc ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of <e2> tumor </e2> necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and <e1> zinc </e1> ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor <e2> necrosis </e2> factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and <e1> zinc </e1> ions in renal tissue resulted from cisplatin administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of <e2> tumor </e2> necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from <e1> cisplatin </e1> administration .
NO_RELATION	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor <e2> necrosis </e2> factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from <e1> cisplatin </e1> administration .
NO_RELATION	Also , histopathological <e2> renal tissue damage </e2> mediated by <e1> cisplatin </e1> was ameliorated by coenzyme Q10 treatment .
NO_RELATION	Also , histopathological <e2> renal tissue damage </e2> mediated by cisplatin was ameliorated by <e1> coenzyme Q10 </e1> treatment .
NO_RELATION	It was concluded that <e1> coenzyme Q10 </e1> represents a potential therapeutic option to protect against acute cisplatin <e2> nephrotoxicity </e2> commonly encountered in clinical practice .
NO_RELATION	It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute <e1> cisplatin </e1> <e2> nephrotoxicity </e2> commonly encountered in clinical practice .
NO_RELATION	<e1> Metformin </e1> prevents experimental gentamicin - induced <e2> nephropathy </e2> by a mitochondria - dependent pathway .
NO_RELATION	Metformin prevents experimental <e1> gentamicin </e1> - induced <e2> nephropathy </e2> by a mitochondria - dependent pathway .
NO_RELATION	The antidiabetic drug <e1> metformin </e1> can diminish apoptosis induced by oxidative stress in endothelial cells and prevent <e2> vascular dysfunction </e2> even in nondiabetic patients .
NO_RELATION	Here we tested whether it has a beneficial effect in a rat model of <e1> gentamicin </e1> <e2> toxicity </e2> .
NO_RELATION	<e1> Metformin </e1> treatment fully blocked gentamicin - mediated <e2> acute renal failure </e2> .
CID	Metformin treatment fully blocked <e1> gentamicin </e1> - mediated <e2> acute renal failure </e2> .
NO_RELATION	These in vivo markers of <e2> kidney dysfunction </e2> and their correction by <e1> metformin </e1> were complemented by in vitro studies of mitochondrial function .
NO_RELATION	Thus , our study suggests that pleiotropic effects of <e1> metformin </e1> can lessen gentamicin <e2> nephrotoxicity </e2> and improve mitochondrial homeostasis .
NO_RELATION	Thus , our study suggests that pleiotropic effects of metformin can lessen <e1> gentamicin </e1> <e2> nephrotoxicity </e2> and improve mitochondrial homeostasis .
CID	PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative <e2> delirium </e2> or severe dementia who underwent hip fracture repair under spinal anesthesia with <e1> propofol </e1> sedation .
NO_RELATION	PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe <e2> dementia </e2> who underwent hip fracture repair under spinal anesthesia with <e1> propofol </e1> sedation .
NO_RELATION	PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe dementia who underwent <e2> hip fracture </e2> repair under spinal anesthesia with <e1> propofol </e1> sedation .
NO_RELATION	CONCLUSION : The use of light <e1> propofol </e1> sedation decreased the prevalence of <e2> postoperative delirium </e2> by 50 % compared with deep sedation .
NO_RELATION	<e1> Sorafenib </e1> - induced acute <e2> myocardial infarction </e2> due to coronary artery spasm .
CID	<e1> Sorafenib </e1> - induced acute myocardial infarction due to <e2> coronary artery spasm </e2> .
NO_RELATION	Addition of oral <e1> nicorandil </e1> reduced his symptoms and maintained <e2> stable angina </e2> status .
CID	We report the first case of <e1> sorafenib </e1> - induced <e2> coronary artery spasm </e2> .
CID	RESULTS : The results indicate that <e1> ciprofloxacin </e1> - and norfloxacin - treated rats showed <e2> anxious behaviour </e2> in comparison to control rats in all the parameters studied .
CID	RESULTS : The results indicate that ciprofloxacin - and <e1> norfloxacin </e1> - treated rats showed <e2> anxious behaviour </e2> in comparison to control rats in all the parameters studied .
CID	Myocardial Fas ligand expression increases susceptibility to <e1> AZT </e1> - induced <e2> cardiomyopathy </e2> .
CID	METHODS AND RESULTS : In order to investigate whether the HAART component <e1> zidovudine </e1> ( 3 ' - azido - 2 ' , 3 ' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of <e2> DCM </e2> , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .
CID	METHODS AND RESULTS : In order to investigate whether the HAART component zidovudine ( <e1> 3 ' - azido - 2 ' , 3 ' - deoxythymidine </e1> ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of <e2> DCM </e2> , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .
CID	METHODS AND RESULTS : In order to investigate whether the HAART component zidovudine ( 3 ' - azido - 2 ' , 3 ' - deoxythymidine ; <e1> AZT </e1> ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of <e2> DCM </e2> , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .
CID	METHODS AND RESULTS : In order to investigate whether the HAART component zidovudine ( 3 ' - azido - 2 ' , 3 ' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of <e2> DCM </e2> , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of <e1> AZT </e1> ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .
CID	In contrast , <e1> AZT </e1> - treated FasL Tg mice developed <e2> cardiac dilation </e2> and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .
CID	<e1> Valproate </e1> - induced <e2> chorea </e2> and encephalopathy in atypical nonketotic hyperglycinemia .
CID	<e1> Valproate </e1> - induced chorea and <e2> encephalopathy </e2> in atypical nonketotic hyperglycinemia .
NO_RELATION	<e1> Valproate </e1> - induced chorea and encephalopathy in atypical <e2> nonketotic hyperglycinemia </e2> .
NO_RELATION	<e2> Nonketotic hyperglycinemia </e2> is a disorder of amino acid metabolism in which a defect in the <e1> glycine </e1> cleavage system leads to an accumulation of glycine in the brain and other body compartments .
NO_RELATION	Nonketotic hyperglycinemia is a <e2> disorder of amino acid metabolism </e2> in which a defect in the <e1> glycine </e1> cleavage system leads to an accumulation of glycine in the brain and other body compartments .
NO_RELATION	<e2> Nonketotic hyperglycinemia </e2> is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of <e1> glycine </e1> in the brain and other body compartments .
NO_RELATION	Nonketotic hyperglycinemia is a <e2> disorder of amino acid metabolism </e2> in which a defect in the glycine cleavage system leads to an accumulation of <e1> glycine </e1> in the brain and other body compartments .
NO_RELATION	This report describes a patient with mild <e2> language delay </e2> and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of <e1> valproate </e1> therapy .
NO_RELATION	This report describes a patient with mild language delay and <e2> mental retardation </e2> , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of <e1> valproate </e1> therapy .
NO_RELATION	This report describes a patient with mild language delay and mental retardation , who was found to have <e2> nonketotic hyperglycinemia </e2> following her presentation with acute encephalopathy and chorea shortly after initiation of <e1> valproate </e1> therapy .
CID	This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute <e2> encephalopathy </e2> and chorea shortly after initiation of <e1> valproate </e1> therapy .
CID	This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and <e2> chorea </e2> shortly after initiation of <e1> valproate </e1> therapy .
NO_RELATION	Microinjection of <e1> ritanserin </e1> into the CA1 region of hippocampus improves scopolamine - induced <e2> amnesia </e2> in adult male rats .
CID	Microinjection of ritanserin into the CA1 region of hippocampus improves <e1> scopolamine </e1> - induced <e2> amnesia </e2> in adult male rats .
NO_RELATION	The effect of <e1> ritanserin </e1> ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced <e2> amnesia </e2> in Morris water maze ( MWM ) was investigated .
CID	The effect of ritanserin ( 5 - HT2 antagonist ) on <e1> scopolamine </e1> ( muscarinic cholinergic antagonist ) - induced <e2> amnesia </e2> in Morris water maze ( MWM ) was investigated .
NO_RELATION	Our findings show that microinjection of <e1> ritanserin </e1> into the CA1 region of the hippocampus improves the scopolamine - induced <e2> amnesia </e2> .
CID	Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the <e1> scopolamine </e1> - induced <e2> amnesia </e2> .
CID	With this model , we were able to identify diffuse cortical <e2> hypoxia </e2> in the <e1> puromycin aminonucleoside </e1> - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .
CID	With this model , we were able to identify diffuse cortical hypoxia in the <e1> puromycin aminonucleoside </e1> - induced <e2> nephrotic syndrome </e2> and focal and segmental hypoxia in the remnant kidney model .
CID	With this model , we were able to identify diffuse cortical hypoxia in the <e1> puromycin aminonucleoside </e1> - induced nephrotic syndrome and focal and segmental <e2> hypoxia </e2> in the remnant kidney model .
CID	Expression of the <e2> hypoxia </e2> - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the <e1> puromycin aminonucleoside </e1> model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .
CID	However , caution is required when <e1> cyclophosphamide </e1> or anthracyclines such as mitoxantrone are used in patients with a possible underlying <e2> heart damage </e2> , for example , systemic sclerosis patients .
NO_RELATION	However , caution is required when <e1> cyclophosphamide </e1> or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , <e2> systemic sclerosis </e2> patients .
NO_RELATION	However , caution is required when cyclophosphamide or <e1> anthracyclines </e1> such as mitoxantrone are used in patients with a possible underlying <e2> heart damage </e2> , for example , systemic sclerosis patients .
NO_RELATION	However , caution is required when cyclophosphamide or <e1> anthracyclines </e1> such as mitoxantrone are used in patients with a possible underlying heart damage , for example , <e2> systemic sclerosis </e2> patients .
CID	However , caution is required when cyclophosphamide or anthracyclines such as <e1> mitoxantrone </e1> are used in patients with a possible underlying <e2> heart damage </e2> , for example , systemic sclerosis patients .
NO_RELATION	However , caution is required when cyclophosphamide or anthracyclines such as <e1> mitoxantrone </e1> are used in patients with a possible underlying heart damage , for example , <e2> systemic sclerosis </e2> patients .
NO_RELATION	Immunohistochemical study on inducible type of <e1> nitric oxide </e1> ( iNOS ) , basic fibroblast growth factor ( bFGF ) and <e2> tumor </e2> growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and theophylline , vasodilators .
NO_RELATION	Immunohistochemical study on inducible type of <e1> nitric oxide </e1> ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in <e2> arteritis </e2> induced in rats by fenoldopam and theophylline , vasodilators .
NO_RELATION	Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and <e2> tumor </e2> growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by <e1> fenoldopam </e1> and theophylline , vasodilators .
CID	Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in <e2> arteritis </e2> induced in rats by <e1> fenoldopam </e1> and theophylline , vasodilators .
NO_RELATION	Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and <e2> tumor </e2> growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and <e1> theophylline </e1> , vasodilators .
CID	Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in <e2> arteritis </e2> induced in rats by fenoldopam and <e1> theophylline </e1> , vasodilators .
CID	<e2> Arteritis </e2> induced in rats by vasodilators , <e1> fenoldopam </e1> and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .
NO_RELATION	Arteritis induced in rats by vasodilators , <e1> fenoldopam </e1> and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and <e2> tumor </e2> growth factor - beta1 ( TGF - beta1 ) .
CID	<e2> Arteritis </e2> induced in rats by vasodilators , fenoldopam and <e1> theophylline </e1> , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .
NO_RELATION	Arteritis induced in rats by vasodilators , fenoldopam and <e1> theophylline </e1> , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and <e2> tumor </e2> growth factor - beta1 ( TGF - beta1 ) .
NO_RELATION	<e2> Arteritis </e2> induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of <e1> nitric oxide </e1> synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .
NO_RELATION	Arteritis induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of <e1> nitric oxide </e1> synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and <e2> tumor </e2> growth factor - beta1 ( TGF - beta1 ) .
CID	<e1> Topiramate </e1> - induced <e2> nephrolithiasis </e2> .
NO_RELATION	<e1> Topiramate </e1> is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating <e2> refractory seizures </e2> .
NO_RELATION	These factors can lead to the development of <e1> calcium phosphate </e1> <e2> nephrolithiasis </e2> .
CID	We report the first two cases of <e1> topiramate </e1> - induced <e2> nephrolithiasis </e2> in the urologic literature .
NO_RELATION	<e1> Spironolactone </e1> : is it a novel drug for the prevention of amphotericin B - related <e2> hypokalemia </e2> in cancer patients ?
NO_RELATION	<e1> Spironolactone </e1> : is it a novel drug for the prevention of amphotericin B - related hypokalemia in <e2> cancer </e2> patients ?
CID	Spironolactone : is it a novel drug for the prevention of <e1> amphotericin B </e1> - related <e2> hypokalemia </e2> in cancer patients ?
NO_RELATION	Spironolactone : is it a novel drug for the prevention of <e1> amphotericin B </e1> - related hypokalemia in <e2> cancer </e2> patients ?
NO_RELATION	OBJECTIVE : <e2> Nephrotoxicity </e2> is the major adverse effect of <e1> amphotericin B </e1> ( AmB ) , often limiting administration of full dosage .
NO_RELATION	OBJECTIVE : <e2> Nephrotoxicity </e2> is the major adverse effect of amphotericin B ( <e1> AmB </e1> ) , often limiting administration of full dosage .
NO_RELATION	Selective distal tubular epithelial <e2> toxicity </e2> seems to be responsible for the profound <e1> potassium </e1> wasting that is a major clinical side effect of treatment with AmB .
NO_RELATION	Selective distal tubular epithelial <e2> toxicity </e2> seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with <e1> AmB </e1> .
NO_RELATION	<e1> Potassium </e1> depletion also potentiates the tubular <e2> toxicity </e2> of AmB .
NO_RELATION	Potassium depletion also potentiates the tubular <e2> toxicity </e2> of <e1> AmB </e1> .
NO_RELATION	This study was designed to assess the ability of <e1> spironolactone </e1> to reduce potassium requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on AmB treatment .
NO_RELATION	This study was designed to assess the ability of <e1> spironolactone </e1> to reduce potassium requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on AmB treatment .
NO_RELATION	This study was designed to assess the ability of spironolactone to reduce <e1> potassium </e1> requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on AmB treatment .
NO_RELATION	This study was designed to assess the ability of spironolactone to reduce <e1> potassium </e1> requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on AmB treatment .
CID	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent <e2> hypokalemia </e2> in neutropenic patients on <e1> AmB </e1> treatment .
NO_RELATION	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in <e2> neutropenic </e2> patients on <e1> AmB </e1> treatment .
NO_RELATION	METHODS : In this study 26 patients with various <e2> hematological disorders </e2> were randomized to receive either intravenous <e1> AmB </e1> alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .
NO_RELATION	METHODS : In this study 26 patients with various hematological disorders were randomized to receive either intravenous <e1> AmB </e1> alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected <e2> fungal infection </e2> .
NO_RELATION	METHODS : In this study 26 patients with various <e2> hematological disorders </e2> were randomized to receive either intravenous AmB alone or <e1> AmB </e1> and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .
NO_RELATION	METHODS : In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or <e1> AmB </e1> and oral spironolactone 100 mg twice daily when developing a proven or suspected <e2> fungal infection </e2> .
NO_RELATION	METHODS : In this study 26 patients with various <e2> hematological disorders </e2> were randomized to receive either intravenous AmB alone or AmB and oral <e1> spironolactone </e1> 100 mg twice daily when developing a proven or suspected fungal infection .
NO_RELATION	METHODS : In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral <e1> spironolactone </e1> 100 mg twice daily when developing a proven or suspected <e2> fungal infection </e2> .
NO_RELATION	CONCLUSION : This study showed that <e1> spironolactone </e1> can reduce potassium requirements and prevent <e2> hypokalemia </e2> by reducing urinary potassium loss in neutropenic patients on AmB treatment .
NO_RELATION	CONCLUSION : This study showed that <e1> spironolactone </e1> can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in <e2> neutropenic </e2> patients on AmB treatment .
NO_RELATION	CONCLUSION : This study showed that spironolactone can reduce <e1> potassium </e1> requirements and prevent <e2> hypokalemia </e2> by reducing urinary potassium loss in neutropenic patients on AmB treatment .
NO_RELATION	CONCLUSION : This study showed that spironolactone can reduce <e1> potassium </e1> requirements and prevent hypokalemia by reducing urinary potassium loss in <e2> neutropenic </e2> patients on AmB treatment .
NO_RELATION	CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent <e2> hypokalemia </e2> by reducing urinary <e1> potassium </e1> loss in neutropenic patients on AmB treatment .
NO_RELATION	CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary <e1> potassium </e1> loss in <e2> neutropenic </e2> patients on AmB treatment .
CID	CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent <e2> hypokalemia </e2> by reducing urinary potassium loss in neutropenic patients on <e1> AmB </e1> treatment .
NO_RELATION	CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in <e2> neutropenic </e2> patients on <e1> AmB </e1> treatment .
NO_RELATION	<e1> Dopamine </e1> ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of <e2> epileptic seizures </e2> arising in the limbic system .
NO_RELATION	Dopamine ( <e1> DA </e1> ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of <e2> epileptic seizures </e2> arising in the limbic system .
NO_RELATION	In this respect , little is known about the role of <e1> DA </e1> receptors in the occurrence of <e2> epilepsy </e2> - induced neuronal cell death .
CID	Here we analyze the occurrence of <e2> seizures </e2> and neurotoxicity in D2R - / - mice treated with the cholinergic agonist <e1> pilocarpine </e1> .
NO_RELATION	Here we analyze the occurrence of seizures and <e2> neurotoxicity </e2> in D2R - / - mice treated with the cholinergic agonist <e1> pilocarpine </e1> .
CID	However , <e1> pilocarpine </e1> - induced <e2> seizures </e2> result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .
CID	However , pilocarpine - induced <e2> seizures </e2> result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to <e1> KA </e1> .
NO_RELATION	Thus , the absence of D2R lowers the threshold for <e2> seizures </e2> induced by both <e1> glutamate </e1> and acetylcholine .
NO_RELATION	Thus , the absence of D2R lowers the threshold for <e2> seizures </e2> induced by both glutamate and <e1> acetylcholine </e1> .
CID	Treatment of <e1> risperidone </e1> - induced <e2> hyperprolactinemia </e2> with a dopamine agonist in children .
NO_RELATION	Treatment of risperidone - induced <e2> hyperprolactinemia </e2> with a <e1> dopamine </e1> agonist in children .
CID	BACKGROUND : <e1> Risperidone </e1> , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with <e2> hyperprolactinemia </e2> in adults and children .
CID	We report the successful treatment of <e1> risperidone </e1> - induced <e2> hyperprolactinemia </e2> with cabergoline in youth .
NO_RELATION	We report the successful treatment of risperidone - induced <e2> hyperprolactinemia </e2> with <e1> cabergoline </e1> in youth .
CID	METHODS : We undertook a retrospective case review of four children with <e1> risperidone </e1> - induced <e2> hyperprolactinemia </e2> treated with cabergoline .
NO_RELATION	METHODS : We undertook a retrospective case review of four children with risperidone - induced <e2> hyperprolactinemia </e2> treated with <e1> cabergoline </e1> .
NO_RELATION	RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of <e2> Mental Disorders </e2> ( fourth edition ) bipolar disorder or psychoses , with <e1> risperidone </e1> - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
NO_RELATION	RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) <e2> bipolar disorder </e2> or psychoses , with <e1> risperidone </e1> - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
NO_RELATION	RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or <e2> psychoses </e2> , with <e1> risperidone </e1> - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
NO_RELATION	RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of <e2> Mental Disorders </e2> ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with <e1> cabergoline </e1> ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
NO_RELATION	RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) <e2> bipolar disorder </e2> or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with <e1> cabergoline </e1> ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
NO_RELATION	RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or <e2> psychoses </e2> , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with <e1> cabergoline </e1> ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
NO_RELATION	CONCLUSIONS : <e1> Cabergoline </e1> may be useful for the treatment of risperidone - induced <e2> hyperprolactinemia </e2> in youth ; however , further research is needed .
CID	CONCLUSIONS : Cabergoline may be useful for the treatment of <e1> risperidone </e1> - induced <e2> hyperprolactinemia </e2> in youth ; however , further research is needed .
CID	<e2> Cholestatic jaundice </e2> associated with the use of <e1> metformin </e1> .
CID	We report a patient who developed <e2> cholestatic jaundice </e2> shortly after initiation of treatment with <e1> metformin hydrochloride </e1> .
NO_RELATION	<e1> Metformin hydrochloride </e1> was discontinued , and the patient ' s <e2> jaundice </e2> resolved slowly over a period of several months .
NO_RELATION	Given the onset of his <e2> jaundice </e2> 2 wk after the initiation of <e1> metformin </e1> , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .
NO_RELATION	Given the onset of his jaundice 2 wk after the initiation of <e1> metformin </e1> , we believe that this case represents an example of metformin - associated <e2> hepatotoxicity </e2> , the first such case reported .
NO_RELATION	Given the onset of his <e2> jaundice </e2> 2 wk after the initiation of metformin , we believe that this case represents an example of <e1> metformin </e1> - associated hepatotoxicity , the first such case reported .
NO_RELATION	Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of <e1> metformin </e1> - associated <e2> hepatotoxicity </e2> , the first such case reported .
CID	Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with <e1> vigabatrin </e1> - attributed <e2> visual field constriction </e2> .
CID	PURPOSE : Symptomatic <e2> visual field constriction </e2> thought to be associated with <e1> vigabatrin </e1> has been reported .
CID	The current study investigated the visual fields and visual electrophysiology of eight patients with known <e1> vigabatrin </e1> - attributed <e2> visual field loss </e2> , three of whom were reported previously .
CID	CONCLUSION : Marked <e2> visual field constriction </e2> appears to be associated with <e1> vigabatrin </e1> therapy .
NO_RELATION	BACKGROUND : The aim of this study is to evaluate the effects of <e1> RAPA </e1> conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) <e2> toxicity </e2> .
NO_RELATION	BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing <e1> cyclosporine </e1> ( CsA ) or tacrolimus ( Tac ) <e2> toxicity </e2> .
NO_RELATION	BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( <e1> CsA </e1> ) or tacrolimus ( Tac ) <e2> toxicity </e2> .
NO_RELATION	BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or <e1> tacrolimus </e1> ( Tac ) <e2> toxicity </e2> .
NO_RELATION	BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( <e1> Tac </e1> ) <e2> toxicity </e2> .
CID	The indications for switch were chronic <e1> CsA </e1> or Tac <e2> nephrotoxicity </e2> ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity ( 12 ) , acute CsA or Tac <e2> toxicity </e2> ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe <e2> facial dysmorphism </e2> ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , <e2> posttransplant lymphoproliferative disorder </e2> ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( <e2> PTLD </e2> ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic <e1> CsA </e1> or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and <e2> hepatotoxicity </e2> in 1 .
CID	The indications for switch were chronic CsA or <e1> Tac </e1> <e2> nephrotoxicity </e2> ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity ( 12 ) , acute CsA or Tac <e2> toxicity </e2> ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe <e2> facial dysmorphism </e2> ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , <e2> posttransplant lymphoproliferative disorder </e2> ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( <e2> PTLD </e2> ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or <e1> Tac </e1> nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and <e2> hepatotoxicity </e2> in 1 .
CID	The indications for switch were chronic CsA or Tac <e2> nephrotoxicity </e2> ( 12 ) , acute <e1> CsA </e1> or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute <e1> CsA </e1> or Tac <e2> toxicity </e2> ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute <e1> CsA </e1> or Tac toxicity ( 3 ) , severe <e2> facial dysmorphism </e2> ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute <e1> CsA </e1> or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , <e2> posttransplant lymphoproliferative disorder </e2> ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute <e1> CsA </e1> or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( <e2> PTLD </e2> ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute <e1> CsA </e1> or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and <e2> hepatotoxicity </e2> in 1 .
CID	The indications for switch were chronic CsA or Tac <e2> nephrotoxicity </e2> ( 12 ) , acute CsA or <e1> Tac </e1> toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or <e1> Tac </e1> <e2> toxicity </e2> ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or <e1> Tac </e1> toxicity ( 3 ) , severe <e2> facial dysmorphism </e2> ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or <e1> Tac </e1> toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , <e2> posttransplant lymphoproliferative disorder </e2> ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or <e1> Tac </e1> toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( <e2> PTLD </e2> ) in remission ( 2 ) , and hepatotoxicity in 1 .
NO_RELATION	The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or <e1> Tac </e1> toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and <e2> hepatotoxicity </e2> in 1 .
NO_RELATION	RESULTS : In the 12 patients switched because of chronic <e2> nephrotoxicity </e2> there was a significant decrease in serum <e1> creatinine </e1> [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .
NO_RELATION	<e1> RAPA </e1> was discontinued in four patients , because of <e2> pneumonia </e2> in two , PTLD in one , and oral aphtous ulcers in one .
NO_RELATION	<e1> RAPA </e1> was discontinued in four patients , because of pneumonia in two , <e2> PTLD </e2> in one , and oral aphtous ulcers in one .
NO_RELATION	<e1> RAPA </e1> was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral <e2> aphtous ulcers </e2> in one .
NO_RELATION	However , when converting patients to <e1> RAPA </e1> drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and <e2> Pneumocystis carinii pneumonia </e2> prophylaxis should be given .
CID	Worsening of <e1> levodopa </e1> - induced <e2> dyskinesias </e2> by motor and mental tasks .
NO_RELATION	Ten patients who had <e2> Parkinson ' s disease </e2> with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of <e1> apomorphine </e1> .
CID	Ten patients who had Parkinson ' s disease with disabling <e2> dyskinesia </e2> were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of <e1> apomorphine </e1> .
CID	Ten patients who had Parkinson ' s disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose <e2> dyskinesia </e2> following administration of an effective single dose of <e1> apomorphine </e1> .
CID	<e2> Structural and functional impairment of mitochondria </e2> in <e1> adriamycin </e1> - induced cardiomyopathy in mice : suppression of cytochrome c oxidase II gene expression .
NO_RELATION	Structural and functional impairment of mitochondria in <e1> adriamycin </e1> - induced <e2> cardiomyopathy </e2> in mice : suppression of cytochrome c oxidase II gene expression .
NO_RELATION	The use of <e1> adriamycin </e1> ( ADR ) in <e2> cancer </e2> chemotherapy has been limited due to its cumulative cardiovascular toxicity .
NO_RELATION	The use of <e1> adriamycin </e1> ( ADR ) in cancer chemotherapy has been limited due to its cumulative <e2> cardiovascular toxicity </e2> .
NO_RELATION	The use of adriamycin ( <e1> ADR </e1> ) in <e2> cancer </e2> chemotherapy has been limited due to its cumulative cardiovascular toxicity .
NO_RELATION	The use of adriamycin ( <e1> ADR </e1> ) in cancer chemotherapy has been limited due to its cumulative <e2> cardiovascular toxicity </e2> .
NO_RELATION	Our results indicated that 1 ) treatment of mice with <e1> ADR </e1> caused <e2> cardiovascular arrhythmias </e2> characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .
CID	Our results indicated that 1 ) treatment of mice with <e1> ADR </e1> caused cardiovascular arrhythmias characterized by <e2> bradycardia </e2> , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .
NO_RELATION	Our results indicated that 1 ) treatment of mice with <e1> ADR </e1> caused cardiovascular arrhythmias characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent <e2> swelling </e2> , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .
CID	Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of <e1> ADR </e1> on cardiovascular function involve <e2> mitochondrial structural and functional impairment </e2> .
CID	Enhanced <e2> bradycardia </e2> induced by beta - adrenoceptor antagonists in rats pretreated with <e1> isoniazid </e1> .
CID	High doses of <e1> isoniazid </e1> increase <e2> hypotension </e2> induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .
NO_RELATION	High doses of <e1> isoniazid </e1> increase hypotension induced by vasodilators and change the accompanying reflex <e2> tachycardia </e2> to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .
CID	High doses of <e1> isoniazid </e1> increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to <e2> bradycardia </e2> , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .
NO_RELATION	High doses of isoniazid increase <e2> hypotension </e2> induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain <e1> gamma - aminobutyric acid </e1> ( GABA ) .
NO_RELATION	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex <e2> tachycardia </e2> to bradycardia , an interaction attributed to decreased synthesis of brain <e1> gamma - aminobutyric acid </e1> ( GABA ) .
NO_RELATION	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to <e2> bradycardia </e2> , an interaction attributed to decreased synthesis of brain <e1> gamma - aminobutyric acid </e1> ( GABA ) .
NO_RELATION	High doses of isoniazid increase <e2> hypotension </e2> induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( <e1> GABA </e1> ) .
NO_RELATION	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex <e2> tachycardia </e2> to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( <e1> GABA </e1> ) .
NO_RELATION	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to <e2> bradycardia </e2> , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( <e1> GABA </e1> ) .
CID	In the present study , the possible enhancement by <e1> isoniazid </e1> of <e2> bradycardia </e2> induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .
NO_RELATION	In the present study , the possible enhancement by isoniazid of <e2> bradycardia </e2> induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with <e1> chloralose </e1> - urethane .
NO_RELATION	In the present study , the possible enhancement by isoniazid of <e2> bradycardia </e2> induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - <e1> urethane </e1> .
CID	<e1> Isoniazid </e1> significantly increased <e2> bradycardia </e2> after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .
NO_RELATION	Isoniazid significantly increased <e2> bradycardia </e2> after <e1> propranolol </e1> , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .
NO_RELATION	Isoniazid significantly increased <e2> bradycardia </e2> after propranolol , <e1> pindolol </e1> , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .
NO_RELATION	Isoniazid significantly increased <e2> bradycardia </e2> after propranolol , pindolol , <e1> labetalol </e1> and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .
NO_RELATION	Isoniazid significantly increased <e2> bradycardia </e2> after propranolol , pindolol , labetalol and <e1> atenolol </e1> , as well as after clonidine , but not after hexamethonium or carbachol .
NO_RELATION	Isoniazid significantly increased <e2> bradycardia </e2> after propranolol , pindolol , labetalol and atenolol , as well as after <e1> clonidine </e1> , but not after hexamethonium or carbachol .
NO_RELATION	Isoniazid significantly increased <e2> bradycardia </e2> after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after <e1> hexamethonium </e1> or carbachol .
NO_RELATION	Isoniazid significantly increased <e2> bradycardia </e2> after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or <e1> carbachol </e1> .
CID	Epileptogenic activity of <e1> folic acid </e1> after drug induces <e2> SLE </e2> ( folic acid and epilepsy ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of <e1> folic acid </e1> after drug induces SLE ( folic acid and <e2> epilepsy </e2> ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of <e1> folic acid </e1> after drug induces SLE ( folic acid and epilepsy ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in <e2> epileptic </e2> women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of <e1> folic acid </e1> after drug induces SLE ( folic acid and epilepsy ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural <e2> birth defects </e2> and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of <e1> folic acid </e1> after drug induces SLE ( folic acid and epilepsy ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and <e2> epilepsy </e2> - related side effects .
CID	Epileptogenic activity of folic acid after drug induces <e2> SLE </e2> ( <e1> folic acid </e1> and epilepsy ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of folic acid after drug induces SLE ( <e1> folic acid </e1> and <e2> epilepsy </e2> ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of folic acid after drug induces SLE ( <e1> folic acid </e1> and epilepsy ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in <e2> epileptic </e2> women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of folic acid after drug induces SLE ( <e1> folic acid </e1> and epilepsy ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural <e2> birth defects </e2> and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of folic acid after drug induces SLE ( <e1> folic acid </e1> and epilepsy ) OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and <e2> epilepsy </e2> - related side effects .
CID	Epileptogenic activity of folic acid after drug induces <e2> SLE </e2> ( folic acid and epilepsy ) OBJECTIVE : To study the effect of <e1> folic acid </e1> - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of folic acid after drug induces SLE ( folic acid and <e2> epilepsy </e2> ) OBJECTIVE : To study the effect of <e1> folic acid </e1> - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy ) OBJECTIVE : To study the effect of <e1> folic acid </e1> - containing multivitamin supplementation in <e2> epileptic </e2> women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy ) OBJECTIVE : To study the effect of <e1> folic acid </e1> - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural <e2> birth defects </e2> and epilepsy - related side effects .
NO_RELATION	Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy ) OBJECTIVE : To study the effect of <e1> folic acid </e1> - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and <e2> epilepsy </e2> - related side effects .
NO_RELATION	RESULTS : Of 60 <e2> epileptic </e2> women with periconceptional <e1> folic acid </e1> ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed epilepsy - related side effects during the periconception period .
NO_RELATION	RESULTS : Of 60 epileptic women with periconceptional <e1> folic acid </e1> ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed <e2> epilepsy </e2> - related side effects during the periconception period .
NO_RELATION	This 22 - year - old <e2> epileptic </e2> woman was treated continuously by <e1> carbamazepine </e1> and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .
NO_RELATION	This 22 - year - old <e2> epileptic </e2> woman was treated continuously by carbamazepine and a <e1> folic acid </e1> ( 1 mg ) - containing multivitamin from the 20th week of gestation .
NO_RELATION	CONCLUSIONS : The <e2> epileptic </e2> pregnant patient ' s autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of <e1> folic acid </e1> triggered a cluster of seizures .
NO_RELATION	CONCLUSIONS : The epileptic pregnant patient ' s <e2> autoimmune disease </e2> ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of <e1> folic acid </e1> triggered a cluster of seizures .
CID	CONCLUSIONS : The epileptic pregnant patient ' s autoimmune disease ( probably drug - induced <e2> lupus </e2> ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of <e1> folic acid </e1> triggered a cluster of seizures .
CID	CONCLUSIONS : The epileptic pregnant patient ' s autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of <e1> folic acid </e1> triggered a cluster of <e2> seizures </e2> .
NO_RELATION	Physiological dose ( < 1 mg ) of <e1> folic acid </e1> both in healthy and 60 <e2> epileptic </e2> women , all without any autoimmune disease , did not increase the risk for epileptic seizures .
NO_RELATION	Physiological dose ( < 1 mg ) of <e1> folic acid </e1> both in healthy and 60 epileptic women , all without any <e2> autoimmune disease </e2> , did not increase the risk for epileptic seizures .
NO_RELATION	Physiological dose ( < 1 mg ) of <e1> folic acid </e1> both in healthy and 60 epileptic women , all without any autoimmune disease , did not increase the risk for <e2> epileptic seizures </e2> .
NO_RELATION	Effects of <e1> cisapride </e1> on symptoms and postcibal small - bowel motor function in patients with <e2> irritable bowel syndrome </e2> .
NO_RELATION	Our aim was to assess the effects of long - term treatment with a prokinetic agent , <e1> cisapride </e1> , on postprandial jejunal motility and symptoms in the <e2> irritable bowel syndrome </e2> ( IBS ) .
NO_RELATION	Our aim was to assess the effects of long - term treatment with a prokinetic agent , <e1> cisapride </e1> , on postprandial jejunal motility and symptoms in the irritable bowel syndrome ( <e2> IBS </e2> ) .
NO_RELATION	METHODS : Thirty - eight patients with <e2> IBS </e2> ( constipation - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week ' s treatment [ <e1> cisapride </e1> , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .
NO_RELATION	METHODS : Thirty - eight patients with IBS ( <e2> constipation </e2> - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week ' s treatment [ <e1> cisapride </e1> , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .
NO_RELATION	METHODS : Thirty - eight patients with IBS ( constipation - predominant , n = 17 ; <e2> diarrhoea </e2> - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week ' s treatment [ <e1> cisapride </e1> , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .
NO_RELATION	RESULTS : In <e2> diarrhoea </e2> - predominant patients significant differences in contraction characteristics were observed between the <e1> cisapride </e1> and placebo groups .
NO_RELATION	In <e1> cisapride </e1> - treated <e2> diarrhoea </e2> - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .
NO_RELATION	In cisapride - treated <e2> diarrhoea </e2> - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , <e1> cisapride </e1> versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .
NO_RELATION	In cisapride - treated <e2> diarrhoea </e2> - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , <e1> cisapride </e1> versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .
NO_RELATION	In cisapride - treated <e2> diarrhoea </e2> - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , <e1> cisapride </e1> versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .
NO_RELATION	Symptom scores relating to the severity of <e2> constipation </e2> were lower in <e1> cisapride </e1> - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / - 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .
NO_RELATION	Symptom scores relating to the severity of constipation were lower in <e1> cisapride </e1> - treated <e2> constipation </e2> - predominant IBS patients [ score , 54 + / - 5 versus 67 + / - 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .
NO_RELATION	Symptom scores relating to the severity of constipation were lower in <e1> cisapride </e1> - treated constipation - predominant <e2> IBS </e2> patients [ score , 54 + / - 5 versus 67 + / - 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .
NO_RELATION	Symptom scores relating to the severity of <e2> constipation </e2> were lower in cisapride - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / - 14 mm , <e1> cisapride </e1> versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .
NO_RELATION	Symptom scores relating to the severity of constipation were lower in cisapride - treated <e2> constipation </e2> - predominant IBS patients [ score , 54 + / - 5 versus 67 + / - 14 mm , <e1> cisapride </e1> versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .
NO_RELATION	Symptom scores relating to the severity of constipation were lower in cisapride - treated constipation - predominant <e2> IBS </e2> patients [ score , 54 + / - 5 versus 67 + / - 14 mm , <e1> cisapride </e1> versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .
NO_RELATION	<e2> Diarrhoea </e2> - predominant IBS patients had a higher pain score after <e1> cisapride </e1> therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .
NO_RELATION	Diarrhoea - predominant <e2> IBS </e2> patients had a higher pain score after <e1> cisapride </e1> therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .
NO_RELATION	Diarrhoea - predominant IBS patients had a higher <e2> pain </e2> score after <e1> cisapride </e1> therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .
NO_RELATION	<e2> Diarrhoea </e2> - predominant IBS patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , <e1> cisapride </e1> versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .
NO_RELATION	Diarrhoea - predominant <e2> IBS </e2> patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , <e1> cisapride </e1> versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .
NO_RELATION	Diarrhoea - predominant IBS patients had a higher <e2> pain </e2> score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , <e1> cisapride </e1> versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .
NO_RELATION	CONCLUSION : <e1> Cisapride </e1> affects jejunal contraction characteristics and some symptoms in <e2> IBS </e2> .
CID	<e1> Clarithromycin </e1> - induced <e2> ventricular tachycardia </e2> .
CID	Although the side - effect profile of <e1> erythromycin </e1> is established , including <e2> gastroenteritis </e2> and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer macrolides is still being recorded .
NO_RELATION	Although the side - effect profile of erythromycin is established , including <e2> gastroenteritis </e2> and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer <e1> macrolides </e1> is still being recorded .
NO_RELATION	<e2> Cardiotoxicity </e2> has been demonstrated after both intravenous and oral administration of <e1> erythromycin </e1> but has never been reported with the newer macrolides .
NO_RELATION	<e2> Cardiotoxicity </e2> has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer <e1> macrolides </e1> .
NO_RELATION	We report a case of <e2> ventricular dysrhythmias </e2> that occurred after six therapeutic doses of <e1> clarithromycin </e1> .
CID	Persistent <e2> nephrogenic diabetes insipidus </e2> following <e1> lithium </e1> therapy .
CID	Ten years previously he had been diagnosed to have <e1> lithium </e1> - induced <e2> nephrogenic diabetes insipidus </e2> , and lithium therapy had been discontinued .
CID	Ten years previously he had been diagnosed to have lithium - induced <e2> nephrogenic diabetes insipidus </e2> , and <e1> lithium </e1> therapy had been discontinued .
CID	He remained thirsty and <e2> polyuric </e2> despite cessation of <e1> lithium </e1> and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of nephrogenic diabetes insipidus .
CID	He remained thirsty and polyuric despite cessation of <e1> lithium </e1> and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of <e2> nephrogenic diabetes insipidus </e2> .
NO_RELATION	He remained thirsty and <e2> polyuric </e2> despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and <e1> vasopressin </e1> secretion , with clear evidence of nephrogenic diabetes insipidus .
NO_RELATION	He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and <e1> vasopressin </e1> secretion , with clear evidence of <e2> nephrogenic diabetes insipidus </e2> .
CID	<e1> Lithium </e1> induced <e2> nephrogenic diabetes insipidus </e2> is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped .
CID	<e1> Lithium </e1> induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but <e2> polyuria </e2> persisted in this patient for ten years after lithium was stopped .
CID	Lithium induced <e2> nephrogenic diabetes insipidus </e2> is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after <e1> lithium </e1> was stopped .
CID	Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but <e2> polyuria </e2> persisted in this patient for ten years after <e1> lithium </e1> was stopped .
CID	We discuss the possible renal mechanisms and the implications for management of patients with <e1> lithium </e1> - induced <e2> nephrogenic diabetes insipidus </e2> .
NO_RELATION	Cardiac function was assessed in long - term survivors of malignant <e2> bone tumors </e2> who were treated according to <e1> Rosen ' s T5 or T10 protocol </e1> , both including doxorubicin .
NO_RELATION	Cardiac function was assessed in long - term survivors of malignant <e2> bone tumors </e2> who were treated according to Rosen ' s T5 or T10 protocol , both including <e1> doxorubicin </e1> .
NO_RELATION	The incidence of <e1> doxorubicin </e1> - induced <e2> cardiotoxicity </e2> is high and increases with follow - up , irrespective of cumulative dose .
CID	<e2> Venous complications </e2> of <e1> midazolam </e1> versus diazepam .
CID	<e2> Venous complications </e2> of midazolam versus <e1> diazepam </e1> .
CID	Although some studies have suggested fewer <e2> venous complications </e2> are associated with <e1> midazolam </e1> than with diazepam for endoscopic procedures , this variable has not been well documented .
CID	Although some studies have suggested fewer <e2> venous complications </e2> are associated with midazolam than with <e1> diazepam </e1> for endoscopic procedures , this variable has not been well documented .
CID	We prospectively evaluated the incidence of <e2> venous complications </e2> after intravenous injection of <e1> diazepam </e1> or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .
CID	We prospectively evaluated the incidence of <e2> venous complications </e2> after intravenous injection of diazepam or <e1> midazolam </e1> in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .
CID	Overall , <e2> venous complications </e2> were more frequent with <e1> diazepam </e1> ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .
CID	Overall , <e2> venous complications </e2> were more frequent with diazepam ( 22 of 62 patients ) than with <e1> midazolam </e1> ( 4 of 60 patients ) ( p < 0 . 001 ) .
NO_RELATION	<e2> Pain </e2> at the injection site occurred in 35 % ( 22 of 62 ) of patients in the <e1> diazepam </e1> group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .
NO_RELATION	<e2> Pain </e2> at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the <e1> midazolam </e1> group ( p < 0 . 001 ) .
NO_RELATION	Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , <e1> alcohol </e1> use , and <e2> pain </e2> during the injection had no effect on the incidence of venous complications .
NO_RELATION	Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , <e1> alcohol </e1> use , and pain during the injection had no effect on the incidence of <e2> venous complications </e2> .
CID	<e2> Tetany </e2> and rhabdomyolysis due to surreptitious <e1> furosemide </e1> - - importance of magnesium supplementation .
CID	Tetany and <e2> rhabdomyolysis </e2> due to surreptitious <e1> furosemide </e1> - - importance of magnesium supplementation .
NO_RELATION	<e2> Tetany </e2> and rhabdomyolysis due to surreptitious furosemide - - importance of <e1> magnesium </e1> supplementation .
NO_RELATION	Tetany and <e2> rhabdomyolysis </e2> due to surreptitious furosemide - - importance of <e1> magnesium </e1> supplementation .
NO_RELATION	While severe <e2> hypokalemia </e2> may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by <e1> potassium </e1> and calcium supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe hypokalemia may cause <e2> muscle weakness </e2> , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by <e1> potassium </e1> and calcium supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe hypokalemia may cause muscle weakness , severe <e2> hypomagnesemia </e2> is associated with muscle spasms and tetany which cannot be corrected by <e1> potassium </e1> and calcium supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with <e2> muscle spasms </e2> and tetany which cannot be corrected by <e1> potassium </e1> and calcium supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and <e2> tetany </e2> which cannot be corrected by <e1> potassium </e1> and calcium supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe <e2> hypokalemia </e2> may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and <e1> calcium </e1> supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe hypokalemia may cause <e2> muscle weakness </e2> , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and <e1> calcium </e1> supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe hypokalemia may cause muscle weakness , severe <e2> hypomagnesemia </e2> is associated with muscle spasms and tetany which cannot be corrected by potassium and <e1> calcium </e1> supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with <e2> muscle spasms </e2> and tetany which cannot be corrected by potassium and <e1> calcium </e1> supplementation alone ( 1 , 2 ) .
NO_RELATION	While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and <e2> tetany </e2> which cannot be corrected by potassium and <e1> calcium </e1> supplementation alone ( 1 , 2 ) .
NO_RELATION	Symptomatic <e2> hypokalemia </e2> has been reported in such patients ( 3 - 7 ) and in one case hypocalcemia was observed ( 8 ) , but the effects of <e1> magnesium </e1> depletion were not noted in these patients .
NO_RELATION	Symptomatic hypokalemia has been reported in such patients ( 3 - 7 ) and in one case <e2> hypocalcemia </e2> was observed ( 8 ) , but the effects of <e1> magnesium </e1> depletion were not noted in these patients .
NO_RELATION	Loss of <e1> glutamate </e1> decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced <e2> seizures </e2> .
CID	Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following <e1> pilocarpine </e1> - induced <e2> seizures </e2> .
NO_RELATION	In situ hybridization methods were used to determine if <e1> glutamic acid </e1> decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to <e2> seizure </e2> - induced damage in a model of chronic seizures .
NO_RELATION	In situ hybridization methods were used to determine if <e1> glutamic acid </e1> decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic <e2> seizures </e2> .
CID	Sprague - Dawley rats were injected intraperitoneally with <e1> pilocarpine </e1> , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced <e2> seizures </e2> .
CID	Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after <e1> pilocarpine </e1> - induced <e2> seizures </e2> .
NO_RELATION	Additional neuronanatomical studies , including <e1> cresyl violet </e1> staining , <e2> neuronal degeneration </e2> methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .
NO_RELATION	Additional neuronanatomical studies , including <e1> cresyl violet </e1> staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to <e2> neuronal loss </e2> rather than to a decrease in GAD mRNA levels .
NO_RELATION	Protective effect of <e1> misoprostol </e1> on indomethacin induced <e2> renal dysfunction </e2> in elderly patients .
CID	Protective effect of misoprostol on <e1> indomethacin </e1> induced <e2> renal dysfunction </e2> in elderly patients .
CID	CONCLUSION : Hospitalized elderly patients are at risk for developing <e1> indomethacin </e1> related <e2> renal dysfunction </e2> .
NO_RELATION	Addition of <e1> misoprostol </e1> can minimize this <e2> renal impairment </e2> without affecting pain control .
NO_RELATION	Addition of <e1> misoprostol </e1> can minimize this renal impairment without affecting <e2> pain </e2> control .
NO_RELATION	<e2> Nephrotoxic </e2> effects of <e1> aminoglycoside </e1> treatment on renal protein reabsorption and accumulation .
NO_RELATION	Thus , <e1> aminoglycosides </e1> may act as nephrotoxicants at glomerular and / or tubular level inducing <e2> impairment of renal reabsorption </e2> and accumulation of proteins .
NO_RELATION	Its antiarrhythmic effectiveness surpasses that of <e1> propranolol </e1> and pindolol inhibiting the ouabain <e2> arrhythmia </e2> in dogs and cats .
NO_RELATION	Its antiarrhythmic effectiveness surpasses that of propranolol and <e1> pindolol </e1> inhibiting the ouabain <e2> arrhythmia </e2> in dogs and cats .
CID	Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the <e1> ouabain </e1> <e2> arrhythmia </e2> in dogs and cats .
CID	<e2> Chorea </e2> associated with <e1> oral contraception </e1> .
CID	Three patients developed <e2> chorea </e2> while receiving <e1> oral contraceptives </e1> .
CID	The third patient had acute <e1> amphetamine </e1> - induced <e2> chorea </e2> after prolonged oral contraception .
CID	The third patient had acute amphetamine - induced <e2> chorea </e2> after prolonged <e1> oral contraception </e1> .
NO_RELATION	Reversal of <e1> ammonia </e1> <e2> coma </e2> in rats by L - dopa : a peripheral effect .
NO_RELATION	Reversal of ammonia <e2> coma </e2> in rats by <e1> L - dopa </e1> : a peripheral effect .
NO_RELATION	<e1> Ammonia </e1> <e2> coma </e2> was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .
CID	Ammonia <e2> coma </e2> was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol <e1> NH4CL </e1> .
NO_RELATION	This <e2> coma </e2> was prevented with 1 . 68 mmol <e1> L - dopa </e1> given by gastric intubation 15 minutes before the ammonium salt injection .
NO_RELATION	This <e2> coma </e2> was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the <e1> ammonium salt </e1> injection .
NO_RELATION	Intraventricular infusion of <e1> dopamine </e1> sufficient to raise the brain dopamine to the same extent did not prevent the ammonia <e2> coma </e2> nor affect the blood and brain ammonia concentrations .
NO_RELATION	Intraventricular infusion of dopamine sufficient to raise the brain <e1> dopamine </e1> to the same extent did not prevent the ammonia <e2> coma </e2> nor affect the blood and brain ammonia concentrations .
NO_RELATION	Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the <e1> ammonia </e1> <e2> coma </e2> nor affect the blood and brain ammonia concentrations .
NO_RELATION	Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia <e2> coma </e2> nor affect the blood and brain <e1> ammonia </e1> concentrations .
NO_RELATION	Bilateral nephrectomy eliminated the beneficial effect of <e1> L - dopa </e1> on blood and brain ammonia and the ammonia <e2> coma </e2> was not prevented .
NO_RELATION	Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain <e1> ammonia </e1> and the ammonia <e2> coma </e2> was not prevented .
NO_RELATION	Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the <e1> ammonia </e1> <e2> coma </e2> was not prevented .
NO_RELATION	Thus , the reduction in blood and brain <e1> ammonia </e1> and the prevention of ammonia <e2> coma </e2> after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .
NO_RELATION	Thus , the reduction in blood and brain ammonia and the prevention of <e1> ammonia </e1> <e2> coma </e2> after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .
NO_RELATION	Thus , the reduction in blood and brain ammonia and the prevention of ammonia <e2> coma </e2> after <e1> L - dopa </e1> , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .
NO_RELATION	Thus , the reduction in blood and brain ammonia and the prevention of ammonia <e2> coma </e2> after L - dopa , can be accounted for by the peripheral effect of <e1> dopamine </e1> on renal function rather than its central action .
NO_RELATION	These results provide a reasonable explanation for the beneficial effects observed in some <e2> encephalopathic </e2> patients receiving <e1> L - dopa </e1> .
CID	<e1> Heparin </e1> - induced <e2> thrombocytopenia </e2> after liver transplantation .
NO_RELATION	BACKGROUND : <e1> Unfractionated heparin sodium </e1> ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent <e2> thrombosis </e2> after liver transplantation .
NO_RELATION	BACKGROUND : Unfractionated heparin sodium ( <e1> UFH </e1> ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent <e2> thrombosis </e2> after liver transplantation .
NO_RELATION	BACKGROUND : Unfractionated heparin sodium ( UFH ) or <e1> low - molecular weight heparin </e1> ( LMWH ) is used in anticoagulant protocols at several institutions to prevent <e2> thrombosis </e2> after liver transplantation .
CID	<e1> Heparin </e1> - induced <e2> thrombocytopenia </e2> ( HIT ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .
CID	<e1> Heparin </e1> - induced thrombocytopenia ( <e2> HIT </e2> ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .
CID	Heparin - induced <e2> thrombocytopenia </e2> ( HIT ) is an adverse immune - mediated reaction to <e1> heparin </e1> , resulting in platelet count decreases of more than 50 % .
CID	Heparin - induced thrombocytopenia ( <e2> HIT </e2> ) is an adverse immune - mediated reaction to <e1> heparin </e1> , resulting in platelet count decreases of more than 50 % .
CID	The frequencies of <e2> HIT </e2> after liver transplantation and platelet factor 4 / <e1> heparin </e1> - reactive antibody ( HIT antibody ) positivity in liver transplantation patients , however , are unknown .
CID	The frequencies of HIT after liver transplantation and platelet factor 4 / <e1> heparin </e1> - reactive antibody ( <e2> HIT </e2> antibody ) positivity in liver transplantation patients , however , are unknown .
NO_RELATION	The <e1> heparin </e1> - induced <e2> platelet aggregation </e2> test was negative in these patients .
CID	None of the subjects / patients developed <e1> UFH </e1> - related <e2> HIT </e2> .
CID	<e1> PTU </e1> - associated <e2> vasculitis </e2> in a girl with Turner Syndrome and Graves ' disease .
NO_RELATION	<e1> PTU </e1> - associated vasculitis in a girl with <e2> Turner Syndrome </e2> and Graves ' disease .
NO_RELATION	<e1> PTU </e1> - associated vasculitis in a girl with Turner Syndrome and <e2> Graves ' disease </e2> .
CID	The diagnosis of <e1> propylthiouracil </e1> ( PTU ) - associated <e2> vasculitis </e2> was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .
CID	The diagnosis of propylthiouracil ( <e1> PTU </e1> ) - associated <e2> vasculitis </e2> was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .
CID	The diagnosis of propylthiouracil ( PTU ) - associated <e2> vasculitis </e2> was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of <e1> PTU </e1> .
CID	<e1> Succinylcholine </e1> - induced <e2> masseter muscle rigidity </e2> during bronchoscopic removal of a tracheal foreign body .
CID	Here , we describe a case of severe <e2> masseter muscle rigidity </e2> ( jaw of steel ) after <e1> succinylcholine </e1> ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .
CID	Here , we describe a case of severe masseter muscle rigidity ( <e2> jaw of steel </e2> ) after <e1> succinylcholine </e1> ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .
CID	Here , we describe a case of severe <e2> masseter muscle rigidity </e2> ( jaw of steel ) after succinylcholine ( <e1> Sch </e1> ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .
CID	Here , we describe a case of severe masseter muscle rigidity ( <e2> jaw of steel </e2> ) after succinylcholine ( <e1> Sch </e1> ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .
NO_RELATION	Anesthesia was continued uneventfully with <e1> propofol </e1> infusion while all facilities were available to detect and treat <e2> malignant hyperthermia </e2> .
CID	Minor <e2> neurological dysfunction </e2> , cognitive development , and somatic development at the age of 3 to 7 years after <e1> dexamethasone </e1> treatment in very - low birth - weight infants .
CID	The objective of this study was to assess minor <e2> neurological dysfunction </e2> , cognitive development , and somatic development after <e1> dexamethasone </e1> therapy in very - low - birthweight infants .
CID	After <e1> dexamethasone </e1> treatment , children showed a higher rate of minor <e2> neurological dysfunctions </e2> .
CID	Force overflow and <e1> levodopa </e1> - induced <e2> dyskinesias </e2> in Parkinson ' s disease .
NO_RELATION	Force overflow and <e1> levodopa </e1> - induced dyskinesias in <e2> Parkinson ' s disease </e2> .
NO_RELATION	We assessed force coordination of the hand in <e2> Parkinson ' s disease </e2> and its relationship to motor complications of <e1> levodopa </e1> therapy , particularly to levodopa - induced dyskinesias ( LID ) .
CID	We assessed force coordination of the hand in Parkinson ' s disease and its relationship to motor complications of <e1> levodopa </e1> therapy , particularly to levodopa - induced <e2> dyskinesias </e2> ( LID ) .
CID	We assessed force coordination of the hand in Parkinson ' s disease and its relationship to motor complications of <e1> levodopa </e1> therapy , particularly to levodopa - induced dyskinesias ( <e2> LID </e2> ) .
NO_RELATION	We assessed force coordination of the hand in <e2> Parkinson ' s disease </e2> and its relationship to motor complications of levodopa therapy , particularly to <e1> levodopa </e1> - induced dyskinesias ( LID ) .
CID	We assessed force coordination of the hand in Parkinson ' s disease and its relationship to motor complications of levodopa therapy , particularly to <e1> levodopa </e1> - induced <e2> dyskinesias </e2> ( LID ) .
CID	We assessed force coordination of the hand in Parkinson ' s disease and its relationship to motor complications of levodopa therapy , particularly to <e1> levodopa </e1> - induced dyskinesias ( <e2> LID </e2> ) .
NO_RELATION	We studied two groups of <e2> Parkinson ' s disease </e2> patients with ( Parkinson ' s disease + LID , n = 23 ) and without <e1> levodopa </e1> - induced dyskinesias ( Parkinson ' s disease - LID , n = 10 ) , and age - matched healthy controls .
NO_RELATION	We studied two groups of Parkinson ' s disease patients with ( <e2> Parkinson ' s disease </e2> + LID , n = 23 ) and without <e1> levodopa </e1> - induced dyskinesias ( Parkinson ' s disease - LID , n = 10 ) , and age - matched healthy controls .
CID	We studied two groups of Parkinson ' s disease patients with ( Parkinson ' s disease + <e2> LID </e2> , n = 23 ) and without <e1> levodopa </e1> - induced dyskinesias ( Parkinson ' s disease - LID , n = 10 ) , and age - matched healthy controls .
CID	We studied two groups of Parkinson ' s disease patients with ( Parkinson ' s disease + LID , n = 23 ) and without <e1> levodopa </e1> - induced <e2> dyskinesias </e2> ( Parkinson ' s disease - LID , n = 10 ) , and age - matched healthy controls .
NO_RELATION	We studied two groups of Parkinson ' s disease patients with ( Parkinson ' s disease + LID , n = 23 ) and without <e1> levodopa </e1> - induced dyskinesias ( <e2> Parkinson ' s disease </e2> - LID , n = 10 ) , and age - matched healthy controls .
CID	We studied two groups of Parkinson ' s disease patients with ( Parkinson ' s disease + LID , n = 23 ) and without <e1> levodopa </e1> - induced dyskinesias ( Parkinson ' s disease - <e2> LID </e2> , n = 10 ) , and age - matched healthy controls .
NO_RELATION	The motor score of the Unified <e2> Parkinson ' s Disease </e2> Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF <e1> levodopa </e1> .
CID	The motor score of the Unified Parkinson ' s Disease Rating Scale , a <e2> dyskinesia </e2> score and force in a grip - lift paradigm were assessed ON and OFF <e1> levodopa </e1> .
NO_RELATION	In <e2> Parkinson ' s disease </e2> + LID , the force involved in pressing down the object before lifting was significantly increased by <e1> levodopa </e1> ( by 61 % , P < 0 . 05 ) .
CID	In Parkinson ' s disease + <e2> LID </e2> , the force involved in pressing down the object before lifting was significantly increased by <e1> levodopa </e1> ( by 61 % , P < 0 . 05 ) .
CID	Postinfarction <e2> ventricular septal defect </e2> associated with long - term <e1> steroid </e1> therapy .
CID	Two cases of postinfarction <e2> ventricular septal rupture </e2> in patients on long - term <e1> steroid </e1> therapy are presented and the favourable outcome in both cases described .
CID	A possible association between <e1> steroid </e1> therapy and subsequent postinfarction <e2> septal rupture </e2> is discussed .
CID	<e2> Angioedema </e2> associated with <e1> droperidol </e1> administration .
NO_RELATION	We report the case of a previously healthy 19 - year - old man with no known <e2> drug allergies </e2> in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of <e1> droperidol </e1> .
CID	We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom <e2> angioedema </e2> with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of <e1> droperidol </e1> .
NO_RELATION	We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom angioedema with significant <e2> tongue swelling </e2> and protrusion developed within 10 minutes of the administration of a single IV dose of <e1> droperidol </e1> .
CID	<e1> Clarithromycin </e1> - associated <e2> visual hallucinations </e2> in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis .
NO_RELATION	<e1> Clarithromycin </e1> - associated visual hallucinations in a patient with <e2> chronic renal failure </e2> on continuous ambulatory peritoneal dialysis .
NO_RELATION	Unreported in the literature is <e2> visual hallucinations </e2> occurring in association with the new <e1> macrolide </e1> antibiotic , clarithromycin .
CID	Unreported in the literature is <e2> visual hallucinations </e2> occurring in association with the new macrolide antibiotic , <e1> clarithromycin </e1> .
NO_RELATION	The combination of a relatively high dose of <e1> clarithromycin </e1> in face of <e2> chronic renal failure </e2> in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this neurotoxic side effect .
NO_RELATION	The combination of a relatively high dose of <e1> clarithromycin </e1> in face of chronic renal failure in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this <e2> neurotoxic </e2> side effect .
NO_RELATION	The combination of a relatively high dose of clarithromycin in face of <e2> chronic renal failure </e2> in a functionally anephric patient , with underlying <e1> aluminum </e1> intoxication , may have facilitated the appearance of this neurotoxic side effect .
NO_RELATION	The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient , with underlying <e1> aluminum </e1> intoxication , may have facilitated the appearance of this <e2> neurotoxic </e2> side effect .
NO_RELATION	Acute <e2> renal toxicity </e2> of <e1> doxorubicin </e1> ( adriamycin ) - loaded cyanoacrylate nanoparticles .
NO_RELATION	Acute <e2> renal toxicity </e2> of doxorubicin ( <e1> adriamycin </e1> ) - loaded cyanoacrylate nanoparticles .
NO_RELATION	Acute <e2> renal toxicity </e2> of doxorubicin ( adriamycin ) - loaded <e1> cyanoacrylate </e1> nanoparticles .
NO_RELATION	Acute <e1> doxorubicin </e1> - loaded nanoparticle ( DXNP ) <e2> renal toxicity </e2> was explored in both normal rats and rats with experimental glomerulonephritis .
NO_RELATION	Acute <e1> doxorubicin </e1> - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental <e2> glomerulonephritis </e2> .
CID	A 3 times higher <e2> proteinuria </e2> appeared in animals treated with DXNP than in those treated with <e1> DX </e1> .
NO_RELATION	In rats with immune experimental <e2> glomerulonephritis </e2> , 5 / 6 rats given <e1> DX </e1> died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .
CID	<e2> Proteinuria </e2> appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after <e1> doxorubicin </e1> treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .
CID	<e2> Proteinuria </e2> appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and <e1> DX </e1> .
NO_RELATION	These results demonstrate that , in these experimental conditions , DXNP killed less animals than free <e1> DX </e1> , despite of an enhanced <e2> renal toxicity </e2> of the former .
CID	<e1> Etoposide </e1> - related <e2> myocardial infarction </e2> .
CID	The occurrence of a <e2> myocardial infarction </e2> is reported after chemotherapy containing <e1> etoposide </e1> , in a man with no risk factors for coronary heart disease .
NO_RELATION	The occurrence of a myocardial infarction is reported after chemotherapy containing <e1> etoposide </e1> , in a man with no risk factors for <e2> coronary heart disease </e2> .
CID	Subjective assessment of <e2> sexual dysfunction </e2> of patients on long - term administration of <e1> digoxin </e1> .
NO_RELATION	The patients of the study and control group ( without <e1> digoxin </e1> ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the <e2> rheumatic heart disease </e2> patients .
CID	Fatal <e2> aplastic anemia </e2> due to <e1> indomethacin </e1> - - lymphocyte transformation tests in vitro .
CID	Although <e1> indomethacin </e1> has been implicated as a possible cause of <e2> aplastic anemia </e2> on the basis of a few clinical observations , its role has not been definitely established .
NO_RELATION	A case of fatal <e2> aplastic anemia </e2> is described in which no drugs other than <e1> allopurinol </e1> and indomethacin were given .
CID	A case of fatal <e2> aplastic anemia </e2> is described in which no drugs other than allopurinol and <e1> indomethacin </e1> were given .
CID	A positive lymphocyte transformation test with <e1> indomethacin </e1> in vitro further substantiates the potential role of this drug in causing <e2> aplastic anemia </e2> in a susceptible patient .
CID	Plasma and urinary lipids and lipoproteins during the development of <e2> nephrotic syndrome </e2> induced in the rat by <e1> puromycin aminonucleoside </e1> .
CID	This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in <e2> nephrotic syndrome </e2> induced by <e1> puromycin aminonucleoside </e1> were due to nephrotic syndrome per se , or , at least in part , to the aminonucleoside .
CID	This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by <e1> puromycin aminonucleoside </e1> were due to <e2> nephrotic syndrome </e2> per se , or , at least in part , to the aminonucleoside .
CID	This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in <e2> nephrotic syndrome </e2> induced by puromycin aminonucleoside were due to nephrotic syndrome per se , or , at least in part , to the <e1> aminonucleoside </e1> .
CID	This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to <e2> nephrotic syndrome </e2> per se , or , at least in part , to the <e1> aminonucleoside </e1> .
CID	The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of <e1> puromycin aminonucleoside </e1> ( 20 mg / kg for 7 days ) and the subsequent development of <e2> nephrotic syndrome </e2> .
NO_RELATION	In pre - <e2> nephrotic </e2> stage the plasma level of <e1> fatty acids </e1> , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .
NO_RELATION	In pre - <e2> nephrotic </e2> stage the plasma level of fatty acids , <e1> triacylglycerol </e1> and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .
NO_RELATION	In pre - <e2> nephrotic </e2> stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , <e1> cholesteryl esters </e1> and HDL remained constant .
CID	Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived <e2> fulminant hepatic failure </e2> after <e1> paracetamol </e1> overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .
NO_RELATION	Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <e1> paracetamol </e1> <e2> overdose </e2> , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .
CID	Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <e1> paracetamol </e1> overdose , whereas activities were increased equally in patients with <e2> fulminant hepatic failure </e2> due to viral hepatitis whether or not they survived .
NO_RELATION	Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <e1> paracetamol </e1> overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to <e2> viral hepatitis </e2> whether or not they survived .
CID	Transketolase abnormality in <e1> tolazamide </e1> - induced <e2> Wernicke ' s encephalopathy </e2> .
NO_RELATION	We studied a <e1> thiamine </e1> - dependent enzyme , transketolase , from fibroblasts of a <e2> diabetic </e2> patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
NO_RELATION	We studied a <e1> thiamine </e1> - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed <e2> Wernicke ' s encephalopathy </e2> when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
NO_RELATION	We studied a <e1> thiamine </e1> - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic <e2> Wernicke - Korsakoff syndrome </e2> .
NO_RELATION	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a <e2> diabetic </e2> patient who developed Wernicke ' s encephalopathy when treated with <e1> tolazamide </e1> , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
CID	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed <e2> Wernicke ' s encephalopathy </e2> when treated with <e1> tolazamide </e1> , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
NO_RELATION	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke ' s encephalopathy when treated with <e1> tolazamide </e1> , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic <e2> Wernicke - Korsakoff syndrome </e2> .
NO_RELATION	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a <e2> diabetic </e2> patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for <e1> thiamine pyrophosphate </e1> ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
NO_RELATION	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed <e2> Wernicke ' s encephalopathy </e2> when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for <e1> thiamine pyrophosphate </e1> ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
NO_RELATION	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for <e1> thiamine pyrophosphate </e1> ( TPP ) ] , as previously reported in postalcoholic <e2> Wernicke - Korsakoff syndrome </e2> .
NO_RELATION	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a <e2> diabetic </e2> patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( <e1> TPP </e1> ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
NO_RELATION	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed <e2> Wernicke ' s encephalopathy </e2> when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( <e1> TPP </e1> ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .
NO_RELATION	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( <e1> TPP </e1> ) ] , as previously reported in postalcoholic <e2> Wernicke - Korsakoff syndrome </e2> .
NO_RELATION	We found that the above - mentioned patient and one of the <e2> diabetic </e2> kindreds with no history of Wernicke ' s encephalopathy had abnormal transketolase as determined by its Km for <e1> TPP </e1> .
NO_RELATION	We found that the above - mentioned patient and one of the diabetic kindreds with no history of <e2> Wernicke ' s encephalopathy </e2> had abnormal transketolase as determined by its Km for <e1> TPP </e1> .
NO_RELATION	These data suggest a similarity between postalcoholic <e2> Wernicke - Korsakoff syndrome </e2> and the patient with <e1> tolazamide </e1> - induced Wernicke ' s encephalopathy from the standpoint of transketolase abnormality .
CID	These data suggest a similarity between postalcoholic Wernicke - Korsakoff syndrome and the patient with <e1> tolazamide </e1> - induced <e2> Wernicke ' s encephalopathy </e2> from the standpoint of transketolase abnormality .
CID	Mechanisms of <e2> myocardial ischemia </e2> induced by <e1> epinephrine </e1> : comparison with exercise - induced ischemia .
NO_RELATION	Mechanisms of myocardial ischemia induced by <e1> epinephrine </e1> : comparison with exercise - induced <e2> ischemia </e2> .
CID	The role of <e1> epinephrine </e1> in eliciting <e2> myocardial ischemia </e2> was examined in patients with coronary artery disease .
NO_RELATION	The role of <e1> epinephrine </e1> in eliciting myocardial ischemia was examined in patients with <e2> coronary artery disease </e2> .
NO_RELATION	Objective signs of <e2> ischemia </e2> and factors increasing myocardial <e1> oxygen </e1> consumption were compared during epinephrine infusion and supine bicycle exercise .
NO_RELATION	Objective signs of <e2> ischemia </e2> and factors increasing myocardial oxygen consumption were compared during <e1> epinephrine </e1> infusion and supine bicycle exercise .
CID	Both <e1> epinephrine </e1> and exercise produced <e2> myocardial ischemia </e2> as evidenced by ST segment depression and angina .
NO_RELATION	Both <e1> epinephrine </e1> and exercise produced myocardial ischemia as evidenced by ST segment <e2> depression </e2> and angina .
NO_RELATION	Both <e1> epinephrine </e1> and exercise produced myocardial ischemia as evidenced by ST segment depression and <e2> angina </e2> .
CID	However , the mechanisms of <e2> myocardial ischemia </e2> induced by <e1> epinephrine </e1> were significantly different from those of exercise .
CID	Exercise - induced <e2> myocardial ischemia </e2> was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while <e1> epinephrine </e1> - induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .
NO_RELATION	Exercise - induced myocardial ischemia was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while <e1> epinephrine </e1> - induced <e2> ischemia </e2> was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .
NO_RELATION	These findings indicate that <e2> ischemia </e2> produced by <e1> epinephrine </e1> , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .
CID	Transient <e2> contralateral rotation </e2> following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by <e1> amphetamine </e1> .
NO_RELATION	Transient contralateral rotation following unilateral <e2> substantia nigra lesion </e2> reflects susceptibility of the nigrostriatal system to exhaustion by <e1> amphetamine </e1> .
NO_RELATION	Following unilateral <e1> 6 - OHDA </e1> induced <e2> SN lesion </e2> , a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling .
NO_RELATION	Following unilateral <e1> 6 - OHDA </e1> induced SN lesion , a transient period of <e2> contralateral rotation </e2> has been reported to precede the predominant ipsilateral circling .
NO_RELATION	Following unilateral <e1> 6 - OHDA </e1> induced SN lesion , a transient period of contralateral rotation has been reported to precede the predominant <e2> ipsilateral circling </e2> .
CID	In order to clarify the nature of this initial <e2> contralateral rotation </e2> we examined the effect of the duration of recovery period after the lesion , on <e1> amphetamine </e1> - induced rotational behavior .
CID	In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion , on <e1> amphetamine </e1> - induced <e2> rotational behavior </e2> .
CID	A substantial degree of contralateral preference was still evident when <e1> amphetamine </e1> was administered for the first time 24 days after lesioning , indicating involvement of spared cells in the <e2> contralateral rotation </e2> .
CID	However , regardless of the duration of recovery ( and irrespective of either lesion volume , <e1> amphetamine </e1> dose , or post - lesion motor exercise ) , amphetamine - induced <e2> rotation </e2> tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .
CID	However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , <e1> amphetamine </e1> - induced <e2> rotation </e2> tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .
CID	However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , amphetamine - induced <e2> rotation </e2> tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further <e1> amphetamine </e1> injections .
CID	These findings suggest that <e1> amphetamine </e1> has an irreversible effect on the post - lesion DA pool contributing to <e2> contralateral rotation </e2> .
NO_RELATION	It has been suggested that adenylate cyclase inhibition may be important in the development of both <e2> nephrogenic diabetes insipidus </e2> and hypothyroidism during <e1> lithium </e1> treatment .
CID	It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and <e2> hypothyroidism </e2> during <e1> lithium </e1> treatment .
CID	<e2> Hypothyroidism </e2> developed in eight patients while they were taking <e1> lithium </e1> .
NO_RELATION	Sensitivity of erythroid progenitor colonies to erythropoietin in <e1> azidothymidine </e1> treated <e2> immunodeficient </e2> mice .
CID	The <e2> anaemia </e2> induced by <e1> 3 ' - azido - 3 ' dideoxythymidine </e1> ( AZT ) is poorly understood .
CID	The <e2> anaemia </e2> induced by 3 ' - azido - 3 ' dideoxythymidine ( <e1> AZT </e1> ) is poorly understood .
NO_RELATION	We have used a murine model of <e2> AIDS </e2> , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if <e1> AZT </e1> - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .
NO_RELATION	We have used a murine model of AIDS , <e2> infection </e2> of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if <e1> AZT </e1> - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .
NO_RELATION	We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine <e2> leukaemia </e2> ( MuLV ) virus , to determine if <e1> AZT </e1> - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .
CID	We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if <e1> AZT </e1> - induced <e2> anaemia </e2> is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .
CID	<e1> AZT </e1> produced <e2> anaemia </e2> in both groups , in a dose - dependent fashion .
CID	Despite the <e2> anaemia </e2> , the number of splenic and bone marrow BFU - e in <e1> AZT </e1> treated mice increased up to five - fold over levels observed in infected untreated animals after 15 d of treatment .
CID	The mean plasma levels of EPO observed in <e1> AZT </e1> treated mice were appropriate for the degree of <e2> anaemia </e2> observed when compared with phenylhydrazine ( PHZ ) treated mice .
NO_RELATION	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of <e2> anaemia </e2> observed when compared with <e1> phenylhydrazine </e1> ( PHZ ) treated mice .
NO_RELATION	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of <e2> anaemia </e2> observed when compared with phenylhydrazine ( <e1> PHZ </e1> ) treated mice .
CID	The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in <e1> AZT </e1> and PHZ treated mice with similar degrees of <e2> anaemia </e2> .
NO_RELATION	The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in AZT and <e1> PHZ </e1> treated mice with similar degrees of <e2> anaemia </e2> .
NO_RELATION	However , <e2> reticulocytosis </e2> was inappropriate for the degree of anaemia observed in <e1> AZT </e1> treated infected mice .
CID	However , reticulocytosis was inappropriate for the degree of <e2> anaemia </e2> observed in <e1> AZT </e1> treated infected mice .
CID	<e1> AZT </e1> - induced peripheral <e2> anaemia </e2> in the face of increased numbers of BFU - e and increased levels of plasma EPO suggest a lesion in terminal differentiation .
CID	Detection of abnormal cardiac adrenergic neuron activity in <e1> adriamycin </e1> - induced <e2> cardiomyopathy </e2> with iodine - 125 - metaiodobenzylguanidine .
NO_RELATION	Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced <e2> cardiomyopathy </e2> with <e1> iodine - 125 - metaiodobenzylguanidine </e1> .
CID	Using a rat model of <e1> adriamycin </e1> - induced <e2> cardiomyopathy </e2> , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .
CID	Using a rat model of <e1> adriamycin </e1> - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin <e2> cardiomyopathy </e2> .
CID	Using a rat model of adriamycin - induced <e2> cardiomyopathy </e2> , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in <e1> adriamycin </e1> cardiomyopathy .
CID	Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in <e1> adriamycin </e1> <e2> cardiomyopathy </e2> .
NO_RELATION	The degree of <e2> vacuolar degeneration of myocardial cells </e2> was analyzed in relation to the duration of <e1> adriamycin </e1> treatment ( 2 mg / kg , once a week ) .
NO_RELATION	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight <e2> myocardial impairment </e2> ( scattered or focal vacuolar degeneration ) indicates that <e1> MIBG </e1> scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .
NO_RELATION	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal <e2> vacuolar degeneration </e2> ) indicates that <e1> MIBG </e1> scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .
NO_RELATION	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that <e1> MIBG </e1> scintigraphy may be a useful method for detection of adriamycin - induced <e2> cardiomyopathy </e2> .
CID	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight <e2> myocardial impairment </e2> ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of <e1> adriamycin </e1> - induced cardiomyopathy .
NO_RELATION	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal <e2> vacuolar degeneration </e2> ) indicates that MIBG scintigraphy may be a useful method for detection of <e1> adriamycin </e1> - induced cardiomyopathy .
CID	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of <e1> adriamycin </e1> - induced <e2> cardiomyopathy </e2> .
CID	<e2> Amnestic syndrome </e2> associated with <e1> propranolol </e1> toxicity : a case report .
NO_RELATION	Amnestic syndrome associated with <e1> propranolol </e1> <e2> toxicity </e2> : a case report .
NO_RELATION	An elderly woman developed an <e2> Alzheimer </e2> - like subacute dementia as a result of <e1> propranolol </e1> toxicity .
NO_RELATION	An elderly woman developed an Alzheimer - like subacute <e2> dementia </e2> as a result of <e1> propranolol </e1> toxicity .
NO_RELATION	An elderly woman developed an Alzheimer - like subacute dementia as a result of <e1> propranolol </e1> <e2> toxicity </e2> .
NO_RELATION	Injections of <e1> ketamine </e1> in doses from 100 microgram to 3 mg into the artery produced a <e2> depression </e2> of the SA nodal activity by a direct action .
CID	Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the <e1> ketamine </e1> - induced <e2> tachycardia </e2> , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .
CID	The use of serum cholinesterase in <e1> succinylcholine </e1> <e2> apnoea </e2> .
CID	Fifteen patients demonstrating unexpected prolonged <e2> apnoea </e2> lasting several hours after <e1> succinylcholine </e1> have been treated by a new preparation of human serum cholinesterase .
CID	The use of serum cholinesterase in <e1> succinylcholine </e1> <e2> apnoea </e2> provided considerable relief to both patient and anaesthetist .
CID	<e2> Orthostatic hypotension </e2> occurs following alpha 2 - adrenoceptor blockade in chronic <e1> prazosin </e1> - pretreated conscious spontaneously hypertensive rats .
NO_RELATION	Orthostatic hypotension occurs following alpha 2 - adrenoceptor blockade in chronic <e1> prazosin </e1> - pretreated conscious spontaneously <e2> hypertensive </e2> rats .
NO_RELATION	Studies were performed to evaluate whether chronic <e1> prazosin </e1> treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously <e2> hypertensive </e2> rats ( SHR ) .
CID	However , the head - up tilt induced <e2> orthostatic hypotension </e2> in the SHR treated with <e1> prazosin </e1> ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .
NO_RELATION	However , the head - up tilt induced <e2> orthostatic hypotension </e2> in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with <e1> rauwolscine </e1> ( less than + 2 % MAP , n = 6 ) .
CID	Head - up tilts in these rats did not produce <e2> orthostatic hypotension </e2> when performed either prior to or after acute dosing of <e1> prazosin </e1> ( 0 . 1 mg kg - 1 i . p . ) .
CID	The pressor responses and <e2> bradycardia </e2> to the alpha 1 - agonist <e1> cirazoline </e1> ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .
CID	The pressor responses and <e2> bradycardia </e2> to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist <e1> Abbott - 53693 </e1> ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .
CID	The pressor responses and <e2> bradycardia </e2> to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and <e1> noradrenaline </e1> ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .
NO_RELATION	The pressor responses and <e2> bradycardia </e2> to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic <e1> prazosin </e1> pretreatment .
CID	Both the pressor and <e2> bradycardia </e2> effects of <e1> cirazoline </e1> were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .
NO_RELATION	Both the pressor and <e2> bradycardia </e2> effects of cirazoline were abolished in chronic <e1> prazosin </e1> treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .
CID	On the other hand , the pressor effects of <e1> Abbott - 53693 </e1> were similar in both groups of SHR , but the accompanying <e2> bradycardia </e2> was greater in SHR with chronic prazosin treatment than without such treatment .
NO_RELATION	On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying <e2> bradycardia </e2> was greater in SHR with chronic <e1> prazosin </e1> treatment than without such treatment .
CID	Furthermore , the <e2> bradycardia </e2> that accompanied the <e1> noradrenaline </e1> - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )
NO_RELATION	Furthermore , the <e2> bradycardia </e2> that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic <e1> prazosin </e1> treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )
NO_RELATION	A forty - six year - old premenopausal woman developed <e2> headache </e2> , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of <e1> progesterone </e1> and estradiol .
NO_RELATION	A forty - six year - old premenopausal woman developed headache , <e2> nausea </e2> and vomiting , left hemiparesis and seizure two days after parenteral use of <e1> progesterone </e1> and estradiol .
NO_RELATION	A forty - six year - old premenopausal woman developed headache , nausea and <e2> vomiting </e2> , left hemiparesis and seizure two days after parenteral use of <e1> progesterone </e1> and estradiol .
NO_RELATION	A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left <e2> hemiparesis </e2> and seizure two days after parenteral use of <e1> progesterone </e1> and estradiol .
NO_RELATION	A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and <e2> seizure </e2> two days after parenteral use of <e1> progesterone </e1> and estradiol .
NO_RELATION	A forty - six year - old premenopausal woman developed <e2> headache </e2> , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> .
NO_RELATION	A forty - six year - old premenopausal woman developed headache , <e2> nausea </e2> and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> .
NO_RELATION	A forty - six year - old premenopausal woman developed headache , nausea and <e2> vomiting </e2> , left hemiparesis and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> .
NO_RELATION	A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left <e2> hemiparesis </e2> and seizure two days after parenteral use of progesterone and <e1> estradiol </e1> .
NO_RELATION	A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and <e2> seizure </e2> two days after parenteral use of progesterone and <e1> estradiol </e1> .
NO_RELATION	In this case , the authors postulate that the use of <e1> estradiol </e1> and progesterone and the underlying <e2> DM </e2> increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .
NO_RELATION	In this case , the authors postulate that the use of <e1> estradiol </e1> and progesterone and the underlying DM increased vascular thrombogenicity , which provided a common denominator for <e2> thrombosis of both the ICA and the venous sinus </e2> .
NO_RELATION	In this case , the authors postulate that the use of estradiol and <e1> progesterone </e1> and the underlying <e2> DM </e2> increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .
NO_RELATION	In this case , the authors postulate that the use of estradiol and <e1> progesterone </e1> and the underlying DM increased vascular thrombogenicity , which provided a common denominator for <e2> thrombosis of both the ICA and the venous sinus </e2> .
NO_RELATION	<e1> Chloroquine </e1> related complete <e2> heart block </e2> with blindness : case report .
CID	<e1> Chloroquine </e1> related complete heart block with <e2> blindness </e2> : case report .
NO_RELATION	A 27 - year old African woman with history of regular <e1> chloroquine </e1> ingestion presented with progressive <e2> deterioration of vision </e2> , easy fatiguability , dyspnoea , dizziness progressing to syncopal attacks .
CID	A 27 - year old African woman with history of regular <e1> chloroquine </e1> ingestion presented with progressive deterioration of vision , easy <e2> fatiguability </e2> , dyspnoea , dizziness progressing to syncopal attacks .
CID	A 27 - year old African woman with history of regular <e1> chloroquine </e1> ingestion presented with progressive deterioration of vision , easy fatiguability , <e2> dyspnoea </e2> , dizziness progressing to syncopal attacks .
CID	A 27 - year old African woman with history of regular <e1> chloroquine </e1> ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , <e2> dizziness </e2> progressing to syncopal attacks .
CID	A 27 - year old African woman with history of regular <e1> chloroquine </e1> ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , dizziness progressing to <e2> syncopal attacks </e2> .
CID	Ophthalmological assessment revealed features of <e1> chloroquine </e1> <e2> retinopathy </e2> , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern .
CID	Ophthalmological assessment revealed features of <e1> chloroquine </e1> retinopathy , cardiac assessment revealed features of <e2> heart failure </e2> and a complete heart block with right bundle branch block pattern .
NO_RELATION	Ophthalmological assessment revealed features of <e1> chloroquine </e1> retinopathy , cardiac assessment revealed features of heart failure and a complete <e2> heart block </e2> with right bundle branch block pattern .
CID	Ophthalmological assessment revealed features of <e1> chloroquine </e1> retinopathy , cardiac assessment revealed features of heart failure and a complete heart block with <e2> right bundle branch block </e2> pattern .
NO_RELATION	The <e2> heart block </e2> was treated by pacemaker insertion and the heart failure resolved spontaneously following <e1> chloroquine </e1> discontinuation .
CID	The heart block was treated by pacemaker insertion and the <e2> heart failure </e2> resolved spontaneously following <e1> chloroquine </e1> discontinuation .
NO_RELATION	Systemic <e2> toxicity </e2> and resuscitation in <e1> bupivacaine </e1> - , levobupivacaine - , or ropivacaine - infused rats .
NO_RELATION	Systemic <e2> toxicity </e2> and resuscitation in bupivacaine - , <e1> levobupivacaine </e1> - , or ropivacaine - infused rats .
NO_RELATION	Systemic <e2> toxicity </e2> and resuscitation in bupivacaine - , levobupivacaine - , or <e1> ropivacaine </e1> - infused rats .
NO_RELATION	We compared the systemic <e2> toxicity </e2> of <e1> bupivacaine </e1> , levobupivacaine , and ropivacaine in anesthetized rats .
NO_RELATION	We compared the systemic <e2> toxicity </e2> of bupivacaine , <e1> levobupivacaine </e1> , and ropivacaine in anesthetized rats .
NO_RELATION	We compared the systemic <e2> toxicity </e2> of bupivacaine , levobupivacaine , and <e1> ropivacaine </e1> in anesthetized rats .
CID	The cumulative doses of <e1> levobupivacaine </e1> and ropivacaine that produced <e2> seizures </e2> were similar and were larger than those of bupivacaine .
CID	The cumulative doses of levobupivacaine and <e1> ropivacaine </e1> that produced <e2> seizures </e2> were similar and were larger than those of bupivacaine .
NO_RELATION	The cumulative doses of levobupivacaine and ropivacaine that produced <e2> seizures </e2> were similar and were larger than those of <e1> bupivacaine </e1> .
CID	The cumulative doses of <e1> levobupivacaine </e1> that produced <e2> dysrhythmias </e2> and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .
CID	The cumulative doses of <e1> levobupivacaine </e1> that produced dysrhythmias and <e2> asystole </e2> were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .
CID	The cumulative doses of levobupivacaine that produced <e2> dysrhythmias </e2> and asystole were smaller than the corresponding doses of <e1> ropivacaine </e1> , but they were larger than those of bupivacaine .
CID	The cumulative doses of levobupivacaine that produced dysrhythmias and <e2> asystole </e2> were smaller than the corresponding doses of <e1> ropivacaine </e1> , but they were larger than those of bupivacaine .
NO_RELATION	The cumulative doses of levobupivacaine that produced <e2> dysrhythmias </e2> and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of <e1> bupivacaine </e1> .
NO_RELATION	The cumulative doses of levobupivacaine that produced dysrhythmias and <e2> asystole </e2> were smaller than the corresponding doses of ropivacaine , but they were larger than those of <e1> bupivacaine </e1> .
NO_RELATION	We conclude that the systemic <e2> toxicity </e2> of <e1> levobupivacaine </e1> is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
CID	We conclude that the systemic toxicity of <e1> levobupivacaine </e1> is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
NO_RELATION	We conclude that the systemic <e2> toxicity </e2> of levobupivacaine is intermediate between that of <e1> ropivacaine </e1> and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
CID	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of <e1> ropivacaine </e1> and bupivacaine when administered at the same rate and that ropivacaine - induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
NO_RELATION	We conclude that the systemic <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and <e1> bupivacaine </e1> when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
NO_RELATION	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and <e1> bupivacaine </e1> when administered at the same rate and that ropivacaine - induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
NO_RELATION	We conclude that the systemic <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that <e1> ropivacaine </e1> - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
CID	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that <e1> ropivacaine </e1> - induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
NO_RELATION	We conclude that the systemic <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by <e1> bupivacaine </e1> or levobupivacaine .
NO_RELATION	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by <e1> bupivacaine </e1> or levobupivacaine .
NO_RELATION	We conclude that the systemic <e2> toxicity </e2> of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or <e1> levobupivacaine </e1> .
CID	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced <e2> cardiac arrest </e2> appears to be more susceptible to treatment than that induced by bupivacaine or <e1> levobupivacaine </e1> .
NO_RELATION	<e1> 22 - oxacalcitriol </e1> suppresses <e2> secondary hyperparathyroidism </e2> without inducing low bone turnover in dogs with renal failure .
NO_RELATION	<e1> 22 - oxacalcitriol </e1> suppresses secondary hyperparathyroidism without inducing <e2> low bone turnover </e2> in dogs with renal failure .
NO_RELATION	<e1> 22 - oxacalcitriol </e1> suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with <e2> renal failure </e2> .
NO_RELATION	BACKGROUND : <e1> Calcitriol </e1> therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with <e2> renal failure </e2> but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .
CID	BACKGROUND : <e1> Calcitriol </e1> therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including <e2> hypercalcemia </e2> and / or marked suppression of bone turnover , which may lead to adynamic bone disease .
CID	BACKGROUND : <e1> Calcitriol </e1> therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked <e2> suppression of bone turnover </e2> , which may lead to adynamic bone disease .
CID	BACKGROUND : <e1> Calcitriol </e1> therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to <e2> adynamic bone disease </e2> .
NO_RELATION	This study was undertaken to determine the effects of <e1> OCT </e1> on serum PTH levels and bone turnover in states of normal or <e2> impaired renal function </e2> .
NO_RELATION	RESULTS : In Nx dogs , <e1> OCT </e1> significantly decreased serum PTH levels soon after the induction of <e2> renal insufficiency </e2> .
NO_RELATION	In long - standing <e2> secondary hyperparathyroidism </e2> , <e1> OCT </e1> ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .
NO_RELATION	In Nx dogs , <e1> OCT </e1> reversed abnormal bone formation , such as <e2> woven osteoid </e2> and fibrosis , but did not significantly alter the level of bone turnover .
NO_RELATION	In Nx dogs , <e1> OCT </e1> reversed abnormal bone formation , such as woven osteoid and <e2> fibrosis </e2> , but did not significantly alter the level of bone turnover .
CID	CONCLUSIONS : These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of <e2> hypercalcemia </e2> in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .
NO_RELATION	CONCLUSIONS : These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of hypercalcemia in experimental dogs with <e2> renal insufficiency </e2> , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .
NO_RELATION	CONCLUSIONS : These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of <e2> secondary hyperparathyroidism </e2> because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .
NO_RELATION	CONCLUSIONS : These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce <e2> low bone turnover </e2> and , therefore , does not increase the risk of adynamic bone disease .
NO_RELATION	CONCLUSIONS : These results indicate that even though <e1> OCT </e1> does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of <e2> adynamic bone disease </e2> .
NO_RELATION	Chemotherapy of advanced inoperable <e2> non - small cell lung cancer </e2> with <e1> paclitaxel </e1> : a phase II trial .
NO_RELATION	<e1> Paclitaxel </e1> ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different <e2> tumor </e2> types , notably ovarian and breast carcinoma .
NO_RELATION	<e1> Paclitaxel </e1> ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably <e2> ovarian and breast carcinoma </e2> .
NO_RELATION	Paclitaxel ( <e1> Taxol </e1> ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different <e2> tumor </e2> types , notably ovarian and breast carcinoma .
NO_RELATION	Paclitaxel ( <e1> Taxol </e1> ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably <e2> ovarian and breast carcinoma </e2> .
NO_RELATION	Two phase II trials of 24 - hour <e1> paclitaxel </e1> infusions in chemotherapy - naive patients with stage IIIB or IV <e2> non - small cell lung cancer </e2> ( NSCLC ) reported response rates of 21 % and 24 % .
NO_RELATION	Two phase II trials of 24 - hour <e1> paclitaxel </e1> infusions in chemotherapy - naive patients with stage IIIB or IV non - small cell lung cancer ( <e2> NSCLC </e2> ) reported response rates of 21 % and 24 % .
NO_RELATION	We investigated the efficacy and <e2> toxicity </e2> of a 3 - hour <e1> paclitaxel </e1> infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC .
NO_RELATION	We investigated the efficacy and toxicity of a 3 - hour <e1> paclitaxel </e1> infusion in a phase II trial in patients with inoperable stage IIIB or IV <e2> NSCLC </e2> .
NO_RELATION	<e1> Paclitaxel </e1> is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic <e2> toxicity </e2> .
NO_RELATION	Further phase II studies with <e1> paclitaxel </e1> combined with other drugs active against <e2> NSCLC </e2> are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .
NO_RELATION	Further phase II studies with paclitaxel combined with other drugs active against <e2> NSCLC </e2> are indicated , and phase III studies comparing <e1> paclitaxel </e1> with standard chemotherapy remain to be completed .
CID	<e2> Cerebral hemorrhage </e2> associated with <e1> phenylpropanolamine </e1> in combination with caffeine .
CID	<e2> Cerebral hemorrhage </e2> associated with phenylpropanolamine in combination with <e1> caffeine </e1> .
CID	<e1> Phenylpropanolamine </e1> ( PPA ) is a drug that has been associated with serious side effects including <e2> stroke </e2> .
CID	Phenylpropanolamine ( <e1> PPA </e1> ) is a drug that has been associated with serious side effects including <e2> stroke </e2> .
CID	In order to determine if <e1> PPA </e1> / caffeine can lead to <e2> stroke </e2> in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .
CID	In order to determine if <e1> PPA </e1> / caffeine can lead to stroke in normotensive and / or <e2> hypertensive </e2> rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .
NO_RELATION	In order to determine if PPA / <e1> caffeine </e1> can lead to <e2> stroke </e2> in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .
CID	In order to determine if PPA / <e1> caffeine </e1> can lead to stroke in normotensive and / or <e2> hypertensive </e2> rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .
CID	A single <e1> PPA </e1> / caffeine administration ( same dose ) lead to acute <e2> hypertension </e2> in both the normotensive and hypertensive animals .
CID	A single <e1> PPA </e1> / caffeine administration ( same dose ) lead to acute hypertension in both the normotensive and <e2> hypertensive </e2> animals .
CID	A single PPA / <e1> caffeine </e1> administration ( same dose ) lead to acute <e2> hypertension </e2> in both the normotensive and hypertensive animals .
CID	A single PPA / <e1> caffeine </e1> administration ( same dose ) lead to acute hypertension in both the normotensive and <e2> hypertensive </e2> animals .
CID	These results suggest that <e1> PPA </e1> / caffeine can lead to <e2> cerebral hemorrhage </e2> in previously hypertensive animals when administered in greater than the allowed dosage .
CID	These results suggest that <e1> PPA </e1> / caffeine can lead to cerebral hemorrhage in previously <e2> hypertensive </e2> animals when administered in greater than the allowed dosage .
CID	These results suggest that PPA / <e1> caffeine </e1> can lead to <e2> cerebral hemorrhage </e2> in previously hypertensive animals when administered in greater than the allowed dosage .
CID	These results suggest that PPA / <e1> caffeine </e1> can lead to cerebral hemorrhage in previously <e2> hypertensive </e2> animals when administered in greater than the allowed dosage .
NO_RELATION	Long - term efficacy and <e2> toxicity </e2> of high - dose <e1> amiodarone </e1> therapy for ventricular tachycardia or ventricular fibrillation .
NO_RELATION	Long - term efficacy and toxicity of high - dose <e1> amiodarone </e1> therapy for <e2> ventricular tachycardia </e2> or ventricular fibrillation .
NO_RELATION	Long - term efficacy and toxicity of high - dose <e1> amiodarone </e1> therapy for ventricular tachycardia or <e2> ventricular fibrillation </e2> .
NO_RELATION	<e1> Amiodarone </e1> was administered to 154 patients who had sustained , symptomatic <e2> ventricular tachycardia </e2> ( VT ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .
NO_RELATION	<e1> Amiodarone </e1> was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( <e2> VT </e2> ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .
NO_RELATION	<e1> Amiodarone </e1> was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( VT ) ( n = 118 ) or a <e2> cardiac arrest </e2> ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .
NO_RELATION	Sixty - nine percent of patients continued treatment with <e1> amiodarone </e1> and had no recurrence of symptomatic <e2> VT </e2> or ventricular fibrillation ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .
NO_RELATION	Sixty - nine percent of patients continued treatment with <e1> amiodarone </e1> and had no recurrence of symptomatic VT or <e2> ventricular fibrillation </e2> ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .
NO_RELATION	Sixty - nine percent of patients continued treatment with <e1> amiodarone </e1> and had no recurrence of symptomatic VT or ventricular fibrillation ( <e2> VF </e2> ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .
NO_RELATION	Six percent of the patients had a nonfatal recurrence of <e2> VT </e2> and were successfully managed by continuing <e1> amiodarone </e1> at a higher dose or by the addition of a conventional antiarrhythmic drug .
NO_RELATION	Although large - dose <e1> amiodarone </e1> is highly effective in the long - term treatment of <e2> VT </e2> or VF refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .
NO_RELATION	Although large - dose <e1> amiodarone </e1> is highly effective in the long - term treatment of VT or <e2> VF </e2> refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .
NO_RELATION	Although large - dose <e1> amiodarone </e1> is highly effective in the long - term treatment of VT or VF refractory to conventional antiarrhythmic drugs , it causes significant <e2> toxicity </e2> in approximately 50 % of patients .
NO_RELATION	However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with <e2> VT </e2> or VF can be successfully managed with <e1> amiodarone </e1> .
NO_RELATION	However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with VT or <e2> VF </e2> can be successfully managed with <e1> amiodarone </e1> .
NO_RELATION	Effect of <e1> calcium chloride </e1> and 4 - aminopyridine therapy on desipramine <e2> toxicity </e2> in rats .
NO_RELATION	Effect of calcium chloride and <e1> 4 - aminopyridine </e1> therapy on desipramine <e2> toxicity </e2> in rats .
NO_RELATION	Effect of calcium chloride and 4 - aminopyridine therapy on <e1> desipramine </e1> <e2> toxicity </e2> in rats .
NO_RELATION	This study addressed the potential role of <e1> calcium </e1> channel blockade in tricyclic antidepressant - induced <e2> hypotension </e2> .
NO_RELATION	METHODS : Two interventions were studied that have been shown previously to improve blood pressure with <e1> calcium </e1> channel blocker <e2> overdose </e2> .
CID	Anesthetized rats received the tricyclic antidepressant <e1> desipramine </e1> IP to produce <e2> hypotension </e2> , QRS prolongation , and bradycardia .
CID	Anesthetized rats received the tricyclic antidepressant <e1> desipramine </e1> IP to produce hypotension , QRS prolongation , and <e2> bradycardia </e2> .
NO_RELATION	RESULTS : <e1> NaHCO3 </e1> briefly ( 5 min ) reversed <e2> hypotension </e2> and QRS prolongation .
CID	The incidence of <e2> ventricular arrhythmias </e2> ( p = 0 . 004 ) and seizures ( p = 0 . 03 ) in the <e1> CaCl2 </e1> group was higher than the other groups .
NO_RELATION	The incidence of ventricular arrhythmias ( p = 0 . 004 ) and <e2> seizures </e2> ( p = 0 . 03 ) in the <e1> CaCl2 </e1> group was higher than the other groups .
NO_RELATION	CONCLUSION : The administration of <e1> CaCl2 </e1> or 4 - aminopyridine did not reverse tricyclic antidepressant - induced <e2> hypotension </e2> in rats .
NO_RELATION	CONCLUSION : The administration of CaCl2 or <e1> 4 - aminopyridine </e1> did not reverse tricyclic antidepressant - induced <e2> hypotension </e2> in rats .
NO_RELATION	<e1> CaCl2 </e1> therapy may possibly worsen both <e2> cardiovascular and central nervous system toxicity </e2> .
NO_RELATION	These findings do not support a role for <e1> calcium </e1> channel inhibition in the pathogenesis of tricyclic antidepressant - induced <e2> hypotension </e2> .
NO_RELATION	Phase I trial of <e1> 13 - cis - retinoic acid </e1> in children with <e2> neuroblastoma </e2> following bone marrow transplantation .
NO_RELATION	PURPOSE : Treatment of <e2> neuroblastoma </e2> cell lines with <e1> 13 - cis - retinoic acid </e1> ( cis - RA ) can cause sustained inhibition of proliferation .
NO_RELATION	PURPOSE : Treatment of <e2> neuroblastoma </e2> cell lines with 13 - cis - retinoic acid ( <e1> cis - RA </e1> ) can cause sustained inhibition of proliferation .
NO_RELATION	Since <e1> cis - RA </e1> has demonstrated clinical responses in <e2> neuroblastoma </e2> patients , it may be effective in preventing relapse after cytotoxic therapy .
NO_RELATION	This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , <e2> toxicities </e2> , and pharmacokinetics of <e1> cis - RA </e1> administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ) .
NO_RELATION	This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , toxicities , and pharmacokinetics of <e1> cis - RA </e1> administered on an intermittent schedule in children with <e2> neuroblastoma </e2> following bone marrow transplantation ( BMT ) .
NO_RELATION	All <e2> toxicities </e2> resolved after <e1> cis - RA </e1> was discontinued .
CID	The DLT included <e2> hypercalcemia </e2> , and may be predicted by serum <e1> cis - RA </e1> levels .
NO_RELATION	The effect of <e1> calcium chloride </e1> injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , <e2> mydriasis </e2> , tremor and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .
NO_RELATION	The effect of <e1> calcium chloride </e1> injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , <e2> tremor </e2> and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .
NO_RELATION	The effect of <e1> calcium chloride </e1> injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and <e2> clonic - tonic convulsions </e2> produced by carbachol and eserine injected similarly was investigated .
CID	The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , <e2> mydriasis </e2> , tremor and clonic - tonic convulsions produced by <e1> carbachol </e1> and eserine injected similarly was investigated .
CID	The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , <e2> tremor </e2> and clonic - tonic convulsions produced by <e1> carbachol </e1> and eserine injected similarly was investigated .
CID	The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and <e2> clonic - tonic convulsions </e2> produced by <e1> carbachol </e1> and eserine injected similarly was investigated .
CID	The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , <e2> mydriasis </e2> , tremor and clonic - tonic convulsions produced by carbachol and <e1> eserine </e1> injected similarly was investigated .
CID	The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , <e2> tremor </e2> and clonic - tonic convulsions produced by carbachol and <e1> eserine </e1> injected similarly was investigated .
CID	The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and <e2> clonic - tonic convulsions </e2> produced by carbachol and <e1> eserine </e1> injected similarly was investigated .
CID	On the other hand , <e2> mydriasis </e2> , tremor and clonic - tonic convulsions evoked by <e1> carbachol </e1> and eserine were not significantly changed by calcium chloride .
CID	On the other hand , mydriasis , <e2> tremor </e2> and clonic - tonic convulsions evoked by <e1> carbachol </e1> and eserine were not significantly changed by calcium chloride .
CID	On the other hand , mydriasis , tremor and <e2> clonic - tonic convulsions </e2> evoked by <e1> carbachol </e1> and eserine were not significantly changed by calcium chloride .
CID	On the other hand , <e2> mydriasis </e2> , tremor and clonic - tonic convulsions evoked by carbachol and <e1> eserine </e1> were not significantly changed by calcium chloride .
CID	On the other hand , mydriasis , <e2> tremor </e2> and clonic - tonic convulsions evoked by carbachol and <e1> eserine </e1> were not significantly changed by calcium chloride .
CID	On the other hand , mydriasis , tremor and <e2> clonic - tonic convulsions </e2> evoked by carbachol and <e1> eserine </e1> were not significantly changed by calcium chloride .
NO_RELATION	On the other hand , <e2> mydriasis </e2> , tremor and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by <e1> calcium chloride </e1> .
NO_RELATION	On the other hand , mydriasis , <e2> tremor </e2> and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by <e1> calcium chloride </e1> .
NO_RELATION	On the other hand , mydriasis , tremor and <e2> clonic - tonic convulsions </e2> evoked by carbachol and eserine were not significantly changed by <e1> calcium chloride </e1> .
NO_RELATION	It is apparent that <e1> calcium chloride </e1> can " dissociate " vocalization and fighting from autonomic and motor phenomena such as <e2> mydriasis </e2> , tremor and clonic - tonic convulsions caused by carbachol and eserine .
NO_RELATION	It is apparent that <e1> calcium chloride </e1> can " dissociate " vocalization and fighting from autonomic and motor phenomena such as mydriasis , <e2> tremor </e2> and clonic - tonic convulsions caused by carbachol and eserine .
NO_RELATION	It is apparent that <e1> calcium chloride </e1> can " dissociate " vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and <e2> clonic - tonic convulsions </e2> caused by carbachol and eserine .
CID	It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as <e2> mydriasis </e2> , tremor and clonic - tonic convulsions caused by <e1> carbachol </e1> and eserine .
CID	It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as mydriasis , <e2> tremor </e2> and clonic - tonic convulsions caused by <e1> carbachol </e1> and eserine .
CID	It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and <e2> clonic - tonic convulsions </e2> caused by <e1> carbachol </e1> and eserine .
CID	It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as <e2> mydriasis </e2> , tremor and clonic - tonic convulsions caused by carbachol and <e1> eserine </e1> .
CID	It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as mydriasis , <e2> tremor </e2> and clonic - tonic convulsions caused by carbachol and <e1> eserine </e1> .
CID	It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and <e2> clonic - tonic convulsions </e2> caused by carbachol and <e1> eserine </e1> .
NO_RELATION	Multiple side effects of <e1> penicillamine </e1> therapy in one patient with <e2> rheumatoid arthritis </e2> .
CID	<e2> Skin rashes </e2> , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> therapy in patients with rheumatoid arthritis .
CID	Skin rashes , <e2> proteinuria </e2> , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> therapy in patients with rheumatoid arthritis .
CID	Skin rashes , proteinuria , <e2> systemic lupus erythematosus </e2> , polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> therapy in patients with rheumatoid arthritis .
CID	Skin rashes , proteinuria , systemic lupus erythematosus , <e2> polymyositis </e2> and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> therapy in patients with rheumatoid arthritis .
CID	Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and <e2> myasthenia gravis </e2> have all been recorded as complications of <e1> penicillamine </e1> therapy in patients with rheumatoid arthritis .
NO_RELATION	Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of <e1> penicillamine </e1> therapy in patients with <e2> rheumatoid arthritis </e2> .
NO_RELATION	The <e2> skin lesion </e2> resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson ' s disease but not in patients with rheumatoid arthritis treated with <e1> penicillamine </e1> .
NO_RELATION	The skin lesion resembled <e2> elastosis perforans serpiginosa </e2> , which has been reported as a rare side effect in patients with Wilson ' s disease but not in patients with rheumatoid arthritis treated with <e1> penicillamine </e1> .
NO_RELATION	The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with <e2> Wilson ' s disease </e2> but not in patients with rheumatoid arthritis treated with <e1> penicillamine </e1> .
NO_RELATION	The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson ' s disease but not in patients with <e2> rheumatoid arthritis </e2> treated with <e1> penicillamine </e1> .
CID	Although most patients were receiving several drugs , <e1> Mellaril </e1> ( thioridazine ) appeared to be responsible for five cases of <e2> ventricular tachycardia </e2> , one of which was fatal in a 35 year old woman .
CID	Although most patients were receiving several drugs , Mellaril ( <e1> thioridazine </e1> ) appeared to be responsible for five cases of <e2> ventricular tachycardia </e2> , one of which was fatal in a 35 year old woman .
NO_RELATION	<e2> Supraventricular tachycardia </e2> developed in one patient receiving <e1> Thorazine </e1> ( chlorpromazine ) .
NO_RELATION	<e2> Supraventricular tachycardia </e2> developed in one patient receiving Thorazine ( <e1> chlorpromazine </e1> ) .
CID	<e1> Aventyl </e1> ( nortriptyline ) and Elavil ( amitriptyline ) each produced <e2> left bundle branch block </e2> in a 73 year old woman .
CID	Aventyl ( <e1> nortriptyline </e1> ) and Elavil ( amitriptyline ) each produced <e2> left bundle branch block </e2> in a 73 year old woman .
CID	Aventyl ( nortriptyline ) and <e1> Elavil </e1> ( amitriptyline ) each produced <e2> left bundle branch block </e2> in a 73 year old woman .
CID	Aventyl ( nortriptyline ) and Elavil ( <e1> amitriptyline </e1> ) each produced <e2> left bundle branch block </e2> in a 73 year old woman .
NO_RELATION	The <e2> ventricular arrhythmias </e2> responded to intravenous administration of <e1> lidocaine </e1> and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .
NO_RELATION	The <e2> ventricular arrhythmias </e2> responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of <e1> propranolol </e1> combined with ventricular pacing in one .
NO_RELATION	A prospective clinical trial is suggested to quantify the risk of <e2> cardiac complications </e2> to patients receiving <e1> phenothiazines </e1> or tricyclic antidepressant drugs .
NO_RELATION	Serotonergic drugs , <e1> benzodiazepines </e1> and baclofen block muscimol - induced <e2> myoclonic jerks </e2> in a strain of mice .
NO_RELATION	Serotonergic drugs , benzodiazepines and <e1> baclofen </e1> block muscimol - induced <e2> myoclonic jerks </e2> in a strain of mice .
CID	Serotonergic drugs , benzodiazepines and baclofen block <e1> muscimol </e1> - induced <e2> myoclonic jerks </e2> in a strain of mice .
CID	In male Swiss mice , <e1> muscimol </e1> produced <e2> myoclonic jerks </e2> .
NO_RELATION	Of the <e1> benzodiazepines </e1> , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the <e2> myoclonic jerks </e2> .
NO_RELATION	Of the benzodiazepines , <e1> clonazepam </e1> ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the <e2> myoclonic jerks </e2> .
NO_RELATION	Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than <e1> diazepam </e1> ( 0 . 3 - 3 mg / kg ) in blocking the <e2> myoclonic jerks </e2> .
NO_RELATION	Considering the fact that <e1> 5 - HTP </e1> and the benzodiazepines have been found to be beneficial in the management of clinical <e2> myoclonus </e2> , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
NO_RELATION	Considering the fact that <e1> 5 - HTP </e1> and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced <e2> myoclonus </e2> seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
NO_RELATION	Considering the fact that 5 - HTP and the <e1> benzodiazepines </e1> have been found to be beneficial in the management of clinical <e2> myoclonus </e2> , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
NO_RELATION	Considering the fact that 5 - HTP and the <e1> benzodiazepines </e1> have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced <e2> myoclonus </e2> seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
CID	Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical <e2> myoclonus </e2> , the <e1> muscimol </e1> - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
CID	Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the <e1> muscimol </e1> - induced <e2> myoclonus </e2> seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
NO_RELATION	Our present study indicated the possible value of <e1> MK - 212 </e1> and ( - ) - baclofen in the management of clinical <e2> myoclonus </e2> .
NO_RELATION	Our present study indicated the possible value of MK - 212 and ( - ) - <e1> baclofen </e1> in the management of clinical <e2> myoclonus </e2> .
NO_RELATION	Following short exposure to oral <e1> prednisone </e1> , both boys developed <e2> lethargy </e2> , increasing somnolence , polydipsia , polyphagia , and polyuria .
NO_RELATION	Following short exposure to oral <e1> prednisone </e1> , both boys developed lethargy , increasing <e2> somnolence </e2> , polydipsia , polyphagia , and polyuria .
NO_RELATION	Following short exposure to oral <e1> prednisone </e1> , both boys developed lethargy , increasing somnolence , <e2> polydipsia </e2> , polyphagia , and polyuria .
NO_RELATION	Following short exposure to oral <e1> prednisone </e1> , both boys developed lethargy , increasing somnolence , polydipsia , <e2> polyphagia </e2> , and polyuria .
NO_RELATION	Following short exposure to oral <e1> prednisone </e1> , both boys developed lethargy , increasing somnolence , polydipsia , polyphagia , and <e2> polyuria </e2> .
NO_RELATION	Nonketotic <e2> lactic acidosis </e2> was present in one and ketosis without a known serum <e1> lactate </e1> level was present in the other .
NO_RELATION	Nonketotic lactic acidosis was present in one and <e2> ketosis </e2> without a known serum <e1> lactate </e1> level was present in the other .
NO_RELATION	Effects of active constituents of Crocus sativus L . , <e1> crocin </e1> on streptozocin - induced model of sporadic <e2> Alzheimer ' s disease </e2> in male rats .
CID	Effects of active constituents of Crocus sativus L . , crocin on <e1> streptozocin </e1> - induced model of sporadic <e2> Alzheimer ' s disease </e2> in male rats .
NO_RELATION	In the present study , the effect of <e1> crocins </e1> on sporadic <e2> Alzheimer ' s disease </e2> induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .
CID	In the present study , the effect of crocins on sporadic <e2> Alzheimer ' s disease </e2> induced by intracerebroventricular ( icv ) <e1> streptozocin </e1> ( STZ ) in male rats was investigated .
CID	In the present study , the effect of crocins on sporadic <e2> Alzheimer ' s disease </e2> induced by intracerebroventricular ( icv ) streptozocin ( <e1> STZ </e1> ) in male rats was investigated .
CID	In <e2> Alzheimer ' s disease </e2> groups , rats were injected with <e1> STZ </e1> - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .
CID	In <e2> Alzheimer ' s disease </e2> groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar <e1> STZ </e1> - icv application was repeated .
NO_RELATION	In addition , <e1> crocin </e1> in the mentioned dose could significantly attenuated <e2> learning and memory impairment </e2> in treated STZ - injected group in passive avoidance test .
NO_RELATION	In addition , crocin in the mentioned dose could significantly attenuated <e2> learning and memory impairment </e2> in treated <e1> STZ </e1> - injected group in passive avoidance test .
NO_RELATION	CONCLUSION : Therefore , these results demonstrate the effectiveness of <e1> crocin </e1> ( 30 mg / kg ) in antagonizing the <e2> cognitive deficits </e2> caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer ' s disease .
NO_RELATION	CONCLUSION : Therefore , these results demonstrate the effectiveness of <e1> crocin </e1> ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of <e2> neurodegenerative diseases </e2> such as Alzheimer ' s disease .
NO_RELATION	CONCLUSION : Therefore , these results demonstrate the effectiveness of <e1> crocin </e1> ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as <e2> Alzheimer ' s disease </e2> .
CID	CONCLUSION : Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the <e2> cognitive deficits </e2> caused by <e1> STZ </e1> - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer ' s disease .
NO_RELATION	CONCLUSION : Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by <e1> STZ </e1> - icv in rats and its potential in the treatment of <e2> neurodegenerative diseases </e2> such as Alzheimer ' s disease .
CID	CONCLUSION : Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by <e1> STZ </e1> - icv in rats and its potential in the treatment of neurodegenerative diseases such as <e2> Alzheimer ' s disease </e2> .
NO_RELATION	Rosaceiform <e2> dermatitis </e2> associated with topical <e1> tacrolimus </e1> treatment .
NO_RELATION	We describe herein 3 patients who developed <e2> rosacea </e2> - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % <e1> tacrolimus </e1> ointment for facial dermatitis .
NO_RELATION	We describe herein 3 patients who developed rosacea - like <e2> dermatitis </e2> eruptions while using 0 . 03 % or 0 . 1 % <e1> tacrolimus </e1> ointment for facial dermatitis .
NO_RELATION	We describe herein 3 patients who developed rosacea - like dermatitis <e2> eruptions </e2> while using 0 . 03 % or 0 . 1 % <e1> tacrolimus </e1> ointment for facial dermatitis .
NO_RELATION	We describe herein 3 patients who developed rosacea - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % <e1> tacrolimus </e1> ointment for <e2> facial dermatitis </e2> .
NO_RELATION	Continuous topical use of immunomodulators such as <e1> tacrolimus </e1> or pimecrolimus should be regarded as a potential cause of rosaceiform <e2> dermatitis </e2> , although many cases have not been reported .
CID	Continuous topical use of immunomodulators such as tacrolimus or <e1> pimecrolimus </e1> should be regarded as a potential cause of rosaceiform <e2> dermatitis </e2> , although many cases have not been reported .
CID	<e1> Tacrine </e1> , administered in LiCl pre - treated rats , induces electrocorticographic <e2> seizures </e2> and delayed hippocampal damage .
CID	<e1> Tacrine </e1> , administered in LiCl pre - treated rats , induces electrocorticographic seizures and delayed <e2> hippocampal damage </e2> .
CID	Tacrine , administered in <e1> LiCl </e1> pre - treated rats , induces electrocorticographic <e2> seizures </e2> and delayed hippocampal damage .
CID	Tacrine , administered in <e1> LiCl </e1> pre - treated rats , induces electrocorticographic seizures and delayed <e2> hippocampal damage </e2> .
CID	In addition , <e1> tacrine </e1> - loaded nanoparticles administration induced <e2> damage of neuronal cells </e2> in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .
CID	In addition , tacrine - loaded nanoparticles administration induced <e2> damage of neuronal cells </e2> in CA1 field of the hippocampus in all treated animals , while the saline solution of <e1> tacrine </e1> only in 60 % of animals .
NO_RELATION	In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the <e1> tacrine </e1> - lithium model of <e2> epilepsy </e2> in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .
NO_RELATION	In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - <e1> lithium </e1> model of <e2> epilepsy </e2> in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .
NO_RELATION	This study was designed to evaluate the effects of <e1> pilocarpine </e1> and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig <e2> arrhythmia </e2> models .
CID	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both <e1> aconitine </e1> - induced rat and ouabain - induced guinea pig <e2> arrhythmia </e2> models .
CID	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and <e1> ouabain </e1> - induced guinea pig <e2> arrhythmia </e2> models .
NO_RELATION	The current data showed that <e1> pilocarpine </e1> significantly delayed onset of <e2> arrhythmias </e2> , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .
NO_RELATION	The current data showed that <e1> pilocarpine </e1> significantly delayed onset of arrhythmias , decreased the time course of <e2> ventricular tachycardia and fibrillation </e2> , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .
NO_RELATION	The current data showed that <e1> pilocarpine </e1> significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced <e2> arrhythmia </e2> score , and increased the survival time of arrhythmic rats and guinea pigs .
NO_RELATION	The current data showed that <e1> pilocarpine </e1> significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of <e2> arrhythmic </e2> rats and guinea pigs .
NO_RELATION	These data suggest that <e1> pilocarpine </e1> produced antiarrhythmic actions on <e2> arrhythmic </e2> rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M ( 3 ) - mAChR .
CID	These data suggest that pilocarpine produced antiarrhythmic actions on <e2> arrhythmic </e2> rat and guinea pig models induced by <e1> aconitine </e1> or ouabain via stimulating the cardiac M ( 3 ) - mAChR .
CID	These data suggest that pilocarpine produced antiarrhythmic actions on <e2> arrhythmic </e2> rat and guinea pig models induced by aconitine or <e1> ouabain </e1> via stimulating the cardiac M ( 3 ) - mAChR .
NO_RELATION	<e1> Disulfiram </e1> - induced transient <e2> optic and peripheral neuropathy </e2> : a case report .
NO_RELATION	AIM : To report a case of <e2> optic and peripheral neuropathy </e2> after chronic use of <e1> disulfiram </e1> for alcohol dependence management .
NO_RELATION	AIM : To report a case of optic and peripheral neuropathy after chronic use of <e1> disulfiram </e1> for <e2> alcohol dependence </e2> management .
NO_RELATION	He had been taking <e1> disulfiram </e1> for <e2> alcohol dependence </e2> for the preceding 3 years .
NO_RELATION	Sustained clinical improvement of a patient with decompensated <e2> hepatitis B </e2> virus - related cirrhosis after treatment with <e1> lamivudine </e1> monotherapy .
NO_RELATION	Sustained clinical improvement of a patient with decompensated hepatitis B virus - related <e2> cirrhosis </e2> after treatment with <e1> lamivudine </e1> monotherapy .
NO_RELATION	The administration of <e1> lamivudine </e1> to patients with HBV - related <e2> cirrhosis </e2> , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .
CID	Dual effects of <e1> melatonin </e1> on barbiturate - induced <e2> narcosis </e2> in rats .
NO_RELATION	Dual effects of melatonin on <e1> barbiturate </e1> - induced <e2> narcosis </e2> in rats .
CID	<e1> Melatonin </e1> affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced <e2> narcosis </e2> .
CID	<e1> Melatonin </e1> pre - treatment affected in a dual manner barbiturate <e2> narcosis </e2> , however , no dose - effect correlation was found .
NO_RELATION	Melatonin pre - treatment affected in a dual manner <e1> barbiturate </e1> <e2> narcosis </e2> , however , no dose - effect correlation was found .
NO_RELATION	In particular , low doses reduced the latency to and prolonged the duration of <e1> barbiturate </e1> <e2> narcosis </e2> .
CID	In contrast , the highest dose of <e1> melatonin </e1> ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of <e2> narcosis </e2> , and a reduction in mortality rate .
CID	<e1> Melatonin </e1> 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced <e2> narcosis </e2> .
CID	Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of <e1> ketamine </e1> - or diazepam - induced <e2> narcosis </e2> .
CID	Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or <e1> diazepam </e1> - induced <e2> narcosis </e2> .
CID	Thus , the dual action of <e1> melatonin </e1> on pharmacological <e2> narcosis </e2> seems to be specific for the barbiturate mechanism of action .
NO_RELATION	Thus , the dual action of melatonin on pharmacological <e2> narcosis </e2> seems to be specific for the <e1> barbiturate </e1> mechanism of action .
CID	Effects of <e1> NIK - 247 </e1> on cholinesterase and scopolamine - induced <e2> amnesia </e2> .
CID	Effects of NIK - 247 on cholinesterase and <e1> scopolamine </e1> - induced <e2> amnesia </e2> .
CID	The effects of <e1> NIK - 247 </e1> on cholinesterase , scopolamine - induced <e2> amnesia </e2> and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .
CID	The effects of NIK - 247 on cholinesterase , <e1> scopolamine </e1> - induced <e2> amnesia </e2> and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .
CID	The effects of NIK - 247 on cholinesterase , scopolamine - induced <e2> amnesia </e2> and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors <e1> tacrine </e1> and E - 2020 .
CID	The effects of NIK - 247 on cholinesterase , scopolamine - induced <e2> amnesia </e2> and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and <e1> E - 2020 </e1> .
CID	significantly improved the <e2> amnesia </e2> induced by <e1> scopolamine </e1> ( 0 . 5 mg / kg s . c . ) in rats performing a passive avoidance task .
CID	These findings suggest that <e1> NIK - 247 </e1> at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced <e2> amnesia </e2> but does not affect spontaneous movement .
CID	These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves <e1> scopolamine </e1> - induced <e2> amnesia </e2> but does not affect spontaneous movement .
NO_RELATION	The findings suggest that <e1> NIK - 247 </e1> may be a useful drug for the treatment of <e2> Alzheimer ' s disease </e2> .
CID	Nightmares and <e2> hallucinations </e2> after long - term intake of <e1> tramadol </e1> combined with antidepressants .
NO_RELATION	<e1> Tramadol </e1> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat <e2> cancer </e2> pain and chronic non malignant pain .
NO_RELATION	<e1> Tramadol </e1> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer <e2> pain </e2> and chronic non malignant pain .
NO_RELATION	<e1> Tramadol </e1> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant <e2> pain </e2> .
NO_RELATION	This drug was initiated in association with <e1> paroxetine </e1> and dosulepine hydrochloride in a <e2> tetraparetic </e2> patient with chronic pain .
NO_RELATION	This drug was initiated in association with <e1> paroxetine </e1> and dosulepine hydrochloride in a tetraparetic patient with <e2> chronic pain </e2> .
NO_RELATION	This drug was initiated in association with paroxetine and <e1> dosulepine hydrochloride </e1> in a <e2> tetraparetic </e2> patient with chronic pain .
NO_RELATION	This drug was initiated in association with paroxetine and <e1> dosulepine hydrochloride </e1> in a tetraparetic patient with <e2> chronic pain </e2> .
CID	Fifty - six days after initiation of the treatment the patient presented <e2> hallucinations </e2> that only stopped after the withdrawal of psycho - active drugs and <e1> tramadol </e1> .
CID	BMT was used to treat severe <e2> aplastic anemia </e2> which was caused by <e1> gold </e1> in one case and D - penicillamine in the other .
CID	BMT was used to treat severe <e2> aplastic anemia </e2> which was caused by gold in one case and <e1> D - penicillamine </e1> in the other .
CID	<e2> Acute experimental models of renal damage </e2> to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of <e1> hexachloro - 1 : 3 - butadiene </e1> ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .
CID	<e2> Acute experimental models of renal damage </e2> to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( <e1> HCBD </e1> ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .
CID	<e2> Acute experimental models of renal damage </e2> to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , <e1> puromycin aminonucleoside </e1> ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .
CID	<e2> Acute experimental models of renal damage </e2> to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( <e1> PAN </e1> ) , and 2 - bromoethylamine ( BEA ) , respectively .
CID	<e2> Acute experimental models of renal damage </e2> to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and <e1> 2 - bromoethylamine </e1> ( BEA ) , respectively .
CID	<e2> Acute experimental models of renal damage </e2> to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( <e1> BEA </e1> ) , respectively .
NO_RELATION	Tubular damage produced by <e1> HCBD </e1> or BEA was discriminated both quantitatively and qualitatively from <e2> glomerular damage </e2> produced by PAN .
NO_RELATION	Tubular damage produced by HCBD or <e1> BEA </e1> was discriminated both quantitatively and qualitatively from <e2> glomerular damage </e2> produced by PAN .
NO_RELATION	Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from <e2> glomerular damage </e2> produced by <e1> PAN </e1> .
CID	<e2> Neuromuscular blockade </e2> with <e1> magnesium sulfate </e1> and nifedipine .
CID	<e2> Neuromuscular blockade </e2> with magnesium sulfate and <e1> nifedipine </e1> .
CID	A patient who received tocolysis with <e1> nifedipine </e1> developed <e2> neuromuscular blockade </e2> after 500 mg of magnesium sulfate was administered .
CID	A patient who received tocolysis with nifedipine developed <e2> neuromuscular blockade </e2> after 500 mg of <e1> magnesium sulfate </e1> was administered .
NO_RELATION	This reaction demonstrates that <e1> nifedipine </e1> can seriously potentiate the <e2> toxicity </e2> of magnesium .
NO_RELATION	This reaction demonstrates that nifedipine can seriously potentiate the <e2> toxicity </e2> of <e1> magnesium </e1> .
NO_RELATION	The frequency and predictability of <e2> hematuria </e2> are not precise , and at least daily monitoring by urine Hematest is essential , adding <e1> Mesna </e1> to the infusate in patients with persistent hematuria .
NO_RELATION	The frequency and predictability of hematuria are not precise , and at least daily monitoring by urine Hematest is essential , adding <e1> Mesna </e1> to the infusate in patients with persistent <e2> hematuria </e2> .
CID	<e2> Myocardial infarction </e2> in pregnancy associated with <e1> clomiphene citrate </e1> for ovulation induction : a case report .
CID	<e2> Thromboembolism </e2> is a rare but life - threatening complication that has been reported after ovulation induction with <e1> CC </e1> .
NO_RELATION	CASE : A 33 - year - old woman with a 5 - week gestation had recently received <e1> CC </e1> for ovulation induction and presented with <e2> chest pain </e2> .
CID	CONCLUSION : This appears to be the first reported case documenting a possible association between <e1> CC </e1> and <e2> myocardial infarction </e2> .
NO_RELATION	<e2> Thrombosis </e2> might be a rare but hazardous complication of <e1> CC </e1> .
NO_RELATION	<e2> Hepatonecrosis </e2> and cholangitis related to long - term <e1> phenobarbital </e1> therapy : an autopsy report of two patients .
CID	Hepatonecrosis and <e2> cholangitis </e2> related to long - term <e1> phenobarbital </e1> therapy : an autopsy report of two patients .
CID	<e1> Phenobarbital </e1> ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic <e2> liver disease </e2> .
CID	Phenobarbital ( <e1> PB </e1> ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic <e2> liver disease </e2> .
CID	Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that <e1> PB </e1> - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic <e2> liver disease </e2> .
NO_RELATION	Here we report of two adult patients with a long history of <e2> epilepsy </e2> treated with <e1> PB </e1> who died suddenly : one as consequence of cardiac arrest , the other of acute bronchopneumonia .
NO_RELATION	Here we report of two adult patients with a long history of epilepsy treated with <e1> PB </e1> who died suddenly : one as consequence of <e2> cardiac arrest </e2> , the other of acute bronchopneumonia .
NO_RELATION	Here we report of two adult patients with a long history of epilepsy treated with <e1> PB </e1> who died suddenly : one as consequence of cardiac arrest , the other of acute <e2> bronchopneumonia </e2> .
CID	Our findings illustrate that <e1> PB </e1> may be associated with chronic <e2> liver damage </e2> , which may lead to more serious and deleterious consequences .
NO_RELATION	For this reason , each clinician should recognize this entity in the differential diagnosis of <e1> PB </e1> - related asymptomatic <e2> chronic hepatic enzyme dysfunction </e2> .
CID	<e1> Ethambutol </e1> - associated <e2> optic neuropathy </e2> .
NO_RELATION	INTRODUCTION : <e1> Ethambutol </e1> is used in the treatment of <e2> tuberculosis </e2> , which is still prevalent in Southeast Asia , and can be associated with permanent visual loss .
CID	INTRODUCTION : <e1> Ethambutol </e1> is used in the treatment of tuberculosis , which is still prevalent in Southeast Asia , and can be associated with permanent <e2> visual loss </e2> .
CID	CLINICAL PICTURE : Three patients with <e1> ethambutol </e1> - associated toxic <e2> optic neuropathy </e2> are described .
CID	CONCLUSIONS : <e1> Ethambutol </e1> usage is associated with permanent <e2> visual loss </e2> and should be avoided if possible or used with caution and proper ophthalmological follow - up .
NO_RELATION	Tolerability of <e1> nimesulide </e1> and paracetamol in patients with NSAID - induced <e2> urticaria </e2> / angioedema .
CID	Tolerability of <e1> nimesulide </e1> and paracetamol in patients with NSAID - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	Tolerability of nimesulide and <e1> paracetamol </e1> in patients with NSAID - induced <e2> urticaria </e2> / angioedema .
CID	Tolerability of nimesulide and <e1> paracetamol </e1> in patients with NSAID - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	Tolerability of nimesulide and paracetamol in patients with <e1> NSAID </e1> - induced <e2> urticaria </e2> / angioedema .
CID	Tolerability of nimesulide and paracetamol in patients with <e1> NSAID </e1> - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	In this study we investigated tolerability and reliability of <e1> nimesulide </e1> and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced <e2> urticaria </e2> / angioedema .
CID	In this study we investigated tolerability and reliability of <e1> nimesulide </e1> and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	In this study we investigated tolerability and reliability of nimesulide and <e1> paracetamol </e1> in a very large number of patients with an exclusive well - documented history of NSAID - induced <e2> urticaria </e2> / angioedema .
CID	In this study we investigated tolerability and reliability of nimesulide and <e1> paracetamol </e1> in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of <e1> NSAID </e1> - induced <e2> urticaria </e2> / angioedema .
CID	In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of <e1> NSAID </e1> - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	A single - placebo - controlled oral challenge procedure with <e1> nimesulide </e1> or paracetamol was applied to 829 patients with a history of NSAID - induced <e2> urticaria </e2> / angioedema .
CID	A single - placebo - controlled oral challenge procedure with <e1> nimesulide </e1> or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	A single - placebo - controlled oral challenge procedure with nimesulide or <e1> paracetamol </e1> was applied to 829 patients with a history of NSAID - induced <e2> urticaria </e2> / angioedema .
CID	A single - placebo - controlled oral challenge procedure with nimesulide or <e1> paracetamol </e1> was applied to 829 patients with a history of NSAID - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of <e1> NSAID </e1> - induced <e2> urticaria </e2> / angioedema .
CID	A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of <e1> NSAID </e1> - induced urticaria / <e2> angioedema </e2> .
NO_RELATION	Furthermore , 18 . 28 % of patients with a history of chronic <e2> urticaria </e2> and 11 . 8 % of subjects with an history of <e1> NSAID </e1> - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .
NO_RELATION	Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of <e1> NSAID </e1> - induced <e2> urticaria </e2> / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .
CID	Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of <e1> NSAID </e1> - induced urticaria / <e2> angioedema </e2> or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .
CID	Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of <e1> NSAID </e1> - induced urticaria / angioedema or <e2> angioedema </e2> alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .
NO_RELATION	Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of <e1> NSAID </e1> - induced urticaria / angioedema or angioedema alone ( with or without chronic <e2> urticaria </e2> ) resulted to be intolerant to alternative drugs .
NO_RELATION	Taken together , our results confirm the good tolerability of <e1> nimesulide </e1> and paracetamol in patients who experienced <e2> urticaria </e2> / angioedema caused by NSAIDs .
CID	Taken together , our results confirm the good tolerability of <e1> nimesulide </e1> and paracetamol in patients who experienced urticaria / <e2> angioedema </e2> caused by NSAIDs .
NO_RELATION	Taken together , our results confirm the good tolerability of nimesulide and <e1> paracetamol </e1> in patients who experienced <e2> urticaria </e2> / angioedema caused by NSAIDs .
CID	Taken together , our results confirm the good tolerability of nimesulide and <e1> paracetamol </e1> in patients who experienced urticaria / <e2> angioedema </e2> caused by NSAIDs .
NO_RELATION	Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced <e2> urticaria </e2> / angioedema caused by <e1> NSAIDs </e1> .
CID	Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / <e2> angioedema </e2> caused by <e1> NSAIDs </e1> .
NO_RELATION	However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic <e2> urticaria </e2> and , above all , by a history of <e1> NSAID </e1> - induced angioedema .
CID	However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of <e1> NSAID </e1> - induced <e2> angioedema </e2> .
CID	Effects of <e1> verapamil </e1> on <e2> atrial fibrillation </e2> and its electrophysiological determinants in dogs .
NO_RELATION	BACKGROUND : <e2> Atrial tachycardia </e2> - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type <e1> Ca </e1> ( 2 + ) current .
NO_RELATION	BACKGROUND : Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of <e2> atrial fibrillation </e2> ( AF ) and decreases L - type <e1> Ca </e1> ( 2 + ) current .
NO_RELATION	BACKGROUND : Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( <e2> AF </e2> ) and decreases L - type <e1> Ca </e1> ( 2 + ) current .
NO_RELATION	There is also a clinical suggestion that acute L - type <e1> Ca </e1> ( 2 ) channel blockade can promote <e2> AF </e2> , consistent with an AF promoting effect of Ca ( 2 + ) channel inhibition .
NO_RELATION	There is also a clinical suggestion that acute L - type <e1> Ca </e1> ( 2 ) channel blockade can promote AF , consistent with an <e2> AF </e2> promoting effect of Ca ( 2 + ) channel inhibition .
NO_RELATION	There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote <e2> AF </e2> , consistent with an AF promoting effect of <e1> Ca </e1> ( 2 + ) channel inhibition .
NO_RELATION	There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote AF , consistent with an <e2> AF </e2> promoting effect of <e1> Ca </e1> ( 2 + ) channel inhibition .
NO_RELATION	METHODS : To evaluate the potential mechanisms of <e2> AF </e2> promotion by <e1> Ca </e1> ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .
CID	METHODS : To evaluate the potential mechanisms of <e2> AF </e2> promotion by Ca ( 2 + ) channel blockers , we administered <e1> verapamil </e1> to morphine - chloralose anesthetized dogs .
NO_RELATION	METHODS : To evaluate the potential mechanisms of <e2> AF </e2> promotion by Ca ( 2 + ) channel blockers , we administered verapamil to <e1> morphine </e1> - chloralose anesthetized dogs .
NO_RELATION	METHODS : To evaluate the potential mechanisms of <e2> AF </e2> promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - <e1> chloralose </e1> anesthetized dogs .
CID	RESULTS : <e1> Verapamil </e1> caused <e2> AF </e2> promotion in six dogs , increasing mean duration of AF induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs .
CID	RESULTS : <e1> Verapamil </e1> caused AF promotion in six dogs , increasing mean duration of <e2> AF </e2> induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs .
CID	In these experiments , <e1> verapamil </e1> shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of <e2> AF </e2> ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .
NO_RELATION	<e1> Diltiazem </e1> did not affect ERP , <e2> AF </e2> cycle length or AF duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .
NO_RELATION	<e1> Diltiazem </e1> did not affect ERP , AF cycle length or <e2> AF </e2> duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .
CID	Diltiazem did not affect ERP , <e2> AF </e2> cycle length or AF duration , but produced conduction acceleration similar to that caused by <e1> verapamil </e1> ( n = 5 ) .
CID	Diltiazem did not affect ERP , AF cycle length or <e2> AF </e2> duration , but produced conduction acceleration similar to that caused by <e1> verapamil </e1> ( n = 5 ) .
CID	In the presence of autonomic blockade , <e1> verapamil </e1> failed to promote <e2> AF </e2> and increased , rather than decreasing , refractoriness .
CID	Epicardial mapping suggested that <e1> verapamil </e1> promoted <e2> AF </e2> by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .
CID	CONCLUSIONS : <e1> Verapamil </e1> promotes <e2> AF </e2> in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .
NO_RELATION	CONCLUSIONS : Verapamil promotes <e2> AF </e2> in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by <e1> diltiazem </e1> .
CID	<e2> Hypotension </e2> , bradycardia , and asystole after high - dose intravenous <e1> methylprednisolone </e1> in a monitored patient .
CID	Hypotension , <e2> bradycardia </e2> , and asystole after high - dose intravenous <e1> methylprednisolone </e1> in a monitored patient .
CID	Hypotension , bradycardia , and <e2> asystole </e2> after high - dose intravenous <e1> methylprednisolone </e1> in a monitored patient .
CID	We report a case of <e2> hypotension </e2> , bradycardia , and asystole after intravenous administration of high - dose <e1> methylprednisolone </e1> in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .
CID	We report a case of hypotension , <e2> bradycardia </e2> , and asystole after intravenous administration of high - dose <e1> methylprednisolone </e1> in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .
CID	We report a case of hypotension , bradycardia , and <e2> asystole </e2> after intravenous administration of high - dose <e1> methylprednisolone </e1> in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .
NO_RELATION	This study reviews the current proposed mechanisms of <e2> sudden death </e2> after a high dose of intravenous <e1> methylprednisolone </e1> ( IVMP ) .
NO_RELATION	This study reviews the current proposed mechanisms of <e2> sudden death </e2> after a high dose of intravenous methylprednisolone ( <e1> IVMP </e1> ) .
CID	Lifetime treatment of mice with <e1> azidothymidine </e1> ( AZT ) produces <e2> myelodysplasia </e2> .
CID	Lifetime treatment of mice with azidothymidine ( <e1> AZT </e1> ) produces <e2> myelodysplasia </e2> .
CID	<e1> AZT </e1> has induced a <e2> macrocytic anemia </e2> in AIDS patients on long term AZT therapy .
NO_RELATION	<e1> AZT </e1> has induced a macrocytic anemia in <e2> AIDS </e2> patients on long term AZT therapy .
CID	AZT has induced a <e2> macrocytic anemia </e2> in AIDS patients on long term <e1> AZT </e1> therapy .
NO_RELATION	AZT has induced a macrocytic anemia in <e2> AIDS </e2> patients on long term <e1> AZT </e1> therapy .
CID	Above mentioned <e1> AZT </e1> incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the <e2> myelodysplastic syndrome </e2> .
NO_RELATION	Influence of diet free of <e1> NAD </e1> - precursors on acetaminophen <e2> hepatotoxicity </e2> in mice .
CID	Influence of diet free of NAD - precursors on <e1> acetaminophen </e1> <e2> hepatotoxicity </e2> in mice .
NO_RELATION	Recently , we demonstrated the hepatoprotective effects of <e1> nicotinic acid amide </e1> , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - <e2> hepatitis </e2> , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .
NO_RELATION	Recently , we demonstrated the hepatoprotective effects of <e1> nicotinic acid amide </e1> , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced <e2> liver injury </e2> involves a step which depends on adenoribosylation .
NO_RELATION	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of <e1> poly ( ADP - ribose ) </e1> polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - <e2> hepatitis </e2> , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .
NO_RELATION	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of <e1> poly ( ADP - ribose ) </e1> polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced <e2> liver injury </e2> involves a step which depends on adenoribosylation .
CID	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from <e1> acetaminophen </e1> ( AAP ) - <e2> hepatitis </e2> , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .
CID	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from <e1> acetaminophen </e1> ( AAP ) - hepatitis , suggesting that the AAP - induced <e2> liver injury </e2> involves a step which depends on adenoribosylation .
CID	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( <e1> AAP </e1> ) - <e2> hepatitis </e2> , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .
CID	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( <e1> AAP </e1> ) - hepatitis , suggesting that the AAP - induced <e2> liver injury </e2> involves a step which depends on adenoribosylation .
CID	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - <e2> hepatitis </e2> , suggesting that the <e1> AAP </e1> - induced liver injury involves a step which depends on adenoribosylation .
CID	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the <e1> AAP </e1> - induced <e2> liver injury </e2> involves a step which depends on adenoribosylation .
NO_RELATION	The present study investigates the effects of a diet free of precursors of <e1> NAD </e1> , the substrate on which PARP acts , in female NMRI mice with AAP <e2> hepatitis </e2> and evaluates the influence of simultaneous ethanol consumption in these animals .
CID	The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with <e1> AAP </e1> <e2> hepatitis </e2> and evaluates the influence of simultaneous ethanol consumption in these animals .
CID	The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP <e2> hepatitis </e2> and evaluates the influence of simultaneous <e1> ethanol </e1> consumption in these animals .
NO_RELATION	<e2> Liver injuries </e2> were quantified as serum activities of <e1> glutamate </e1> - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .
NO_RELATION	<e2> Liver injuries </e2> were quantified as serum activities of glutamate - <e1> oxaloacetate </e1> transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .
NO_RELATION	<e2> Liver injuries </e2> were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and <e1> glutamate </e1> - pyruvate transaminase ( GPT ) .
NO_RELATION	<e2> Liver injuries </e2> were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - <e1> pyruvate </e1> transaminase ( GPT ) .
CID	In these animals , only minor increases of serum transaminase activities were measured in the presence of <e1> AAP </e1> , and unlike the exacerbation caused by ethanol in mice on a standard diet , the <e2> liver damage </e2> was inhibited by 50 % by ethanol .
CID	In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by <e1> ethanol </e1> in mice on a standard diet , the <e2> liver damage </e2> was inhibited by 50 % by ethanol .
CID	In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the <e2> liver damage </e2> was inhibited by 50 % by <e1> ethanol </e1> .
NO_RELATION	A further 64 % reduction of <e2> hepatitis </e2> was observed , when <e1> NAA </e1> was given to ethanol / AAP - mice .
CID	A further 64 % reduction of <e2> hepatitis </e2> was observed , when NAA was given to <e1> ethanol </e1> / AAP - mice .
CID	A further 64 % reduction of <e2> hepatitis </e2> was observed , when NAA was given to ethanol / <e1> AAP </e1> - mice .
CID	Our results provide evidence that the <e1> AAP </e1> - induced <e2> hepatitis </e2> and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme ' s substrate NAD .
CID	Our results provide evidence that the AAP - induced <e2> hepatitis </e2> and its exacerbation by <e1> ethanol </e1> can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme ' s substrate NAD .
NO_RELATION	Our results provide evidence that the AAP - induced <e2> hepatitis </e2> and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by <e1> NAA </e1> or by dietary depletion of the enzyme ' s substrate NAD .
NO_RELATION	Our results provide evidence that the AAP - induced <e2> hepatitis </e2> and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme ' s substrate <e1> NAD </e1> .
NO_RELATION	We see the main application of <e1> NAA </e1> as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid <e2> hepatic damage </e2> in patients treated with this widely used analgesic .
CID	We see the main application of NAA as for the combinational use in pharmaceutical preparations of <e1> acetaminophen </e1> in order to avoid <e2> hepatic damage </e2> in patients treated with this widely used analgesic .
NO_RELATION	Antiarrhythmic plasma concentrations of <e1> cibenzoline </e1> on canine <e2> ventricular arrhythmias </e2> .
CID	Using two - stage coronary ligation - , <e1> digitalis </e1> - , and adrenaline - induced canine <e2> ventricular arrhythmias </e2> , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .
CID	Using two - stage coronary ligation - , <e1> digitalis </e1> - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each <e2> arrhythmia </e2> model was determined .
CID	Using two - stage coronary ligation - , digitalis - , and <e1> adrenaline </e1> - induced canine <e2> ventricular arrhythmias </e2> , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .
CID	Using two - stage coronary ligation - , digitalis - , and <e1> adrenaline </e1> - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each <e2> arrhythmia </e2> model was determined .
NO_RELATION	Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine <e2> ventricular arrhythmias </e2> , antiarrhythmic effects of <e1> cibenzoline </e1> were examined and the minimum effective plasma concentration for each arrhythmia model was determined .
NO_RELATION	Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of <e1> cibenzoline </e1> were examined and the minimum effective plasma concentration for each <e2> arrhythmia </e2> model was determined .
NO_RELATION	<e1> Cibenzoline </e1> suppressed all the <e2> arrhythmias </e2> , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
NO_RELATION	<e1> Cibenzoline </e1> suppressed all the arrhythmias , and the minimum effective plasma concentrations for <e2> arrhythmias </e2> induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
CID	Cibenzoline suppressed all the <e2> arrhythmias </e2> , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , <e1> digitalis </e1> , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
CID	Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for <e2> arrhythmias </e2> induced by 24 - h coronary ligation , 48 - h coronary ligation , <e1> digitalis </e1> , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
CID	Cibenzoline suppressed all the <e2> arrhythmias </e2> , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and <e1> adrenaline </e1> were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
CID	Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for <e2> arrhythmias </e2> induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and <e1> adrenaline </e1> were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
CID	The concentration for <e1> adrenaline </e1> - induced <e2> arrhythmia </e2> was significantly higher than those for the other types of arrhythmias .
CID	The concentration for <e1> adrenaline </e1> - induced arrhythmia was significantly higher than those for the other types of <e2> arrhythmias </e2> .
NO_RELATION	Because <e1> cibenzoline </e1> had only weak <e2> hypotensive </e2> and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .
NO_RELATION	Because <e1> cibenzoline </e1> had only weak hypotensive and sinus node <e2> depressive </e2> effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .
NO_RELATION	Because <e1> cibenzoline </e1> had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation <e2> arrhythmia </e2> dogs , its clinical usefulness is expected .
CID	Immunopathology of <e1> penicillamine </e1> - induced <e2> glomerular disease </e2> .
NO_RELATION	Four patients with <e2> rheumatoid arthritis </e2> developed heavy proteinuria after five to 12 months of treatment with <e1> D - penicillamine </e1> .
CID	Four patients with rheumatoid arthritis developed heavy <e2> proteinuria </e2> after five to 12 months of treatment with <e1> D - penicillamine </e1> .
NO_RELATION	<e2> Ventricular fibrillation </e2> from <e1> diatrizoate </e1> with and without chelating agents .
NO_RELATION	The <e2> toxicity </e2> of <e1> Renografin 76 % </e1> was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .
NO_RELATION	The <e2> toxicity </e2> of Renografin 76 % was compared with that of <e1> Hypaque 76 % </e1> by selective injection of each into the right coronary artery of dogs .
NO_RELATION	<e2> Ventricular fibrillation </e2> occurred significantly more often with <e1> Renografin </e1> , suggesting that chelating agents contribute to toxicity in coronary angiography .
NO_RELATION	Ventricular fibrillation occurred significantly more often with <e1> Renografin </e1> , suggesting that chelating agents contribute to <e2> toxicity </e2> in coronary angiography .
NO_RELATION	Rapid reversal of anticoagulation reduces <e2> hemorrhage </e2> volume in a mouse model of <e1> warfarin </e1> - associated intracerebral hemorrhage .
CID	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of <e1> warfarin </e1> - associated <e2> intracerebral hemorrhage </e2> .
CID	<e1> Warfarin </e1> - associated <e2> intracerebral hemorrhage </e2> ( W - ICH ) is a severe type of stroke .
CID	<e1> Warfarin </e1> - associated intracerebral hemorrhage ( W - <e2> ICH </e2> ) is a severe type of stroke .
NO_RELATION	<e1> Warfarin </e1> - associated intracerebral hemorrhage ( W - ICH ) is a severe type of <e2> stroke </e2> .
NO_RELATION	We provide experimental data suggesting <e1> PCC </e1> to be an effective acute treatment for W - <e2> ICH </e2> in terms of reducing hemorrhagic blood volume .
CID	This study examined the utility of biometry for detecting <e1> alcohol </e1> - related fetal <e2> growth impairment </e2> .
CID	Any <e1> alcohol </e1> consumption postpregnancy recognition among the heavy drinkers resulted in <e2> reduced cerebellar growth </e2> as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers .
CID	Any <e1> alcohol </e1> consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as <e2> decreased cranial to body growth </e2> in comparison with women who either quit drinking or who were nondrinkers .
NO_RELATION	Urinary symptoms and quality of life changes in Thai women with <e2> overactive bladder </e2> after <e1> tolterodine </e1> treatment .
NO_RELATION	OBJECTIVES : To study the urinary symptoms and quality of life changes in Thai women with <e2> overactive bladder </e2> ( OAB ) after <e1> tolterodine </e1> treatment .
NO_RELATION	OBJECTIVES : To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( <e2> OAB </e2> ) after <e1> tolterodine </e1> treatment .
NO_RELATION	CONCLUSION : <e1> Tolterodine </e1> was well tolerated and its effects improved the quality of life in Thai women with <e2> OAB </e2> .
CID	Absence of acute cerebral vasoconstriction after <e1> cocaine </e1> - associated <e2> subarachnoid hemorrhage </e2> .
NO_RELATION	INTRODUCTION : <e1> Cocaine </e1> use has been associated with <e2> neurovascular complications </e2> , including arterial vasoconstriction and vasculitis .
NO_RELATION	INTRODUCTION : <e1> Cocaine </e1> use has been associated with neurovascular complications , including arterial vasoconstriction and <e2> vasculitis </e2> .
CID	Information on these effects could be obtained from angiograms of patients with <e1> cocaine </e1> - associated <e2> subarachnoid hemorrhage </e2> ( SAH ) who underwent angiography shortly after cocaine use .
CID	Information on these effects could be obtained from angiograms of patients with <e1> cocaine </e1> - associated subarachnoid hemorrhage ( <e2> SAH </e2> ) who underwent angiography shortly after cocaine use .
CID	Information on these effects could be obtained from angiograms of patients with cocaine - associated <e2> subarachnoid hemorrhage </e2> ( SAH ) who underwent angiography shortly after <e1> cocaine </e1> use .
CID	Information on these effects could be obtained from angiograms of patients with cocaine - associated subarachnoid hemorrhage ( <e2> SAH </e2> ) who underwent angiography shortly after <e1> cocaine </e1> use .
CID	METHODS : We screened patients with <e2> SAH </e2> retrospectively and identified those with positive urine toxicology for <e1> cocaine </e1> or its metabolites .
NO_RELATION	CONCLUSION : No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or <e2> vasculitis </e2> could be found in patients who underwent angiography after aneurysmal SAH associated with <e1> cocaine </e1> use .
CID	CONCLUSION : No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after <e2> aneurysmal </e2> SAH associated with <e1> cocaine </e1> use .
CID	CONCLUSION : No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal <e2> SAH </e2> associated with <e1> cocaine </e1> use .
NO_RELATION	The authors describe the unusual association between diffuse B - cell <e2> gastric lymphoma </e2> and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of <e1> doxorubicin </e1> - based chemotherapy in the same patient .
NO_RELATION	The authors describe the unusual association between diffuse B - cell gastric lymphoma and <e2> myotonic dystrophy </e2> , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of <e1> doxorubicin </e1> - based chemotherapy in the same patient .
NO_RELATION	The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult <e2> muscular dystrophy </e2> , and sudden atrial fibrillation following one cycle of <e1> doxorubicin </e1> - based chemotherapy in the same patient .
CID	The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden <e2> atrial fibrillation </e2> following one cycle of <e1> doxorubicin </e1> - based chemotherapy in the same patient .
NO_RELATION	A phase II study of <e1> thalidomide </e1> in advanced metastatic <e2> renal cell carcinoma </e2> .
NO_RELATION	OBJECTIVES : To evaluate the <e2> toxicity </e2> and activity of <e1> thalidomide </e1> in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .
NO_RELATION	OBJECTIVES : To evaluate the toxicity and activity of <e1> thalidomide </e1> in patients with advanced metastatic <e2> renal cell cancer </e2> and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .
NO_RELATION	CONCLUSION : These results are consistent with a low level of activity of <e1> thalidomide </e1> in <e2> renal cell carcinoma </e2> .
NO_RELATION	The dose - response relationship , if any , of <e1> thalidomide </e1> for <e2> renal cell carcinoma </e2> is unclear .
NO_RELATION	<e1> Haloperidol </e1> ( 1 mg / kg ip ) induced <e2> parkinsonian </e2> - like muscle rigidity , measured as an increased resistance of a rat ' s hind foot to passive flexion and extension at the ankle joint .
CID	<e1> Haloperidol </e1> ( 1 mg / kg ip ) induced parkinsonian - like <e2> muscle rigidity </e2> , measured as an increased resistance of a rat ' s hind foot to passive flexion and extension at the ankle joint .
NO_RELATION	<e1> AIDA </e1> in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced <e2> muscle rigidity </e2> .
CID	AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the <e1> haloperidol </e1> - induced <e2> muscle rigidity </e2> .
NO_RELATION	Acute <e2> cholestatic hepatitis </e2> after exposure to <e1> isoflurane </e1> .
NO_RELATION	OBJECTIVE : To report a case of acute <e2> cholestatic hepatitis </e2> following exposure to the inhalational anesthetic <e1> isoflurane </e1> .
NO_RELATION	No other medications were involved except for <e1> dipyrone </e1> for <e2> analgesia </e2> .
NO_RELATION	CONCLUSIONS : <e1> Isoflurane </e1> , a common anesthetic agent , can cause severe <e2> cholestatic hepatitis </e2> .
CID	Calcitonin gene - related peptide levels during <e1> nitric oxide </e1> - induced <e2> headache </e2> in patients with chronic tension - type headache .
NO_RELATION	Calcitonin gene - related peptide levels during <e1> nitric oxide </e1> - induced headache in patients with chronic <e2> tension - type headache </e2> .
CID	It has been proposed that <e1> nitric oxide </e1> ( NO ) induced <e2> headache </e2> in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .
NO_RELATION	It has been proposed that <e1> nitric oxide </e1> ( NO ) induced headache in <e2> primary headaches </e2> may be associated with release of calcitonin gene - related peptide ( CGRP ) .
CID	It has been proposed that nitric oxide ( <e1> NO </e1> ) induced <e2> headache </e2> in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .
NO_RELATION	It has been proposed that nitric oxide ( <e1> NO </e1> ) induced headache in <e2> primary headaches </e2> may be associated with release of calcitonin gene - related peptide ( CGRP ) .
CID	In the present study we aimed to investigate plasma levels of CGRP during <e2> headache </e2> induced by the <e1> NO </e1> donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .
NO_RELATION	In the present study we aimed to investigate plasma levels of CGRP during headache induced by the <e1> NO </e1> donor glyceryl trinitrate ( GTN ) in 16 patients with chronic <e2> tension - type headache </e2> and 16 healthy controls .
CID	In the present study we aimed to investigate plasma levels of CGRP during <e2> headache </e2> induced by the NO donor <e1> glyceryl trinitrate </e1> ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .
NO_RELATION	In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor <e1> glyceryl trinitrate </e1> ( GTN ) in 16 patients with chronic <e2> tension - type headache </e2> and 16 healthy controls .
CID	In the present study we aimed to investigate plasma levels of CGRP during <e2> headache </e2> induced by the NO donor glyceryl trinitrate ( <e1> GTN </e1> ) in 16 patients with chronic tension - type headache and 16 healthy controls .
NO_RELATION	In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( <e1> GTN </e1> ) in 16 patients with chronic <e2> tension - type headache </e2> and 16 healthy controls .
CID	The subjects were randomly allocated to receive 0 . 5 microg / kg / min <e1> GTN </e1> or placebo over 20 min on two <e2> headache </e2> - free days .
CID	Both patients and controls developed significantly stronger immediate <e2> headache </e2> on the <e1> GTN </e1> day than on the placebo day and the headache was significantly more pronounced in patients than in controls .
CID	Both patients and controls developed significantly stronger immediate headache on the <e1> GTN </e1> day than on the placebo day and the <e2> headache </e2> was significantly more pronounced in patients than in controls .
CID	The present study indicates that <e1> NO </e1> - induced immediate <e2> headache </e2> is not associated with release of CGRP .
NO_RELATION	<e2> Myocardial ischemia </e2> due to coronary artery spasm during <e1> dobutamine </e1> stress echocardiography .
CID	Myocardial ischemia due to <e2> coronary artery spasm </e2> during <e1> dobutamine </e1> stress echocardiography .
NO_RELATION	<e1> Dobutamine </e1> stress echocardiography ( DSE ) is a useful and safe provocation test for <e2> myocardial ischemia </e2> .
NO_RELATION	The aim of the present study is to examine whether <e2> myocardial ischemia </e2> due to coronary spasm is induced by <e1> dobutamine </e1> .
CID	The aim of the present study is to examine whether myocardial ischemia due to <e2> coronary spasm </e2> is induced by <e1> dobutamine </e1> .
NO_RELATION	Coronary spasm was induced by intracoronary injection of <e1> acetylcholine </e1> , and no fixed <e2> coronary artery stenosis </e2> was documented on angiograms in all patients .
CID	These findings indicate that <e1> dobutamine </e1> can provoke <e2> coronary spasm </e2> in some patients with coronary spastic angina .
CID	These findings indicate that <e1> dobutamine </e1> can provoke coronary spasm in some patients with <e2> coronary spastic angina </e2> .
NO_RELATION	<e1> Nitric oxide </e1> synthase expression in the course of lead - induced <e2> hypertension </e2> .
CID	Nitric oxide synthase expression in the course of <e1> lead </e1> - induced <e2> hypertension </e2> .
NO_RELATION	We recently showed elevated reactive <e1> oxygen </e1> species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced <e2> hypertension </e2> .
NO_RELATION	We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of <e1> NO </e1> metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced <e2> hypertension </e2> .
NO_RELATION	We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased <e1> NO </e1> sequestration as nitrotyrosine in various tissues in rats with lead - induced <e2> hypertension </e2> .
NO_RELATION	We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as <e1> nitrotyrosine </e1> in various tissues in rats with lead - induced <e2> hypertension </e2> .
CID	We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with <e1> lead </e1> - induced <e2> hypertension </e2> .
CID	This study was designed to discern whether the reduction in urinary NOx in <e1> lead </e1> - induced <e2> hypertension </e2> is , in part , due to depressed NO synthase ( NOS ) expression .
NO_RELATION	This study was designed to discern whether the reduction in urinary NOx in lead - induced <e2> hypertension </e2> is , in part , due to depressed <e1> NO </e1> synthase ( NOS ) expression .
NO_RELATION	<e1> Vitamin E </e1> supplementation ameliorated <e2> hypertension </e2> , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .
NO_RELATION	Vitamin E supplementation ameliorated <e2> hypertension </e2> , lowered plasma <e1> MDA </e1> concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .
CID	In conclusion , <e1> lead </e1> - induced <e2> hypertension </e2> in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .
NO_RELATION	This is , in part , due to ROS - mediated <e1> NO </e1> inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with <e2> hypertension </e2> .
CID	This is , in part , due to ROS - mediated NO inactivation , <e1> lead </e1> - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with <e2> hypertension </e2> .
NO_RELATION	Risk for <e2> valvular heart disease </e2> among users of <e1> fenfluramine </e1> and dexfenfluramine who underwent echocardiography before use of medication .
NO_RELATION	Risk for <e2> valvular heart disease </e2> among users of fenfluramine and <e1> dexfenfluramine </e1> who underwent echocardiography before use of medication .
NO_RELATION	BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of <e1> fenfluramine </e1> and dexfenfluramine had <e2> valvular disease </e2> , these drugs were withdrawn from the market .
NO_RELATION	BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and <e1> dexfenfluramine </e1> had <e2> valvular disease </e2> , these drugs were withdrawn from the market .
NO_RELATION	OBJECTIVE : To determine the risk for new or worsening <e2> valvular abnormalities </e2> among users of <e1> fenfluramine </e1> or dexfenfluramine who underwent echocardiography before they began to take these medications .
NO_RELATION	OBJECTIVE : To determine the risk for new or worsening <e2> valvular abnormalities </e2> among users of fenfluramine or <e1> dexfenfluramine </e1> who underwent echocardiography before they began to take these medications .
NO_RELATION	RESULTS : Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving <e1> fenfluramine </e1> - phentermine developed <e2> valvular heart disease </e2> .
NO_RELATION	RESULTS : Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - <e1> phentermine </e1> developed <e2> valvular heart disease </e2> .
NO_RELATION	BACKGROUND : The most striking of <e1> carboplatin </e1> ' s advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of <e2> neurotoxic </e2> effects .
NO_RELATION	BACKGROUND : The most striking of carboplatin ' s advantages ( <e1> CBDCA </e1> ) over cisplatin ( CDDP ) is its markedly reduced rate of <e2> neurotoxic </e2> effects .
NO_RELATION	BACKGROUND : The most striking of carboplatin ' s advantages ( CBDCA ) over <e1> cisplatin </e1> ( CDDP ) is its markedly reduced rate of <e2> neurotoxic </e2> effects .
NO_RELATION	BACKGROUND : The most striking of carboplatin ' s advantages ( CBDCA ) over cisplatin ( <e1> CDDP </e1> ) is its markedly reduced rate of <e2> neurotoxic </e2> effects .
NO_RELATION	However , the use of <e1> CBDCA </e1> higher - intensity schedules and the association with other <e2> neurotoxic </e2> drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage .
CID	However , the use of <e1> CBDCA </e1> higher - intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to <e2> peripheral nervous system damage </e2> .
CID	RESULTS : <e1> CBDCA </e1> administration induced dose - dependent <e2> peripheral neurotoxicity </e2> .
NO_RELATION	CONCLUSIONS : <e1> CBDCA </e1> is <e2> neurotoxic </e2> in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .
NO_RELATION	CONCLUSIONS : <e1> CBDCA </e1> is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that <e2> neurotoxicity </e2> is induced in the two drugs by the same mechanism .
NO_RELATION	CONCLUSIONS : CBDCA is <e2> neurotoxic </e2> in our model , and the type of pathological changes it induces are so closely similar to those caused by <e1> CDDP </e1> that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .
NO_RELATION	CONCLUSIONS : CBDCA is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by <e1> CDDP </e1> that it is probable that <e2> neurotoxicity </e2> is induced in the two drugs by the same mechanism .
NO_RELATION	Since <e1> tamoxifen </e1> is widely used in <e2> breast cancer </e2> treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .
NO_RELATION	Since <e1> tamoxifen </e1> is widely used in breast cancer treatment and has been proposed for the prevention of <e2> breast cancer </e2> , its endometrial iatrogenic effects must be carefully examined .
CID	We have investigated the association between <e2> endometrial cancer </e2> and <e1> tamoxifen </e1> use or other treatments in women treated for breast cancer in a case - control study .
NO_RELATION	We have investigated the association between endometrial cancer and <e1> tamoxifen </e1> use or other treatments in women treated for <e2> breast cancer </e2> in a case - control study .
CID	Women who had received <e1> tamoxifen </e1> were significantly more likely to have <e2> endometrial cancer </e2> diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .
CID	Women who had <e2> endometrial cancer </e2> and had received <e1> tamoxifen </e1> had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .
NO_RELATION	Women who had endometrial cancer and had received <e1> tamoxifen </e1> had more <e2> advanced disease </e2> and poorer prognosis than those with endometrial cancer who had not received this treatment .
CID	Women who had endometrial cancer and had received <e1> tamoxifen </e1> had more advanced disease and poorer prognosis than those with <e2> endometrial cancer </e2> who had not received this treatment .
CID	Our results suggest a causal role of <e1> tamoxifen </e1> in <e2> endometrial cancer </e2> , particularly when used as currently proposed for breast cancer prevention .
NO_RELATION	Our results suggest a causal role of <e1> tamoxifen </e1> in endometrial cancer , particularly when used as currently proposed for <e2> breast cancer </e2> prevention .
CID	<e2> Endometrial cancers </e2> diagnosed in women treated with <e1> tamoxifen </e1> have poorer prognosis .
NO_RELATION	Women who receive <e1> tamoxifen </e1> for <e2> breast cancer </e2> should be offered gynaecological surveillance during and after treatment .
NO_RELATION	A long - term evaluation of the risk - benefit ratio of <e1> tamoxifen </e1> as a preventive treatment for <e2> breast cancer </e2> is clearly warranted .
CID	<e2> Granulosa cell tumor of the ovary </e2> associated with antecedent <e1> tamoxifen </e1> use .
NO_RELATION	Review of the literature reveals an association between <e1> tamoxifen </e1> use and gynecologic <e2> tumors </e2> .
NO_RELATION	CASE : A 52 - year - old postmenopausal woman was treated with <e1> tamoxifen </e1> for stage II estrogen receptor - positive <e2> breast carcinoma </e2> .
NO_RELATION	CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II <e1> estrogen </e1> receptor - positive <e2> breast carcinoma </e2> .
CID	CONCLUSION : Patients with <e1> tamoxifen </e1> - induced <e2> liver dysfunction </e2> may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism .
NO_RELATION	CONCLUSION : Patients with <e1> tamoxifen </e1> - induced liver dysfunction may be at increased risk for <e2> granulosa cell tumors </e2> because of alterations in tamoxifen metabolism .
CID	CONCLUSION : Patients with tamoxifen - induced <e2> liver dysfunction </e2> may be at increased risk for granulosa cell tumors because of alterations in <e1> tamoxifen </e1> metabolism .
NO_RELATION	CONCLUSION : Patients with tamoxifen - induced liver dysfunction may be at increased risk for <e2> granulosa cell tumors </e2> because of alterations in <e1> tamoxifen </e1> metabolism .
CID	A murine model of <e2> adenomyosis </e2> : the effects of hyperprolactinemia induced by <e1> fluoxetine hydrochloride </e1> , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .
CID	A murine model of adenomyosis : the effects of <e2> hyperprolactinemia </e2> induced by <e1> fluoxetine hydrochloride </e1> , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .
CID	A murine model of adenomyosis : the effects of hyperprolactinemia induced by <e1> fluoxetine hydrochloride </e1> , a selective serotonin reuptake inhibitor , on <e2> adenomyosis </e2> induction in Wistar albino rats .
NO_RELATION	A murine model of <e2> adenomyosis </e2> : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective <e1> serotonin </e1> reuptake inhibitor , on adenomyosis induction in Wistar albino rats .
NO_RELATION	A murine model of adenomyosis : the effects of <e2> hyperprolactinemia </e2> induced by fluoxetine hydrochloride , a selective <e1> serotonin </e1> reuptake inhibitor , on adenomyosis induction in Wistar albino rats .
NO_RELATION	A murine model of adenomyosis : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective <e1> serotonin </e1> reuptake inhibitor , on <e2> adenomyosis </e2> induction in Wistar albino rats .
CID	OBJECTIVE : The aim of this study was to investigate whether <e1> fluoxetine </e1> given to castrated and noncastrated rats caused <e2> hyperprolactinemia </e2> and its effects with respect to adenomyosis .
CID	OBJECTIVE : The aim of this study was to investigate whether <e1> fluoxetine </e1> given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to <e2> adenomyosis </e2> .
CID	DESIGN : <e1> Fluoxetine </e1> , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce <e2> hyperprolactinemia </e2> .
NO_RELATION	DESIGN : Fluoxetine , a <e1> serotonin </e1> reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce <e2> hyperprolactinemia </e2> .
CID	Histological studies revealed 11 cases of <e2> adenomyosis </e2> , all within the noncastrated group receiving <e1> fluoxetine </e1> .
CID	Effects of deliberate <e2> hypotension </e2> induced by <e1> labetalol </e1> with isoflurane on neuropsychological function .
CID	Effects of deliberate <e2> hypotension </e2> induced by labetalol with <e1> isoflurane </e1> on neuropsychological function .
CID	Twenty - four patients were anaesthetized for middle - ear surgery with deliberate <e2> hypotension </e2> induced by <e1> labetalol </e1> with isoflurane ( hypotensive group ) .
CID	Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by <e1> labetalol </e1> with isoflurane ( <e2> hypotensive </e2> group ) .
CID	Twenty - four patients were anaesthetized for middle - ear surgery with deliberate <e2> hypotension </e2> induced by labetalol with <e1> isoflurane </e1> ( hypotensive group ) .
CID	Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by labetalol with <e1> isoflurane </e1> ( <e2> hypotensive </e2> group ) .
CID	The results indicate that <e2> hypotension </e2> induced by <e1> labetalol </e1> with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .
CID	The results indicate that <e2> hypotension </e2> induced by labetalol with <e1> isoflurane </e1> has no significant harmful effects on mental functions compared to normotensive anaesthesia .
CID	Somewhat fewer cardiovascular and local sequelae were found in the <e1> midazolam </e1> group , but , although <e2> apnoea </e2> occurred less often in the midazolam group it lasted longer .
CID	Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although <e2> apnoea </e2> occurred less often in the <e1> midazolam </e1> group it lasted longer .
NO_RELATION	<e2> Cardiotoxic </e2> and possible leukemogenic effects of <e1> adriamycin </e1> in nonhuman primates .
CID	8 of the 10 monkeys developed <e2> congestive heart failure </e2> at an average cumulative <e1> adriamycin </e1> dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .
NO_RELATION	Histologically , the <e2> myocardial lesions </e2> resembled those found in human <e1> anthracycline </e1> - induced cardiomyopathy .
NO_RELATION	Histologically , the myocardial lesions resembled those found in human <e1> anthracycline </e1> - induced <e2> cardiomyopathy </e2> .
CID	1 of the 10 monkeys developed <e2> acute myeloblastic leukemia </e2> after receiving 324 mg / m2 of <e1> adriamycin </e1> ; the 10th monkey is alive and well 26 months after the last dose of drug .
NO_RELATION	Our results suggest that <e1> adriamycin </e1> is a more potent cardiotoxin in monkeys than in man , and that <e2> leukemia </e2> may be a consequence of prolonged treatment with this drug .
CID	<e1> Doxorubicin </e1> <e2> cardiomyopathy </e2> in children with left - sided Wilms tumor .
NO_RELATION	<e1> Doxorubicin </e1> cardiomyopathy in children with left - sided <e2> Wilms tumor </e2> .
NO_RELATION	Two children with <e2> Wilms tumor </e2> of the left kidney experienced severe <e1> anthracycline </e1> cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .
NO_RELATION	Two children with Wilms tumor of the left kidney experienced severe <e1> anthracycline </e1> <e2> cardiomyopathy </e2> after irradiation to the tumor bed and conventional dosage of doxorubicin .
NO_RELATION	Two children with Wilms tumor of the left kidney experienced severe <e1> anthracycline </e1> cardiomyopathy after irradiation to the <e2> tumor </e2> bed and conventional dosage of doxorubicin .
NO_RELATION	Two children with <e2> Wilms tumor </e2> of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of <e1> doxorubicin </e1> .
CID	Two children with Wilms tumor of the left kidney experienced severe anthracycline <e2> cardiomyopathy </e2> after irradiation to the tumor bed and conventional dosage of <e1> doxorubicin </e1> .
NO_RELATION	Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the <e2> tumor </e2> bed and conventional dosage of <e1> doxorubicin </e1> .
CID	The <e2> cardiomyopathy </e2> is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of <e1> doxorubicin </e1> and irradiation on cardiac muscle .
NO_RELATION	The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left <e2> Wilms tumor </e2> include the lower portion of the heart and 2 ) to the interaction of <e1> doxorubicin </e1> and irradiation on cardiac muscle .
NO_RELATION	It is recommended that <e1> doxorubicin </e1> dosage be sharply restricted in children with <e2> Wilms tumor </e2> of the left kidney who receive postoperative irradiation .
NO_RELATION	Promotional effects of <e1> testosterone </e1> and dietary fat on prostate <e2> carcinogenesis </e2> in genetically susceptible rats .
CID	Conventional LW rats , implanted with <e1> testosterone </e1> at age 4 months , developed a higher incidence of <e2> prostate cancer </e2> after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .
NO_RELATION	Conventional LW rats , implanted with <e1> testosterone </e1> at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross <e2> tumors </e2> , and 40 % when it included microscopic tumors .
NO_RELATION	Conventional LW rats , implanted with <e1> testosterone </e1> at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic <e2> tumors </e2> .
CID	Preliminary results indicate that <e1> testosterone </e1> - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed <e2> prostate cancer </e2> after intervals of 6 - 12 months .
CID	Conventional SD rats fed diet L - 485 and treated with <e1> testosterone </e1> developed only <e2> prostatitis </e2> .
CID	<e1> Mitomycin C </e1> associated <e2> hemolytic uremic syndrome </e2> .
CID	<e1> Mitomycin C </e1> associated <e2> Hemolytic Uremic Syndrome </e2> ( HUS ) is a potentially fatal but uncommon condition that is not yet widely recognised .
CID	<e1> Mitomycin C </e1> associated Hemolytic Uremic Syndrome ( <e2> HUS </e2> ) is a potentially fatal but uncommon condition that is not yet widely recognised .
NO_RELATION	It consists of microangiopathic <e2> hemolytic anemia </e2> , thrombocytopenia and progressive renal failure associated with <e1> mitomycin C </e1> treatment and affects about 10 % of patients treated with this agent .
NO_RELATION	It consists of microangiopathic hemolytic anemia , <e2> thrombocytopenia </e2> and progressive renal failure associated with <e1> mitomycin C </e1> treatment and affects about 10 % of patients treated with this agent .
CID	It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive <e2> renal failure </e2> associated with <e1> mitomycin C </e1> treatment and affects about 10 % of patients treated with this agent .
CID	The <e2> renal failure </e2> usually develops about 8 - 10 mth after start of <e1> mitomycin C </e1> treatment and the mortality is approximately 60 % from renal failure or pulmonary edema .
CID	The renal failure usually develops about 8 - 10 mth after start of <e1> mitomycin C </e1> treatment and the mortality is approximately 60 % from <e2> renal failure </e2> or pulmonary edema .
NO_RELATION	The renal failure usually develops about 8 - 10 mth after start of <e1> mitomycin C </e1> treatment and the mortality is approximately 60 % from renal failure or <e2> pulmonary edema </e2> .
NO_RELATION	We describe the clinical course and pathological findings in a 65 yr - old man with <e2> gastric adenocarcinoma </e2> who developed renal failure and thrombocytopenia while on treatment with <e1> mitomycin C </e1> and died in pulmonary edema .
CID	We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed <e2> renal failure </e2> and thrombocytopenia while on treatment with <e1> mitomycin C </e1> and died in pulmonary edema .
NO_RELATION	We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and <e2> thrombocytopenia </e2> while on treatment with <e1> mitomycin C </e1> and died in pulmonary edema .
NO_RELATION	We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with <e1> mitomycin C </e1> and died in <e2> pulmonary edema </e2> .
NO_RELATION	Although there have been anecdotal reports of <e2> cardiac toxicity </e2> associated with <e1> fluorouracil </e1> ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .
NO_RELATION	Although there have been anecdotal reports of <e2> cardiac toxicity </e2> associated with fluorouracil ( <e1> 5 - FU </e1> ) therapy , this phenomenon has not been studied in a systematic fashion .
NO_RELATION	We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing <e1> 5 - FU </e1> infusion for treatment of solid <e2> tumors </e2> in order to assess the incidence of ischemic ST changes .
CID	We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing <e1> 5 - FU </e1> infusion for treatment of solid tumors in order to assess the incidence of <e2> ischemic </e2> ST changes .
CID	<e2> Anginal </e2> episodes were rare : only one patient had angina ( during <e1> 5 - FU </e1> infusion ) .
CID	Anginal episodes were rare : only one patient had <e2> angina </e2> ( during <e1> 5 - FU </e1> infusion ) .
CID	The incidence of <e2> ischemic </e2> episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to <e1> 5 - FU </e1> infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .
CID	The incidence of <e2> ischemic </e2> episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during <e1> 5 - FU </e1> infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .
CID	The incidence of <e2> ischemic </e2> episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before <e1> 5 - FU </e1> v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .
CID	The incidence of <e2> ischemic </e2> episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during <e1> 5 - FU </e1> ( P less than . 01 ) .
CID	We conclude that <e1> 5 - FU </e1> infusion is associated with a significant increase in silent ST segment deviation suggestive of <e2> ischemia </e2> , particularly among patients with coronary artery disease .
NO_RELATION	We conclude that <e1> 5 - FU </e1> infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia , particularly among patients with <e2> coronary artery disease </e2> .
CID	Lethal <e2> anuria </e2> complicating high dose <e1> ifosfamide </e1> chemotherapy in a breast cancer patient with an impaired renal function .
NO_RELATION	Lethal anuria complicating high dose <e1> ifosfamide </e1> chemotherapy in a <e2> breast cancer </e2> patient with an impaired renal function .
CID	Lethal anuria complicating high dose <e1> ifosfamide </e1> chemotherapy in a breast cancer patient with an <e2> impaired renal function </e2> .
NO_RELATION	A sixty - year - old woman with advanced <e2> breast cancer </e2> , previously treated with <e1> cisplatin </e1> , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .
NO_RELATION	A sixty - year - old woman with advanced breast cancer , previously treated with <e1> cisplatin </e1> , developed an irreversible lethal <e2> renal failure </e2> with anuria , the day after 5 g / m2 bolus ifosfamide .
NO_RELATION	A sixty - year - old woman with advanced breast cancer , previously treated with <e1> cisplatin </e1> , developed an irreversible lethal renal failure with <e2> anuria </e2> , the day after 5 g / m2 bolus ifosfamide .
NO_RELATION	A sixty - year - old woman with advanced <e2> breast cancer </e2> , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus <e1> ifosfamide </e1> .
NO_RELATION	A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal <e2> renal failure </e2> with anuria , the day after 5 g / m2 bolus <e1> ifosfamide </e1> .
CID	A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with <e2> anuria </e2> , the day after 5 g / m2 bolus <e1> ifosfamide </e1> .
CID	<e1> Ifosfamide </e1> is a known <e2> nephrotoxic </e2> drug with demonstrated tubulopathies .
CID	<e1> Ifosfamide </e1> is a known nephrotoxic drug with demonstrated <e2> tubulopathies </e2> .
CID	We strongly suspect that this lethal <e2> anuria </e2> was mainly due to <e1> ifosfamide </e1> , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .
NO_RELATION	We strongly suspect that this lethal anuria was mainly due to <e1> ifosfamide </e1> , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient <e2> hypotension </e2> .
NO_RELATION	We strongly suspect that this lethal <e2> anuria </e2> was mainly due to ifosfamide , occurring in a patient having received previous <e1> cisplatin </e1> chemotherapy and with poor kidney perfusion due to transient hypotension .
NO_RELATION	We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous <e1> cisplatin </e1> chemotherapy and with poor kidney perfusion due to transient <e2> hypotension </e2> .
CID	We recommend careful use of <e1> ifosfamide </e1> in patients pretreated with <e2> nephrotoxic </e2> chemotherapy and inadequate renal perfusion .
CID	Central <e2> vein thrombosis </e2> and topical <e1> dipivalyl epinephrine </e1> .
CID	A report is given on an 83 - year - old female who acquired central <e2> vein thrombosis </e2> in her seeing eye one day after having started topical medication with <e1> dipivalyl epinephrine </e1> for advanced glaucoma discovered in the other eye .
NO_RELATION	A report is given on an 83 - year - old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with <e1> dipivalyl epinephrine </e1> for advanced <e2> glaucoma </e2> discovered in the other eye .
CID	Amelioration of <e1> bendrofluazide </e1> - induced <e2> hypokalemia </e2> by timolol .
NO_RELATION	Amelioration of bendrofluazide - induced <e2> hypokalemia </e2> by <e1> timolol </e1> .
NO_RELATION	The beta adrenergic blocking drug , <e1> timolol </e1> , tended to correct the <e2> hypokalemia </e2> of short - term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant .
CID	The beta adrenergic blocking drug , timolol , tended to correct the <e2> hypokalemia </e2> of short - term <e1> bendrofluazide </e1> treatment in 6 healthy male subjects and although the effect was small it was significant .
CID	OBJECTIVE : The aim of the present study was to investigate the effect of <e1> risperidone </e1> - induced <e2> hyperprolactinemia </e2> on trabecular bone mineral density ( BMD ) in children and adolescents .
CID	RESULTS : <e2> Hyperprolactinemia </e2> was present in 49 % of 83 boys ( n = 41 ) treated with <e1> risperidone </e1> for a mean of 2 . 9 years .
NO_RELATION	Serum <e1> testosterone </e1> concentration increased with pubertal status but was not affected by <e2> hyperprolactinemia </e2> .
NO_RELATION	Of 13 documented <e2> fractures </e2> , 3 occurred after <e1> risperidone </e1> and SSRIs were started , and none occurred in patients with hyperprolactinemia .
CID	Of 13 documented fractures , 3 occurred after <e1> risperidone </e1> and SSRIs were started , and none occurred in patients with <e2> hyperprolactinemia </e2> .
CID	CONCLUSIONS : This is the first study to link <e1> risperidone </e1> - induced <e2> hyperprolactinemia </e2> and SSRI treatment to lower BMD in children and adolescents .
CID	<e2> Seizures </e2> associated with <e1> levofloxacin </e1> : case presentation and literature review .
CID	PURPOSE : We present a case of a patient who developed <e2> seizures </e2> shortly after initiating treatment with <e1> levofloxacin </e1> and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .
CID	PURPOSE : We present a case of a patient who developed seizures shortly after initiating treatment with <e1> levofloxacin </e1> and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced <e2> seizures </e2> .
CID	PURPOSE : We present a case of a patient who developed <e2> seizures </e2> shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of <e1> levofloxacin </e1> - induced seizures .
CID	PURPOSE : We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of <e1> levofloxacin </e1> - induced <e2> seizures </e2> .
CID	RESULTS : Six cases of <e1> levofloxacin </e1> - induced <e2> seizures </e2> have been reported in the literature .
NO_RELATION	Mice lacking mPGES - 1 are resistant to <e1> lithium </e1> - induced <e2> polyuria </e2> .
NO_RELATION	Cyclooxygenase - 2 activity is required for the development of <e1> lithium </e1> - induced <e2> polyuria </e2> .
NO_RELATION	The present study was undertaken to assess <e1> lithium </e1> - induced <e2> polyuria </e2> in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .
NO_RELATION	The present study was undertaken to assess lithium - induced <e2> polyuria </e2> in mice deficient in microsomal <e1> prostaglandin E </e1> synthase - 1 ( mPGES - 1 ) .
CID	A 2 - wk administration of <e1> LiCl </e1> ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked <e2> polyuria </e2> with hyposmotic urine .
NO_RELATION	In contrast , mPGES - 1 - / - mice were largely resistant to <e1> lithium </e1> - induced <e2> polyuria </e2> and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .
NO_RELATION	In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced <e2> polyuria </e2> and a urine concentrating defect , accompanied by nearly complete blockade of high urine <e1> PGE ( 2 ) </e1> and cAMP output .
NO_RELATION	We conclude that mPGES - 1 - derived <e1> PGE ( 2 ) </e1> mediates lithium - induced <e2> polyuria </e2> likely via inhibition of AQP2 and NKCC2 expression .
NO_RELATION	We conclude that mPGES - 1 - derived PGE ( 2 ) mediates <e1> lithium </e1> - induced <e2> polyuria </e2> likely via inhibition of AQP2 and NKCC2 expression .
NO_RELATION	Recently , a number of commercial lots of <e1> heparin </e1> products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a <e2> hypotensive </e2> response in pigs following a single high - dose infusion .
CID	Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated <e1> chondroitin sulfate </e1> ( OSCS ) derivative that could elicit a <e2> hypotensive </e2> response in pigs following a single high - dose infusion .
NO_RELATION	Using both contaminated <e1> heparin </e1> products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent <e2> hypotension </e2> in pigs .
CID	<e1> Doxorubicin </e1> <e2> cardiomyopathy </e2> - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .
NO_RELATION	<e1> Doxorubicin </e1> cardiomyopathy - induced <e2> inflammation </e2> and apoptosis are attenuated by gene deletion of the kinin B1 receptor .
NO_RELATION	Clinical use of the <e1> anthracycline </e1> doxorubicin ( DOX ) is limited by its <e2> cardiotoxic </e2> effects , which are attributed to the induction of apoptosis .
NO_RELATION	Clinical use of the anthracycline <e1> doxorubicin </e1> ( DOX ) is limited by its <e2> cardiotoxic </e2> effects , which are attributed to the induction of apoptosis .
NO_RELATION	Clinical use of the anthracycline doxorubicin ( <e1> DOX </e1> ) is limited by its <e2> cardiotoxic </e2> effects , which are attributed to the induction of apoptosis .
CID	To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of <e1> DOX </e1> <e2> cardiomyopathy </e2> , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .
NO_RELATION	To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of <e1> DOX </e1> cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac <e2> inflammation </e2> and apoptosis after induction of DOX - induced cardiomyopathy .
CID	To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of <e1> DOX </e1> cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced <e2> cardiomyopathy </e2> .
CID	To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX <e2> cardiomyopathy </e2> , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of <e1> DOX </e1> - induced cardiomyopathy .
NO_RELATION	To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac <e2> inflammation </e2> and apoptosis after induction of <e1> DOX </e1> - induced cardiomyopathy .
CID	To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of <e1> DOX </e1> - induced <e2> cardiomyopathy </e2> .
NO_RELATION	<e1> DOX </e1> control mice showed <e2> cardiac dysfunction </e2> measured by pressure - volume loops in vivo .
NO_RELATION	In <e1> DOX </e1> B1R ( - / - ) mice , <e2> cardiac dysfunction </e2> was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .
NO_RELATION	In DOX B1R ( - / - ) mice , <e2> cardiac dysfunction </e2> was improved compared to <e1> DOX </e1> control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .
CID	These findings suggest that B1R is detrimental in <e1> DOX </e1> <e2> cardiomyopathy </e2> in that it mediates the inflammatory response and apoptosis .
CID	These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human <e1> DOX </e1> <e2> cardiomyopathy </e2> .
CID	<e2> Hepatotoxicity </e2> associated with <e1> sulfasalazine </e1> in inflammatory arthritis : A case series from a local surveillance of serious adverse events .
NO_RELATION	Hepatotoxicity associated with <e1> sulfasalazine </e1> in inflammatory <e2> arthritis </e2> : A case series from a local surveillance of serious adverse events .
CID	Patients ' , who had <e2> hepatotoxicity </e2> on <e1> sulfasalazine </e1> and met a definition of a serious ADR , were identified .
CID	The likely frequency of <e2> hepatotoxicity </e2> with <e1> sulfasalazine </e1> was estimated by making a series of conservative assumptions .
CID	The likely frequency of serious <e2> hepatotoxicity </e2> with <e1> sulfasalazine </e1> was estimated at 0 . 4 % of treated patients .
CID	CONCLUSION : Serious <e2> hepatotoxicity </e2> associated with <e1> sulfasalazine </e1> appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .
CID	An evaluation of <e1> amikacin </e1> <e2> nephrotoxicity </e2> in the hematology / oncology population .
NO_RELATION	<e1> Amikacin </e1> is an aminoglycoside commonly used to provide empirical double gram - negative treatment for <e2> febrile neutropenia </e2> and other suspected infections .
NO_RELATION	<e1> Amikacin </e1> is an aminoglycoside commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected <e2> infections </e2> .
NO_RELATION	Amikacin is an <e1> aminoglycoside </e1> commonly used to provide empirical double gram - negative treatment for <e2> febrile neutropenia </e2> and other suspected infections .
NO_RELATION	Amikacin is an <e1> aminoglycoside </e1> commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected <e2> infections </e2> .
CID	To evaluate <e1> amikacin </e1> - associated <e2> nephrotoxicity </e2> in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .
NO_RELATION	Forty patients with a diagnosis consistent with a <e2> hematologic / oncologic disorder </e2> that required treatment with an <e1> aminoglycoside </e1> were randomized to either conventional or extended - interval amikacin .
NO_RELATION	Forty patients with a diagnosis consistent with a <e2> hematologic / oncologic disorder </e2> that required treatment with an aminoglycoside were randomized to either conventional or extended - interval <e1> amikacin </e1> .
NO_RELATION	The occurrence of <e2> nephrotoxicity </e2> by means of an increase in serum <e1> creatinine </e1> and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .
CID	The occurrence of <e2> nephrotoxicity </e2> by means of an increase in serum creatinine and evaluation of efficacy via <e1> amikacin </e1> serum concentrations with respective pathogens were assessed .
NO_RELATION	Although <e1> 3 , 4 - methylenedioxymethamphetamine </e1> ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT <e2> neurotoxic lesions </e2> on functions in which 5 - HT is involved , such as cognitive function .
NO_RELATION	Although 3 , 4 - methylenedioxymethamphetamine ( <e1> MDMA </e1> or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT <e2> neurotoxic lesions </e2> on functions in which 5 - HT is involved , such as cognitive function .
NO_RELATION	Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or <e1> ecstasy </e1> ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT <e2> neurotoxic lesions </e2> on functions in which 5 - HT is involved , such as cognitive function .
NO_RELATION	Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain <e1> serotonin </e1> ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT <e2> neurotoxic lesions </e2> on functions in which 5 - HT is involved , such as cognitive function .
NO_RELATION	Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( <e1> 5 - HT </e1> ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT <e2> neurotoxic lesions </e2> on functions in which 5 - HT is involved , such as cognitive function .
NO_RELATION	Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of <e1> MDMA </e1> - induced 5 - HT <e2> neurotoxic lesions </e2> on functions in which 5 - HT is involved , such as cognitive function .
NO_RELATION	Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced <e1> 5 - HT </e1> <e2> neurotoxic lesions </e2> on functions in which 5 - HT is involved , such as cognitive function .
NO_RELATION	Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT <e2> neurotoxic lesions </e2> on functions in which <e1> 5 - HT </e1> is involved , such as cognitive function .
CID	In contrast , no evidence of <e2> memory impairment </e2> was observed in moderate <e1> MDMA </e1> users .
CID	While the use of <e1> MDMA </e1> in quantities that may be considered " moderate " is not associated with <e2> impaired memory functioning </e2> , heavy use of MDMA use may lead to long lasting memory impairments .
CID	While the use of <e1> MDMA </e1> in quantities that may be considered " moderate " is not associated with impaired memory functioning , heavy use of MDMA use may lead to long lasting <e2> memory impairments </e2> .
CID	While the use of MDMA in quantities that may be considered " moderate " is not associated with <e2> impaired memory functioning </e2> , heavy use of <e1> MDMA </e1> use may lead to long lasting memory impairments .
CID	While the use of MDMA in quantities that may be considered " moderate " is not associated with impaired memory functioning , heavy use of <e1> MDMA </e1> use may lead to long lasting <e2> memory impairments </e2> .
CID	Aging process of epithelial cells of the rat prostate lateral lobe in experimental <e2> hyperprolactinemia </e2> induced by <e1> haloperidol </e1> .
CID	The aim of the study was to examine the influence of <e2> hyperprolactinemia </e2> , induced by <e1> haloperidol </e1> ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .
CID	The aim of the study was to examine the influence of <e2> hyperprolactinemia </e2> , induced by haloperidol ( <e1> HAL </e1> ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .
CID	Does supplemental <e1> vitamin C </e1> increase <e2> cardiovascular disease </e2> risk in women with diabetes ?
NO_RELATION	Does supplemental <e1> vitamin C </e1> increase cardiovascular disease risk in women with <e2> diabetes </e2> ?
NO_RELATION	These observations led us to hypothesize that a high intake of <e1> vitamin C </e1> in <e2> diabetic </e2> persons might promote atherosclerosis .
NO_RELATION	These observations led us to hypothesize that a high intake of <e1> vitamin C </e1> in diabetic persons might promote <e2> atherosclerosis </e2> .
CID	OBJECTIVE : The objective was to examine the relation between <e1> vitamin C </e1> intake and mortality from <e2> cardiovascular disease </e2> .
CID	DESIGN : We studied the relation between <e1> vitamin C </e1> intake and mortality from total <e2> cardiovascular disease </e2> ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .
NO_RELATION	DESIGN : We studied the relation between <e1> vitamin C </e1> intake and mortality from total cardiovascular disease ( n = 281 ) , <e2> coronary artery disease </e2> ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .
NO_RELATION	DESIGN : We studied the relation between <e1> vitamin C </e1> intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and <e2> stroke </e2> ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .
NO_RELATION	DESIGN : We studied the relation between <e1> vitamin C </e1> intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being <e2> diabetic </e2> at baseline .
NO_RELATION	RESULTS : After adjustment for <e2> cardiovascular disease </e2> risk factors , type of diabetes medication used , duration of diabetes , and intakes of <e1> folate </e1> , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of <e2> diabetes </e2> medication used , duration of diabetes , and intakes of <e1> folate </e1> , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of <e2> diabetes </e2> , and intakes of <e1> folate </e1> , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of <e1> folate </e1> , vitamin E , and beta - carotene , the adjusted relative risks of total <e2> cardiovascular disease </e2> mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for <e2> cardiovascular disease </e2> risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , <e1> vitamin E </e1> , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of <e2> diabetes </e2> medication used , duration of diabetes , and intakes of folate , <e1> vitamin E </e1> , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of <e2> diabetes </e2> , and intakes of folate , <e1> vitamin E </e1> , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , <e1> vitamin E </e1> , and beta - carotene , the adjusted relative risks of total <e2> cardiovascular disease </e2> mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for <e2> cardiovascular disease </e2> risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and <e1> beta - carotene </e1> , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of <e2> diabetes </e2> medication used , duration of diabetes , and intakes of folate , vitamin E , and <e1> beta - carotene </e1> , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of <e2> diabetes </e2> , and intakes of folate , vitamin E , and <e1> beta - carotene </e1> , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and <e1> beta - carotene </e1> , the adjusted relative risks of total <e2> cardiovascular disease </e2> mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
CID	RESULTS : After adjustment for <e2> cardiovascular disease </e2> risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total <e1> vitamin C </e1> intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of <e2> diabetes </e2> medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total <e1> vitamin C </e1> intake from food and supplements .
NO_RELATION	RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of <e2> diabetes </e2> , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total <e1> vitamin C </e1> intake from food and supplements .
CID	RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total <e2> cardiovascular disease </e2> mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total <e1> vitamin C </e1> intake from food and supplements .
CID	<e1> Vitamin C </e1> intake was unrelated to mortality from <e2> cardiovascular disease </e2> in the nondiabetic subjects at baseline .
CID	CONCLUSION : A high <e1> vitamin C </e1> intake from supplements is associated with an increased risk of <e2> cardiovascular disease </e2> mortality in postmenopausal women with diabetes .
NO_RELATION	CONCLUSION : A high <e1> vitamin C </e1> intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with <e2> diabetes </e2> .
NO_RELATION	Absolute and attributable risk of <e2> venous thromboembolism </e2> in women on combined <e1> cyproterone acetate </e1> and ethinylestradiol .
NO_RELATION	Absolute and attributable risk of <e2> venous thromboembolism </e2> in women on combined cyproterone acetate and <e1> ethinylestradiol </e1> .
NO_RELATION	OBJECTIVE : To achieve absolute risk estimates of <e2> venous thromboembolism </e2> ( VTE ) among women on <e1> cyproterone acetate </e1> plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .
NO_RELATION	OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( <e2> VTE </e2> ) among women on <e1> cyproterone acetate </e1> plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .
NO_RELATION	OBJECTIVE : To achieve absolute risk estimates of <e2> venous thromboembolism </e2> ( VTE ) among women on cyproterone acetate plus <e1> ethinylestradiol </e1> ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .
NO_RELATION	OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( <e2> VTE </e2> ) among women on cyproterone acetate plus <e1> ethinylestradiol </e1> ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .
NO_RELATION	OBJECTIVE : To achieve absolute risk estimates of <e2> venous thromboembolism </e2> ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( <e1> CPA </e1> / EE ) , and among women on combined oral contraceptives ( COCs ) .
NO_RELATION	OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( <e2> VTE </e2> ) among women on cyproterone acetate plus ethinylestradiol ( <e1> CPA </e1> / EE ) , and among women on combined oral contraceptives ( COCs ) .
NO_RELATION	OBJECTIVE : To achieve absolute risk estimates of <e2> venous thromboembolism </e2> ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / <e1> EE </e1> ) , and among women on combined oral contraceptives ( COCs ) .
NO_RELATION	OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( <e2> VTE </e2> ) among women on cyproterone acetate plus ethinylestradiol ( CPA / <e1> EE </e1> ) , and among women on combined oral contraceptives ( COCs ) .
CID	OBJECTIVE : To achieve absolute risk estimates of <e2> venous thromboembolism </e2> ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on <e1> combined oral contraceptives </e1> ( COCs ) .
CID	OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( <e2> VTE </e2> ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on <e1> combined oral contraceptives </e1> ( COCs ) .
CID	OBJECTIVE : To achieve absolute risk estimates of <e2> venous thromboembolism </e2> ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( <e1> COCs </e1> ) .
CID	OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( <e2> VTE </e2> ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( <e1> COCs </e1> ) .
CID	RESULTS : During the time frame of the study , 330 women were found to have had <e2> VTE </e2> while on <e1> COCs </e1> .
CID	The corresponding absolute risk of <e2> VTE </e2> was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on <e1> COCs </e1> , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .
NO_RELATION	The corresponding absolute risk of <e2> VTE </e2> was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on <e1> levonorgestrel </e1> - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .
CID	The corresponding absolute risk of <e2> VTE </e2> was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing <e1> COCs </e1> , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .
NO_RELATION	The corresponding absolute risk of <e2> VTE </e2> was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on <e1> CPA </e1> / EE .
NO_RELATION	The corresponding absolute risk of <e2> VTE </e2> was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / <e1> EE </e1> .
CID	CONCLUSION : Our results suggest the absolute risk of <e2> VTE </e2> among Danish women on <e1> COCs </e1> is similar to that among women taking CPA / EE .
NO_RELATION	CONCLUSION : Our results suggest the absolute risk of <e2> VTE </e2> among Danish women on COCs is similar to that among women taking <e1> CPA </e1> / EE .
NO_RELATION	CONCLUSION : Our results suggest the absolute risk of <e2> VTE </e2> among Danish women on COCs is similar to that among women taking CPA / <e1> EE </e1> .
NO_RELATION	Effect of <e1> lindane </e1> on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced <e2> neurotoxicity </e2> .
NO_RELATION	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in <e1> lindane </e1> induced <e2> neurotoxicity </e2> .
NO_RELATION	Induction studies have further shown that while pretreatment of <e1> 3 - methylcholanthrene </e1> ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced <e2> convulsions </e2> , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .
NO_RELATION	Induction studies have further shown that while pretreatment of <e1> 3 - methylcholanthrene </e1> ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced <e2> convulsions </e2> .
NO_RELATION	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( <e1> MC </e1> ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced <e2> convulsions </e2> , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .
NO_RELATION	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( <e1> MC </e1> ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced <e2> convulsions </e2> .
CID	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of <e1> lindane </e1> induced <e2> convulsions </e2> , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .
CID	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of <e1> lindane </e1> induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced <e2> convulsions </e2> .
NO_RELATION	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced <e2> convulsions </e2> , pretreatment with <e1> phenobarbital </e1> ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .
NO_RELATION	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with <e1> phenobarbital </e1> ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced <e2> convulsions </e2> .
NO_RELATION	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced <e2> convulsions </e2> , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or <e1> ethanol </e1> , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .
NO_RELATION	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or <e1> ethanol </e1> , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced <e2> convulsions </e2> .
CID	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced <e2> convulsions </e2> , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of <e1> lindane </e1> induced convulsions .
CID	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of <e1> lindane </e1> induced <e2> convulsions </e2> .
CID	Similarly , when the P450 - mediated metabolism of <e1> lindane </e1> was blocked by cobalt chloride incidence of <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .
NO_RELATION	Similarly , when the P450 - mediated metabolism of <e1> lindane </e1> was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2> .
NO_RELATION	Similarly , when the P450 - mediated metabolism of lindane was blocked by <e1> cobalt chloride </e1> incidence of <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .
NO_RELATION	Similarly , when the P450 - mediated metabolism of lindane was blocked by <e1> cobalt chloride </e1> incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2> .
CID	Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of <e2> convulsions </e2> was increased in animals treated with <e1> lindane </e1> indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .
NO_RELATION	Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with <e1> lindane </e1> indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2> .
CID	Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of <e2> convulsions </e2> was increased in animals treated with lindane indicating that <e1> lindane </e1> per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .
NO_RELATION	Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that <e1> lindane </e1> per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2> .
NO_RELATION	Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of <e2> convulsions </e2> was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or <e1> ethanol </e1> inducible P450 isoenzymes are involved in its neurobehavioral toxicity .
NO_RELATION	Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or <e1> ethanol </e1> inducible P450 isoenzymes are involved in its neurobehavioral <e2> toxicity </e2> .
CID	<e2> Seizure </e2> associated with sleep deprivation and sustained - release <e1> bupropion </e1> .
NO_RELATION	Seizure associated with <e2> sleep deprivation </e2> and sustained - release <e1> bupropion </e1> .
CID	This case report describes a generalized <e2> seizure </e2> associated with sustained - release <e1> bupropion </e1> use and sleep deprivation .
NO_RELATION	This case report describes a generalized seizure associated with sustained - release <e1> bupropion </e1> use and <e2> sleep deprivation </e2> .
CID	After 5 weeks of <e1> bupropion </e1> use , the subject experienced a generalized tonic clonic <e2> seizure </e2> after staying up nearly all night packing and moving to a new residence .
NO_RELATION	We suggest that <e2> sleep deprivation </e2> may add to the risk of <e1> bupropion </e1> - associated seizures .
CID	We suggest that sleep deprivation may add to the risk of <e1> bupropion </e1> - associated <e2> seizures </e2> .
NO_RELATION	METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the <e2> nephrotoxic </e2> effects of an iso - osmolar , dimeric , nonionic contrast medium , <e1> iodixanol </e1> , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .
CID	METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the <e2> nephrotoxic </e2> effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , <e1> iohexol </e1> .
NO_RELATION	The study involved 129 patients with <e2> diabetes </e2> with serum <e1> creatinine </e1> concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .
NO_RELATION	CONCLUSIONS : <e2> Nephropathy </e2> induced by contrast medium may be less likely to develop in high - risk patients when <e1> iodixanol </e1> is used rather than a low - osmolar , nonionic contrast medium .
CID	Experimental cranial <e2> pain </e2> elicited by <e1> capsaicin </e1> : a PET study .
CID	A small amount of <e1> capsaicin </e1> was administered subcutaneously in the right forehead to evoke a burning <e2> painful </e2> sensation in the first division of the trigeminal nerve .
CID	<e2> Neuroleptic malignant syndrome </e2> with <e1> risperidone </e1> .
NO_RELATION	<e2> Neuroleptic malignant syndrome </e2> is thought to be a result of <e1> dopamine </e1> D2 receptor blockade in the striatum of the basal ganglia .
NO_RELATION	The high ratio is believed to impart the low frequency of <e2> extrapyramidal symptoms </e2> with <e1> risperidone </e1> at low dosages .
CID	A 73 - year - old woman developed <e2> neuroleptic malignant syndrome </e2> after monotherapy with <e1> risperidone </e1> .
CID	It appears that the protection from extrapyramidal side effects observed with <e1> risperidone </e1> does not ensure protection from <e2> neuroleptic malignant syndrome </e2> .
NO_RELATION	Plasma concentration and urine excretion of the renin - <e1> angiotensin </e1> system proteins are altered in rats with <e2> nephrotic syndrome </e2> ( NS ) .
NO_RELATION	Plasma concentration and urine excretion of the renin - <e1> angiotensin </e1> system proteins are altered in rats with nephrotic syndrome ( <e2> NS </e2> ) .
CID	<e2> NS </e2> was induced by a single injection of <e1> puromycin amino - nucleoside </e1> ( PAN ) .
CID	<e2> NS </e2> was induced by a single injection of puromycin amino - nucleoside ( <e1> PAN </e1> ) .
CID	Although a great urinary excretion and half - normal plasma levels of Ao were observed on day 6 after <e1> PAN </e1> injection , when <e2> NS </e2> was clearly established , hepatic Ao mRNA levels did not change .
CID	These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute <e2> NS </e2> induced by <e1> PAN </e1> .
CID	<e1> Cyclophosphamide </e1> associated <e2> bladder cancer </e2> - - a highly aggressive disease : analysis of 12 cases .
NO_RELATION	PURPOSE : We gained knowledge of the etiology , treatment and prevention of <e1> cyclophosphamide </e1> associated <e2> urothelial cancer </e2> .
CID	MATERIALS AND METHODS : The medical records of 6 men and 6 women ( mean age 55 years ) with <e1> cyclophosphamide </e1> associated <e2> bladder cancer </e2> were reviewed .
CID	CONCLUSIONS : <e1> Cyclophosphamide </e1> associated <e2> bladder tumor </e2> is an aggressive disease .
CID	<e2> Leg and back pain </e2> after spinal anaesthesia involving hyperbaric 5 % <e1> lignocaine </e1> .
NO_RELATION	Five of the 13 patients ( 38 % ) with <e2> pain </e2> and seven of the 41 patients ( 17 % ) without pain admitted to a high <e1> alcohol </e1> intake , which might be a contributing factor .
NO_RELATION	Five of the 13 patients ( 38 % ) with pain and seven of the 41 patients ( 17 % ) without <e2> pain </e2> admitted to a high <e1> alcohol </e1> intake , which might be a contributing factor .
CID	<e2> Leg and / or back pain </e2> is associated with the intrathecal use of hyperbaric 5 % <e1> lignocaine </e1> .
CID	Acute blood pressure elevations with <e1> caffeine </e1> in men with borderline systemic <e2> hypertension </e2> .
CID	Whether the vasoconstrictive actions of <e1> caffeine </e1> are enhanced in <e2> hypertensive </e2> persons has not been demonstrated .
CID	Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved <e2> hypertensive </e2> BP levels after <e1> caffeine </e1> ingestion .
CID	Thus , in borderline <e2> hypertensive </e2> men , exaggerated responses to <e1> caffeine </e1> were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline hypertensives .
CID	Thus , in borderline hypertensive men , exaggerated responses to <e1> caffeine </e1> were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline <e2> hypertensives </e2> .
CID	<e2> Hallucinations </e2> and <e1> ifosfamide </e1> - induced neurotoxicity .
NO_RELATION	Hallucinations and <e1> ifosfamide </e1> - induced <e2> neurotoxicity </e2> .
CID	BACKGROUND : <e2> Hallucinations </e2> as a symptom of central neurotoxicity are a known but poorly described side effect of <e1> ifosfamide </e1> .
NO_RELATION	BACKGROUND : Hallucinations as a symptom of central <e2> neurotoxicity </e2> are a known but poorly described side effect of <e1> ifosfamide </e1> .
CID	Most cases of <e1> ifosfamide </e1> - induced <e2> hallucinations </e2> have been reported with other mental status changes .
CID	METHODS : The authors interviewed six persons with <e1> ifosfamide </e1> - induced <e2> hallucinations </e2> in the presence of a clear sensorium .
CID	The clinician should be alerted for possible <e1> ifosfamide </e1> - induced <e2> hallucinations </e2> , which may occur without other signs of neurotoxicity .
NO_RELATION	The clinician should be alerted for possible <e1> ifosfamide </e1> - induced hallucinations , which may occur without other signs of <e2> neurotoxicity </e2> .
NO_RELATION	If <e2> agitation </e2> becomes marked , high - potency neuroleptics ( i . e . , <e1> haloperidol </e1> ) may be effective .
CID	<e1> Chlorpropamide </e1> - induced <e2> optic neuropathy </e2> .
NO_RELATION	A 65 - year - old woman with <e2> adult - onset diabetes </e2> treated with <e1> chlorpropamide </e1> ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .
CID	A 65 - year - old woman with adult - onset diabetes treated with <e1> chlorpropamide </e1> ( Diabenese ) had a <e2> toxic optic neuropathy </e2> that resolved with discontinuation of chlorpropamide therapy .
NO_RELATION	A 65 - year - old woman with <e2> adult - onset diabetes </e2> treated with chlorpropamide ( <e1> Diabenese </e1> ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .
CID	A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( <e1> Diabenese </e1> ) had a <e2> toxic optic neuropathy </e2> that resolved with discontinuation of chlorpropamide therapy .
NO_RELATION	A 65 - year - old woman with <e2> adult - onset diabetes </e2> treated with chlorpropamide ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of <e1> chlorpropamide </e1> therapy .
CID	A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( Diabenese ) had a <e2> toxic optic neuropathy </e2> that resolved with discontinuation of <e1> chlorpropamide </e1> therapy .
CID	<e1> Levodopa </e1> - induced <e2> dyskinesia </e2> and thalamotomy .
CID	<e1> Levodopa </e1> - induced <e2> dyskinesia </e2> of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .
NO_RELATION	<e1> Levodopa </e1> - induced dyskinesia of the limbs in thirteen cases of <e2> Parkinsonism </e2> , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .
NO_RELATION	<e1> Levodopa </e1> - induced dyskinesia of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or <e2> dystonic </e2> in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .
CID	Control of <e1> levodopa </e1> - induced <e2> dyskinesias </e2> by thalamic lesions in the course of routine treatment of Parkinsonism is discussed .
NO_RELATION	Control of <e1> levodopa </e1> - induced dyskinesias by <e2> thalamic lesions </e2> in the course of routine treatment of Parkinsonism is discussed .
NO_RELATION	Control of <e1> levodopa </e1> - induced dyskinesias by thalamic lesions in the course of routine treatment of <e2> Parkinsonism </e2> is discussed .
CID	Factors associated with <e2> nephrotoxicity </e2> and clinical outcome in patients receiving <e1> amikacin </e1> .
CID	Data from 60 patients treated with <e1> amikacin </e1> were analyzed for factors associated with <e2> nephrotoxicity </e2> .
CID	Group II also showed a significant decrease of chronic <e2> nephrotoxicity </e2> secondary to long - term therapy with <e1> cyclosporine </e1> .
CID	We think that even these lower dosages of <e1> cyclosporine </e1> can cause chronic <e2> nephrotoxicity </e2> and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .
CID	Reversible <e2> cholestasis </e2> with bile duct injury following <e1> azathioprine </e1> therapy .
CID	Reversible cholestasis with <e2> bile duct injury </e2> following <e1> azathioprine </e1> therapy .
NO_RELATION	A 67 - year - old patient , with primary <e2> polymyositis </e2> and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of <e1> azathioprine </e1> therapy .
NO_RELATION	A 67 - year - old patient , with primary polymyositis and without previous evidence of <e2> liver disease </e2> , developed clinical and biochemical features of severe cholestasis 3 months after initiation of <e1> azathioprine </e1> therapy .
CID	A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe <e2> cholestasis </e2> 3 months after initiation of <e1> azathioprine </e1> therapy .
CID	It is believed that this is the first reported case of reversible <e1> azathioprine </e1> - induced <e2> cholestasis </e2> associated with histological evidence of bile duct injury .
CID	It is believed that this is the first reported case of reversible <e1> azathioprine </e1> - induced cholestasis associated with histological evidence of <e2> bile duct injury </e2> .
CID	Renal function and hemodynamics during prolonged <e1> isoflurane </e1> - induced <e2> hypotension </e2> in humans .
CID	The effect of <e1> isoflurane </e1> - induced <e2> hypotension </e2> on glomerular function and renal blood flow was investigated in 20 human subjects .
CID	<e2> Hypotension </e2> was induced for 236 . 9 + / - 15 . 1 min by increasing the <e1> isoflurane </e1> inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .
CID	We conclude that renal compensatory mechanisms are preserved during <e1> isoflurane </e1> - induced <e2> hypotension </e2> and that renal function and hemodynamics quickly return to normal when normotension is resumed .
NO_RELATION	The drug effect studied was the antagonism by <e1> metoprolol </e1> of terbutaline - induced <e2> hypokalemia </e2> .
CID	The drug effect studied was the antagonism by metoprolol of <e1> terbutaline </e1> - induced <e2> hypokalemia </e2> .
CID	<e1> Cefotetan </e1> - induced immune <e2> hemolytic anemia </e2> .
NO_RELATION	Immune <e2> hemolytic anemia </e2> due to a drug - adsorption mechanism has been described primarily in patients receiving <e1> penicillins </e1> and first - generation cephalosporins .
NO_RELATION	Immune <e2> hemolytic anemia </e2> due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation <e1> cephalosporins </e1> .
NO_RELATION	We describe a patient who developed <e2> anemia </e2> while receiving intravenous <e1> cefotetan </e1> .
CID	<e2> Acute renal failure </e2> subsequent to the administration of <e1> rifampicin </e1> .
NO_RELATION	The patients had developed transient <e2> renal failure </e2> after the intermittent administration of <e1> rifampicin </e1> .
NO_RELATION	<e2> Hepatitis B </e2> immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to <e1> hepatitis B surface antigen </e1> ( HBsAG ) - positive donors .
NO_RELATION	Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing <e2> type B hepatitis </e2> after needle - stick exposure to <e1> hepatitis B surface antigen </e1> ( HBsAG ) - positive donors .
NO_RELATION	<e2> Hepatitis B </e2> immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to hepatitis B surface antigen ( <e1> HBsAG </e1> ) - positive donors .
NO_RELATION	Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing <e2> type B hepatitis </e2> after needle - stick exposure to hepatitis B surface antigen ( <e1> HBsAG </e1> ) - positive donors .
CID	<e2> Serotonin syndrome </e2> from <e1> venlafaxine </e1> - tranylcypromine interaction .
CID	<e2> Serotonin syndrome </e2> from venlafaxine - <e1> tranylcypromine </e1> interaction .
NO_RELATION	Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , <e2> muscle rigidity </e2> , salivation , confusion , agitation and hyperthermia .
NO_RELATION	Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , <e2> salivation </e2> , confusion , agitation and hyperthermia .
NO_RELATION	Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , <e2> confusion </e2> , agitation and hyperthermia .
NO_RELATION	Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , <e2> agitation </e2> and hyperthermia .
NO_RELATION	Excessive stimulation of <e1> serotonin </e1> 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and <e2> hyperthermia </e2> .
NO_RELATION	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering , <e2> muscle rigidity </e2> , salivation , confusion , agitation and hyperthermia .
NO_RELATION	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering , muscle rigidity , <e2> salivation </e2> , confusion , agitation and hyperthermia .
NO_RELATION	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering , muscle rigidity , salivation , <e2> confusion </e2> , agitation and hyperthermia .
NO_RELATION	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering , muscle rigidity , salivation , confusion , <e2> agitation </e2> and hyperthermia .
NO_RELATION	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of <e1> serotonin </e1> excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and <e2> hyperthermia </e2> .
CID	We report a <e1> venlafaxine </e1> - MAOI interaction that resulted in the <e2> serotonin syndrome </e2> in a 23 - y - old male who was taking tranylcypromine for depression .
NO_RELATION	We report a <e1> venlafaxine </e1> - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking tranylcypromine for <e2> depression </e2> .
CID	We report a venlafaxine - MAOI interaction that resulted in the <e2> serotonin syndrome </e2> in a 23 - y - old male who was taking <e1> tranylcypromine </e1> for depression .
NO_RELATION	We report a venlafaxine - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking <e1> tranylcypromine </e1> for <e2> depression </e2> .
NO_RELATION	Effect of nondopaminergic drugs on <e1> L - dopa </e1> - induced <e2> dyskinesias </e2> in MPTP - treated monkeys .
NO_RELATION	Effect of nondopaminergic drugs on L - dopa - induced <e2> dyskinesias </e2> in <e1> MPTP </e1> - treated monkeys .
CID	A group of four monkeys was rendered <e2> parkinsonian </e2> with the toxin <e1> MPTP </e1> .
NO_RELATION	A series of agents acting primarily on neurotransmitters other than <e1> dopamine </e1> were then tested in combination with L - DOPA to see if the <e2> dyskinetic </e2> movements would be modified .
NO_RELATION	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with <e1> L - DOPA </e1> to see if the <e2> dyskinetic </e2> movements would be modified .
NO_RELATION	Several drugs , including <e1> clonidine </e1> , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology .
NO_RELATION	Several drugs , including <e1> clonidine </e1> , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology .
NO_RELATION	Several drugs , including clonidine , <e1> physostigmine </e1> , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology .
NO_RELATION	Several drugs , including clonidine , <e1> physostigmine </e1> , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology .
NO_RELATION	Several drugs , including clonidine , physostigmine , <e1> methysergide </e1> , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology .
NO_RELATION	Several drugs , including clonidine , physostigmine , <e1> methysergide </e1> , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology .
NO_RELATION	Several drugs , including clonidine , physostigmine , methysergide , <e1> 5 - MDOT </e1> , propranolol , and MK - 801 , markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology .
NO_RELATION	Several drugs , including clonidine , physostigmine , methysergide , <e1> 5 - MDOT </e1> , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology .
NO_RELATION	Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , <e1> propranolol </e1> , and MK - 801 , markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology .
NO_RELATION	Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , <e1> propranolol </e1> , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology .
NO_RELATION	Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and <e1> MK - 801 </e1> , markedly reduced the <e2> dyskinetic </e2> movements but at the cost of a return of parkinsonian symptomatology .
NO_RELATION	Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and <e1> MK - 801 </e1> , markedly reduced the dyskinetic movements but at the cost of a return of <e2> parkinsonian </e2> symptomatology .
NO_RELATION	However , <e1> yohimbine </e1> and meperidine reduced predominantly the <e2> dyskinetic </e2> movements .
NO_RELATION	However , yohimbine and <e1> meperidine </e1> reduced predominantly the <e2> dyskinetic </e2> movements .
NO_RELATION	<e1> Baclofen </e1> was also useful in one monkey against a more <e2> dystonic </e2> form of dyskinesia .
NO_RELATION	<e1> Baclofen </e1> was also useful in one monkey against a more dystonic form of <e2> dyskinesia </e2> .
NO_RELATION	<e1> Atropine </e1> converted the <e2> dystonic </e2> movements into chorea .
NO_RELATION	<e1> Atropine </e1> converted the dystonic movements into <e2> chorea </e2> .
NO_RELATION	<e1> CCNU </e1> ( lomustine ) <e2> toxicity </e2> in dogs : a retrospective study ( 2002 - 07 ) .
NO_RELATION	CCNU ( <e1> lomustine </e1> ) <e2> toxicity </e2> in dogs : a retrospective study ( 2002 - 07 ) .
NO_RELATION	OBJECTIVE : To describe the incidence of <e2> haematological , renal , hepatic and gastrointestinal toxicities </e2> in tumour - bearing dogs receiving <e1> 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea </e1> ( CCNU ) .
NO_RELATION	OBJECTIVE : To describe the incidence of <e2> haematological , renal , hepatic and gastrointestinal toxicities </e2> in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( <e1> CCNU </e1> ) .
NO_RELATION	RESULTS : Of the 206 dogs treated with <e1> CCNU </e1> , 185 met the inclusion criteria for at least one class of <e2> toxicity </e2> .
NO_RELATION	<e1> CCNU </e1> was used most commonly in the treatment of <e2> lymphoma </e2> , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .
NO_RELATION	<e1> CCNU </e1> was used most commonly in the treatment of lymphoma , <e2> mast cell tumour </e2> , brain tumour , histiocytic tumours and epitheliotropic lymphoma .
NO_RELATION	<e1> CCNU </e1> was used most commonly in the treatment of lymphoma , mast cell tumour , <e2> brain tumour </e2> , histiocytic tumours and epitheliotropic lymphoma .
NO_RELATION	<e1> CCNU </e1> was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , <e2> histiocytic tumours </e2> and epitheliotropic lymphoma .
NO_RELATION	<e1> CCNU </e1> was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and <e2> epitheliotropic lymphoma </e2> .
NO_RELATION	Potential renal <e2> toxicity </e2> and elevated <e1> alanine </e1> transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .
NO_RELATION	CONCLUSIONS : <e1> CCNU </e1> - associated <e2> toxicity </e2> in dogs is common , but is usually not life threatening .
NO_RELATION	Neuroactive <e1> steroids </e1> protect against pilocarpine - and kainic acid - induced limbic <e2> seizures </e2> and status epilepticus in mice .
NO_RELATION	Neuroactive <e1> steroids </e1> protect against pilocarpine - and kainic acid - induced limbic seizures and <e2> status epilepticus </e2> in mice .
CID	Neuroactive steroids protect against <e1> pilocarpine </e1> - and kainic acid - induced limbic <e2> seizures </e2> and status epilepticus in mice .
CID	Neuroactive steroids protect against <e1> pilocarpine </e1> - and kainic acid - induced limbic seizures and <e2> status epilepticus </e2> in mice .
CID	Neuroactive steroids protect against pilocarpine - and <e1> kainic acid </e1> - induced limbic <e2> seizures </e2> and status epilepticus in mice .
CID	Neuroactive steroids protect against pilocarpine - and <e1> kainic acid </e1> - induced limbic seizures and <e2> status epilepticus </e2> in mice .
NO_RELATION	Several structurally related metabolites of <e1> progesterone </e1> ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced <e2> seizures </e2> in mice .
NO_RELATION	Several structurally related metabolites of progesterone ( <e1> 3 alpha - hydroxy pregnane - 20 - ones </e1> ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced <e2> seizures </e2> in mice .
NO_RELATION	Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and <e1> deoxycorticosterone </e1> ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced <e2> seizures </e2> in mice .
NO_RELATION	Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( <e1> 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones </e1> ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced <e2> seizures </e2> in mice .
CID	Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against <e1> pilocarpine </e1> - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced <e2> seizures </e2> in mice .
CID	Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , <e1> kainic acid </e1> - and N - methyl - D - aspartate ( NMDA ) - induced <e2> seizures </e2> in mice .
NO_RELATION	Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and <e1> N - methyl - D - aspartate </e1> ( NMDA ) - induced <e2> seizures </e2> in mice .
NO_RELATION	Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( <e1> NMDA </e1> ) - induced <e2> seizures </e2> in mice .
NO_RELATION	<e1> Steroids </e1> with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor <e2> seizures </e2> and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .
NO_RELATION	<e1> Steroids </e1> with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor seizures and <e2> status epilepticus </e2> ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .
CID	Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against <e1> pilocarpine </e1> ( 416 mg / kg , s . c . ) - induced limbic motor <e2> seizures </e2> and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .
CID	Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against <e1> pilocarpine </e1> ( 416 mg / kg , s . c . ) - induced limbic motor seizures and <e2> status epilepticus </e2> ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .
NO_RELATION	Although the neuroactive <e1> steroids </e1> were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine <e2> seizures </e2> , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive <e1> steroids </e1> were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive <e1> steroids </e1> were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2> .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the <e1> benzodiazepine </e1> clonazepam in protecting against pilocarpine <e2> seizures </e2> , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the <e1> benzodiazepine </e1> clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the <e1> benzodiazepine </e1> clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2> .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine <e1> clonazepam </e1> in protecting against pilocarpine <e2> seizures </e2> , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine <e1> clonazepam </e1> in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine <e1> clonazepam </e1> in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2> .
CID	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against <e1> pilocarpine </e1> <e2> seizures </e2> , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
CID	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against <e1> pilocarpine </e1> seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against <e1> pilocarpine </e1> seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2> .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine <e2> seizures </e2> , <e1> steroids </e1> with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , <e1> steroids </e1> with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , <e1> steroids </e1> with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2> .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine <e2> seizures </e2> , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than <e1> clonazepam </e1> , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection ) than <e1> clonazepam </e1> , indicating that some neuroactive steroids may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than <e1> clonazepam </e1> , indicating that some neuroactive steroids may have lower relative <e2> toxicity </e2> .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine <e2> seizures </e2> , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive <e1> steroids </e1> may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for <e2> seizure </e2> protection ) than clonazepam , indicating that some neuroactive <e1> steroids </e1> may have lower relative toxicity .
NO_RELATION	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive <e1> steroids </e1> may have lower relative <e2> toxicity </e2> .
NO_RELATION	<e1> Steroids </e1> with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic <e2> seizures </e2> induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .
NO_RELATION	<e1> Steroids </e1> with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the <e2> seizures </e2> .
CID	Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic <e2> seizures </e2> induced by <e1> kainic acid </e1> ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .
CID	Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by <e1> kainic acid </e1> ( 32 mg / kg , s . c . ) , but did not completely protect against the <e2> seizures </e2> .
NO_RELATION	However , when a second dose of the <e1> steroid </e1> was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic <e2> seizures </e2> and status epilepticus was obtained .
NO_RELATION	However , when a second dose of the <e1> steroid </e1> was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic seizures and <e2> status epilepticus </e2> was obtained .
CID	However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the <e1> kainic acid </e1> - induced limbic <e2> seizures </e2> and status epilepticus was obtained .
CID	However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the <e1> kainic acid </e1> - induced limbic seizures and <e2> status epilepticus </e2> was obtained .
NO_RELATION	The <e1> steroids </e1> also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA <e2> seizures </e2> or lethality .
NO_RELATION	The steroids also caused a dose - dependent delay in <e1> NMDA </e1> ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA <e2> seizures </e2> or lethality .
NO_RELATION	The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against <e1> NMDA </e1> <e2> seizures </e2> or lethality .
NO_RELATION	We conclude that neuroactive <e1> steroids </e1> are highly effective in protecting against pilocarpine - and kainic acid - induced <e2> seizures </e2> and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .
NO_RELATION	We conclude that neuroactive <e1> steroids </e1> are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and <e2> status epilepticus </e2> in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .
NO_RELATION	We conclude that neuroactive <e1> steroids </e1> are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of <e2> status epilepticus </e2> in humans .
CID	We conclude that neuroactive steroids are highly effective in protecting against <e1> pilocarpine </e1> - and kainic acid - induced <e2> seizures </e2> and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .
CID	We conclude that neuroactive steroids are highly effective in protecting against <e1> pilocarpine </e1> - and kainic acid - induced seizures and <e2> status epilepticus </e2> in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .
CID	We conclude that neuroactive steroids are highly effective in protecting against <e1> pilocarpine </e1> - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of <e2> status epilepticus </e2> in humans .
CID	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and <e1> kainic acid </e1> - induced <e2> seizures </e2> and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .
CID	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and <e1> kainic acid </e1> - induced seizures and <e2> status epilepticus </e2> in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .
CID	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and <e1> kainic acid </e1> - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of <e2> status epilepticus </e2> in humans .
NO_RELATION	The safety and efficacy of combination <e1> N - butyl - deoxynojirimycin </e1> ( SC - 48334 ) and zidovudine in patients with <e2> HIV - 1 infection </e2> and 200 - 500 CD4 cells / mm3 .
NO_RELATION	The safety and efficacy of combination N - butyl - deoxynojirimycin ( <e1> SC - 48334 </e1> ) and zidovudine in patients with <e2> HIV - 1 infection </e2> and 200 - 500 CD4 cells / mm3 .
NO_RELATION	The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and <e1> zidovudine </e1> in patients with <e2> HIV - 1 infection </e2> and 200 - 500 CD4 cells / mm3 .
NO_RELATION	The mean <e1> SC - 48334 </e1> steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human <e2> immunodeficiency </e2> virus ( HIV ) .
NO_RELATION	<e1> CB 3717 </e1> , N10 - propargyl - 5 , 8 - dideazafolic acid , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose <e2> cytotoxicity </e2> is mediated solely through the inhibition of this enzyme .
NO_RELATION	CB 3717 , <e1> N10 - propargyl - 5 , 8 - dideazafolic acid </e1> , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose <e2> cytotoxicity </e2> is mediated solely through the inhibition of this enzyme .
NO_RELATION	As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than <e1> CB 3717 </e1> , respectively , and their formation may , therefore , be an important determinant of CB 3717 <e2> cytotoxicity </e2> .
NO_RELATION	As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than CB 3717 , respectively , and their formation may , therefore , be an important determinant of <e1> CB 3717 </e1> <e2> cytotoxicity </e2> .
NO_RELATION	In early clinical studies with <e1> CB 3717 </e1> , activity has been seen in <e2> breast cancer </e2> , ovarian cancer , hepatoma , and mesothelioma .
NO_RELATION	In early clinical studies with <e1> CB 3717 </e1> , activity has been seen in breast cancer , <e2> ovarian cancer </e2> , hepatoma , and mesothelioma .
NO_RELATION	In early clinical studies with <e1> CB 3717 </e1> , activity has been seen in breast cancer , ovarian cancer , <e2> hepatoma </e2> , and mesothelioma .
NO_RELATION	In early clinical studies with <e1> CB 3717 </e1> , activity has been seen in breast cancer , ovarian cancer , hepatoma , and <e2> mesothelioma </e2> .
NO_RELATION	<e1> Ethopropazine </e1> and benztropine in neuroleptic - induced <e2> parkinsonism </e2> .
NO_RELATION	Ethopropazine and <e1> benztropine </e1> in neuroleptic - induced <e2> parkinsonism </e2> .
NO_RELATION	In a 12 - week controlled study <e1> ethopropazine </e1> was compared to benztropine in the treatment of <e2> parkinsonism </e2> induced by fluphenazine enanthate in 60 schizophrenic outpatients .
NO_RELATION	In a 12 - week controlled study <e1> ethopropazine </e1> was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 <e2> schizophrenic </e2> outpatients .
NO_RELATION	In a 12 - week controlled study ethopropazine was compared to <e1> benztropine </e1> in the treatment of <e2> parkinsonism </e2> induced by fluphenazine enanthate in 60 schizophrenic outpatients .
NO_RELATION	In a 12 - week controlled study ethopropazine was compared to <e1> benztropine </e1> in the treatment of parkinsonism induced by fluphenazine enanthate in 60 <e2> schizophrenic </e2> outpatients .
CID	In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of <e2> parkinsonism </e2> induced by <e1> fluphenazine enanthate </e1> in 60 schizophrenic outpatients .
NO_RELATION	In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by <e1> fluphenazine enanthate </e1> in 60 <e2> schizophrenic </e2> outpatients .
NO_RELATION	<e1> Ethopropazine </e1> and benztropine were found to be equally effective in controlling <e2> parkinsonian symptoms </e2> and were as efficacious as procyclidine , their previous antiparkinsonian drug .
NO_RELATION	Ethopropazine and <e1> benztropine </e1> were found to be equally effective in controlling <e2> parkinsonian symptoms </e2> and were as efficacious as procyclidine , their previous antiparkinsonian drug .
NO_RELATION	Ethopropazine and benztropine were found to be equally effective in controlling <e2> parkinsonian symptoms </e2> and were as efficacious as <e1> procyclidine </e1> , their previous antiparkinsonian drug .
CID	However , <e1> benztropine </e1> treated patients had a significant increase in <e2> tardive dyskinesia </e2> compared to their condition during procyclindine treatment , and significantly more anxiety and depression than ethopropazine treated patients .
CID	However , <e1> benztropine </e1> treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more <e2> anxiety </e2> and depression than ethopropazine treated patients .
CID	However , <e1> benztropine </e1> treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and <e2> depression </e2> than ethopropazine treated patients .
NO_RELATION	However , benztropine treated patients had a significant increase in <e2> tardive dyskinesia </e2> compared to their condition during <e1> procyclindine </e1> treatment , and significantly more anxiety and depression than ethopropazine treated patients .
NO_RELATION	However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during <e1> procyclindine </e1> treatment , and significantly more <e2> anxiety </e2> and depression than ethopropazine treated patients .
NO_RELATION	However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during <e1> procyclindine </e1> treatment , and significantly more anxiety and <e2> depression </e2> than ethopropazine treated patients .
NO_RELATION	However , benztropine treated patients had a significant increase in <e2> tardive dyskinesia </e2> compared to their condition during procyclindine treatment , and significantly more anxiety and depression than <e1> ethopropazine </e1> treated patients .
NO_RELATION	However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more <e2> anxiety </e2> and depression than <e1> ethopropazine </e1> treated patients .
NO_RELATION	However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and <e2> depression </e2> than <e1> ethopropazine </e1> treated patients .
NO_RELATION	This suggests that <e1> benztropine </e1> is not the anticholinergic drug of choice in the treatment of neuroleptic - induced <e2> parkinsonian symptoms </e2> , because of its more toxic central and peripheral atropinic effect .
NO_RELATION	Effect of <e1> alpha - tocopherol </e1> and deferoxamine on methamphetamine - induced <e2> neurotoxicity </e2> .
NO_RELATION	Effect of alpha - tocopherol and <e1> deferoxamine </e1> on methamphetamine - induced <e2> neurotoxicity </e2> .
NO_RELATION	Effect of alpha - tocopherol and deferoxamine on <e1> methamphetamine </e1> - induced <e2> neurotoxicity </e2> .
NO_RELATION	<e1> Methamphetamine </e1> ( MA ) - induced dopaminergic <e2> neurotoxicity </e2> is believed to be associated with the increased formation of free radicals .
NO_RELATION	Methamphetamine ( <e1> MA </e1> ) - induced dopaminergic <e2> neurotoxicity </e2> is believed to be associated with the increased formation of free radicals .
NO_RELATION	This study examined the effect of <e1> alpha - tocopherol </e1> ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced <e2> neurotoxicity </e2> .
NO_RELATION	This study examined the effect of alpha - tocopherol ( <e1> alpha - TC </e1> ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced <e2> neurotoxicity </e2> .
NO_RELATION	This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive <e1> oxygen </e1> species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced <e2> neurotoxicity </e2> .
NO_RELATION	This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and <e1> deferoxamine </e1> ( DFO ) , an iron chelator , on the MA - induced <e2> neurotoxicity </e2> .
NO_RELATION	This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( <e1> DFO </e1> ) , an iron chelator , on the MA - induced <e2> neurotoxicity </e2> .
NO_RELATION	This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an <e1> iron </e1> chelator , on the MA - induced <e2> neurotoxicity </e2> .
NO_RELATION	This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the <e1> MA </e1> - induced <e2> neurotoxicity </e2> .
NO_RELATION	<e1> alpha - TC </e1> and DFO attenuated the MA - induced <e2> hyperthermia </e2> as well as the alterations in the locomotor activity .
NO_RELATION	alpha - TC and <e1> DFO </e1> attenuated the MA - induced <e2> hyperthermia </e2> as well as the alterations in the locomotor activity .
CID	alpha - TC and DFO attenuated the <e1> MA </e1> - induced <e2> hyperthermia </e2> as well as the alterations in the locomotor activity .
NO_RELATION	This suggests that <e1> alpha - TC </e1> and DFO ameliorate the MA - induced <e2> neuronal damage </e2> by decreasing the level of oxidative stress .
NO_RELATION	This suggests that alpha - TC and <e1> DFO </e1> ameliorate the MA - induced <e2> neuronal damage </e2> by decreasing the level of oxidative stress .
CID	This suggests that alpha - TC and DFO ameliorate the <e1> MA </e1> - induced <e2> neuronal damage </e2> by decreasing the level of oxidative stress .
NO_RELATION	Use of <e1> dexamethasone </e1> with mesna for the prevention of ifosfamide - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	Use of dexamethasone with <e1> mesna </e1> for the prevention of ifosfamide - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	Use of dexamethasone with mesna for the prevention of <e1> ifosfamide </e1> - induced <e2> hemorrhagic cystitis </e2> .
NO_RELATION	AIM : <e2> Hemorrhagic cystitis </e2> ( HC ) is a limiting side - effect of chemotherapy with <e1> ifosfamide </e1> ( IFS ) .
NO_RELATION	AIM : Hemorrhagic cystitis ( <e2> HC </e2> ) is a limiting side - effect of chemotherapy with <e1> ifosfamide </e1> ( IFS ) .
NO_RELATION	AIM : <e2> Hemorrhagic cystitis </e2> ( HC ) is a limiting side - effect of chemotherapy with ifosfamide ( <e1> IFS </e1> ) .
NO_RELATION	AIM : Hemorrhagic cystitis ( <e2> HC </e2> ) is a limiting side - effect of chemotherapy with ifosfamide ( <e1> IFS </e1> ) .
NO_RELATION	In the study presented here , we investigated the use of <e1> dexamethasone </e1> in combination with mesna for the prevention of IFS - induced <e2> HC </e2> .
NO_RELATION	In the study presented here , we investigated the use of dexamethasone in combination with <e1> mesna </e1> for the prevention of IFS - induced <e2> HC </e2> .
NO_RELATION	In the study presented here , we investigated the use of dexamethasone in combination with mesna for the prevention of <e1> IFS </e1> - induced <e2> HC </e2> .
NO_RELATION	CONCLUSION : <e1> Dexamethasone </e1> in combination with mesna was efficient in blocking IFS - induced <e2> HC </e2> .
NO_RELATION	CONCLUSION : Dexamethasone in combination with <e1> mesna </e1> was efficient in blocking IFS - induced <e2> HC </e2> .
NO_RELATION	CONCLUSION : Dexamethasone in combination with mesna was efficient in blocking <e1> IFS </e1> - induced <e2> HC </e2> .
NO_RELATION	However , the replacement of last two doses of <e1> mesna </e1> with saline or all of the mesna doses with dexamethasone did not prevent <e2> HC </e2> .
NO_RELATION	However , the replacement of last two doses of mesna with saline or all of the <e1> mesna </e1> doses with dexamethasone did not prevent <e2> HC </e2> .
NO_RELATION	However , the replacement of last two doses of mesna with saline or all of the mesna doses with <e1> dexamethasone </e1> did not prevent <e2> HC </e2> .
NO_RELATION	<e1> Reserpine </e1> ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in <e2> orofacial dyskinesia </e2> , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .
CID	<e1> Reserpine </e1> ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of <e2> tardive dyskinesia </e2> .
CID	<e1> Reserpine </e1> also produced <e2> tremor </e2> and catalepsy , which are signs suggestive of Parkinson ' s disease .
CID	<e1> Reserpine </e1> also produced tremor and <e2> catalepsy </e2> , which are signs suggestive of Parkinson ' s disease .
NO_RELATION	<e1> Reserpine </e1> also produced tremor and catalepsy , which are signs suggestive of <e2> Parkinson ' s disease </e2> .
NO_RELATION	<e1> MK - 801 </e1> ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and <e2> catalepsy </e2> induced by reserpine .
CID	MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and <e2> catalepsy </e2> induced by <e1> reserpine </e1> .
NO_RELATION	However , <e1> MK - 801 </e1> injection produced a significant increase of <e2> tremor </e2> in reserpine - treated mice .
CID	However , MK - 801 injection produced a significant increase of <e2> tremor </e2> in <e1> reserpine </e1> - treated mice .
NO_RELATION	<e1> Reserpine </e1> ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce <e2> oral dyskinesia </e2> in mice .
NO_RELATION	Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by <e1> apomophine </e1> injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce <e2> oral dyskinesia </e2> in mice .
CID	On the other hand , <e1> reserpine </e1> induced increases in <e2> tremor </e2> and catalepsy compared to control mice .
CID	On the other hand , <e1> reserpine </e1> induced increases in tremor and <e2> catalepsy </e2> compared to control mice .
NO_RELATION	<e1> MK - 801 </e1> ( 0 . 1 mg / kg ) administration attenuated the <e2> catalepsy </e2> and tremor induced by reserpine .
NO_RELATION	<e1> MK - 801 </e1> ( 0 . 1 mg / kg ) administration attenuated the catalepsy and <e2> tremor </e2> induced by reserpine .
CID	MK - 801 ( 0 . 1 mg / kg ) administration attenuated the <e2> catalepsy </e2> and tremor induced by <e1> reserpine </e1> .
CID	MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and <e2> tremor </e2> induced by <e1> reserpine </e1> .
CID	Pretreatment with <e1> reserpine </e1> ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in <e2> tremor </e2> and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .
CID	Pretreatment with <e1> reserpine </e1> ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and <e2> catalepsy </e2> , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .
NO_RELATION	Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in <e2> tremor </e2> and catalepsy , whereas <e1> MK - 801 </e1> ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .
NO_RELATION	Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and <e2> catalepsy </e2> , whereas <e1> MK - 801 </e1> ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .
CID	Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in <e2> tremor </e2> and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of <e1> reserpine </e1> .
CID	Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and <e2> catalepsy </e2> , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of <e1> reserpine </e1> .
CID	These results show that <e1> reserpine </e1> produces different and <e2> abnormal movements </e2> , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .
NO_RELATION	These results show that <e1> reserpine </e1> produces different and abnormal movements , which are related to dose and schedule employed and can be considered as <e2> parkinsonian </e2> - like and tardive dsykinesia signs .
CID	These results show that <e1> reserpine </e1> produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and <e2> tardive dsykinesia </e2> signs .
NO_RELATION	The glutamatergic blockage produced by <e1> NMDA </e1> can restore these signs , such as vacuous chewing movements , tongue protrusions , <e2> catalepsy </e2> and tremor according to the employed model .
NO_RELATION	The glutamatergic blockage produced by <e1> NMDA </e1> can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and <e2> tremor </e2> according to the employed model .
NO_RELATION	Effect of <e1> glyceryl trinitrate </e1> on the <e2> sphincter of Oddi spasm </e2> evoked by prostigmine - morphine administration .
NO_RELATION	Effect of glyceryl trinitrate on the <e2> sphincter of Oddi spasm </e2> evoked by <e1> prostigmine </e1> - morphine administration .
NO_RELATION	Effect of glyceryl trinitrate on the <e2> sphincter of Oddi spasm </e2> evoked by prostigmine - <e1> morphine </e1> administration .
NO_RELATION	OBJECTIVE : In this study the effect of <e1> glyceryl trinitrate </e1> on the prostigmine - morphine - induced <e2> sphincter of Oddi spasm </e2> was evaluated in nine female patients with sphincter of Oddi dyskinesia .
NO_RELATION	OBJECTIVE : In this study the effect of <e1> glyceryl trinitrate </e1> on the prostigmine - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with <e2> sphincter of Oddi dyskinesia </e2> .
NO_RELATION	OBJECTIVE : In this study the effect of glyceryl trinitrate on the <e1> prostigmine </e1> - morphine - induced <e2> sphincter of Oddi spasm </e2> was evaluated in nine female patients with sphincter of Oddi dyskinesia .
CID	OBJECTIVE : In this study the effect of glyceryl trinitrate on the <e1> prostigmine </e1> - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with <e2> sphincter of Oddi dyskinesia </e2> .
NO_RELATION	OBJECTIVE : In this study the effect of glyceryl trinitrate on the prostigmine - <e1> morphine </e1> - induced <e2> sphincter of Oddi spasm </e2> was evaluated in nine female patients with sphincter of Oddi dyskinesia .
CID	OBJECTIVE : In this study the effect of glyceryl trinitrate on the prostigmine - <e1> morphine </e1> - induced sphincter of Oddi spasm was evaluated in nine female patients with <e2> sphincter of Oddi dyskinesia </e2> .
NO_RELATION	METHOD : <e2> Sphincter of Oddi spasm </e2> was induced by <e1> prostigmine </e1> - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .
NO_RELATION	METHOD : <e2> Sphincter of Oddi spasm </e2> was induced by prostigmine - <e1> morphine </e1> administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .
NO_RELATION	METHOD : <e2> Sphincter of Oddi spasm </e2> was induced by prostigmine - morphine administration ( 0 . 5 mg <e1> prostigmine </e1> intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .
NO_RELATION	METHOD : <e2> Sphincter of Oddi spasm </e2> was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg <e1> morphine </e1> subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .
NO_RELATION	CONCLUSION : These results provide the first evidence of the effectiveness of <e1> glyceryl trinitrate </e1> on the morphine - induced <e2> sphincter of Oddi spasm </e2> in humans .
NO_RELATION	CONCLUSION : These results provide the first evidence of the effectiveness of glyceryl trinitrate on the <e1> morphine </e1> - induced <e2> sphincter of Oddi spasm </e2> in humans .
NO_RELATION	Since <e1> glyceryl trinitrate </e1> is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of <e2> sphincter of Oddi dyskinesia </e2> .
CID	Since glyceryl trinitrate is able to overcome even the drastic effect of <e1> morphine </e1> , it might be of relevance in the treatment of <e2> sphincter of Oddi dyskinesia </e2> .
NO_RELATION	Occasional case reports have shown that acute <e2> myopathy </e2> may occur in patients treated with massive doses of <e1> corticosteroids </e1> .
NO_RELATION	Nutritional intake , measured daily in 15 animals , showed a significant <e2> reduction of food intake </e2> in the <e1> steroid </e1> - treated groups ( - 50 and - 79 % in M and T , respectively ) .
CID	Nutritional intake , measured daily in 15 animals , showed a significant <e2> reduction of food intake </e2> in the steroid - treated groups ( - 50 and - 79 % in <e1> M </e1> and T , respectively ) .
CID	Nutritional intake , measured daily in 15 animals , showed a significant <e2> reduction of food intake </e2> in the steroid - treated groups ( - 50 and - 79 % in M and <e1> T </e1> , respectively ) .
NO_RELATION	Half - relaxation time was prolonged in both <e1> steroid </e1> groups , and time to peak tension was longer with M , whereas <e2> tetanic </e2> tensions were similar .
NO_RELATION	Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with <e1> M </e1> , whereas <e2> tetanic </e2> tensions were similar .
NO_RELATION	ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber <e2> atrophy </e2> in the <e1> steroid </e1> groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .
NO_RELATION	ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the <e1> steroid </e1> groups and also diaphragmatic type IIa <e2> atrophy </e2> with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .
NO_RELATION	ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the <e1> steroid </e1> groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of <e2> necrosis </e2> .
CID	ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber <e2> atrophy </e2> in the steroid groups and also diaphragmatic type IIa atrophy with <e1> T </e1> , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .
CID	ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa <e2> atrophy </e2> with <e1> T </e1> , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .
NO_RELATION	ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with <e1> T </e1> , whereas histologic examinations revealed a normal muscular pattern with absence of <e2> necrosis </e2> .
CID	Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , <e1> T </e1> , and PF ) , showed that <e2> muscle atrophy </e2> was considerably less pronounced in PF animals than in T - treated animals .
CID	Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that <e2> muscle atrophy </e2> was considerably less pronounced in PF animals than in <e1> T </e1> - treated animals .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of <e1> steroids </e1> induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb <e2> atrophy </e2> , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of <e1> steroids </e1> induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle <e2> necrosis </e2> ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of <e1> steroids </e1> induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb <e2> atrophy </e2> was not caused by acute nutritional deprivation alone .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of <e1> steroids </e1> induced predominantly type IIb <e2> atrophy </e2> , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of <e1> steroids </e1> induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle <e2> necrosis </e2> ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of <e1> steroids </e1> induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb <e2> atrophy </e2> was not caused by acute nutritional deprivation alone .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb <e2> atrophy </e2> , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither <e1> steroid </e1> caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither <e1> steroid </e1> caused muscle <e2> necrosis </e2> ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .
NO_RELATION	We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither <e1> steroid </e1> caused muscle necrosis ; ( 4 ) type IIb <e2> atrophy </e2> was not caused by acute nutritional deprivation alone .
NO_RELATION	Refractory <e2> cardiogenic shock </e2> and complete heart block after <e1> verapamil </e1> SR and metoprolol treatment .
CID	Refractory cardiogenic shock and complete <e2> heart block </e2> after <e1> verapamil </e1> SR and metoprolol treatment .
NO_RELATION	Refractory <e2> cardiogenic shock </e2> and complete heart block after verapamil SR and <e1> metoprolol </e1> treatment .
CID	Refractory cardiogenic shock and complete <e2> heart block </e2> after verapamil SR and <e1> metoprolol </e1> treatment .
CID	A seventy - eight - year - old woman presented with complete <e2> heart block </e2> and refractory hypotension two days after a therapeutic dose of sustained - release <e1> verapamil </e1> with concomitant use of metoprolol .
CID	A seventy - eight - year - old woman presented with complete heart block and refractory <e2> hypotension </e2> two days after a therapeutic dose of sustained - release <e1> verapamil </e1> with concomitant use of metoprolol .
CID	A seventy - eight - year - old woman presented with complete <e2> heart block </e2> and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of <e1> metoprolol </e1> .
CID	A seventy - eight - year - old woman presented with complete heart block and refractory <e2> hypotension </e2> two days after a therapeutic dose of sustained - release verapamil with concomitant use of <e1> metoprolol </e1> .
NO_RELATION	The patient continued to remain <e2> hypotensive </e2> with complete heart block , even with multiple uses of intravenous <e1> atropine </e1> as well as high doses of pressor agents such as dopamine and dobutamine .
NO_RELATION	The patient continued to remain hypotensive with complete <e2> heart block </e2> , even with multiple uses of intravenous <e1> atropine </e1> as well as high doses of pressor agents such as dopamine and dobutamine .
NO_RELATION	The patient continued to remain <e2> hypotensive </e2> with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as <e1> dopamine </e1> and dobutamine .
NO_RELATION	The patient continued to remain hypotensive with complete <e2> heart block </e2> , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as <e1> dopamine </e1> and dobutamine .
NO_RELATION	The patient continued to remain <e2> hypotensive </e2> with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and <e1> dobutamine </e1> .
NO_RELATION	The patient continued to remain hypotensive with complete <e2> heart block </e2> , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and <e1> dobutamine </e1> .
NO_RELATION	However , shortly after the use of intravenous <e1> calcium chloride </e1> , the refractory <e2> hypotension </e2> and complete heart block resolved .
NO_RELATION	However , shortly after the use of intravenous <e1> calcium chloride </e1> , the refractory hypotension and complete <e2> heart block </e2> resolved .
NO_RELATION	Extensive experimental and limited clinical data have shown that <e1> lometrexol </e1> has activity against <e2> tumours </e2> which are refractory to other drugs , notably methotrexate .
NO_RELATION	Extensive experimental and limited clinical data have shown that lometrexol has activity against <e2> tumours </e2> which are refractory to other drugs , notably <e1> methotrexate </e1> .
NO_RELATION	However , the initial clinical development of <e1> lometrexol </e1> was curtailed because of severe and cumulative antiproliferative <e2> toxicities </e2> .
NO_RELATION	Preclinical murine studies demonstrated that the <e2> toxicity </e2> of <e1> lometrexol </e1> can be prevented by low dose folic acid administration , i . e .
NO_RELATION	Preclinical murine studies demonstrated that the <e2> toxicity </e2> of lometrexol can be prevented by low dose <e1> folic acid </e1> administration , i . e .
NO_RELATION	This observation prompted a Phase I clinical study of <e1> lometrexol </e1> given with folic acid supplementation which has confirmed that the <e2> toxicity </e2> of lometrexol can be markedly reduced by folic acid supplementation .
NO_RELATION	This observation prompted a Phase I clinical study of lometrexol given with <e1> folic acid </e1> supplementation which has confirmed that the <e2> toxicity </e2> of lometrexol can be markedly reduced by folic acid supplementation .
NO_RELATION	This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the <e2> toxicity </e2> of <e1> lometrexol </e1> can be markedly reduced by folic acid supplementation .
NO_RELATION	This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the <e2> toxicity </e2> of lometrexol can be markedly reduced by <e1> folic acid </e1> supplementation .
NO_RELATION	There was no clear relationship between clinical <e2> toxicity </e2> and the extent of plasma <e1> folate </e1> elevation .
NO_RELATION	Associated studies demonstrated that <e1> lometrexol </e1> plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce <e2> toxicity </e2> by enhancing lometrexol plasma clearance .
NO_RELATION	Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by <e1> folic acid </e1> administration indicating that supplementation is unlikely to reduce <e2> toxicity </e2> by enhancing lometrexol plasma clearance .
NO_RELATION	Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce <e2> toxicity </e2> by enhancing <e1> lometrexol </e1> plasma clearance .
CID	Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of <e1> prostaglandin E2 </e1> - induced <e2> hyperalgesia </e2> .
NO_RELATION	<e1> Morphine </e1> did not , however , alter the <e2> hyperalgesia </e2> induced by 8 - bromo cyclic adenosine monophosphate .
CID	Morphine did not , however , alter the <e2> hyperalgesia </e2> induced by <e1> 8 - bromo cyclic adenosine monophosphate </e1> .
NO_RELATION	Adequate timing of <e1> ribavirin </e1> reduction in patients with <e2> hemolysis </e2> during combination therapy of interferon and ribavirin for chronic hepatitis C .
NO_RELATION	Adequate timing of <e1> ribavirin </e1> reduction in patients with hemolysis during combination therapy of interferon and ribavirin for <e2> chronic hepatitis C </e2> .
NO_RELATION	Adequate timing of ribavirin reduction in patients with <e2> hemolysis </e2> during combination therapy of <e1> interferon </e1> and ribavirin for chronic hepatitis C .
NO_RELATION	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of <e1> interferon </e1> and ribavirin for <e2> chronic hepatitis C </e2> .
NO_RELATION	Adequate timing of ribavirin reduction in patients with <e2> hemolysis </e2> during combination therapy of interferon and <e1> ribavirin </e1> for chronic hepatitis C .
NO_RELATION	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and <e1> ribavirin </e1> for <e2> chronic hepatitis C </e2> .
CID	BACKGROUND : <e2> Hemolytic anemia </e2> is one of the major adverse events of the combination therapy of <e1> interferon </e1> and ribavirin .
CID	BACKGROUND : <e2> Hemolytic anemia </e2> is one of the major adverse events of the combination therapy of interferon and <e1> ribavirin </e1> .
CID	Because of <e1> ribavirin </e1> - related <e2> hemolytic anemia </e2> , dose reduction is a common event in this therapy .
NO_RELATION	In this clinical retrospective cohort study we have examined the suitable timing of <e1> ribavirin </e1> reduction in patients with <e2> hemolysis </e2> during combination therapy .
NO_RELATION	However , 10 of 37 patients with reduction of <e1> ribavirin </e1> could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or <e2> anemia </e2> - related severe side effects occurred ( group B ) .
CID	Increased expression and apical targeting of renal ENaC subunits in <e1> puromycin aminonucleoside </e1> - induced <e2> nephrotic syndrome </e2> in rats .
NO_RELATION	<e2> Nephrotic syndrome </e2> is often accompanied by <e1> sodium </e1> retention and generalized edema .
NO_RELATION	Nephrotic syndrome is often accompanied by <e1> sodium </e1> retention and generalized <e2> edema </e2> .
CID	After 7 days , <e1> PAN </e1> treatment induced significant <e2> proteinuria </e2> , hypoalbuminemia , decreased urinary sodium excretion , and extensive ascites .
CID	After 7 days , <e1> PAN </e1> treatment induced significant proteinuria , <e2> hypoalbuminemia </e2> , decreased urinary sodium excretion , and extensive ascites .
CID	After 7 days , <e1> PAN </e1> treatment induced significant proteinuria , hypoalbuminemia , decreased urinary sodium excretion , and extensive <e2> ascites </e2> .
NO_RELATION	After 7 days , PAN treatment induced significant <e2> proteinuria </e2> , hypoalbuminemia , decreased urinary <e1> sodium </e1> excretion , and extensive ascites .
NO_RELATION	After 7 days , PAN treatment induced significant proteinuria , <e2> hypoalbuminemia </e2> , decreased urinary <e1> sodium </e1> excretion , and extensive ascites .
NO_RELATION	After 7 days , PAN treatment induced significant proteinuria , hypoalbuminemia , decreased urinary <e1> sodium </e1> excretion , and extensive <e2> ascites </e2> .
NO_RELATION	In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the <e1> sodium </e1> retention associated with PAN - induced <e2> nephrotic syndrome </e2> .
CID	In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with <e1> PAN </e1> - induced <e2> nephrotic syndrome </e2> .
NO_RELATION	Patients participating in a randomised trial of <e1> anastrozole </e1> , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without <e2> breast cancer </e2> ( n = 35 ) completed a battery of neuropsychological measures .
NO_RELATION	Patients participating in a randomised trial of anastrozole , <e1> tamoxifen </e1> alone or combined ( ATAC ) ( n = 94 ) and a group of women without <e2> breast cancer </e2> ( n = 35 ) completed a battery of neuropsychological measures .
NO_RELATION	Association of <e1> nitric oxide </e1> production and apoptosis in a model of experimental <e2> nephropathy </e2> .
NO_RELATION	We have studied the role of <e1> NO </e1> and its association with apoptosis in an experimental model of <e2> nephrotic syndrome </e2> induced by a single injection of adriamycin ( ADR ) .
CID	We have studied the role of NO and its association with apoptosis in an experimental model of <e2> nephrotic syndrome </e2> induced by a single injection of <e1> adriamycin </e1> ( ADR ) .
CID	We have studied the role of NO and its association with apoptosis in an experimental model of <e2> nephrotic syndrome </e2> induced by a single injection of adriamycin ( <e1> ADR </e1> ) .
NO_RELATION	Rats were stratified into control groups and <e1> ADR </e1> - induced <e2> nephropathy </e2> groups .
NO_RELATION	RESULTS : Histopathological examination of the kidneys of rats treated with <e1> ADR </e1> revealed focal areas of <e2> mesangial proliferation </e2> and mild tubulointerstitial inflammation .
NO_RELATION	RESULTS : Histopathological examination of the kidneys of rats treated with <e1> ADR </e1> revealed focal areas of mesangial proliferation and mild <e2> tubulointerstitial inflammation </e2> .
NO_RELATION	Urine <e1> nitrite </e1> levels were significantly increased in the ADR - <e2> nephropathy </e2> group ( P < 0 . 05 ) .
NO_RELATION	Urine nitrite levels were significantly increased in the <e1> ADR </e1> - <e2> nephropathy </e2> group ( P < 0 . 05 ) .
NO_RELATION	In the IPRK <e1> phenylephrine </e1> and acetylcholine related responses were significantly impaired in the ADR - <e2> nephropathy </e2> group .
NO_RELATION	In the IPRK phenylephrine and <e1> acetylcholine </e1> related responses were significantly impaired in the ADR - <e2> nephropathy </e2> group .
NO_RELATION	In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the <e1> ADR </e1> - <e2> nephropathy </e2> group .
NO_RELATION	However , in the <e1> ADR </e1> - <e2> nephropathy </e2> group , numerous apoptotic cells were identified in the tubulointerstitial areas .
NO_RELATION	CONCLUSION : We suggest that interactions between <e1> NO </e1> and apoptosis are important in the pathogenesis of the ADR - induced <e2> nephrosis </e2> .
NO_RELATION	CONCLUSION : We suggest that interactions between NO and apoptosis are important in the pathogenesis of the <e1> ADR </e1> - induced <e2> nephrosis </e2> .
NO_RELATION	The attenuating effect of <e1> carteolol hydrochloride </e1> , a beta - adrenoceptor antagonist , on neuroleptic - induced <e2> catalepsy </e2> in rats .
NO_RELATION	Therefore , the effects of <e1> carteolol </e1> , a beta - adrenoceptor antagonist , on haloperidol - induced <e2> catalepsy </e2> in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .
CID	Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on <e1> haloperidol </e1> - induced <e2> catalepsy </e2> in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .
NO_RELATION	Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced <e2> catalepsy </e2> in rats were behaviorally studied and compared with those of <e1> propranolol </e1> and biperiden , a muscarinic receptor antagonist .
NO_RELATION	Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced <e2> catalepsy </e2> in rats were behaviorally studied and compared with those of propranolol and <e1> biperiden </e1> , a muscarinic receptor antagonist .
NO_RELATION	<e1> Carteolol </e1> , as well as propranolol and biperiden , inhibited the haloperidol - induced <e2> catalepsy </e2> .
NO_RELATION	Carteolol , as well as <e1> propranolol </e1> and biperiden , inhibited the haloperidol - induced <e2> catalepsy </e2> .
NO_RELATION	Carteolol , as well as propranolol and <e1> biperiden </e1> , inhibited the haloperidol - induced <e2> catalepsy </e2> .
CID	Carteolol , as well as propranolol and biperiden , inhibited the <e1> haloperidol </e1> - induced <e2> catalepsy </e2> .
NO_RELATION	<e1> Carteolol </e1> did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and <e2> hyperlocomotion </e2> in rats .
NO_RELATION	Carteolol did not evoke postsynaptic <e1> dopamine </e1> receptor - stimulating behavioral signs such as stereotypy and <e2> hyperlocomotion </e2> in rats .
NO_RELATION	These results strongly suggest that <e1> carteolol </e1> improves haloperidol - induced <e2> catalepsy </e2> via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .
NO_RELATION	These results strongly suggest that <e1> carteolol </e1> improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of <e2> akathisia </e2> without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .
CID	These results strongly suggest that carteolol improves <e1> haloperidol </e1> - induced <e2> catalepsy </e2> via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .
NO_RELATION	These results strongly suggest that carteolol improves <e1> haloperidol </e1> - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of <e2> akathisia </e2> without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .
NO_RELATION	These results strongly suggest that carteolol improves haloperidol - induced <e2> catalepsy </e2> via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic <e1> dopamine </e1> receptor antagonistic activity .
NO_RELATION	These results strongly suggest that carteolol improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of <e2> akathisia </e2> without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic <e1> dopamine </e1> receptor antagonistic activity .
CID	<e1> Penicillamine </e1> - induced rapidly progressive <e2> glomerulonephritis </e2> in a patient with rheumatoid arthritis .
NO_RELATION	<e1> Penicillamine </e1> - induced rapidly progressive glomerulonephritis in a patient with <e2> rheumatoid arthritis </e2> .
NO_RELATION	A 67 - year - old woman with <e2> rheumatoid arthritis </e2> presented rapidly progressive glomerulonephritis ( RPGN ) after 5 months of <e1> D - penicillamine </e1> ( 250 mg / day ) treatment .
CID	A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive <e2> glomerulonephritis </e2> ( RPGN ) after 5 months of <e1> D - penicillamine </e1> ( 250 mg / day ) treatment .
CID	A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis ( <e2> RPGN </e2> ) after 5 months of <e1> D - penicillamine </e1> ( 250 mg / day ) treatment .
CID	This new case of <e2> RPGN </e2> in the course of <e1> D - penicillamine </e1> treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients .
NO_RELATION	This new case of RPGN in the course of <e1> D - penicillamine </e1> treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and <e2> proteinuria </e2> in these patients .
CID	<e2> Bilateral optic neuropathy </e2> due to combined <e1> ethambutol </e1> and isoniazid treatment .
CID	<e2> Bilateral optic neuropathy </e2> due to combined ethambutol and <e1> isoniazid </e1> treatment .
NO_RELATION	The hazards of optic nerve <e2> toxicity </e2> due to <e1> ethambutol </e1> are known .
NO_RELATION	<e2> Thromboembolic </e2> and other complications of <e1> oral contraceptive </e1> therapy in relationship to pretreatment levels of blood coagulation factors : summary report of a ten - year study .
CID	Thromboembolic and other complications of <e1> oral contraceptive </e1> therapy in relationship to pretreatment levels of <e2> blood coagulation </e2> factors : summary report of a ten - year study .
NO_RELATION	<e2> Cardiac arrest </e2> in a child with cerebral palsy undergoing <e1> sevoflurane </e1> induction of anesthesia after preoperative clonidine .
NO_RELATION	Cardiac arrest in a child with <e2> cerebral palsy </e2> undergoing <e1> sevoflurane </e1> induction of anesthesia after preoperative clonidine .
CID	<e2> Cardiac arrest </e2> in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative <e1> clonidine </e1> .
NO_RELATION	Cardiac arrest in a child with <e2> cerebral palsy </e2> undergoing sevoflurane induction of anesthesia after preoperative <e1> clonidine </e1> .
NO_RELATION	We present a case of a 5 - year - old child with <e2> cerebral palsy </e2> and seizure disorder , receiving <e1> clonidine </e1> for restlessness , who presented for placement of a baclofen pump .
NO_RELATION	We present a case of a 5 - year - old child with cerebral palsy and <e2> seizure disorder </e2> , receiving <e1> clonidine </e1> for restlessness , who presented for placement of a baclofen pump .
NO_RELATION	We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving <e1> clonidine </e1> for <e2> restlessness </e2> , who presented for placement of a baclofen pump .
NO_RELATION	We present a case of a 5 - year - old child with <e2> cerebral palsy </e2> and seizure disorder , receiving clonidine for restlessness , who presented for placement of a <e1> baclofen </e1> pump .
NO_RELATION	We present a case of a 5 - year - old child with cerebral palsy and <e2> seizure disorder </e2> , receiving clonidine for restlessness , who presented for placement of a <e1> baclofen </e1> pump .
NO_RELATION	We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving clonidine for <e2> restlessness </e2> , who presented for placement of a <e1> baclofen </e1> pump .
NO_RELATION	Without the knowledge of the medical personnel , the patient ' s mother administered three doses of <e1> clonidine </e1> during the evening before and morning of surgery to reduce <e2> anxiety </e2> .
CID	There are no previous reports of <e1> clonidine </e1> - associated <e2> cardiac arrest </e2> in a child undergoing induction of anesthesia .
CID	Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the <e2> convulsive </e2> , lethal , locomotor stimulatory and rewarding actions of <e1> cocaine </e1> in mice .
NO_RELATION	In behavioral studies , pretreatment of Swiss Webster mice with <e1> UMB24 </e1> or ( + / - ) - SM 21 significantly attenuated cocaine - induced <e2> convulsions </e2> and locomotor activity , but not lethality .
NO_RELATION	In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - <e1> SM 21 </e1> significantly attenuated cocaine - induced <e2> convulsions </e2> and locomotor activity , but not lethality .
CID	In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated <e1> cocaine </e1> - induced <e2> convulsions </e2> and locomotor activity , but not lethality .
CID	<e1> Methimazole </e1> - induced <e2> cholestatic jaundice </e2> .
NO_RELATION	A 43 - year - old woman had severe <e2> jaundice </e2> and itching 1 month after receiving <e1> methimazole </e1> ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .
CID	A 43 - year - old woman had severe jaundice and <e2> itching </e2> 1 month after receiving <e1> methimazole </e1> ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .
NO_RELATION	A 43 - year - old woman had severe jaundice and itching 1 month after receiving <e1> methimazole </e1> ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of <e2> hyperthyroidism </e2> .
NO_RELATION	A 43 - year - old woman had severe <e2> jaundice </e2> and itching 1 month after receiving methimazole ( 10 mg tid ) and <e1> propranolol </e1> ( 20 mg tid ) for treatment of hyperthyroidism .
NO_RELATION	A 43 - year - old woman had severe jaundice and <e2> itching </e2> 1 month after receiving methimazole ( 10 mg tid ) and <e1> propranolol </e1> ( 20 mg tid ) for treatment of hyperthyroidism .
NO_RELATION	A 43 - year - old woman had severe jaundice and itching 1 month after receiving methimazole ( 10 mg tid ) and <e1> propranolol </e1> ( 20 mg tid ) for treatment of <e2> hyperthyroidism </e2> .
NO_RELATION	<e1> Methimazole </e1> - induced <e2> cholestasis </e2> was diagnosed , and propranolol therapy was resumed .
NO_RELATION	Methimazole - induced <e2> cholestasis </e2> was diagnosed , and <e1> propranolol </e1> therapy was resumed .
CID	<e1> Ciprofloxacin </e1> - induced acute <e2> interstitial nephritis </e2> and autoimmune hemolytic anemia .
NO_RELATION	<e1> Ciprofloxacin </e1> - induced acute interstitial nephritis and <e2> autoimmune hemolytic anemia </e2> .
CID	<e1> Ciprofloxacin </e1> has been associated with several side effects including <e2> interstitial nephritis </e2> and hemolytic anemia .
CID	<e1> Ciprofloxacin </e1> has been associated with several side effects including interstitial nephritis and <e2> hemolytic anemia </e2> .
CID	In this report , we describe a case of <e1> ciprofloxacin </e1> - induced <e2> interstitial nephritis </e2> and autoimmune hemolytic anemia .
NO_RELATION	In this report , we describe a case of <e1> ciprofloxacin </e1> - induced interstitial nephritis and <e2> autoimmune hemolytic anemia </e2> .
NO_RELATION	<e2> Hemolytic anemia </e2> improved after stopping the drug and initiation of <e1> steroid </e1> therapy .
CID	Contribution of <e1> sodium valproate </e1> to the <e2> syndrome of inappropriate secretion of antidiuretic hormone </e2> .
CID	We report the case of a 62 - year - old man who was administered <e1> sodium valproate </e1> ( VPA ) and who subsequently developed the <e2> syndrome of inappropriate secretion of antidiuretic hormone </e2> ( SIADH ) .
CID	We report the case of a 62 - year - old man who was administered <e1> sodium valproate </e1> ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( <e2> SIADH </e2> ) .
CID	We report the case of a 62 - year - old man who was administered sodium valproate ( <e1> VPA </e1> ) and who subsequently developed the <e2> syndrome of inappropriate secretion of antidiuretic hormone </e2> ( SIADH ) .
CID	We report the case of a 62 - year - old man who was administered sodium valproate ( <e1> VPA </e1> ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( <e2> SIADH </e2> ) .
NO_RELATION	He had been taking <e1> VPA </e1> for treatment of idiopathic generalized <e2> tonic - clonic convulsions </e2> since he was 56 years old .
CID	We consider this episode of <e2> SIADH </e2> to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of <e1> VPA </e1> .
NO_RELATION	We consider this episode of SIADH to be the result of a combination of factors including a <e2> weakness of the central nervous system </e2> and the long - term administration of <e1> VPA </e1> .
CID	<e1> Vasopressin </e1> in the treatment of milrinone - induced <e2> hypotension </e2> in severe heart failure .
NO_RELATION	<e1> Vasopressin </e1> in the treatment of milrinone - induced hypotension in severe <e2> heart failure </e2> .
CID	Vasopressin in the treatment of <e1> milrinone </e1> - induced <e2> hypotension </e2> in severe heart failure .
NO_RELATION	Vasopressin in the treatment of <e1> milrinone </e1> - induced hypotension in severe <e2> heart failure </e2> .
NO_RELATION	The use of phosphodiesterase inhibitors such as <e1> milrinone </e1> in the treatment of severe <e2> heart failure </e2> is frequently restricted because they cause vasodilation and hypotension .
CID	The use of phosphodiesterase inhibitors such as <e1> milrinone </e1> in the treatment of severe heart failure is frequently restricted because they cause vasodilation and <e2> hypotension </e2> .
NO_RELATION	In patients with decompensated <e2> heart failure </e2> with hypotension after treatment with <e1> milrinone </e1> , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .
CID	In patients with decompensated heart failure with <e2> hypotension </e2> after treatment with <e1> milrinone </e1> , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .
NO_RELATION	In patients with decompensated <e2> heart failure </e2> with hypotension after treatment with milrinone , low doses of <e1> vasopressin </e1> restored blood pressure without inhibiting the inotropic effect of milrinone .
CID	In patients with decompensated heart failure with <e2> hypotension </e2> after treatment with milrinone , low doses of <e1> vasopressin </e1> restored blood pressure without inhibiting the inotropic effect of milrinone .
NO_RELATION	In patients with decompensated <e2> heart failure </e2> with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of <e1> milrinone </e1> .
CID	In patients with decompensated heart failure with <e2> hypotension </e2> after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of <e1> milrinone </e1> .
CID	Two halogenated anesthetics , <e1> enflurane </e1> and isoflurane , have been associated with an allergic - type <e2> hepatic injury </e2> both alone and following previous exposure to halothane .
CID	Two halogenated anesthetics , enflurane and <e1> isoflurane </e1> , have been associated with an allergic - type <e2> hepatic injury </e2> both alone and following previous exposure to halothane .
CID	Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type <e2> hepatic injury </e2> both alone and following previous exposure to <e1> halothane </e1> .
CID	<e1> Halothane </e1> <e2> hepatitis </e2> appears to involve an aberrant immune response .
NO_RELATION	An antibody response to a protein - bound biotransformation product ( <e1> trifluoroacetyl </e1> adduct ) has been detected on halothane <e2> hepatitis </e2> patients .
CID	An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on <e1> halothane </e1> <e2> hepatitis </e2> patients .
NO_RELATION	This study was performed to determine cross - reactivity between <e1> enflurane </e1> and isoflurane with the <e2> hypersensitivity </e2> induced by halothane .
NO_RELATION	This study was performed to determine cross - reactivity between enflurane and <e1> isoflurane </e1> with the <e2> hypersensitivity </e2> induced by halothane .
NO_RELATION	This study was performed to determine cross - reactivity between enflurane and isoflurane with the <e2> hypersensitivity </e2> induced by <e1> halothane </e1> .
NO_RELATION	This supports and extends previous evidence for a mechanism by which <e1> enflurane </e1> and / or isoflurane could produce a <e2> hypersensitivity </e2> condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .
CID	This supports and extends previous evidence for a mechanism by which <e1> enflurane </e1> and / or isoflurane could produce a hypersensitivity condition similar to that of halothane <e2> hepatitis </e2> either alone or subsequent to halothane administration .
NO_RELATION	This supports and extends previous evidence for a mechanism by which enflurane and / or <e1> isoflurane </e1> could produce a <e2> hypersensitivity </e2> condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .
CID	This supports and extends previous evidence for a mechanism by which enflurane and / or <e1> isoflurane </e1> could produce a hypersensitivity condition similar to that of halothane <e2> hepatitis </e2> either alone or subsequent to halothane administration .
NO_RELATION	This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a <e2> hypersensitivity </e2> condition similar to that of <e1> halothane </e1> hepatitis either alone or subsequent to halothane administration .
CID	This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of <e1> halothane </e1> <e2> hepatitis </e2> either alone or subsequent to halothane administration .
NO_RELATION	This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a <e2> hypersensitivity </e2> condition similar to that of halothane hepatitis either alone or subsequent to <e1> halothane </e1> administration .
CID	This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane <e2> hepatitis </e2> either alone or subsequent to <e1> halothane </e1> administration .
NO_RELATION	Induction by <e1> paracetamol </e1> of <e2> bladder and liver tumours </e2> in the rat .
NO_RELATION	<e2> Papillomas </e2> of the transitional epithelium of the bladder developed in all <e1> paracetamol </e1> - treated groups , and three rats bore bladder carcinomas .
CID	Papillomas of the transitional epithelium of the bladder developed in all <e1> paracetamol </e1> - treated groups , and three rats bore <e2> bladder carcinomas </e2> .
CID	Additionally , 20 to 25 % of <e1> paracetamol </e1> - treated rats developed <e2> hyperplasia </e2> of the bladder epithelium , which was not coincident with the presence of bladder calculi .
NO_RELATION	Additionally , 20 to 25 % of <e1> paracetamol </e1> - treated rats developed hyperplasia of the bladder epithelium , which was not coincident with the presence of <e2> bladder calculi </e2> .
NO_RELATION	A low yield of <e2> tumours </e2> at various other sites also arose following <e1> paracetamol </e1> feeding .
CID	An electron microscope study of the livers of <e1> paracetamol </e1> - treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known <e2> hepatocarcinogens </e2> .
CID	In addition to <e2> muscle damage </e2> , severe damage was also seen in harderian glands , especially after exposure to <e1> mepivacaine </e1> and lidocaine plus epinephrine .
CID	In addition to <e2> muscle damage </e2> , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and <e1> lidocaine </e1> plus epinephrine .
NO_RELATION	In addition to <e2> muscle damage </e2> , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus <e1> epinephrine </e1> .
NO_RELATION	Reversal of neuroleptic - induced <e2> catalepsy </e2> by novel <e1> aryl - piperazine </e1> anxiolytic drugs .
NO_RELATION	The novel anxiolytic drug , <e1> buspirone </e1> , reverses <e2> catalepsy </e2> induced by haloperidol .
CID	The novel anxiolytic drug , buspirone , reverses <e2> catalepsy </e2> induced by <e1> haloperidol </e1> .
NO_RELATION	A series of <e1> aryl - piperazine </e1> analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced <e2> catalepsy </e2> .
NO_RELATION	A series of aryl - piperazine analogues of <e1> buspirone </e1> and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced <e2> catalepsy </e2> .
NO_RELATION	A series of aryl - piperazine analogues of buspirone and other <e1> 5 - hydroxytryptaminergic agonists </e1> were tested for their ability to reverse haloperidol induced <e2> catalepsy </e2> .
CID	A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse <e1> haloperidol </e1> induced <e2> catalepsy </e2> .
NO_RELATION	Those drugs with strong affinity for <e1> 5 - hydroxytryptamine1a </e1> receptors were able to reverse <e2> catalepsy </e2> .
NO_RELATION	However , inhibition of postsynaptic <e1> 5 - HT </e1> receptors neither inhibited nor potentiated reversal of <e2> catalepsy </e2> and leaves open the question as to the site or mechanism for this effect .
CID	<e1> Diazepam </e1> facilitates reflex <e2> bradycardia </e2> in conscious rats .
CID	Also , reflex <e2> bradycardia </e2> was produced in rats by intravenous infusion of <e1> adrenaline </e1> ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .
CID	Intravenous pretreatment of the rats with <e1> diazepam </e1> , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex <e2> bradycardia </e2> .
CID	Intravenous pretreatment of the rats with diazepam , although causing no change in the <e1> adrenaline </e1> - induced pressor effect , did enhance the adrenaline - induced reflex <e2> bradycardia </e2> .
CID	Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the <e1> adrenaline </e1> - induced reflex <e2> bradycardia </e2> .
CID	However , the <e1> diazepam </e1> enhancement of adrenaline - induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .
CID	However , the diazepam enhancement of <e1> adrenaline </e1> - induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .
NO_RELATION	However , the diazepam enhancement of adrenaline - induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of <e1> picrotoxin </e1> ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .
NO_RELATION	However , the diazepam enhancement of adrenaline - induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks <e1> chloride </e1> channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .
NO_RELATION	However , the diazepam enhancement of adrenaline - induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the <e1> benzodiazepine </e1> - GABA - chloride channel macromolecular complex ) .
NO_RELATION	However , the diazepam enhancement of adrenaline - induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - <e1> GABA </e1> - chloride channel macromolecular complex ) .
NO_RELATION	However , the diazepam enhancement of adrenaline - induced reflex <e2> bradycardia </e2> was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - <e1> chloride </e1> channel macromolecular complex ) .
CID	The data indicate that <e1> diazepam </e1> acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex <e2> bradycardia </e2> mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .
NO_RELATION	The data indicate that diazepam acts through the <e1> benzodiazepine </e1> - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex <e2> bradycardia </e2> mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .
NO_RELATION	The data indicate that diazepam acts through the benzodiazepine - <e1> GABA </e1> - chloride channel macromolecular complex within the central nervous system to facilitate reflex <e2> bradycardia </e2> mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .
NO_RELATION	The data indicate that diazepam acts through the benzodiazepine - GABA - <e1> chloride </e1> channel macromolecular complex within the central nervous system to facilitate reflex <e2> bradycardia </e2> mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .
NO_RELATION	Chronic <e1> carbamazepine </e1> inhibits the development of local anesthetic <e2> seizures </e2> kindled by cocaine and lidocaine .
CID	Chronic carbamazepine inhibits the development of local anesthetic <e2> seizures </e2> kindled by <e1> cocaine </e1> and lidocaine .
CID	Chronic carbamazepine inhibits the development of local anesthetic <e2> seizures </e2> kindled by cocaine and <e1> lidocaine </e1> .
NO_RELATION	The effects of <e1> carbamazepine </e1> ( CBZ ) treatment on local anesthetic - kindled <e2> seizures </e2> and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .
NO_RELATION	The effects of carbamazepine ( <e1> CBZ </e1> ) treatment on local anesthetic - kindled <e2> seizures </e2> and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .
NO_RELATION	The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled <e2> seizures </e2> and lethality were evaluated in different stages of the kindling process and under different methods of <e1> CBZ </e1> administration .
NO_RELATION	Chronic oral <e1> CBZ </e1> inhibited the development of both lidocaine - and cocaine - induced <e2> seizures </e2> , but had little effect on the fully developed local anesthetic seizures .
NO_RELATION	Chronic oral <e1> CBZ </e1> inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic <e2> seizures </e2> .
CID	Chronic oral CBZ inhibited the development of both <e1> lidocaine </e1> - and cocaine - induced <e2> seizures </e2> , but had little effect on the fully developed local anesthetic seizures .
CID	Chronic oral CBZ inhibited the development of both <e1> lidocaine </e1> - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic <e2> seizures </e2> .
CID	Chronic oral CBZ inhibited the development of both lidocaine - and <e1> cocaine </e1> - induced <e2> seizures </e2> , but had little effect on the fully developed local anesthetic seizures .
CID	Chronic oral CBZ inhibited the development of both lidocaine - and <e1> cocaine </e1> - induced seizures , but had little effect on the fully developed local anesthetic <e2> seizures </e2> .
NO_RELATION	Chronic <e1> CBZ </e1> also decreased the incidence of <e2> seizure </e2> - related mortality in the cocaine - injected rats .
CID	Chronic CBZ also decreased the incidence of <e2> seizure </e2> - related mortality in the <e1> cocaine </e1> - injected rats .
NO_RELATION	Acute <e1> CBZ </e1> over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced <e2> seizures </e2> .
CID	Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed <e1> lidocaine </e1> - kindled or acute cocaine - induced <e2> seizures </e2> .
CID	Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute <e1> cocaine </e1> - induced <e2> seizures </e2> .
NO_RELATION	injection of <e1> CBZ </e1> ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled <e2> seizures </e2> .
CID	injection of CBZ ( 15 mg / kg ) also was without effect on the development of <e1> lidocaine </e1> - or cocaine - kindled <e2> seizures </e2> .
CID	injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or <e1> cocaine </e1> - kindled <e2> seizures </e2> .
NO_RELATION	The differential effects of <e1> CBZ </e1> depending upon stage of <e2> seizure </e2> development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .
NO_RELATION	The differential effects of <e1> CBZ </e1> depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled <e2> seizures </e2> .
NO_RELATION	<e1> D - penicillamine </e1> in the treatment of <e2> localized scleroderma </e2> .
NO_RELATION	Case reports of 11 patients with severe , extensive <e2> localized scleroderma </e2> who were treated with <e1> D - penicillamine </e1> are summarized in this article .
CID	<e1> D - Penicillamine </e1> caused <e2> nephrotic syndrome </e2> in 1 patient and milder reversible proteinuria in 3 other patients ; none developed renal insufficiency .
CID	<e1> D - Penicillamine </e1> caused nephrotic syndrome in 1 patient and milder reversible <e2> proteinuria </e2> in 3 other patients ; none developed renal insufficiency .
NO_RELATION	<e1> D - Penicillamine </e1> caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients ; none developed <e2> renal insufficiency </e2> .
NO_RELATION	These data suggest that <e1> D - penicillamine </e1> may be effective in severe cases of <e2> localized scleroderma </e2> .
CID	Preservation of renal blood flow during <e2> hypotension </e2> induced with <e1> fenoldopam </e1> in dogs .
CID	The hypothesis that <e1> fenoldopam </e1> could be used to induce <e2> hypotension </e2> and preserve blood flow to the kidney was tested .
CID	Renal blood flow ( RBF ) increased during <e1> fenoldopam </e1> - induced <e2> hypotension </e2> 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .
CID	Renal blood flow ( RBF ) increased during <e1> fenoldopam </e1> - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced <e2> hypotension </e2> ( P less than 0 . 01 ) .
NO_RELATION	Renal blood flow ( RBF ) increased during fenoldopam - induced <e2> hypotension </e2> 11 + / - 7 per cent and decreased 21 + / - 8 per cent during <e1> sodium </e1> nitroprusside - induced hypotension ( P less than 0 . 01 ) .
NO_RELATION	Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during <e1> sodium </e1> nitroprusside - induced <e2> hypotension </e2> ( P less than 0 . 01 ) .
CID	Renal blood flow ( RBF ) increased during fenoldopam - induced <e2> hypotension </e2> 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium <e1> nitroprusside </e1> - induced hypotension ( P less than 0 . 01 ) .
CID	Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium <e1> nitroprusside </e1> - induced <e2> hypotension </e2> ( P less than 0 . 01 ) .
CID	Sodium <e1> nitroprusside </e1> is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced <e2> hypotension </e2> .
NO_RELATION	Fenoldopam is a selective <e1> dopamine </e1> - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced <e2> hypotension </e2> .
NO_RELATION	Antiarrhythmic effects of optical isomers of <e1> cibenzoline </e1> on canine <e2> ventricular arrhythmias </e2> .
NO_RELATION	Antiarrhythmic effects of ( + ) - <e1> cibenzoline </e1> and ( - ) - cibenzoline were examined using two canine <e2> ventricular arrhythmia </e2> models .
NO_RELATION	Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - <e1> cibenzoline </e1> were examined using two canine <e2> ventricular arrhythmia </e2> models .
NO_RELATION	<e1> Digitalis </e1> <e2> arrhythmia </e2> , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in pentobarbital - anesthetized dogs .
NO_RELATION	Digitalis <e2> arrhythmia </e2> , which is suppressed by <e1> Na </e1> channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in pentobarbital - anesthetized dogs .
CID	Digitalis <e2> arrhythmia </e2> , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of <e1> ouabain </e1> in pentobarbital - anesthetized dogs .
NO_RELATION	Digitalis <e2> arrhythmia </e2> , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in <e1> pentobarbital </e1> - anesthetized dogs .
NO_RELATION	<e2> Adrenaline arrhythmia </e2> , which is suppressed by <e1> Ca </e1> channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .
CID	<e2> Adrenaline arrhythmia </e2> , which is suppressed by Ca channel blockers , was induced by <e1> adrenaline </e1> infusion in halothane - anesthetized dogs .
NO_RELATION	<e2> Adrenaline arrhythmia </e2> , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in <e1> halothane </e1> - anesthetized dogs .
NO_RELATION	( + ) - <e1> cibenzoline </e1> suppressed digitalis - and adrenaline - induced <e2> arrhythmias </e2> , respectively .
NO_RELATION	( + ) - cibenzoline suppressed <e1> digitalis </e1> - and adrenaline - induced <e2> arrhythmias </e2> , respectively .
CID	( + ) - cibenzoline suppressed digitalis - and <e1> adrenaline </e1> - induced <e2> arrhythmias </e2> , respectively .
NO_RELATION	The minimum effective plasma concentrations of ( + ) - <e1> cibenzoline </e1> for digitalis - and adrenaline - induced <e2> arrhythmias </e2> were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
NO_RELATION	The minimum effective plasma concentrations of ( + ) - cibenzoline for <e1> digitalis </e1> - and adrenaline - induced <e2> arrhythmias </e2> were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
CID	The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and <e1> adrenaline </e1> - induced <e2> arrhythmias </e2> were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
NO_RELATION	of ( - ) - <e1> cibenzoline </e1> suppressed the digitalis - induced <e2> arrhythmia </e2> , whereas 5 mg / kg i . v .
NO_RELATION	of ( - ) - cibenzoline suppressed the <e1> digitalis </e1> - induced <e2> arrhythmia </e2> , whereas 5 mg / kg i . v .
CID	was needed to suppress <e1> adrenaline </e1> - induced <e2> arrhythmias </e2> .
NO_RELATION	The minimum effective plasma concentrations of ( - ) - <e1> cibenzoline </e1> for digitalis - and adrenaline - induced <e2> arrhythmia </e2> were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
NO_RELATION	The minimum effective plasma concentrations of ( - ) - cibenzoline for <e1> digitalis </e1> - and adrenaline - induced <e2> arrhythmia </e2> were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
CID	The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and <e1> adrenaline </e1> - induced <e2> arrhythmia </e2> were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
NO_RELATION	Effect of methanolic extract of <e1> Hibiscus rosa sinensis </e1> ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial <e2> dyskinesia </e2> and neurochemical alterations .
CID	Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on <e1> reserpine </e1> - induced orofacial <e2> dyskinesia </e2> and neurochemical alterations .
NO_RELATION	The results of the present study suggested that <e1> Hibiscus rosa sinensis </e1> had a protective role against reserpine - induced orofacial <e2> dyskinesia </e2> and oxidative stress .
CID	The results of the present study suggested that Hibiscus rosa sinensis had a protective role against <e1> reserpine </e1> - induced orofacial <e2> dyskinesia </e2> and oxidative stress .
NO_RELATION	Comparison of aqueous and gellan ophthalmic <e1> timolol </e1> with placebo on the 24 - hour heart rate response in patients on treatment for <e2> glaucoma </e2> .
NO_RELATION	DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous <e1> timolol </e1> ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for <e2> glaucoma </e2> to quantify the reduction in mean heart rate .
NO_RELATION	DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( <e1> timolol </e1> solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for <e2> glaucoma </e2> to quantify the reduction in mean heart rate .
NO_RELATION	DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % <e1> timolol </e1> suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for <e2> glaucoma </e2> to quantify the reduction in mean heart rate .
NO_RELATION	DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( <e1> timolol </e1> gellan ) on the 24 - hour heart rate in patients currently being treated for <e2> glaucoma </e2> to quantify the reduction in mean heart rate .
NO_RELATION	METHODS : Forty - three Caucasian patients with primary <e2> open - angle glaucoma </e2> or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , <e1> timolol </e1> solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .
NO_RELATION	METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or <e2> ocular hypertension </e2> with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , <e1> timolol </e1> solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .
NO_RELATION	METHODS : Forty - three Caucasian patients with primary <e2> open - angle glaucoma </e2> or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or <e1> timolol </e1> gellan ( morning in both eyes with placebo in the evening ) .
NO_RELATION	METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or <e2> ocular hypertension </e2> with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or <e1> timolol </e1> gellan ( morning in both eyes with placebo in the evening ) .
CID	<e1> 5 flourouracil </e1> - induced <e2> apical ballooning syndrome </e2> : a case report .
NO_RELATION	She underwent recent chemotherapy with <e1> fluorouracil </e1> for metastatic <e2> colorectal cancer </e2> .
NO_RELATION	In our patient , both supraphysiologic levels of plasma <e1> catecholamines </e1> and stress related neuropeptides caused by <e2> cancer </e2> diagnosis as well as chemotherapy may have contributed the development of ABS .
NO_RELATION	In our patient , both supraphysiologic levels of plasma <e1> catecholamines </e1> and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of <e2> ABS </e2> .
CID	Reduction of <e2> pain </e2> during induction with target - controlled <e1> propofol </e1> and remifentanil .
NO_RELATION	Reduction of <e2> pain </e2> during induction with target - controlled propofol and <e1> remifentanil </e1> .
CID	BACKGROUND : <e2> Pain </e2> on injection of <e1> propofol </e1> is unpleasant .
CID	We hypothesized that <e1> propofol </e1> infusion <e2> pain </e2> might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .
NO_RELATION	We hypothesized that propofol infusion <e2> pain </e2> might be prevented by infusing <e1> remifentanil </e1> before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .
CID	We hypothesized that propofol infusion <e2> pain </e2> might be prevented by infusing remifentanil before starting the <e1> propofol </e1> infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .
NO_RELATION	A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of <e1> remifentanil </e1> to prevent the <e2> pain </e2> without producing complications .
NO_RELATION	<e1> Remifentanil </e1> - related complications were assessed during the remifentanil infusion , and <e2> pain </e2> caused by propofol was evaluated using a four - point scale during the propofol infusion .
NO_RELATION	Remifentanil - related complications were assessed during the <e1> remifentanil </e1> infusion , and <e2> pain </e2> caused by propofol was evaluated using a four - point scale during the propofol infusion .
CID	Remifentanil - related complications were assessed during the remifentanil infusion , and <e2> pain </e2> caused by <e1> propofol </e1> was evaluated using a four - point scale during the propofol infusion .
CID	Remifentanil - related complications were assessed during the remifentanil infusion , and <e2> pain </e2> caused by propofol was evaluated using a four - point scale during the <e1> propofol </e1> infusion .
CID	CONCLUSIONS : During induction of anaesthesia with TCI of <e1> propofol </e1> and remifentanil , a significant reduction in propofol infusion <e2> pain </e2> was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .
NO_RELATION	CONCLUSIONS : During induction of anaesthesia with TCI of propofol and <e1> remifentanil </e1> , a significant reduction in propofol infusion <e2> pain </e2> was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .
CID	CONCLUSIONS : During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in <e1> propofol </e1> infusion <e2> pain </e2> was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .
NO_RELATION	CONCLUSIONS : During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion <e2> pain </e2> was achieved without significant complications by prior administration of <e1> remifentanil </e1> at a target Ce of 4 ng ml ( - 1 ) .
NO_RELATION	Prenatal exposure to <e1> fluoxetine </e1> induces <e2> fetal pulmonary hypertension </e2> in the rat .
CID	Epidemiological data suggest that <e1> fluoxetine </e1> exposure prenatally increases the prevalence of persistent <e2> pulmonary hypertension syndrome </e2> of the newborn .
CID	The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a <e2> pulmonary hypertension </e2> protective <e1> fluoxetine </e1> effect in adult rodents .
NO_RELATION	As compared with controls , <e1> fluoxetine </e1> exposure resulted in <e2> fetal pulmonary hypertension </e2> as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .
CID	CONCLUSIONS : In contrast to the adult , <e1> fluoxetine </e1> exposure in utero induces <e2> pulmonary hypertension </e2> in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .
CID	<e2> Syncope </e2> and QT prolongation among patients treated with <e1> methadone </e1> for heroin dependence in the city of Copenhagen .
CID	Syncope and <e2> QT prolongation </e2> among patients treated with <e1> methadone </e1> for heroin dependence in the city of Copenhagen .
NO_RELATION	<e2> Syncope </e2> and QT prolongation among patients treated with methadone for <e1> heroin </e1> dependence in the city of Copenhagen .
NO_RELATION	Syncope and <e2> QT prolongation </e2> among patients treated with methadone for <e1> heroin </e1> dependence in the city of Copenhagen .
NO_RELATION	Prolongation of the QT interval in the ECG of patients with <e2> torsade de pointes </e2> ( TdP ) has been reported in <e1> methadone </e1> users .
NO_RELATION	Prolongation of the QT interval in the ECG of patients with torsade de pointes ( <e2> TdP </e2> ) has been reported in <e1> methadone </e1> users .
NO_RELATION	As <e1> heroin </e1> addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of <e2> syncope </e2> to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .
NO_RELATION	As <e1> heroin </e1> addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of <e2> TdP </e2> in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .
CID	As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of <e2> syncope </e2> to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of <e1> methadone </e1> .
NO_RELATION	As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of <e2> TdP </e2> in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of <e1> methadone </e1> .
CID	The association between opioid dose and QT , and <e1> methadone </e1> dose and reporting of <e2> syncope </e2> was assessed using multivariate linear regression and logistic regression , respectively .
CID	Among the subjects treated with <e1> methadone </e1> , 28 % men and 32 % women had <e2> prolonged QTc interval </e2> .
CID	A 50 mg higher <e1> methadone </e1> dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for <e2> syncope </e2> .
CID	CONCLUSIONS : <e1> Methadone </e1> is associated with <e2> QT prolongation </e2> and higher reporting of syncope in a population of heroin addicts .
CID	CONCLUSIONS : <e1> Methadone </e1> is associated with QT prolongation and higher reporting of <e2> syncope </e2> in a population of heroin addicts .
NO_RELATION	CONCLUSIONS : Methadone is associated with <e2> QT prolongation </e2> and higher reporting of syncope in a population of <e1> heroin </e1> addicts .
NO_RELATION	CONCLUSIONS : Methadone is associated with QT prolongation and higher reporting of <e2> syncope </e2> in a population of <e1> heroin </e1> addicts .
CID	<e2> Peripheral neuropathy </e2> caused by high - dose <e1> cytosine arabinoside </e1> treatment in a patient with acute myeloid leukemia .
NO_RELATION	Peripheral neuropathy caused by high - dose <e1> cytosine arabinoside </e1> treatment in a patient with <e2> acute myeloid leukemia </e2> .
NO_RELATION	The central nervous system <e2> toxicity </e2> of high - dose <e1> cytosine arabinoside </e1> is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .
NO_RELATION	The central nervous system toxicity of high - dose <e1> cytosine arabinoside </e1> is well recognized , but the <e2> toxicity </e2> of cytosine arabinoside in the peripheral nervous system has been infrequently reported .
NO_RELATION	The central nervous system <e2> toxicity </e2> of high - dose cytosine arabinoside is well recognized , but the toxicity of <e1> cytosine arabinoside </e1> in the peripheral nervous system has been infrequently reported .
NO_RELATION	The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the <e2> toxicity </e2> of <e1> cytosine arabinoside </e1> in the peripheral nervous system has been infrequently reported .
NO_RELATION	The first course of high - dose <e1> cytosine arabinoside </e1> resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of <e2> numbness </e2> in his right foot .
NO_RELATION	This <e2> neuropathy </e2> was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of graft - versus - host disease , and the symptoms subsequently responded to <e1> methylprednisolone </e1> .
NO_RELATION	This neuropathy was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of <e2> graft - versus - host disease </e2> , and the symptoms subsequently responded to <e1> methylprednisolone </e1> .
CID	Although the mechanisms of <e2> peripheral neuropathy </e2> are still unclear , high - dose <e1> cytosine arabinoside </e1> is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .
NO_RELATION	<e1> Atorvastatin </e1> prevented and reversed dexamethasone - induced <e2> hypertension </e2> in the rat .
CID	Atorvastatin prevented and reversed <e1> dexamethasone </e1> - induced <e2> hypertension </e2> in the rat .
NO_RELATION	To assess the antioxidant effects of <e1> atorvastatin </e1> ( atorva ) on dexamethasone ( dex ) - induced <e2> hypertension </e2> , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .
NO_RELATION	To assess the antioxidant effects of atorvastatin ( <e1> atorva </e1> ) on dexamethasone ( dex ) - induced <e2> hypertension </e2> , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .
CID	To assess the antioxidant effects of atorvastatin ( atorva ) on <e1> dexamethasone </e1> ( dex ) - induced <e2> hypertension </e2> , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .
CID	To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( <e1> dex </e1> ) - induced <e2> hypertension </e2> , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .
NO_RELATION	To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced <e2> hypertension </e2> , 60 male Sprague - Dawley rats were treated with <e1> atorva </e1> 30 mg / kg / day or tap water for 15 days .
NO_RELATION	<e1> Atorva </e1> reversed dex - induced <e2> hypertension </e2> ( 129 + / - 0 . 6 mmHg , vs .
CID	Atorva reversed <e1> dex </e1> - induced <e2> hypertension </e2> ( 129 + / - 0 . 6 mmHg , vs .
NO_RELATION	Thus , <e1> atorvastatin </e1> prevented and reversed dexamethasone - induced <e2> hypertension </e2> in the rat .
CID	Thus , atorvastatin prevented and reversed <e1> dexamethasone </e1> - induced <e2> hypertension </e2> in the rat .
NO_RELATION	Two prodrugs of potent and selective GluR5 <e1> kainate </e1> receptor antagonists actives in three animal models of <e2> pain </e2> .
NO_RELATION	Their ester prodrugs 6 and 8 were orally active in three models of <e2> pain </e2> : reversal of <e1> formalin </e1> - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .
NO_RELATION	Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of <e1> formalin </e1> - induced paw licking , carrageenan - induced <e2> thermal hyperalgesia </e2> , and capsaicin - induced mechanical hyperalgesia .
NO_RELATION	Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of <e1> formalin </e1> - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced <e2> mechanical hyperalgesia </e2> .
NO_RELATION	Their ester prodrugs 6 and 8 were orally active in three models of <e2> pain </e2> : reversal of formalin - induced paw licking , <e1> carrageenan </e1> - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .
CID	Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , <e1> carrageenan </e1> - induced <e2> thermal hyperalgesia </e2> , and capsaicin - induced mechanical hyperalgesia .
CID	Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , <e1> carrageenan </e1> - induced thermal hyperalgesia , and capsaicin - induced <e2> mechanical hyperalgesia </e2> .
NO_RELATION	Their ester prodrugs 6 and 8 were orally active in three models of <e2> pain </e2> : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and <e1> capsaicin </e1> - induced mechanical hyperalgesia .
CID	Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced <e2> thermal hyperalgesia </e2> , and <e1> capsaicin </e1> - induced mechanical hyperalgesia .
CID	Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and <e1> capsaicin </e1> - induced <e2> mechanical hyperalgesia </e2> .
NO_RELATION	Two recently available immunosuppressive agents , <e1> mycophenolate mofetil </e1> and sirolimus ( rapamycin ) , have no <e2> nephrotoxicity </e2> .
NO_RELATION	Two recently available immunosuppressive agents , mycophenolate mofetil and <e1> sirolimus </e1> ( rapamycin ) , have no <e2> nephrotoxicity </e2> .
NO_RELATION	Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( <e1> rapamycin </e1> ) , have no <e2> nephrotoxicity </e2> .
NO_RELATION	Erythropoietin restores the <e2> anemia </e2> - induced reduction in <e1> cyclophosphamide </e1> cytotoxicity in rat tumors .
NO_RELATION	Erythropoietin restores the anemia - induced reduction in <e1> cyclophosphamide </e1> <e2> cytotoxicity </e2> in rat tumors .
NO_RELATION	Erythropoietin restores the anemia - induced reduction in <e1> cyclophosphamide </e1> cytotoxicity in rat <e2> tumors </e2> .
NO_RELATION	The aim of this study was to examine the impact of <e2> anemia </e2> prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of <e1> cyclophosphamide </e1> in solid experimental tumors .
NO_RELATION	The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the <e2> cytotoxicity </e2> of <e1> cyclophosphamide </e1> in solid experimental tumors .
NO_RELATION	The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of <e1> cyclophosphamide </e1> in solid experimental <e2> tumors </e2> .
CID	<e2> Anemia </e2> was induced using a single dose of <e1> carboplatin </e1> ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .
NO_RELATION	Four days after <e1> carboplatin </e1> treatment , <e2> tumors </e2> ( DS - sarcoma of the rat ) were implanted s . c .
NO_RELATION	Four days after <e1> carboplatin </e1> treatment , tumors ( DS - <e2> sarcoma </e2> of the rat ) were implanted s . c .
NO_RELATION	Neither <e1> carboplatin </e1> nor rHuEPO treatment influenced <e2> tumor </e2> growth rate per se .
NO_RELATION	When <e2> tumors </e2> were treated with a single dose of <e1> cyclophosphamide </e1> ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .
NO_RELATION	When tumors were treated with a single dose of <e1> cyclophosphamide </e1> ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the <e2> tumors </e2> was observed .
NO_RELATION	These results suggest that chemotherapy - induced <e2> anemia </e2> reduces cytotoxicity of <e1> cyclophosphamide </e1> in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .
NO_RELATION	These results suggest that chemotherapy - induced anemia reduces <e2> cytotoxicity </e2> of <e1> cyclophosphamide </e1> in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .
NO_RELATION	These results suggest that chemotherapy - induced anemia reduces cytotoxicity of <e1> cyclophosphamide </e1> in <e2> tumors </e2> , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .
NO_RELATION	These results suggest that chemotherapy - induced anemia reduces cytotoxicity of <e1> cyclophosphamide </e1> in tumors , whereas correction of <e2> anemia </e2> by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .
NO_RELATION	These results suggest that chemotherapy - induced anemia reduces cytotoxicity of <e1> cyclophosphamide </e1> in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to <e2> tumor </e2> tissue .
NO_RELATION	These results suggest that chemotherapy - induced <e2> anemia </e2> reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved <e1> oxygen </e1> supply to tumor tissue .
NO_RELATION	These results suggest that chemotherapy - induced anemia reduces <e2> cytotoxicity </e2> of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved <e1> oxygen </e1> supply to tumor tissue .
NO_RELATION	These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in <e2> tumors </e2> , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved <e1> oxygen </e1> supply to tumor tissue .
NO_RELATION	These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of <e2> anemia </e2> by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved <e1> oxygen </e1> supply to tumor tissue .
NO_RELATION	These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved <e1> oxygen </e1> supply to <e2> tumor </e2> tissue .
CID	The role of nitrergic system in <e1> lidocaine </e1> - induced <e2> convulsion </e2> in the mouse .
NO_RELATION	The effects of <e1> N - nitro - L - arginine - methyl ester </e1> ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced <e2> convulsions </e2> .
NO_RELATION	The effects of N - nitro - L - arginine - methyl ester ( <e1> L - NAME </e1> ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced <e2> convulsions </e2> .
NO_RELATION	The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a <e1> nitric oxide </e1> ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced <e2> convulsions </e2> .
NO_RELATION	The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( <e1> NO </e1> ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced <e2> convulsions </e2> .
NO_RELATION	The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and <e1> L - arginine </e1> , a NO precursor , were investigated on lidocaine - induced <e2> convulsions </e2> .
NO_RELATION	The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a <e1> NO </e1> precursor , were investigated on lidocaine - induced <e2> convulsions </e2> .
CID	The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on <e1> lidocaine </e1> - induced <e2> convulsions </e2> .
NO_RELATION	<e1> L - NAME </e1> ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced <e2> convulsions </e2> .
NO_RELATION	L - NAME ( 100 mg / kg , i . p . ) and <e1> diazepam </e1> ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced <e2> convulsions </e2> .
CID	L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of <e1> lidocaine </e1> ( 50 mg / kg ) - induced <e2> convulsions </e2> .
NO_RELATION	In contrast , the <e1> L - arginine </e1> treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced <e2> convulsions </e2> significantly .
CID	In contrast , the L - arginine treatment increased the incidence of <e1> lidocaine </e1> ( 80 mg / kg , i . p . ) - induced <e2> convulsions </e2> significantly .
NO_RELATION	These results may suggest that <e1> NO </e1> is a proconvulsant mediator in lidocaine - induced <e2> convulsions </e2> .
CID	These results may suggest that NO is a proconvulsant mediator in <e1> lidocaine </e1> - induced <e2> convulsions </e2> .
NO_RELATION	Effect of intravenous <e1> metoprolol </e1> or intravenous metoprolol plus glucagon on dobutamine - induced <e2> myocardial ischemia </e2> .
NO_RELATION	Effect of intravenous metoprolol or intravenous <e1> metoprolol </e1> plus glucagon on dobutamine - induced <e2> myocardial ischemia </e2> .
CID	Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on <e1> dobutamine </e1> - induced <e2> myocardial ischemia </e2> .
CID	CONCLUSION : During <e1> dobutamine </e1> stress testing , metoprolol attenuates or eliminates evidence of <e2> myocardial ischemia </e2> .
NO_RELATION	CONCLUSION : During dobutamine stress testing , <e1> metoprolol </e1> attenuates or eliminates evidence of <e2> myocardial ischemia </e2> .
CID	<e1> Prednisolone </e1> - induced <e2> muscle dysfunction </e2> is caused more by atrophy than by altered acetylcholine receptor expression .
NO_RELATION	<e1> Prednisolone </e1> - induced muscle dysfunction is caused more by <e2> atrophy </e2> than by altered acetylcholine receptor expression .
NO_RELATION	Prednisolone - induced <e2> muscle dysfunction </e2> is caused more by atrophy than by altered <e1> acetylcholine </e1> receptor expression .
NO_RELATION	Prednisolone - induced muscle dysfunction is caused more by <e2> atrophy </e2> than by altered <e1> acetylcholine </e1> receptor expression .
NO_RELATION	On Day 8 , the nerve - evoked peak twitch tensions , <e2> tetanic </e2> tensions , and fatigability , and the dose - response curves of <e1> d - tubocurarine </e1> in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .
NO_RELATION	Our results suggest that the <e2> neuromuscular dysfunction </e2> after <e1> prednisolone </e1> is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .
CID	Our results suggest that the neuromuscular dysfunction after <e1> prednisolone </e1> is dose - dependent , and derives primarily from <e2> muscle atrophy </e2> and derives less so from changes in AChR expression .
NO_RELATION	We suggest that the observed effects are dose - dependent and derive primarily from <e2> muscle atrophy </e2> and derive less from changes in <e1> acetylcholine </e1> receptor expression .
CID	Rapid reversal of life - threatening <e1> diltiazem </e1> - induced <e2> tetany </e2> with calcium chloride .
NO_RELATION	Rapid reversal of life - threatening diltiazem - induced <e2> tetany </e2> with <e1> calcium chloride </e1> .
CID	We describe a patient who developed <e2> tetany </e2> with sudden respiratory arrest after the infusion of intravenous <e1> diltiazem </e1> .
NO_RELATION	We describe a patient who developed tetany with sudden <e2> respiratory arrest </e2> after the infusion of intravenous <e1> diltiazem </e1> .
NO_RELATION	The administration of <e1> calcium chloride </e1> rapidly resolved the patient ' s <e2> tetany </e2> with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .
CID	The emergency physician should be aware that life - threatening <e2> tetany </e2> may accompany the administration of intravenous <e1> diltiazem </e1> and that calcium chloride may be a rapid and effective remedy .
NO_RELATION	The emergency physician should be aware that life - threatening <e2> tetany </e2> may accompany the administration of intravenous diltiazem and that <e1> calcium chloride </e1> may be a rapid and effective remedy .
NO_RELATION	Patients with <e2> aneurysmal subarachnoid hemorrhage </e2> ( SAH ) were randomized to receive either <e1> ketoprofen </e1> , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( <e2> SAH </e2> ) were randomized to receive either <e1> ketoprofen </e1> , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either <e1> ketoprofen </e1> , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of <e2> aneurysmal </e2> SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either <e1> ketoprofen </e1> , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal <e2> SAH </e2> .
NO_RELATION	Patients with <e2> aneurysmal subarachnoid hemorrhage </e2> ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( <e1> ketoprofen </e1> group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( <e2> SAH </e2> ) were randomized to receive either ketoprofen , 100 mg , three times a day ( <e1> ketoprofen </e1> group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( <e1> ketoprofen </e1> group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of <e2> aneurysmal </e2> SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( <e1> ketoprofen </e1> group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal <e2> SAH </e2> .
NO_RELATION	Patients with <e2> aneurysmal subarachnoid hemorrhage </e2> ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , <e1> acetaminophen </e1> , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( <e2> SAH </e2> ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , <e1> acetaminophen </e1> , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , <e1> acetaminophen </e1> , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of <e2> aneurysmal </e2> SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , <e1> acetaminophen </e1> , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal <e2> SAH </e2> .
NO_RELATION	Patients with <e2> aneurysmal subarachnoid hemorrhage </e2> ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( <e1> acetaminophen </e1> group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( <e2> SAH </e2> ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( <e1> acetaminophen </e1> group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( <e1> acetaminophen </e1> group , n = 9 ) starting immediately after the diagnosis of <e2> aneurysmal </e2> SAH .
NO_RELATION	Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( <e1> acetaminophen </e1> group , n = 9 ) starting immediately after the diagnosis of aneurysmal <e2> SAH </e2> .
NO_RELATION	Maximal <e2> platelet aggregation </e2> induced by 6 microM of <e1> adenosine diphosphate </e1> decreased after administration of ketoprofen .
CID	Maximal <e2> platelet aggregation </e2> induced by 6 microM of adenosine diphosphate decreased after administration of <e1> ketoprofen </e1> .
NO_RELATION	In contrast , maximal <e2> platelet aggregation </e2> increased in the <e1> acetaminophen </e1> group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .
NO_RELATION	In contrast , maximal platelet aggregation increased in the <e1> acetaminophen </e1> group on the third postoperative day as compared with the pretreatment <e2> platelet aggregation </e2> results ( P < . 05 ) .
CID	One patient in the <e1> ketoprofen </e1> group developed a postoperative intracranial <e2> hematoma </e2> .
NO_RELATION	<e1> Ketoprofen </e1> but not acetaminophen impaired platelet function in patients with <e2> SAH </e2> .
NO_RELATION	Ketoprofen but not <e1> acetaminophen </e1> impaired platelet function in patients with <e2> SAH </e2> .
NO_RELATION	If <e1> ketoprofen </e1> is used before surgery on cerebral <e2> artery aneurysms </e2> , it may pose an additional risk factor for hemorrhage .
NO_RELATION	If <e1> ketoprofen </e1> is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for <e2> hemorrhage </e2> .
NO_RELATION	Value of <e1> methylprednisolone </e1> in prevention of the <e2> arthralgia </e2> - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .
NO_RELATION	Value of <e1> methylprednisolone </e1> in prevention of the arthralgia - <e2> myalgia </e2> syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .
CID	Value of methylprednisolone in prevention of the <e2> arthralgia </e2> - myalgia syndrome associated with the total dose infusion of <e1> iron dextran </e1> : a double blind randomized trial .
NO_RELATION	Value of methylprednisolone in prevention of the arthralgia - <e2> myalgia </e2> syndrome associated with the total dose infusion of <e1> iron dextran </e1> : a double blind randomized trial .
NO_RELATION	These data demonstrate that administration of <e1> MP </e1> before and after TDI reduces the frequency and severity of the <e2> arthralgia </e2> - myalgia syndrome .
NO_RELATION	These data demonstrate that administration of <e1> MP </e1> before and after TDI reduces the frequency and severity of the arthralgia - <e2> myalgia </e2> syndrome .
NO_RELATION	Forty patients with <e2> Non - Hodgkin ' s Lymphoma </e2> treated with <e1> vincristine </e1> between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .
NO_RELATION	Forty patients with <e2> Non - Hodgkin ' s Lymphoma </e2> treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of <e1> vincristine </e1> on the peripheral nervous system .
NO_RELATION	It is concluded that with the above mentioned <e1> vincristine </e1> dose schedule signs and symptoms of vincristine <e2> neuropathy </e2> are reversible for a great deal and prognosis is fairly good .
NO_RELATION	It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of <e1> vincristine </e1> <e2> neuropathy </e2> are reversible for a great deal and prognosis is fairly good .
CID	A case of <e2> polymyositis </e2> in a patient with primary biliary cirrhosis treated with <e1> D - penicillamine </e1> .
NO_RELATION	A case of polymyositis in a patient with <e2> primary biliary cirrhosis </e2> treated with <e1> D - penicillamine </e1> .
NO_RELATION	Although <e1> D - penicillamine </e1> has been used for many <e2> rheumatologic diseases </e2> , toxicity limits its usefulness in many patients .
NO_RELATION	Although <e1> D - penicillamine </e1> has been used for many rheumatologic diseases , <e2> toxicity </e2> limits its usefulness in many patients .
CID	<e2> Polymyositis </e2> / dermatomyositis can develop as one of the autoimmune complications of <e1> D - penicillamine </e1> treatment , but its exact pathogenesis remains unclear .
NO_RELATION	Polymyositis / <e2> dermatomyositis </e2> can develop as one of the autoimmune complications of <e1> D - penicillamine </e1> treatment , but its exact pathogenesis remains unclear .
NO_RELATION	We report a patient with <e2> primary biliary cirrhosis </e2> , who developed polymyositis while receiving <e1> D - penicillamine </e1> therapy .
CID	We report a patient with primary biliary cirrhosis , who developed <e2> polymyositis </e2> while receiving <e1> D - penicillamine </e1> therapy .
CID	Patients receiving <e1> D - penicillamine </e1> therapy should be followed carefully for the development of autoimmune complications like <e2> polymyositis </e2> / dermatomyositis .
NO_RELATION	Patients receiving <e1> D - penicillamine </e1> therapy should be followed carefully for the development of autoimmune complications like polymyositis / <e2> dermatomyositis </e2> .
CID	Photodistributed <e1> nifedipine </e1> - induced facial <e2> telangiectasia </e2> .
CID	Five months after starting <e1> nifedipine </e1> ( Adalat ) , two patients developed photodistributed facial <e2> telangiectasia </e2> , which became more noticeable with time .
CID	Five months after starting nifedipine ( <e1> Adalat </e1> ) , two patients developed photodistributed facial <e2> telangiectasia </e2> , which became more noticeable with time .
CID	One commenced the closely related drug <e1> amlodipine </e1> 3 years later , with recurrence of <e2> telangiectasia </e2> .
CID	<e2> Nephrotoxicity </e2> of <e1> cyclosporin A </e1> and FK506 : inhibition of calcineurin phosphatase .
CID	<e2> Nephrotoxicity </e2> of cyclosporin A and <e1> FK506 </e1> : inhibition of calcineurin phosphatase .
NO_RELATION	<e1> Cyclosporin A </e1> ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
NO_RELATION	Cyclosporin A ( <e1> CsA </e1> ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
NO_RELATION	Cyclosporin A ( CsA ; 50 mg / kg ) and <e1> Fujimycine </e1> ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
NO_RELATION	Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( <e1> FK506 </e1> ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
NO_RELATION	Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related <e1> macrolide </e1> immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
NO_RELATION	Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant <e1> rapamycin </e1> ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and <e2> hypertrophy </e2> of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
NO_RELATION	The molecular mechanisms of <e1> CsA </e1> and FK506 <e2> toxicity </e2> were investigated .
NO_RELATION	The molecular mechanisms of CsA and <e1> FK506 </e1> <e2> toxicity </e2> were investigated .
CID	These results suggest that the <e2> nephrotoxic </e2> effects of <e1> CsA </e1> and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .
CID	These results suggest that the <e2> nephrotoxic </e2> effects of CsA and <e1> FK506 </e1> is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .
CID	Massive <e2> cerebral edema </e2> associated with fulminant hepatic failure in <e1> acetaminophen </e1> overdose : possible role of cranial decompression .
CID	Massive cerebral edema associated with fulminant <e2> hepatic failure </e2> in <e1> acetaminophen </e1> overdose : possible role of cranial decompression .
NO_RELATION	Massive cerebral edema associated with fulminant hepatic failure in <e1> acetaminophen </e1> <e2> overdose </e2> : possible role of cranial decompression .
CID	We present a patient with fatal <e1> acetaminophen </e1> - induced <e2> fulminant hepatic failure </e2> , with signs and symptoms of cerebral edema , unresponsive to conventional medical therapy .
CID	We present a patient with fatal <e1> acetaminophen </e1> - induced fulminant hepatic failure , with signs and symptoms of <e2> cerebral edema </e2> , unresponsive to conventional medical therapy .
NO_RELATION	<e1> Gentamicin </e1> <e2> nephropathy </e2> in a neonate .
CID	The clinical and autopsy findings in a premature baby who died of <e2> acute renal failure </e2> after therapy with <e1> gentamicin </e1> ( 5 mg / kg / day ) and penicillin are presented .
NO_RELATION	The clinical and autopsy findings in a premature baby who died of <e2> acute renal failure </e2> after therapy with gentamicin ( 5 mg / kg / day ) and <e1> penicillin </e1> are presented .
NO_RELATION	The serum <e1> gentamicin </e1> concentration had reached toxic levels when <e2> anuria </e2> developed .
NO_RELATION	Anti - <e2> carcinogenic </e2> action of <e1> phenobarbital </e1> given simultaneously with diethylnitrosamine in the rat .
NO_RELATION	Anti - <e2> carcinogenic </e2> action of phenobarbital given simultaneously with <e1> diethylnitrosamine </e1> in the rat .
NO_RELATION	The present work has been planned in order to elucidate the effect of <e1> phenobarbital </e1> ( PB : 15 mg per rat of ingested dose ) on <e2> carcinogenesis </e2> when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .
NO_RELATION	The present work has been planned in order to elucidate the effect of phenobarbital ( <e1> PB </e1> : 15 mg per rat of ingested dose ) on <e2> carcinogenesis </e2> when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .
NO_RELATION	The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on <e2> carcinogenesis </e2> when it is administered simultaneously with <e1> diethylnitrosamine </e1> ( DEN : 10 mg / kg / day ) .
NO_RELATION	The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on <e2> carcinogenesis </e2> when it is administered simultaneously with diethylnitrosamine ( <e1> DEN </e1> : 10 mg / kg / day ) .
NO_RELATION	Wistar rats ( 180 g ) were treated by <e1> DEN </e1> alone or by DEN + PB during 2 , 4 and 6 weeks according to our schedule for <e2> hepatocarcinogenesis </e2> .
NO_RELATION	Wistar rats ( 180 g ) were treated by DEN alone or by <e1> DEN </e1> + PB during 2 , 4 and 6 weeks according to our schedule for <e2> hepatocarcinogenesis </e2> .
NO_RELATION	Wistar rats ( 180 g ) were treated by DEN alone or by DEN + <e1> PB </e1> during 2 , 4 and 6 weeks according to our schedule for <e2> hepatocarcinogenesis </e2> .
NO_RELATION	After the end of the treatment , the number and the size of induced PAS positive <e2> preneoplastic foci </e2> was significantly reduced when <e1> PB </e1> was given simultaneously with DEN for 4 and 6 weeks .
CID	After the end of the treatment , the number and the size of induced PAS positive <e2> preneoplastic foci </e2> was significantly reduced when PB was given simultaneously with <e1> DEN </e1> for 4 and 6 weeks .
NO_RELATION	In <e1> DEN </e1> + PB treated rats , the survival was prolonged and the <e2> tumor </e2> incidence decreased as compared with the results obtained by DEN alone .
NO_RELATION	In DEN + <e1> PB </e1> treated rats , the survival was prolonged and the <e2> tumor </e2> incidence decreased as compared with the results obtained by DEN alone .
NO_RELATION	In DEN + PB treated rats , the survival was prolonged and the <e2> tumor </e2> incidence decreased as compared with the results obtained by <e1> DEN </e1> alone .
NO_RELATION	It is concluded that <e1> PB </e1> , which promotes <e2> carcinogenesis </e2> when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .
NO_RELATION	It is concluded that PB , which promotes <e2> carcinogenesis </e2> when administered after the <e1> DEN </e1> treatment , reduces the carcinogen effect when given simultaneously with DEN .
NO_RELATION	It is concluded that PB , which promotes <e2> carcinogenesis </e2> when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with <e1> DEN </e1> .
CID	Post - operative <e2> rigidity </e2> after <e1> fentanyl </e1> administration .
CID	A case of thoraco - abdominal <e2> rigidity </e2> leading to respiratory failure is described in the post - operative period in an elderly patient who received a moderate dose of <e1> fentanyl </e1> .
NO_RELATION	A case of thoraco - abdominal rigidity leading to <e2> respiratory failure </e2> is described in the post - operative period in an elderly patient who received a moderate dose of <e1> fentanyl </e1> .
CID	Postpartum <e2> psychosis </e2> induced by <e1> bromocriptine </e1> .
NO_RELATION	Two multigravida patients with no prior <e2> psychiatric </e2> history were seen with postpartum psychosis , having received <e1> bromocriptine </e1> for inhibition of lactation .
CID	Two multigravida patients with no prior psychiatric history were seen with postpartum <e2> psychosis </e2> , having received <e1> bromocriptine </e1> for inhibition of lactation .
NO_RELATION	Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis , having received <e1> bromocriptine </e1> for <e2> inhibition of lactation </e2> .
CID	<e1> Bromocriptine </e1> given in high doses has been associated with <e2> psychosis </e2> in patients receiving the drug for Parkinson ' s disease .
NO_RELATION	<e1> Bromocriptine </e1> given in high doses has been associated with psychosis in patients receiving the drug for <e2> Parkinson ' s disease </e2> .
CID	These cases demonstrate that <e1> bromocriptine </e1> may cause <e2> psychosis </e2> even when given in low doses .
NO_RELATION	A prospective study on the dose dependency of <e2> cardiotoxicity </e2> induced by <e1> mitomycin C </e1> .
NO_RELATION	Since 1975 <e1> mitomycin C </e1> ( MMC ) has been suggested to be <e2> cardiotoxic </e2> , especially when combined with or given following doxorubicin .
NO_RELATION	Since 1975 mitomycin C ( <e1> MMC </e1> ) has been suggested to be <e2> cardiotoxic </e2> , especially when combined with or given following doxorubicin .
NO_RELATION	Since 1975 mitomycin C ( MMC ) has been suggested to be <e2> cardiotoxic </e2> , especially when combined with or given following <e1> doxorubicin </e1> .
CID	One of the patients developed <e2> cardiac failure </e2> after 30 mg m - 2 <e1> MMC </e1> and only 150 mg m - 2 doxorubicin .
CID	One of the patients developed <e2> cardiac failure </e2> after 30 mg m - 2 MMC and only 150 mg m - 2 <e1> doxorubicin </e1> .
NO_RELATION	Based on the combined data from the present study and the literature , we suggest that <e1> MMC </e1> - related <e2> cardiotoxicity </e2> is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .
NO_RELATION	Based on the combined data from the present study and the literature , we suggest that MMC - related <e2> cardiotoxicity </e2> is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with <e1> doxorubicin </e1> .
NO_RELATION	<e1> Phlorizin </e1> - induced <e2> glycosuria </e2> does not prevent gentamicin nephrotoxicity in rats .
NO_RELATION	<e1> Phlorizin </e1> - induced glycosuria does not prevent gentamicin <e2> nephrotoxicity </e2> in rats .
NO_RELATION	Phlorizin - induced <e2> glycosuria </e2> does not prevent <e1> gentamicin </e1> nephrotoxicity in rats .
NO_RELATION	Phlorizin - induced glycosuria does not prevent <e1> gentamicin </e1> <e2> nephrotoxicity </e2> in rats .
CID	Because rats with <e1> streptozotocin </e1> - induced <e2> diabetes mellitus </e2> ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .
CID	Because rats with <e1> streptozotocin </e1> - induced diabetes mellitus ( <e2> DM </e2> ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .
NO_RELATION	Because rats with <e1> streptozotocin </e1> - induced diabetes mellitus ( DM ) have a high solute diuresis ( <e2> glycosuria </e2> of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .
NO_RELATION	Because rats with <e1> streptozotocin </e1> - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced <e2> acute renal failure </e2> ( ARF ) .
NO_RELATION	Because rats with <e1> streptozotocin </e1> - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( <e2> ARF </e2> ) .
NO_RELATION	Because rats with streptozotocin - induced <e2> diabetes mellitus </e2> ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1> - induced acute renal failure ( ARF ) .
NO_RELATION	Because rats with streptozotocin - induced diabetes mellitus ( <e2> DM </e2> ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1> - induced acute renal failure ( ARF ) .
NO_RELATION	Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( <e2> glycosuria </e2> of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1> - induced acute renal failure ( ARF ) .
CID	Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1> - induced <e2> acute renal failure </e2> ( ARF ) .
CID	Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to <e1> gentamicin </e1> - induced acute renal failure ( <e2> ARF </e2> ) .
NO_RELATION	The protection from <e1> gentamicin </e1> <e2> nephrotoxicity </e2> was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .
NO_RELATION	The protection from <e1> gentamicin </e1> nephrotoxicity was studied in non - <e2> diabetic </e2> rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .
NO_RELATION	The protection from gentamicin <e2> nephrotoxicity </e2> was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular <e1> glucose </e1> reabsorption with phlorizin ( P ) .
NO_RELATION	The protection from gentamicin nephrotoxicity was studied in non - <e2> diabetic </e2> rats with chronic solute diuresis induced by blockage of tubular <e1> glucose </e1> reabsorption with phlorizin ( P ) .
NO_RELATION	The protection from gentamicin <e2> nephrotoxicity </e2> was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with <e1> phlorizin </e1> ( P ) .
NO_RELATION	The protection from gentamicin nephrotoxicity was studied in non - <e2> diabetic </e2> rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with <e1> phlorizin </e1> ( P ) .
NO_RELATION	The protection from gentamicin <e2> nephrotoxicity </e2> was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( <e1> P </e1> ) .
NO_RELATION	The protection from gentamicin nephrotoxicity was studied in non - <e2> diabetic </e2> rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( <e1> P </e1> ) .
NO_RELATION	<e2> DM </e2> rats with mild glycosuria ( similar in degree to that of the <e1> P </e1> treated animals ) were also studied .
NO_RELATION	DM rats with mild <e2> glycosuria </e2> ( similar in degree to that of the <e1> P </e1> treated animals ) were also studied .
NO_RELATION	Group 1 ( <e1> P </e1> alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild <e2> DM </e2> + gentamicin ) .
NO_RELATION	Group 1 ( P alone ) received <e1> P </e1> , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild <e2> DM </e2> + gentamicin ) .
NO_RELATION	Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( <e1> P </e1> + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild <e2> DM </e2> + gentamicin ) .
NO_RELATION	Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + <e1> gentamicin </e1> ) ; Group III ( gentamicin alone ) and Group IV ( mild <e2> DM </e2> + gentamicin ) .
NO_RELATION	Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( <e1> gentamicin </e1> alone ) and Group IV ( mild <e2> DM </e2> + gentamicin ) .
NO_RELATION	Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild <e2> DM </e2> + <e1> gentamicin </e1> ) .
NO_RELATION	<e2> Nephrotoxic </e2> doses ( 40 mg / kg body wt / day ) of <e1> gentamicin </e1> were injected during the last nine days of study to the animals of groups II to IV .
NO_RELATION	In Group I , <e1> P </e1> induced a moderate and stable <e2> glycosuria </e2> ( 3 . 9 + / - 0 . 1 g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .
NO_RELATION	In Group I , <e1> P </e1> induced a moderate and stable glycosuria ( 3 . 9 + / - 0 . 1 g / day , SE ) , and no functional or morphologic evidence of <e2> renal dysfunction </e2> ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .
NO_RELATION	In Group I , <e1> P </e1> induced a moderate and stable glycosuria ( 3 . 9 + / - 0 . 1 g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( <e2> tubular necrosis </e2> score [ maximum 4 ] , zero ) .
NO_RELATION	In Group II , <e1> P </e1> did not prevent gentamicin - <e2> ARF </e2> ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .
NO_RELATION	In Group II , <e1> P </e1> did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and <e2> tubular necrosis </e2> score , 3 . 9 + / - 0 . 1 ) .
CID	In Group II , P did not prevent <e1> gentamicin </e1> - <e2> ARF </e2> ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .
NO_RELATION	In Group II , P did not prevent <e1> gentamicin </e1> - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and <e2> tubular necrosis </e2> score , 3 . 9 + / - 0 . 1 ) .
NO_RELATION	In Group II , P did not prevent gentamicin - <e2> ARF </e2> ( maximal decrease in CCr at day 9 . 89 % , <e1> P </e1> less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .
NO_RELATION	In Group II , P did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , <e1> P </e1> less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and <e2> tubular necrosis </e2> score , 3 . 9 + / - 0 . 1 ) .
NO_RELATION	These values were not different from those of Group III : maximal decrease in CCr 73 % ( <e1> P </e1> less than 0 . 001 ) ; lysozymuria , 2147 + / - 701 micrograms / day ; <e2> tubular necrosis </e2> score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	<e1> Tiapride </e1> in levodopa - induced <e2> involuntary movements </e2> .
CID	Tiapride in <e1> levodopa </e1> - induced <e2> involuntary movements </e2> .
NO_RELATION	<e1> Tiapride </e1> , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose <e2> involuntary movements </e2> in 16 patients with idiopathic Parkinson ' s disease .
NO_RELATION	<e1> Tiapride </e1> , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with <e2> idiopathic Parkinson ' s disease </e2> .
NO_RELATION	Tiapride , a substituted <e1> benzamide </e1> derivative closely related to metoclopramide , reduced levodopa - induced peak dose <e2> involuntary movements </e2> in 16 patients with idiopathic Parkinson ' s disease .
NO_RELATION	Tiapride , a substituted <e1> benzamide </e1> derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with <e2> idiopathic Parkinson ' s disease </e2> .
NO_RELATION	Tiapride , a substituted benzamide derivative closely related to <e1> metoclopramide </e1> , reduced levodopa - induced peak dose <e2> involuntary movements </e2> in 16 patients with idiopathic Parkinson ' s disease .
NO_RELATION	Tiapride , a substituted benzamide derivative closely related to <e1> metoclopramide </e1> , reduced levodopa - induced peak dose involuntary movements in 16 patients with <e2> idiopathic Parkinson ' s disease </e2> .
CID	Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced <e1> levodopa </e1> - induced peak dose <e2> involuntary movements </e2> in 16 patients with idiopathic Parkinson ' s disease .
NO_RELATION	Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced <e1> levodopa </e1> - induced peak dose involuntary movements in 16 patients with <e2> idiopathic Parkinson ' s disease </e2> .
NO_RELATION	<e1> Tiapride </e1> had no effect on levodopa - induced early morning of " off - period " segmental <e2> dystonia </e2> .
NO_RELATION	Tiapride had no effect on <e1> levodopa </e1> - induced early morning of " off - period " segmental <e2> dystonia </e2> .
CID	These results fail to support the notion that <e1> levodopa </e1> - induced <e2> dyskinesias </e2> are caused by overstimulation of a separate group of dopamine receptors .
NO_RELATION	These results fail to support the notion that levodopa - induced <e2> dyskinesias </e2> are caused by overstimulation of a separate group of <e1> dopamine </e1> receptors .
NO_RELATION	Effects of the hippocampal deep brain stimulation on cortical <e2> epileptic </e2> discharges in <e1> penicillin </e1> - induced epilepsy model in rats .
NO_RELATION	Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in <e1> penicillin </e1> - induced <e2> epilepsy </e2> model in rats .
NO_RELATION	The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical <e2> epileptic </e2> activity in <e1> penicillin </e1> - induced epilepsy model .
NO_RELATION	The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in <e1> penicillin </e1> - induced <e2> epilepsy </e2> model .
NO_RELATION	RESULTS : High frequency hippocampal DBS suppressed the acute <e1> penicillin </e1> - induced cortical <e2> epileptic </e2> activity independent from stimulus intensity .
NO_RELATION	Neural correlates of <e1> S - ketamine </e1> induced <e2> psychosis </e2> during overt continuous verbal fluency .
NO_RELATION	The glutamatergic <e1> N - methyl - D - aspartate </e1> ( NMDA ) receptor has been implicated in the pathophysiology of <e2> schizophrenia </e2> .
NO_RELATION	The glutamatergic N - methyl - D - aspartate ( <e1> NMDA </e1> ) receptor has been implicated in the pathophysiology of <e2> schizophrenia </e2> .
NO_RELATION	Administered to healthy volunteers , a subanesthetic dose of the non - competitive <e1> NMDA </e1> receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in <e2> schizophrenia </e2> .
NO_RELATION	Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist <e1> ketamine </e1> leads to psychopathological symptoms similar to those observed in <e2> schizophrenia </e2> .
NO_RELATION	In patients with <e2> schizophrenia </e2> , <e1> ketamine </e1> exacerbates the core symptoms of illness , supporting the hypothesis of a glutamatergic dysfunction .
NO_RELATION	In patients with schizophrenia , <e1> ketamine </e1> exacerbates the core symptoms of illness , supporting the hypothesis of a <e2> glutamatergic dysfunction </e2> .
CID	<e1> Ketamine </e1> elicited <e2> psychosis </e2> like psychopathology .
NO_RELATION	<e1> Ketamine </e1> induces activation changes in healthy subjects similar to those observed in patients with <e2> schizophrenia </e2> , particularly in frontal and temporal brain regions .
NO_RELATION	Our results provide further support for the hypothesis of an <e1> NMDA </e1> receptor dysfunction in the pathophysiology of <e2> schizophrenia </e2> .
NO_RELATION	<e1> Dopamine </e1> is not essential for the development of methamphetamine - induced <e2> neurotoxicity </e2> .
CID	Dopamine is not essential for the development of <e1> methamphetamine </e1> - induced <e2> neurotoxicity </e2> .
NO_RELATION	It is widely believed that <e1> dopamine </e1> ( DA ) mediates methamphetamine ( METH ) - induced <e2> toxicity </e2> to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that <e1> dopamine </e1> ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2> , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that <e1> dopamine </e1> ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2> .
NO_RELATION	It is widely believed that dopamine ( <e1> DA </e1> ) mediates methamphetamine ( METH ) - induced <e2> toxicity </e2> to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( <e1> DA </e1> ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2> , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( <e1> DA </e1> ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2> .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates <e1> methamphetamine </e1> ( METH ) - induced <e2> toxicity </e2> to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates <e1> methamphetamine </e1> ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2> , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates <e1> methamphetamine </e1> ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2> .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( <e1> METH </e1> ) - induced <e2> toxicity </e2> to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( <e1> METH </e1> ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2> , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( <e1> METH </e1> ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2> .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced <e2> toxicity </e2> to brain dopaminergic neurons , because drugs that interfere with <e1> DA </e1> neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with <e1> DA </e1> neurotransmission decrease <e2> toxicity </e2> , whereas drugs that increase DA neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with <e1> DA </e1> neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance <e2> toxicity </e2> .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced <e2> toxicity </e2> to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase <e1> DA </e1> neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease <e2> toxicity </e2> , whereas drugs that increase <e1> DA </e1> neurotransmission enhance toxicity .
NO_RELATION	It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase <e1> DA </e1> neurotransmission enhance <e2> toxicity </e2> .
NO_RELATION	Here we show that the recently reported ability of <e1> L - dihydroxyphenylalanine </e1> to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA <e2> neurotoxicity </e2> is also confounded by drug effects on body temperature .
NO_RELATION	Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of <e1> alpha - methyl - para - tyrosine </e1> on METH - induced DA <e2> neurotoxicity </e2> is also confounded by drug effects on body temperature .
CID	Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on <e1> METH </e1> - induced DA <e2> neurotoxicity </e2> is also confounded by drug effects on body temperature .
NO_RELATION	Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced <e1> DA </e1> <e2> neurotoxicity </e2> is also confounded by drug effects on body temperature .
NO_RELATION	Further , we show that mice genetically engineered to be deficient in brain <e1> DA </e1> develop METH <e2> neurotoxicity </e2> , as long as the thermic effects of METH are preserved .
CID	Further , we show that mice genetically engineered to be deficient in brain DA develop <e1> METH </e1> <e2> neurotoxicity </e2> , as long as the thermic effects of METH are preserved .
CID	Further , we show that mice genetically engineered to be deficient in brain DA develop METH <e2> neurotoxicity </e2> , as long as the thermic effects of <e1> METH </e1> are preserved .
NO_RELATION	In addition , we demonstrate that mice genetically engineered to have unilateral brain <e1> DA </e1> deficits develop METH - induced <e2> dopaminergic deficits </e2> that are of comparable magnitude on both sides of the brain .
NO_RELATION	In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop <e1> METH </e1> - induced <e2> dopaminergic deficits </e2> that are of comparable magnitude on both sides of the brain .
NO_RELATION	Taken together , these findings demonstrate that <e1> DA </e1> is not essential for the development of METH - induced dopaminergic <e2> neurotoxicity </e2> and suggest that mechanisms independent of DA warrant more intense investigation .
CID	Taken together , these findings demonstrate that DA is not essential for the development of <e1> METH </e1> - induced dopaminergic <e2> neurotoxicity </e2> and suggest that mechanisms independent of DA warrant more intense investigation .
NO_RELATION	Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic <e2> neurotoxicity </e2> and suggest that mechanisms independent of <e1> DA </e1> warrant more intense investigation .
NO_RELATION	<e2> Brainstem dysgenesis </e2> in an infant prenatally exposed to <e1> cocaine </e1> .
CID	The protective role of Nrf2 in <e1> streptozotocin </e1> - induced <e2> diabetic nephropathy </e2> .
NO_RELATION	OBJECTIVE : <e2> Diabetic nephropathy </e2> is one of the major causes of renal failure , which is accompanied by the production of reactive <e1> oxygen </e1> species ( ROS ) .
NO_RELATION	OBJECTIVE : Diabetic nephropathy is one of the major causes of <e2> renal failure </e2> , which is accompanied by the production of reactive <e1> oxygen </e1> species ( ROS ) .
CID	RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against <e2> diabetic nephropathy </e2> using human kidney biopsy tissues from diabetic nephropathy patients , a <e1> streptozotocin </e1> - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .
CID	RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from <e2> diabetic nephropathy </e2> patients , a <e1> streptozotocin </e1> - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .
CID	RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients , a <e1> streptozotocin </e1> - induced <e2> diabetic nephropathy </e2> model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .
NO_RELATION	In the animal study , Nrf2 was demonstrated to be crucial in ameliorating <e1> streptozotocin </e1> - induced <e2> renal damage </e2> .
CID	High - dose <e1> tranexamic Acid </e1> is associated with nonischemic clinical <e2> seizures </e2> in cardiac surgical patients .
CID	The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between <e1> TXA </e1> usage and <e2> seizures </e2> after cardiac surgery .
CID	All 24 patients with <e2> seizures </e2> received high doses of <e1> TXA </e1> intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .
CID	CONCLUSION : Our results suggest that use of high - dose <e1> TXA </e1> in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical <e2> seizures </e2> in susceptible patients .
CID	Recurrent <e2> dysosmia </e2> induced by <e1> pyrazinamide </e1> .
NO_RELATION	<e1> Pyrazinamide </e1> can have adverse effects such as <e2> hepatic toxicity </e2> , hyperuricemia or digestive disorders .
NO_RELATION	<e1> Pyrazinamide </e1> can have adverse effects such as hepatic toxicity , <e2> hyperuricemia </e2> or digestive disorders .
CID	We report a case of reversible <e2> olfactory disorder </e2> related to <e1> pyrazinamide </e1> in a woman , with a positive rechallenge .
CID	<e2> Dysosmia </e2> disappeared completely after <e1> pyrazinamide </e1> withdrawal and recurred after its rechallenge .
NO_RELATION	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of <e1> difluoromethylornithine </e1> and sulindac for prevention of sporadic <e2> colorectal adenomas </e2> .
NO_RELATION	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and <e1> sulindac </e1> for prevention of sporadic <e2> colorectal adenomas </e2> .
NO_RELATION	A phase III clinical trial assessed the recurrence of <e2> adenomatous polyps </e2> after treatment for 36 months with <e1> difluoromethylornithine </e1> ( DFMO ) plus sulindac or matched placebos .
NO_RELATION	A phase III clinical trial assessed the recurrence of <e2> adenomatous polyps </e2> after treatment for 36 months with difluoromethylornithine ( <e1> DFMO </e1> ) plus sulindac or matched placebos .
NO_RELATION	A phase III clinical trial assessed the recurrence of <e2> adenomatous polyps </e2> after treatment for 36 months with difluoromethylornithine ( DFMO ) plus <e1> sulindac </e1> or matched placebos .
NO_RELATION	Temporary <e2> hearing loss </e2> is a known toxicity of treatment with <e1> DFMO </e1> , thus a comprehensive approach was developed to analyze serial air conduction audiograms .
NO_RELATION	Temporary hearing loss is a known <e2> toxicity </e2> of treatment with <e1> DFMO </e1> , thus a comprehensive approach was developed to analyze serial air conduction audiograms .
NO_RELATION	There was no significant difference in the proportion of subjects in the <e1> DFMO </e1> plus sulindac group who experienced clinically significant <e2> hearing loss </e2> compared with the placebo group .
CID	There was no significant difference in the proportion of subjects in the DFMO plus <e1> sulindac </e1> group who experienced clinically significant <e2> hearing loss </e2> compared with the placebo group .
CID	Increased <e2> mental slowing </e2> associated with the APOE epsilon4 allele after <e1> trihexyphenidyl </e1> oral anticholinergic challenge in healthy elderly .
NO_RELATION	OBJECTIVES : The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of <e1> trihexyphenidyl </e1> on measures reflecting sedation and <e2> confusion </e2> and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .
NO_RELATION	OBJECTIVES : The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and <e2> confusion </e2> and to investigate the relationship between <e1> trihexyphenidyl </e1> - induced subjective effects and objective memory performance .
CID	RESULTS : A 2 . 0 - mg oral dose of <e1> trihexyphenidyl </e1> resulted in increased subjective ratings of <e2> mental slowness </e2> in carriers of the APOE epsilon4 allele only .
CID	Drug effects as determined by difference scores between 2 . 0 mg <e1> trihexyphenidyl </e1> and placebo on ratings of <e2> mental slowness </e2> significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only .
CID	CONCLUSION : The epsilon4 allele in healthy elderly was associated with increased subjective <e2> mental slowing </e2> after <e1> trihexyphenidyl </e1> anticholinergic challenge .
NO_RELATION	Chronic exposure to <e1> PCPA </e1> alone significantly decreased locomotor activity and increased <e2> irritability </e2> but had no effect on sexual behavior , partner preference , or aggression .
NO_RELATION	Chronic exposure to <e1> PCPA </e1> alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior , partner preference , or <e2> aggression </e2> .
CID	<e1> T </e1> alone had no effect on locomotion , <e2> irritability </e2> , or sexual behavior but increased partner preference and aggression .
CID	<e1> T </e1> alone had no effect on locomotion , irritability , or sexual behavior but increased partner preference and <e2> aggression </e2> .
NO_RELATION	Based on these data , it can be speculated that pubertal AAS users with low central <e1> 5 - HT </e1> may be especially prone to exhibit <e2> aggressive behavior </e2> .
NO_RELATION	Intracavitary chemotherapy ( <e1> paclitaxel </e1> / carboplatin liquid crystalline cubic phases ) for recurrent <e2> glioblastoma </e2> - - clinical observations .
NO_RELATION	Intracavitary chemotherapy ( paclitaxel / <e1> carboplatin </e1> liquid crystalline cubic phases ) for recurrent <e2> glioblastoma </e2> - - clinical observations .
NO_RELATION	For human <e2> glioblastoma </e2> recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of <e1> paclitaxel </e1> and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .
NO_RELATION	For human <e2> glioblastoma </e2> recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and <e1> carboplatin </e1> encapsulated by liquid crystalline cubic phases are examined in a pilot study .
NO_RELATION	A total of 12 patients with a recurrence of a <e2> glioblastoma </e2> multiforme underwent re - resection and received an intracavitary application of <e1> paclitaxel </e1> and carboplatin cubic phases in different dosages .
NO_RELATION	A total of 12 patients with a recurrence of a <e2> glioblastoma </e2> multiforme underwent re - resection and received an intracavitary application of paclitaxel and <e1> carboplatin </e1> cubic phases in different dosages .
CID	Six of the patients received more than 15 mg <e1> paclitaxel </e1> and suffered from moderate to severe <e2> brain edema </e2> , while the remaining patients received only a total of 15 mg paclitaxel .
CID	Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe <e2> brain edema </e2> , while the remaining patients received only a total of 15 mg <e1> paclitaxel </e1> .
CID	<e1> Methylphenidate </e1> - induced <e2> obsessive - compulsive symptoms </e2> in an elderly man .
NO_RELATION	An 82 - year - old man with <e2> treatment - resistant depression </e2> and early Alzheimer ' s disease was started on <e1> methylphenidate </e1> .
NO_RELATION	An 82 - year - old man with treatment - resistant depression and early <e2> Alzheimer ' s disease </e2> was started on <e1> methylphenidate </e1> .
CID	Significant <e2> obsessive - compulsive behavior </e2> ensued but diminished over several weeks when <e1> methylphenidate </e1> was replaced by fluvoxamine .
NO_RELATION	Significant <e2> obsessive - compulsive behavior </e2> ensued but diminished over several weeks when methylphenidate was replaced by <e1> fluvoxamine </e1> .
CID	<e2> Cardiac arrest </e2> after intravenous <e1> metoclopramide </e1> - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest .
CID	Cardiac arrest after intravenous <e1> metoclopramide </e1> - a case of five repeated injections of metoclopramide causing five episodes of <e2> cardiac arrest </e2> .
CID	<e2> Cardiac arrest </e2> after intravenous metoclopramide - a case of five repeated injections of <e1> metoclopramide </e1> causing five episodes of cardiac arrest .
CID	Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of <e1> metoclopramide </e1> causing five episodes of <e2> cardiac arrest </e2> .
CID	We describe a patient where intravenous injection of <e1> metoclopramide </e1> was immediately followed by <e2> asystole </e2> repeatedly .
CID	After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of <e1> metoclopramide </e1> was immediately ( within s ) followed by <e2> asystole </e2> .
CID	We interpret this as episodes of <e2> cardiac arrest </e2> caused by <e1> metoclopramide </e1> .
CID	Severe immune <e2> hemolytic anemia </e2> associated with prophylactic use of <e1> cefotetan </e1> in obstetric and gynecologic procedures .
NO_RELATION	Second - and third - generation <e1> cephalosporins </e1> , especially cefotetan , are increasingly associated with severe , sometimes fatal immune <e2> hemolytic anemia </e2> .
CID	Second - and third - generation cephalosporins , especially <e1> cefotetan </e1> , are increasingly associated with severe , sometimes fatal immune <e2> hemolytic anemia </e2> .
CID	We noticed that 10 of our 35 cases of <e1> cefotetan </e1> - induced <e2> hemolytic anemias </e2> were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .
CID	We noticed that 10 of our 35 cases of cefotetan - induced <e2> hemolytic anemias </e2> were in patients who had received <e1> cefotetan </e1> prophylactically for obstetric and gynecologic procedures .
CID	<e2> Cauda equina syndrome </e2> after spinal anaesthesia with hyperbaric 5 % <e1> lignocaine </e1> : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .
CID	Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % <e1> lignocaine </e1> : a review of six cases of <e2> cauda equina syndrome </e2> reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .
NO_RELATION	Three of the cases were most likely caused by direct <e2> neurotoxicity </e2> of hyperbaric 5 % <e1> lignocaine </e1> .
NO_RELATION	Cortical motor overactivation in <e2> parkinsonian </e2> patients with <e1> L - dopa </e1> - induced peak - dose dyskinesia .
CID	Cortical motor overactivation in parkinsonian patients with <e1> L - dopa </e1> - induced peak - dose <e2> dyskinesia </e2> .
NO_RELATION	We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of <e2> parkinsonian </e2> patients on <e1> L - dopa </e1> medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .
CID	We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on <e1> L - dopa </e1> medication , the first one without L - dopa induced <e2> dyskinesia </e2> ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .
CID	We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on <e1> L - dopa </e1> medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose <e2> dyskinesia </e2> ( n = 15 ) , and of a group of 14 normal subjects .
NO_RELATION	We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of <e2> parkinsonian </e2> patients on L - dopa medication , the first one without <e1> L - dopa </e1> induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .
CID	We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without <e1> L - dopa </e1> induced <e2> dyskinesia </e2> ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .
CID	We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without <e1> L - dopa </e1> induced dyskinesia ( n = 23 ) and the other with moderate peak - dose <e2> dyskinesia </e2> ( n = 15 ) , and of a group of 14 normal subjects .
NO_RELATION	These results are compatible with the hypothesis that an <e2> hyperkinetic </e2> abnormal involuntary movement , like <e1> L - dopa </e1> - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .
CID	These results are compatible with the hypothesis that an hyperkinetic <e2> abnormal involuntary movement </e2> , like <e1> L - dopa </e1> - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .
CID	These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement , like <e1> L - dopa </e1> - induced peak dose <e2> dyskinesia </e2> , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .
CID	<e1> Dexamethasone </e1> - induced <e2> ocular hypertension </e2> in perfusion - cultured human eyes .
CID	In contrast , the <e1> dexamethasone </e1> - treated <e2> hypertensive eyes </e2> had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .
CID	CONCLUSION : <e1> Dexamethasone </e1> treatment of isolated , perfusion - cultured human eyes led to the generation of <e2> ocular hypertension </e2> in approximately 30 % of the dexamethasone - treated eyes .
CID	CONCLUSION : Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of <e2> ocular hypertension </e2> in approximately 30 % of the <e1> dexamethasone </e1> - treated eyes .
NO_RELATION	<e1> Steroid </e1> treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for <e2> corticosteroid glaucoma </e2> and open angle glaucoma .
NO_RELATION	<e1> Steroid </e1> treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and <e2> open angle glaucoma </e2> .
CID	<e2> Cognitive deterioration </e2> from long - term abuse of <e1> dextromethorphan </e1> : a case report .
CID	This report describes a case of <e2> cognitive deterioration </e2> resulting from prolonged use of <e1> DM </e1> .
CID	Complete <e2> heart block </e2> following a single dose of <e1> trazodone </e1> .
CID	Forty minutes after receiving a single starting dose of <e1> trazodone </e1> , a patient developed complete <e2> heart block </e2> .
CID	<e1> Quinidine phenylethylbarbiturate </e1> - induced fulminant <e2> hepatitis </e2> in a pregnant woman .
CID	We report the case of a 19 - year - old Laotian patient affected by fulminant <e2> hepatitis </e2> during the third trimester of her pregnancy after a 1 - month administration of <e1> quinidine phenylethylbarbiturate </e1> .
NO_RELATION	<e1> Quinidine </e1> itself or phenylethylbarbiturate may be responsible for fulminant <e2> hepatitis </e2> in this patient .
CID	Quinidine itself or <e1> phenylethylbarbiturate </e1> may be responsible for fulminant <e2> hepatitis </e2> in this patient .
CID	The epidemiology of the acute <e2> flank pain </e2> syndrome from <e1> suprofen </e1> .
NO_RELATION	Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from <e2> hay fever </e2> and asthma ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use <e1> alcohol </e1> ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .
NO_RELATION	Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from hay fever and <e2> asthma </e2> ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use <e1> alcohol </e1> ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .
NO_RELATION	Possible risk factors included young age , concurrent use of other analgesic agents ( especially <e1> ibuprofen </e1> ) , preexisting <e2> renal disease </e2> , a history of kidney stones , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .
NO_RELATION	Possible risk factors included young age , concurrent use of other analgesic agents ( especially <e1> ibuprofen </e1> ) , preexisting renal disease , a history of <e2> kidney stones </e2> , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .
NO_RELATION	Possible risk factors included young age , concurrent use of other analgesic agents ( especially <e1> ibuprofen </e1> ) , preexisting renal disease , a history of kidney stones , a history of <e2> gout </e2> , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .
CID	<e2> Hemolytic - uremic syndrome </e2> associated with ingestion of <e1> quinine </e1> .
CID	<e2> Hemolytic - uremic syndrome </e2> following <e1> quinine </e1> ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .
CID	<e1> Quinine </e1> - associated <e2> hemolytic - uremic syndrome </e2> probably occurs more often than is recognized .
NO_RELATION	The disease occurred subsequent to the initiation of <e1> heparin </e1> therapy for suspected pelvic <e2> thrombophlebitis </e2> and cleared rapidly subsequent to its discontinuation .
CID	Changes in peroxisomes in preneoplastic liver and <e2> hepatoma </e2> of mice induced by <e1> alpha - benzene hexachloride </e1> .
CID	Peroxisomes in <e2> hepatomas </e2> and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm <e1> alpha - benzene hexachloride </e1> were examined histochemically and electron microscopically .
NO_RELATION	Peroxisomes in hepatomas and hyperplastic preneoplastic <e2> liver lesions </e2> induced in mice by 500 ppm <e1> alpha - benzene hexachloride </e1> were examined histochemically and electron microscopically .
NO_RELATION	Although most of the <e2> hepatomas </e2> were well - differentiated tumors and contained a considerable number of peroxisomes , the tumor cells did not respond to <e1> ethyl - alpha - p - chlorophenoxyisobutyrate </e1> with proliferation of peroxisomes .
NO_RELATION	Although most of the hepatomas were well - differentiated <e2> tumors </e2> and contained a considerable number of peroxisomes , the tumor cells did not respond to <e1> ethyl - alpha - p - chlorophenoxyisobutyrate </e1> with proliferation of peroxisomes .
NO_RELATION	Although most of the hepatomas were well - differentiated tumors and contained a considerable number of peroxisomes , the <e2> tumor </e2> cells did not respond to <e1> ethyl - alpha - p - chlorophenoxyisobutyrate </e1> with proliferation of peroxisomes .
CID	<e1> Quinidine </e1> <e2> hepatitis </e2> .
CID	We concluded that this patient had <e1> quinidine </e1> <e2> hepatotoxicity </e2> and believe that this is the first case reported with liver biopsy documentation .
NO_RELATION	In addition to its use as a stabilizer / rigidifier of membranes , <e1> cholesteryl hemisuccinate </e1> , tris salt ( CS ) administration has also been shown to protect rats from the <e2> hepatotoxic </e2> effects of carbon tetrachloride ( CCl4 ) .
NO_RELATION	In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , <e1> tris salt </e1> ( CS ) administration has also been shown to protect rats from the <e2> hepatotoxic </e2> effects of carbon tetrachloride ( CCl4 ) .
NO_RELATION	In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( <e1> CS </e1> ) administration has also been shown to protect rats from the <e2> hepatotoxic </e2> effects of carbon tetrachloride ( CCl4 ) .
CID	In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the <e2> hepatotoxic </e2> effects of <e1> carbon tetrachloride </e1> ( CCl4 ) .
CID	In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the <e2> hepatotoxic </e2> effects of carbon tetrachloride ( <e1> CCl4 </e1> ) .
NO_RELATION	To further our understanding of the mechanism of <e1> CS </e1> cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of <e1> CS </e1> and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of <e1> CS </e1> , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , <e1> gamma - cholesteryloxybutyric acid </e1> , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , <e1> tris salt </e1> ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( <e1> CSE </e1> ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against <e1> acetaminophen </e1> - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , <e1> adriamycin </e1> - , carbon tetrachloride - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , <e1> carbon tetrachloride </e1> - , chloroform - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , <e1> chloroform </e1> - and galactosamine - induced <e2> toxicity </e2> .
NO_RELATION	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and <e1> galactosamine </e1> - induced <e2> toxicity </e2> .
NO_RELATION	A 24 - h pretreatment of both rats and mice with a single dose of <e1> CS </e1> ( 100mg / kg , i . p . ) , resulted in significant protection against the <e2> hepatotoxic </e2> effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .
NO_RELATION	A 24 - h pretreatment of both rats and mice with a single dose of <e1> CS </e1> ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably <e2> cardiotoxic </e2> ) effect of adriamycin administration .
CID	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the <e2> hepatotoxic </e2> effects of <e1> CCl4 </e1> , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .
NO_RELATION	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of <e1> CCl4 </e1> , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably <e2> cardiotoxic </e2> ) effect of adriamycin administration .
CID	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the <e2> hepatotoxic </e2> effects of CCl4 , <e1> CHCl3 </e1> , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .
NO_RELATION	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , <e1> CHCl3 </e1> , acetaminophen and galactosamine and against the lethal ( and presumably <e2> cardiotoxic </e2> ) effect of adriamycin administration .
CID	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the <e2> hepatotoxic </e2> effects of CCl4 , CHCl3 , <e1> acetaminophen </e1> and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .
NO_RELATION	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , <e1> acetaminophen </e1> and galactosamine and against the lethal ( and presumably <e2> cardiotoxic </e2> ) effect of adriamycin administration .
CID	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the <e2> hepatotoxic </e2> effects of CCl4 , CHCl3 , acetaminophen and <e1> galactosamine </e1> and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .
NO_RELATION	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and <e1> galactosamine </e1> and against the lethal ( and presumably <e2> cardiotoxic </e2> ) effect of adriamycin administration .
NO_RELATION	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the <e2> hepatotoxic </e2> effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of <e1> adriamycin </e1> administration .
CID	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably <e2> cardiotoxic </e2> ) effect of <e1> adriamycin </e1> administration .
NO_RELATION	The mechanism of <e1> CS </e1> protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine <e2> hepatotoxicity </e2> ) .
CID	The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against <e1> galactosamine </e1> <e2> hepatotoxicity </e2> ) .
NO_RELATION	DSMM XI study : dose definition for intravenous <e1> cyclophosphamide </e1> in combination with bortezomib / dexamethasone for remission induction in patients with newly diagnosed <e2> myeloma </e2> .
NO_RELATION	DSMM XI study : dose definition for intravenous cyclophosphamide in combination with <e1> bortezomib </e1> / dexamethasone for remission induction in patients with newly diagnosed <e2> myeloma </e2> .
NO_RELATION	DSMM XI study : dose definition for intravenous cyclophosphamide in combination with bortezomib / <e1> dexamethasone </e1> for remission induction in patients with newly diagnosed <e2> myeloma </e2> .
NO_RELATION	A clinical trial was initiated to evaluate the recommended dose of <e1> cyclophosphamide </e1> in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed <e2> multiple myeloma </e2> ( MM ) .
NO_RELATION	A clinical trial was initiated to evaluate the recommended dose of <e1> cyclophosphamide </e1> in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( <e2> MM </e2> ) .
NO_RELATION	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with <e1> bortezomib </e1> and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed <e2> multiple myeloma </e2> ( MM ) .
NO_RELATION	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with <e1> bortezomib </e1> and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( <e2> MM </e2> ) .
NO_RELATION	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and <e1> dexamethasone </e1> as induction treatment before stem cell transplantation for younger patients with newly diagnosed <e2> multiple myeloma </e2> ( MM ) .
NO_RELATION	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and <e1> dexamethasone </e1> as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( <e2> MM </e2> ) .
NO_RELATION	The results suggest that <e1> bortezomib </e1> in combination with cyclophosphamide at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed <e2> MM </e2> that warrants further investigation .
NO_RELATION	The results suggest that bortezomib in combination with <e1> cyclophosphamide </e1> at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed <e2> MM </e2> that warrants further investigation .
NO_RELATION	The results suggest that bortezomib in combination with cyclophosphamide at 900 mg / m ( 2 ) and <e1> dexamethasone </e1> is an effective induction treatment for patients with newly diagnosed <e2> MM </e2> that warrants further investigation .
NO_RELATION	Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of <e1> telmisartan </e1> and amlodipine versus amlodipine monotherapy in Indian adults with stage II <e2> hypertension </e2> .
NO_RELATION	Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and <e1> amlodipine </e1> versus amlodipine monotherapy in Indian adults with stage II <e2> hypertension </e2> .
NO_RELATION	Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus <e1> amlodipine </e1> monotherapy in Indian adults with stage II <e2> hypertension </e2> .
NO_RELATION	OBJECTIVE : The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of <e1> telmisartan </e1> 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II <e2> hypertension </e2> .
NO_RELATION	OBJECTIVE : The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + <e1> amlodipine </e1> 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II <e2> hypertension </e2> .
NO_RELATION	OBJECTIVE : The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with <e1> amlodipine </e1> 5 - mg monotherapy ( A ) in adult Indian patients with stage II <e2> hypertension </e2> .
CID	<e2> Cutaneous leucocytoclastic vasculitis </e2> associated with <e1> oxacillin </e1> .
NO_RELATION	A 67 - year - old man who was treated with <e1> oxacillin </e1> for one week because of <e2> Staphylococcus aureus bacteremia </e2> , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .
CID	A 67 - year - old man who was treated with <e1> oxacillin </e1> for one week because of Staphylococcus aureus bacteremia , developed <e2> renal failure </e2> and diffuse , symmetric , palpable purpuric lesions on his feet .
NO_RELATION	A 67 - year - old man who was treated with <e1> oxacillin </e1> for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable <e2> purpuric lesions </e2> on his feet .
CID	<e1> Oxacillin </e1> should be included among the drugs that can cause <e2> leucocytoclastic vasculitis </e2> .
NO_RELATION	Pretreatment with <e1> naloxazone </e1> significantly blocked morphine <e2> analgesia </e2> , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .
NO_RELATION	Pretreatment with <e1> naloxazone </e1> significantly blocked morphine analgesia , <e2> catalepsy </e2> and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .
NO_RELATION	Pretreatment with <e1> naloxazone </e1> significantly blocked morphine analgesia , catalepsy and <e2> hypothermia </e2> at a dose which completely eliminated high - affinity binding in brain membranes .
NO_RELATION	Pretreatment with naloxazone significantly blocked <e1> morphine </e1> <e2> analgesia </e2> , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .
CID	Pretreatment with naloxazone significantly blocked <e1> morphine </e1> analgesia , <e2> catalepsy </e2> and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .
CID	Pretreatment with naloxazone significantly blocked <e1> morphine </e1> analgesia , catalepsy and <e2> hypothermia </e2> at a dose which completely eliminated high - affinity binding in brain membranes .
NO_RELATION	Moreover , <e1> naloxazone </e1> significantly attenuated the morphine - induced <e2> hypotension </e2> and respiratory depression , whereas morphine - induced bradycardia was less affected .
NO_RELATION	Moreover , <e1> naloxazone </e1> significantly attenuated the morphine - induced hypotension and <e2> respiratory depression </e2> , whereas morphine - induced bradycardia was less affected .
NO_RELATION	Moreover , <e1> naloxazone </e1> significantly attenuated the morphine - induced hypotension and respiratory depression , whereas morphine - induced <e2> bradycardia </e2> was less affected .
CID	Moreover , naloxazone significantly attenuated the <e1> morphine </e1> - induced <e2> hypotension </e2> and respiratory depression , whereas morphine - induced bradycardia was less affected .
NO_RELATION	Moreover , naloxazone significantly attenuated the <e1> morphine </e1> - induced hypotension and <e2> respiratory depression </e2> , whereas morphine - induced bradycardia was less affected .
CID	Moreover , naloxazone significantly attenuated the <e1> morphine </e1> - induced hypotension and respiratory depression , whereas morphine - induced <e2> bradycardia </e2> was less affected .
CID	Moreover , naloxazone significantly attenuated the morphine - induced <e2> hypotension </e2> and respiratory depression , whereas <e1> morphine </e1> - induced bradycardia was less affected .
NO_RELATION	Moreover , naloxazone significantly attenuated the morphine - induced hypotension and <e2> respiratory depression </e2> , whereas <e1> morphine </e1> - induced bradycardia was less affected .
CID	Moreover , naloxazone significantly attenuated the morphine - induced hypotension and respiratory depression , whereas <e1> morphine </e1> - induced <e2> bradycardia </e2> was less affected .
NO_RELATION	<e1> Dexrazoxane </e1> protects against <e2> myelosuppression </e2> from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .
NO_RELATION	Dexrazoxane protects against <e2> myelosuppression </e2> from the DNA cleavage - enhancing drugs <e1> etoposide </e1> and daunorubicin but not doxorubicin .
NO_RELATION	Dexrazoxane protects against <e2> myelosuppression </e2> from the DNA cleavage - enhancing drugs etoposide and <e1> daunorubicin </e1> but not doxorubicin .
NO_RELATION	Dexrazoxane protects against <e2> myelosuppression </e2> from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not <e1> doxorubicin </e1> .
NO_RELATION	PURPOSE : The <e1> anthracyclines </e1> daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , <e2> myelosuppression </e2> and cardiac toxicity limit their use .
NO_RELATION	PURPOSE : The <e1> anthracyclines </e1> daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and <e2> cardiac toxicity </e2> limit their use .
NO_RELATION	PURPOSE : The anthracyclines <e1> daunorubicin </e1> and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , <e2> myelosuppression </e2> and cardiac toxicity limit their use .
NO_RELATION	PURPOSE : The anthracyclines <e1> daunorubicin </e1> and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and <e2> cardiac toxicity </e2> limit their use .
NO_RELATION	PURPOSE : The anthracyclines daunorubicin and <e1> doxorubicin </e1> and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , <e2> myelosuppression </e2> and cardiac toxicity limit their use .
NO_RELATION	PURPOSE : The anthracyclines daunorubicin and <e1> doxorubicin </e1> and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and <e2> cardiac toxicity </e2> limit their use .
NO_RELATION	PURPOSE : The anthracyclines daunorubicin and doxorubicin and the <e1> epipodophyllotoxin </e1> etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , <e2> myelosuppression </e2> and cardiac toxicity limit their use .
NO_RELATION	PURPOSE : The anthracyclines daunorubicin and doxorubicin and the <e1> epipodophyllotoxin </e1> etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and <e2> cardiac toxicity </e2> limit their use .
NO_RELATION	PURPOSE : The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <e1> etoposide </e1> are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , <e2> myelosuppression </e2> and cardiac toxicity limit their use .
NO_RELATION	PURPOSE : The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <e1> etoposide </e1> are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and <e2> cardiac toxicity </e2> limit their use .
NO_RELATION	<e1> Dexrazoxane </e1> ( ICRF - 187 ) is recommended for protection against anthracycline - induced <e2> cardiotoxicity </e2> .
NO_RELATION	Dexrazoxane ( <e1> ICRF - 187 </e1> ) is recommended for protection against anthracycline - induced <e2> cardiotoxicity </e2> .
NO_RELATION	Dexrazoxane ( ICRF - 187 ) is recommended for protection against <e1> anthracycline </e1> - induced <e2> cardiotoxicity </e2> .
NO_RELATION	EXPERIMENTAL DESIGN : Because of their widespread use , the <e2> hematologic toxicity </e2> following coadministration of <e1> dexrazoxane </e1> and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .
CID	EXPERIMENTAL DESIGN : Because of their widespread use , the <e2> hematologic toxicity </e2> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to <e1> etoposide </e1> , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .
CID	EXPERIMENTAL DESIGN : Because of their widespread use , the <e2> hematologic toxicity </e2> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , <e1> daunorubicin </e1> , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .
CID	EXPERIMENTAL DESIGN : Because of their widespread use , the <e2> hematologic toxicity </e2> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and <e1> doxorubicin </e1> + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .
NO_RELATION	EXPERIMENTAL DESIGN : Because of their widespread use , the <e2> hematologic toxicity </e2> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - <e1> dexrazoxane </e1> was determined in granulocyte - macrophage colony forming assays .
NO_RELATION	RESULTS : Nontoxic doses of <e1> dexrazoxane </e1> reduced <e2> myelosuppression </e2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of <e1> dexrazoxane </e1> reduced myelosuppression and <e2> weight loss </e2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of <e1> dexrazoxane </e1> reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced <e2> myelosuppression </e2> , weight loss , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of <e1> dexrazoxane </e1> reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , <e2> weight loss </e2> , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of <e1> dexrazoxane </e1> reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro <e2> cytotoxicity </e2> from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced <e2> myelosuppression </e2> and weight loss from <e1> daunorubicin </e1> and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
CID	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and <e2> weight loss </e2> from <e1> daunorubicin </e1> and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <e1> daunorubicin </e1> and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced <e2> myelosuppression </e2> , weight loss , nor the in vitro cytotoxicity from doxorubicin .
CID	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <e1> daunorubicin </e1> and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , <e2> weight loss </e2> , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <e1> daunorubicin </e1> and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro <e2> cytotoxicity </e2> from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced <e2> myelosuppression </e2> and weight loss from daunorubicin and <e1> etoposide </e1> in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
CID	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and <e2> weight loss </e2> from daunorubicin and <e1> etoposide </e1> in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <e1> etoposide </e1> in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced <e2> myelosuppression </e2> , weight loss , nor the in vitro cytotoxicity from doxorubicin .
CID	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <e1> etoposide </e1> in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , <e2> weight loss </e2> , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <e1> etoposide </e1> in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro <e2> cytotoxicity </e2> from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced <e2> myelosuppression </e2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , <e1> dexrazoxane </e1> neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and <e2> weight loss </e2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , <e1> dexrazoxane </e1> neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , <e1> dexrazoxane </e1> neither reduced <e2> myelosuppression </e2> , weight loss , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , <e1> dexrazoxane </e1> neither reduced myelosuppression , <e2> weight loss </e2> , nor the in vitro cytotoxicity from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , <e1> dexrazoxane </e1> neither reduced myelosuppression , weight loss , nor the in vitro <e2> cytotoxicity </e2> from doxorubicin .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced <e2> myelosuppression </e2> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from <e1> doxorubicin </e1> .
CID	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and <e2> weight loss </e2> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from <e1> doxorubicin </e1> .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced <e2> myelosuppression </e2> , weight loss , nor the in vitro cytotoxicity from <e1> doxorubicin </e1> .
CID	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , <e2> weight loss </e2> , nor the in vitro cytotoxicity from <e1> doxorubicin </e1> .
NO_RELATION	RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro <e2> cytotoxicity </e2> from <e1> doxorubicin </e1> .
NO_RELATION	Clinical trials in patients with brain <e2> metastases </e2> combining <e1> dexrazoxane </e1> and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .
NO_RELATION	Clinical trials in patients with brain metastases combining <e1> dexrazoxane </e1> and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating <e2> hematologic toxicity </e2> .
NO_RELATION	Clinical trials in patients with brain <e2> metastases </e2> combining dexrazoxane and high doses of <e1> etoposide </e1> is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .
CID	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of <e1> etoposide </e1> is ongoing with the aim of improving efficacy without aggravating <e2> hematologic toxicity </e2> .
NO_RELATION	Effects of the novel compound <e1> aniracetam </e1> ( Ro 13 - 5057 ) upon <e2> impaired learning and memory </e2> in rodents .
NO_RELATION	Effects of the novel compound aniracetam ( <e1> Ro 13 - 5057 </e1> ) upon <e2> impaired learning and memory </e2> in rodents .
NO_RELATION	The effect of <e1> aniracetam </e1> ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of <e1> aniracetam </e1> ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of <e1> aniracetam </e1> ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term <e2> amnesia </e2> for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of <e1> aniracetam </e1> ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of <e1> aniracetam </e1> ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( <e1> Ro 13 - 5057 </e1> , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( <e1> Ro 13 - 5057 </e1> , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( <e1> Ro 13 - 5057 </e1> , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term <e2> amnesia </e2> for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( <e1> Ro 13 - 5057 </e1> , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( <e1> Ro 13 - 5057 </e1> , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , <e1> 1 - anisoyl - 2 - pyrrolidinone </e1> ) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , <e1> 1 - anisoyl - 2 - pyrrolidinone </e1> ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , <e1> 1 - anisoyl - 2 - pyrrolidinone </e1> ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term <e2> amnesia </e2> for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , <e1> 1 - anisoyl - 2 - pyrrolidinone </e1> ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , <e1> 1 - anisoyl - 2 - pyrrolidinone </e1> ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the <e1> scopolamine </e1> - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the <e1> scopolamine </e1> - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
CID	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the <e1> scopolamine </e1> - induced short - term <e2> amnesia </e2> for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
CID	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the <e1> scopolamine </e1> - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the <e1> scopolamine </e1> - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term <e2> amnesia </e2> for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by <e1> chloramphenicol </e1> or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term <e2> amnesia </e2> for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or <e1> cycloheximide </e1> administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally <e2> impaired cognitive functions </e2> ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal <e2> hypercapnia </e2> immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term <e2> amnesia </e2> for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against <e2> amnesia </e2> for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by <e1> cycloheximide </e1> injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or <e2> hypercapnia </e2> applied immediately before retrieval testing ( 24 h after acquisition ) .
NO_RELATION	These improvements or normalizations of <e2> impaired cognitive functions </e2> were seen at oral <e1> aniracetam </e1> doses of 10 - 100 mg / kg .
CID	<e1> Nicotine </e1> potentiation of morphine - induced <e2> catalepsy </e2> in mice .
CID	Nicotine potentiation of <e1> morphine </e1> - induced <e2> catalepsy </e2> in mice .
CID	In the present study , effects of <e1> nicotine </e1> on <e2> catalepsy </e2> induced by morphine in mice have been investigated .
CID	In the present study , effects of nicotine on <e2> catalepsy </e2> induced by <e1> morphine </e1> in mice have been investigated .
CID	<e1> Morphine </e1> but not nicotine induced a dose - dependent <e2> catalepsy </e2> .
CID	Morphine but not <e1> nicotine </e1> induced a dose - dependent <e2> catalepsy </e2> .
NO_RELATION	Intraperitoneal administration of <e1> atropine </e1> , naloxone , mecamylamine , and hexamethonium to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with nicotine .
NO_RELATION	Intraperitoneal administration of atropine , <e1> naloxone </e1> , mecamylamine , and hexamethonium to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with nicotine .
NO_RELATION	Intraperitoneal administration of atropine , naloxone , <e1> mecamylamine </e1> , and hexamethonium to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with nicotine .
NO_RELATION	Intraperitoneal administration of atropine , naloxone , mecamylamine , and <e1> hexamethonium </e1> to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with nicotine .
CID	Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced <e2> catalepsy </e2> induced by a combination of <e1> morphine </e1> with nicotine .
CID	Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced <e2> catalepsy </e2> induced by a combination of morphine with <e1> nicotine </e1> .
NO_RELATION	Intracerebroventricular injection of <e1> atropine </e1> , hexamethonium , and naloxone also decreased <e2> catalepsy </e2> induced by morphine plus nicotine .
NO_RELATION	Intracerebroventricular injection of atropine , <e1> hexamethonium </e1> , and naloxone also decreased <e2> catalepsy </e2> induced by morphine plus nicotine .
NO_RELATION	Intracerebroventricular injection of atropine , hexamethonium , and <e1> naloxone </e1> also decreased <e2> catalepsy </e2> induced by morphine plus nicotine .
CID	Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased <e2> catalepsy </e2> induced by <e1> morphine </e1> plus nicotine .
CID	Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased <e2> catalepsy </e2> induced by morphine plus <e1> nicotine </e1> .
CID	It was concluded that <e1> morphine </e1> <e2> catalepsy </e2> can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .
CID	It was concluded that morphine <e2> catalepsy </e2> can be elicited by opioid and cholinergic receptors , and the potentiation of <e1> morphine </e1> induced by nicotine may also be mediated through cholinergic receptor mechanisms .
CID	It was concluded that morphine <e2> catalepsy </e2> can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by <e1> nicotine </e1> may also be mediated through cholinergic receptor mechanisms .
NO_RELATION	Reduced <e2> cardiotoxicity </e2> and preserved antitumor efficacy of liposome - encapsulated <e1> doxorubicin </e1> and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .
NO_RELATION	Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated <e1> doxorubicin </e1> and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic <e2> breast cancer </e2> .
NO_RELATION	Reduced <e2> cardiotoxicity </e2> and preserved antitumor efficacy of liposome - encapsulated doxorubicin and <e1> cyclophosphamide </e1> compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .
NO_RELATION	Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and <e1> cyclophosphamide </e1> compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic <e2> breast cancer </e2> .
NO_RELATION	Reduced <e2> cardiotoxicity </e2> and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional <e1> doxorubicin </e1> and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .
NO_RELATION	Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional <e1> doxorubicin </e1> and cyclophosphamide in a randomized , multicenter trial of metastatic <e2> breast cancer </e2> .
NO_RELATION	Reduced <e2> cardiotoxicity </e2> and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and <e1> cyclophosphamide </e1> in a randomized , multicenter trial of metastatic breast cancer .
NO_RELATION	Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and <e1> cyclophosphamide </e1> in a randomized , multicenter trial of metastatic <e2> breast cancer </e2> .
NO_RELATION	PURPOSE : To determine whether <e1> Myocet </e1> ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin <e2> cardiotoxicity </e2> while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .
NO_RELATION	PURPOSE : To determine whether <e1> Myocet </e1> ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic <e2> breast cancer </e2> ( MBC ) .
NO_RELATION	PURPOSE : To determine whether <e1> Myocet </e1> ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( <e2> MBC </e2> ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated <e1> doxorubicin </e1> ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin <e2> cardiotoxicity </e2> while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated <e1> doxorubicin </e1> ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic <e2> breast cancer </e2> ( MBC ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated <e1> doxorubicin </e1> ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( <e2> MBC </e2> ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with <e1> cyclophosphamide </e1> significantly reduces doxorubicin <e2> cardiotoxicity </e2> while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with <e1> cyclophosphamide </e1> significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic <e2> breast cancer </e2> ( MBC ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with <e1> cyclophosphamide </e1> significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( <e2> MBC </e2> ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces <e1> doxorubicin </e1> cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic <e2> breast cancer </e2> ( MBC ) .
NO_RELATION	PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces <e1> doxorubicin </e1> cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( <e2> MBC </e2> ) .
NO_RELATION	PATIENTS AND METHODS : Two hundred ninety - seven patients with <e2> MBC </e2> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of <e1> Myocet </e1> ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .
NO_RELATION	PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of <e1> Myocet </e1> ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable <e2> toxicity </e2> .
NO_RELATION	PATIENTS AND METHODS : Two hundred ninety - seven patients with <e2> MBC </e2> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional <e1> doxorubicin </e1> ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .
NO_RELATION	PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional <e1> doxorubicin </e1> ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable <e2> toxicity </e2> .
NO_RELATION	PATIENTS AND METHODS : Two hundred ninety - seven patients with <e2> MBC </e2> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of <e1> cyclophosphamide </e1> ( C ) , every 3 weeks until disease progression or unacceptable toxicity .
NO_RELATION	PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of <e1> cyclophosphamide </e1> ( C ) , every 3 weeks until disease progression or unacceptable <e2> toxicity </e2> .
NO_RELATION	CONCLUSION : <e1> Myocet </e1> improves the therapeutic index of doxorubicin by significantly reducing <e2> cardiotoxicity </e2> and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .
CID	CONCLUSION : <e1> Myocet </e1> improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 <e2> neutropenia </e2> and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .
NO_RELATION	CONCLUSION : <e1> Myocet </e1> improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for <e2> MBC </e2> .
NO_RELATION	CONCLUSION : Myocet improves the therapeutic index of <e1> doxorubicin </e1> by significantly reducing <e2> cardiotoxicity </e2> and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .
CID	CONCLUSION : Myocet improves the therapeutic index of <e1> doxorubicin </e1> by significantly reducing cardiotoxicity and grade 4 <e2> neutropenia </e2> and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .
NO_RELATION	CONCLUSION : Myocet improves the therapeutic index of <e1> doxorubicin </e1> by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for <e2> MBC </e2> .
NO_RELATION	CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing <e2> cardiotoxicity </e2> and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with <e1> cyclophosphamide </e1> as first - line therapy for MBC .
CID	CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 <e2> neutropenia </e2> and provides comparable antitumor efficacy , when used in combination with <e1> cyclophosphamide </e1> as first - line therapy for MBC .
NO_RELATION	CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with <e1> cyclophosphamide </e1> as first - line therapy for <e2> MBC </e2> .
NO_RELATION	Protective effect of a specific platelet - activating factor antagonist , <e1> BN 52021 </e1> , on bupivacaine - induced <e2> cardiovascular impairments </e2> in rats .
NO_RELATION	Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on <e1> bupivacaine </e1> - induced <e2> cardiovascular impairments </e2> in rats .
NO_RELATION	Administration of the local anaesthetic <e1> bupivacaine </e1> ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked <e2> decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) </e2> leading to death ( in 67 % or 90 % of animals respectively ) .
NO_RELATION	Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist <e1> BN 52021 </e1> ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . ) suppressed both the <e2> decrease of MBP and HR </e2> .
NO_RELATION	Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before <e1> bupivacaine </e1> administration ( 2 mg / kg i . v . ) suppressed both the <e2> decrease of MBP and HR </e2> .
NO_RELATION	When <e1> BN 52021 </e1> ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the <e2> decrease of MBP and HR </e2> was observed , whereas the dose of 10 mg / kg was ineffective .
NO_RELATION	When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after <e1> bupivacaine </e1> ( 2 mg / kg ) , a partial reversion of the <e2> decrease of MBP and HR </e2> was observed , whereas the dose of 10 mg / kg was ineffective .
NO_RELATION	Since the administration of <e1> BN 52021 </e1> , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced <e2> cardiovascular toxicity </e2> .
NO_RELATION	Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of <e1> BN 52021 </e1> , a specific antagonist of PAF , against bupivacaine - induced <e2> cardiovascular toxicity </e2> .
NO_RELATION	Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against <e1> bupivacaine </e1> - induced <e2> cardiovascular toxicity </e2> .
NO_RELATION	Thus , consistent with its direct effect on heart , PAF appears to be implicated in <e1> bupivacaine </e1> - induced <e2> cardiovascular alterations </e2> .
NO_RELATION	<e1> Benzylacyclouridine </e1> reverses azidothymidine - induced <e2> marrow suppression </e2> without impairment of anti - human immunodeficiency virus activity .
NO_RELATION	<e1> Benzylacyclouridine </e1> reverses azidothymidine - induced marrow suppression without impairment of anti - human <e2> immunodeficiency </e2> virus activity .
CID	Benzylacyclouridine reverses <e1> azidothymidine </e1> - induced <e2> marrow suppression </e2> without impairment of anti - human immunodeficiency virus activity .
NO_RELATION	Benzylacyclouridine reverses <e1> azidothymidine </e1> - induced marrow suppression without impairment of anti - human <e2> immunodeficiency </e2> virus activity .
NO_RELATION	Increased extracellular concentrations of <e1> uridine </e1> ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman <e2> immunodeficiency </e2> virus ( HIV ) activity .
NO_RELATION	Increased extracellular concentrations of uridine ( <e1> Urd </e1> ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman <e2> immunodeficiency </e2> virus ( HIV ) activity .
NO_RELATION	Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , <e1> azidothymidine </e1> ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman <e2> immunodeficiency </e2> virus ( HIV ) activity .
NO_RELATION	Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( <e1> AZT </e1> ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman <e2> immunodeficiency </e2> virus ( HIV ) activity .
NO_RELATION	Because of the clinical <e2> toxicities </e2> associated with chronic <e1> Urd </e1> administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .
NO_RELATION	Because of the clinical toxicities associated with chronic <e1> Urd </e1> administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced <e2> anemia </e2> and leukopenia was assessed .
NO_RELATION	Because of the clinical toxicities associated with chronic <e1> Urd </e1> administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and <e2> leukopenia </e2> was assessed .
NO_RELATION	Because of the clinical <e2> toxicities </e2> associated with chronic Urd administration , the ability of <e1> benzylacyclouridine </e1> ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .
NO_RELATION	Because of the clinical toxicities associated with chronic Urd administration , the ability of <e1> benzylacyclouridine </e1> ( BAU ) to effect , in vivo , AZT - induced <e2> anemia </e2> and leukopenia was assessed .
NO_RELATION	Because of the clinical toxicities associated with chronic Urd administration , the ability of <e1> benzylacyclouridine </e1> ( BAU ) to effect , in vivo , AZT - induced anemia and <e2> leukopenia </e2> was assessed .
NO_RELATION	Because of the clinical <e2> toxicities </e2> associated with chronic Urd administration , the ability of benzylacyclouridine ( <e1> BAU </e1> ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .
NO_RELATION	Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( <e1> BAU </e1> ) to effect , in vivo , AZT - induced <e2> anemia </e2> and leukopenia was assessed .
NO_RELATION	Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( <e1> BAU </e1> ) to effect , in vivo , AZT - induced anemia and <e2> leukopenia </e2> was assessed .
NO_RELATION	Because of the clinical <e2> toxicities </e2> associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , <e1> AZT </e1> - induced anemia and leukopenia was assessed .
CID	Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , <e1> AZT </e1> - induced <e2> anemia </e2> and leukopenia was assessed .
CID	Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , <e1> AZT </e1> - induced anemia and <e2> leukopenia </e2> was assessed .
NO_RELATION	This agent inhibits <e1> Urd </e1> catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related <e2> toxicity </e2> .
NO_RELATION	This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of <e1> Urd </e1> in a dose - dependent manner , without Urd - related <e2> toxicity </e2> .
NO_RELATION	This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without <e1> Urd </e1> - related <e2> toxicity </e2> .
CID	In mice rendered <e2> anemic </e2> and leukopenic by the administration of <e1> AZT </e1> for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and <e2> leukopenic </e2> by the administration of <e1> AZT </e1> for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and leukopenic by the administration of <e1> AZT </e1> for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced <e2> anemia </e2> and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and leukopenic by the administration of <e1> AZT </e1> for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and <e2> leukopenia </e2> ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
NO_RELATION	In mice rendered anemic and leukopenic by the administration of <e1> AZT </e1> for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved <e2> megaloblastosis </e2> .
CID	In mice rendered <e2> anemic </e2> and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of <e1> AZT </e1> plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and <e2> leukopenic </e2> by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of <e1> AZT </e1> plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of <e1> AZT </e1> plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced <e2> anemia </e2> and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of <e1> AZT </e1> plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and <e2> leukopenia </e2> ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
NO_RELATION	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of <e1> AZT </e1> plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved <e2> megaloblastosis </e2> .
NO_RELATION	In mice rendered <e2> anemic </e2> and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily <e1> BAU </e1> ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
NO_RELATION	In mice rendered anemic and <e2> leukopenic </e2> by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily <e1> BAU </e1> ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
NO_RELATION	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily <e1> BAU </e1> ( 300 mg / kg , orally ) partially reversed AZT - induced <e2> anemia </e2> and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
NO_RELATION	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily <e1> BAU </e1> ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and <e2> leukopenia </e2> ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
NO_RELATION	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily <e1> BAU </e1> ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved <e2> megaloblastosis </e2> .
CID	In mice rendered <e2> anemic </e2> and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed <e1> AZT </e1> - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and <e2> leukopenic </e2> by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed <e1> AZT </e1> - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed <e1> AZT </e1> - induced <e2> anemia </e2> and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
CID	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed <e1> AZT </e1> - induced anemia and <e2> leukopenia </e2> ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .
NO_RELATION	In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed <e1> AZT </e1> - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved <e2> megaloblastosis </e2> .
CID	When coadministered with <e1> AZT </e1> from the onset of drug administration , BAU reduced AZT - induced <e2> marrow toxicity </e2> .
NO_RELATION	When coadministered with AZT from the onset of drug administration , <e1> BAU </e1> reduced AZT - induced <e2> marrow toxicity </e2> .
CID	When coadministered with AZT from the onset of drug administration , BAU reduced <e1> AZT </e1> - induced <e2> marrow toxicity </e2> .
CID	<e1> Cyclophosphamide </e1> - induced <e2> cystitis </e2> in freely - moving conscious rats : behavioral approach to a new model of visceral pain .
NO_RELATION	<e1> Cyclophosphamide </e1> - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of <e2> visceral pain </e2> .
CID	<e1> Cyclophosphamide </e1> ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce <e2> cystitis </e2> .
CID	Cyclophosphamide ( <e1> CP </e1> ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce <e2> cystitis </e2> .
NO_RELATION	Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite <e1> acrolein </e1> , was used to induce <e2> cystitis </e2> .
NO_RELATION	<e1> Morphine </e1> dose - dependently reversed these <e2> behavioral disorders </e2> .
NO_RELATION	At the time of administration of <e1> morphine </e1> , histological modifications of the bladder wall , such as chorionic and muscle layer <e2> edema </e2> , were observed .
CID	CONCLUSIONS : Overall , these results indicate that this experimental model of <e1> CP </e1> - induced <e2> cystitis </e2> may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .
NO_RELATION	CONCLUSIONS : Overall , these results indicate that this experimental model of <e1> CP </e1> - induced cystitis may be an interesting new behavioral model of inflammatory <e2> visceral pain </e2> , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .
CID	CONCLUSIONS : Overall , these results indicate that this experimental model of <e1> CP </e1> - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these <e2> painful syndromes </e2> and thus a better therapeutic approach to them .
CID	<e2> Hyperalgesia </e2> and myoclonus in terminal cancer patients treated with continuous intravenous <e1> morphine </e1> .
CID	Hyperalgesia and <e2> myoclonus </e2> in terminal cancer patients treated with continuous intravenous <e1> morphine </e1> .
NO_RELATION	Hyperalgesia and myoclonus in terminal <e2> cancer </e2> patients treated with continuous intravenous <e1> morphine </e1> .
NO_RELATION	Eight <e2> cancer </e2> patients in the terminal stages of the disease treated with high doses of intravenous <e1> morphine </e1> developed hyperalgesia .
CID	Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous <e1> morphine </e1> developed <e2> hyperalgesia </e2> .
CID	Although only few clinical descriptions of the relationship between <e2> hyperalgesia </e2> / myoclonus and high doses of <e1> morphine </e1> are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .
CID	Although only few clinical descriptions of the relationship between hyperalgesia / <e2> myoclonus </e2> and high doses of <e1> morphine </e1> are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .
CID	Although only few clinical descriptions of the relationship between <e2> hyperalgesia </e2> / myoclonus and high doses of morphine are available , experimental support from animal studies indicates that <e1> morphine </e1> , or its metabolites , plays a causative role for the observed behavioural syndrome .
CID	Although only few clinical descriptions of the relationship between hyperalgesia / <e2> myoclonus </e2> and high doses of morphine are available , experimental support from animal studies indicates that <e1> morphine </e1> , or its metabolites , plays a causative role for the observed behavioural syndrome .
NO_RELATION	<e1> Vancomycin </e1> was curative in 95 % of 43 patients with proven <e2> infection </e2> .
NO_RELATION	<e2> Thrombophlebitis </e2> occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an <e1> aminoglycoside </e1> plus vancomycin .
NO_RELATION	Thrombophlebitis occurred only with infusion through peripheral cannulae ; <e2> nephrotoxicity </e2> and ototoxicity were confined to patients receiving an <e1> aminoglycoside </e1> plus vancomycin .
NO_RELATION	Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and <e2> ototoxicity </e2> were confined to patients receiving an <e1> aminoglycoside </e1> plus vancomycin .
CID	<e2> Thrombophlebitis </e2> occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus <e1> vancomycin </e1> .
NO_RELATION	Thrombophlebitis occurred only with infusion through peripheral cannulae ; <e2> nephrotoxicity </e2> and ototoxicity were confined to patients receiving an aminoglycoside plus <e1> vancomycin </e1> .
CID	Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and <e2> ototoxicity </e2> were confined to patients receiving an aminoglycoside plus <e1> vancomycin </e1> .
NO_RELATION	We conclude that <e1> vancomycin </e1> , administered appropriately , constitutes safe , effective therapy for <e2> infections </e2> caused by susceptible bacteria .
NO_RELATION	Blockade of both D - 1 and D - 2 <e1> dopamine </e1> receptors may induce <e2> catalepsy </e2> in mice .
NO_RELATION	The <e2> catalepsy </e2> induced by <e1> dopamine </e1> antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined .
NO_RELATION	The catalepsy induced by <e1> dopamine </e1> antagonists has been tested and the possible dopamine subtypes involved in <e2> catalepsy </e2> was determined .
NO_RELATION	The <e2> catalepsy </e2> induced by dopamine antagonists has been tested and the possible <e1> dopamine </e1> subtypes involved in catalepsy was determined .
NO_RELATION	The catalepsy induced by dopamine antagonists has been tested and the possible <e1> dopamine </e1> subtypes involved in <e2> catalepsy </e2> was determined .
NO_RELATION	<e1> Dopamine </e1> antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced <e2> catalepsy </e2> .
CID	Dopamine antagonist <e1> fluphenazine </e1> , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced <e2> catalepsy </e2> .
CID	Dopamine antagonist fluphenazine , D - 1 antagonist <e1> SCH 23390 </e1> or D - 2 antagonist sulpiride induced <e2> catalepsy </e2> .
CID	Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist <e1> sulpiride </e1> induced <e2> catalepsy </e2> .
CID	Combination of <e1> SCH 23390 </e1> with sulpiride did not induce <e2> catalepsy </e2> potentiation .
CID	Combination of SCH 23390 with <e1> sulpiride </e1> did not induce <e2> catalepsy </e2> potentiation .
NO_RELATION	D - 1 agonist <e1> SKF 38393 </e1> or D - 2 agonist quinpirole decreased the <e2> catalepsy </e2> induced by fluphenazine , SCH 23390 or sulpiride .
NO_RELATION	D - 1 agonist SKF 38393 or D - 2 agonist <e1> quinpirole </e1> decreased the <e2> catalepsy </e2> induced by fluphenazine , SCH 23390 or sulpiride .
CID	D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the <e2> catalepsy </e2> induced by <e1> fluphenazine </e1> , SCH 23390 or sulpiride .
CID	D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the <e2> catalepsy </e2> induced by fluphenazine , <e1> SCH 23390 </e1> or sulpiride .
CID	D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the <e2> catalepsy </e2> induced by fluphenazine , SCH 23390 or <e1> sulpiride </e1> .
NO_RELATION	Combination of <e1> SKF 38393 </e1> with quinpirole did not cause potentiated inhibitory effect on <e2> catalepsy </e2> induced by dopamine antagonists .
NO_RELATION	Combination of SKF 38393 with <e1> quinpirole </e1> did not cause potentiated inhibitory effect on <e2> catalepsy </e2> induced by dopamine antagonists .
NO_RELATION	Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on <e2> catalepsy </e2> induced by <e1> dopamine </e1> antagonists .
NO_RELATION	Acute analgesic and antiinflammatory activities were ascertained using <e1> acetic acid </e1> induced <e2> writhing </e2> model ( mice ) and carrageenan - induced rat paw edema model , respectively .
NO_RELATION	Acute analgesic and antiinflammatory activities were ascertained using <e1> acetic acid </e1> induced writhing model ( mice ) and carrageenan - induced rat paw <e2> edema </e2> model , respectively .
CID	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced <e2> writhing </e2> model ( mice ) and <e1> carrageenan </e1> - induced rat paw edema model , respectively .
CID	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model ( mice ) and <e1> carrageenan </e1> - induced rat paw <e2> edema </e2> model , respectively .
NO_RELATION	The 47 - year - old female patient , known to have <e2> hypertrophic cardiomyopathy </e2> , was admitted with biventricular failure and managed aggressively with <e1> dobutamine </e1> infusion and other drugs while being assessed for heart transplantation .
NO_RELATION	The 47 - year - old female patient , known to have hypertrophic cardiomyopathy , was admitted with <e2> biventricular failure </e2> and managed aggressively with <e1> dobutamine </e1> infusion and other drugs while being assessed for heart transplantation .
CID	It is likely that the <e2> hypersensitivity </e2> ( eosinophilic ) myocarditis was related to <e1> dobutamine </e1> infusion therapy .
CID	It is likely that the hypersensitivity ( <e2> eosinophilic </e2> ) myocarditis was related to <e1> dobutamine </e1> infusion therapy .
CID	It is likely that the hypersensitivity ( eosinophilic ) <e2> myocarditis </e2> was related to <e1> dobutamine </e1> infusion therapy .
CID	<e1> All - trans - retinoic acid </e1> - induced <e2> erythema nodosum </e2> in patients with acute promyelocytic leukemia .
NO_RELATION	<e1> All - trans - retinoic acid </e1> - induced erythema nodosum in patients with <e2> acute promyelocytic leukemia </e2> .
CID	<e2> Erythema nodosum </e2> associated with <e1> all - trans - retinoic acid </e1> ( ATRA ) for acute promyelocytic leukemia ( APL ) is very rare .
NO_RELATION	Erythema nodosum associated with <e1> all - trans - retinoic acid </e1> ( ATRA ) for <e2> acute promyelocytic leukemia </e2> ( APL ) is very rare .
NO_RELATION	Erythema nodosum associated with <e1> all - trans - retinoic acid </e1> ( ATRA ) for acute promyelocytic leukemia ( <e2> APL </e2> ) is very rare .
CID	<e2> Erythema nodosum </e2> associated with all - trans - retinoic acid ( <e1> ATRA </e1> ) for acute promyelocytic leukemia ( APL ) is very rare .
NO_RELATION	Erythema nodosum associated with all - trans - retinoic acid ( <e1> ATRA </e1> ) for <e2> acute promyelocytic leukemia </e2> ( APL ) is very rare .
NO_RELATION	Erythema nodosum associated with all - trans - retinoic acid ( <e1> ATRA </e1> ) for acute promyelocytic leukemia ( <e2> APL </e2> ) is very rare .
NO_RELATION	We describe four patients with classic <e2> APL </e2> who developed erythema nodosum during <e1> ATRA </e1> therapy .
CID	We describe four patients with classic APL who developed <e2> erythema nodosum </e2> during <e1> ATRA </e1> therapy .
CID	<e2> Fever </e2> and subsequent multiple painful erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after <e1> ATRA </e1> therapy .
NO_RELATION	Fever and subsequent multiple <e2> painful </e2> erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after <e1> ATRA </e1> therapy .
CID	Fever and subsequent multiple painful <e2> erythematous nodules </e2> over extremities developed on D11 , D16 , D17 , and D19 , respectively , after <e1> ATRA </e1> therapy .
CID	<e1> ATRA </e1> seemed to be the most possible etiology of <e2> erythema nodosum </e2> in our patients .
NO_RELATION	Short - term use of <e1> steroid </e1> is very effective in ATRA - induced <e2> erythema nodosum </e2> .
CID	Short - term use of steroid is very effective in <e1> ATRA </e1> - induced <e2> erythema nodosum </e2> .
CID	Delayed - onset <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> .
CID	BACKGROUND : <e1> Heparin </e1> - induced <e2> thrombocytopenia </e2> presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .
NO_RELATION	BACKGROUND : <e1> Heparin </e1> - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without <e2> arterial or venous thromboemboli </e2> .
CID	BACKGROUND : Heparin - induced <e2> thrombocytopenia </e2> presents 5 to 12 days after <e1> heparin </e1> exposure , with or without arterial or venous thromboemboli .
NO_RELATION	BACKGROUND : Heparin - induced thrombocytopenia presents 5 to 12 days after <e1> heparin </e1> exposure , with or without <e2> arterial or venous thromboemboli </e2> .
CID	Delayed recognition and treatment of <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> contribute to poor patient outcomes .
CID	OBJECTIVE : To describe and increase awareness of a clinical scenario in which the onset or manifestations of <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> are delayed .
CID	PATIENTS : 14 patients seen over a 3 - year period in whom <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> became apparent on delayed presentation with thromboembolic complications .
NO_RELATION	PATIENTS : 14 patients seen over a 3 - year period in whom <e1> heparin </e1> - induced thrombocytopenia became apparent on delayed presentation with <e2> thromboembolic </e2> complications .
NO_RELATION	MEASUREMENTS : Platelet counts , onset of objectively determined <e2> thromboembolism </e2> , results of <e1> heparin </e1> - induced platelet factor 4 antibody tests , and outcomes .
CID	RESULTS : Patients went home after hospitalizations that had included <e1> heparin </e1> exposure - - in most cases , with no <e2> thrombocytopenia </e2> recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .
NO_RELATION	RESULTS : Patients went home after hospitalizations that had included <e1> heparin </e1> exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with <e2> thromboembolic </e2> complications .
CID	CONCLUSIONS : Delayed - onset <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> is increasingly being recognized .
CID	To avoid disastrous outcomes , physicians must consider <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .
NO_RELATION	To avoid disastrous outcomes , physicians must consider <e1> heparin </e1> - induced thrombocytopenia whenever a recently hospitalized patient returns with <e2> thromboembolism </e2> ; therapy with alternative anticoagulants , not heparin , should be initiated .
CID	To avoid disastrous outcomes , physicians must consider heparin - induced <e2> thrombocytopenia </e2> whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not <e1> heparin </e1> , should be initiated .
NO_RELATION	To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with <e2> thromboembolism </e2> ; therapy with alternative anticoagulants , not <e1> heparin </e1> , should be initiated .
NO_RELATION	<e1> Valsartan </e1> , a new angiotensin II antagonist for the treatment of essential <e2> hypertension </e2> : a comparative study of the efficacy and safety against amlodipine .
NO_RELATION	Valsartan , a new <e1> angiotensin II </e1> antagonist for the treatment of essential <e2> hypertension </e2> : a comparative study of the efficacy and safety against amlodipine .
NO_RELATION	Valsartan , a new angiotensin II antagonist for the treatment of essential <e2> hypertension </e2> : a comparative study of the efficacy and safety against <e1> amlodipine </e1> .
NO_RELATION	METHODS : One hundred sixty - eight adult outpatients with mild to moderate <e2> hypertension </e2> were randomly allocated in double - blind fashion and equal number to receive 80 mg <e1> valsartan </e1> or 5 mg amlodipine for 12 weeks .
NO_RELATION	METHODS : One hundred sixty - eight adult outpatients with mild to moderate <e2> hypertension </e2> were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg <e1> amlodipine </e1> for 12 weeks .
CID	The incidence of drug - related dependent <e2> edema </e2> was somewhat higher in the <e1> amlodipine </e1> group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .
CID	The incidence of drug - related dependent <e2> edema </e2> was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg <e1> valsartan </e1> ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .
CID	The incidence of drug - related dependent <e2> edema </e2> was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg <e1> amlodipine </e1> ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .
CID	The incidence of drug - related dependent <e2> edema </e2> was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for <e1> valsartan </e1> plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .
CID	The incidence of drug - related dependent <e2> edema </e2> was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg <e1> amlodipine </e1> ; 14 . 3 % for 10 mg amlodipine ) .
CID	The incidence of drug - related dependent <e2> edema </e2> was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg <e1> amlodipine </e1> ) .
NO_RELATION	CONCLUSIONS : The data show that <e1> valsartan </e1> is at least as effective as amlodipine in the treatment of mild to moderate <e2> hypertension </e2> .
NO_RELATION	CONCLUSIONS : The data show that valsartan is at least as effective as <e1> amlodipine </e1> in the treatment of mild to moderate <e2> hypertension </e2> .
NO_RELATION	Oral administration of <e1> KF17837 </e1> ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the <e2> cataleptic </e2> responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner .
NO_RELATION	Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the <e2> cataleptic </e2> responses induced by intracerebroventricular administration of an <e1> adenosine </e1> A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner .
CID	Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the <e2> cataleptic </e2> responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , <e1> CGS 21680 </e1> ( 10 micrograms ) , in a dose - dependent manner .
NO_RELATION	<e1> KF17837 </e1> also reduced the <e2> catalepsy </e2> induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .
CID	KF17837 also reduced the <e2> catalepsy </e2> induced by <e1> haloperidol </e1> ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .
CID	KF17837 also reduced the <e2> catalepsy </e2> induced by haloperidol ( 1 mg / kg i . p . ) and by <e1> reserpine </e1> ( 5 mg / kg i . p . ) .
NO_RELATION	Furthermore , <e1> KF17837 </e1> may be a useful drug in the treatment of <e2> parkinsonism </e2> .
CID	A repeated treatment with <e1> fluvoxamine </e1> ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced <e2> hyperactivity </e2> .
CID	A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the <e1> amphetamine </e1> - induced <e2> hyperactivity </e2> .
CID	The <e2> hyperactivity </e2> induced by <e1> nomifensine </e1> in mice remained unaffected by fluvoxamine .
CID	The <e2> hyperactivity </e2> induced by nomifensine in mice remained unaffected by <e1> fluvoxamine </e1> .
NO_RELATION	Severe <e2> congestive heart failure </e2> patient on <e1> amiodarone </e1> presenting with myxedemic coma : a case report .
NO_RELATION	Severe congestive heart failure patient on <e1> amiodarone </e1> presenting with <e2> myxedemic coma </e2> : a case report .
NO_RELATION	This is a case report of <e2> myxedema coma </e2> secondary to <e1> amiodarone </e1> - induced hypothyroidism in a patient with severe congestive heart failure ( CHF ) .
CID	This is a case report of myxedema coma secondary to <e1> amiodarone </e1> - induced <e2> hypothyroidism </e2> in a patient with severe congestive heart failure ( CHF ) .
NO_RELATION	This is a case report of myxedema coma secondary to <e1> amiodarone </e1> - induced hypothyroidism in a patient with severe <e2> congestive heart failure </e2> ( CHF ) .
NO_RELATION	This is a case report of myxedema coma secondary to <e1> amiodarone </e1> - induced hypothyroidism in a patient with severe congestive heart failure ( <e2> CHF </e2> ) .
NO_RELATION	To our knowledge and after reviewing the literature there is one case report of <e2> myxedema coma </e2> during long term <e1> amiodarone </e1> therapy .
NO_RELATION	Patients with <e2> CHF </e2> on <e1> amiodarone </e1> may suffer serious morbidity and mortality from hypothyroidism , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .
CID	Patients with CHF on <e1> amiodarone </e1> may suffer serious morbidity and mortality from <e2> hypothyroidism </e2> , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .
NO_RELATION	This case report carries an important clinical application given the frequent usage of <e1> amiodarone </e1> among <e2> CHF </e2> patients .
CID	Furthermore , <e1> yohimbine </e1> increased baseline <e2> startle </e2> amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS .
CID	Furthermore , <e1> yohimbine </e1> increased baseline startle amplitude in the LES , while mCPP suppressed baseline <e2> startle </e2> in both the LES and FPS and PTZ suppressed baseline startle in the FPS .
CID	Furthermore , <e1> yohimbine </e1> increased baseline startle amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline <e2> startle </e2> in the FPS .
CID	Furthermore , yohimbine increased baseline <e2> startle </e2> amplitude in the LES , while <e1> mCPP </e1> suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS .
CID	Furthermore , yohimbine increased baseline startle amplitude in the LES , while <e1> mCPP </e1> suppressed baseline <e2> startle </e2> in both the LES and FPS and PTZ suppressed baseline startle in the FPS .
CID	Furthermore , yohimbine increased baseline startle amplitude in the LES , while <e1> mCPP </e1> suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline <e2> startle </e2> in the FPS .
CID	Furthermore , yohimbine increased baseline <e2> startle </e2> amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and <e1> PTZ </e1> suppressed baseline startle in the FPS .
CID	Furthermore , yohimbine increased baseline startle amplitude in the LES , while mCPP suppressed baseline <e2> startle </e2> in both the LES and FPS and <e1> PTZ </e1> suppressed baseline startle in the FPS .
CID	Furthermore , yohimbine increased baseline startle amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and <e1> PTZ </e1> suppressed baseline <e2> startle </e2> in the FPS .
NO_RELATION	Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing <e2> glomerulonephritis </e2> after restarting <e1> sulphasalazine </e1> treatment .
NO_RELATION	A 59 - year - old woman with <e2> ulcerative colitis </e2> developed red eyes , pleural effusion , eosinophilia and urinary abnormalities after restarting of <e1> sulphasalazine </e1> treatment .
NO_RELATION	A 59 - year - old woman with ulcerative colitis developed <e2> red eyes </e2> , pleural effusion , eosinophilia and urinary abnormalities after restarting of <e1> sulphasalazine </e1> treatment .
CID	A 59 - year - old woman with ulcerative colitis developed red eyes , <e2> pleural effusion </e2> , eosinophilia and urinary abnormalities after restarting of <e1> sulphasalazine </e1> treatment .
NO_RELATION	A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , <e2> eosinophilia </e2> and urinary abnormalities after restarting of <e1> sulphasalazine </e1> treatment .
NO_RELATION	A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , eosinophilia and <e2> urinary abnormalities </e2> after restarting of <e1> sulphasalazine </e1> treatment .
CID	Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in <e2> fever </e2> , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
NO_RELATION	Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in fever , <e2> red eyes </e2> , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
NO_RELATION	Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in fever , red eyes , <e2> chest pain </e2> , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
CID	Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the <e2> pleural effusions </e2> , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
CID	Although cessation of <e1> sulphasalazine </e1> treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the <e2> pleural effusion </e2> remained .
NO_RELATION	Although cessation of sulphasalazine treatment resulted in improvements in <e2> fever </e2> , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated <e1> steroid </e1> therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
NO_RELATION	Although cessation of sulphasalazine treatment resulted in improvements in fever , <e2> red eyes </e2> , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated <e1> steroid </e1> therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
NO_RELATION	Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , <e2> chest pain </e2> , titer of C - reactive protein and volume of the pleural effusions , we initiated <e1> steroid </e1> therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
NO_RELATION	Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the <e2> pleural effusions </e2> , we initiated <e1> steroid </e1> therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .
NO_RELATION	Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated <e1> steroid </e1> therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the <e2> pleural effusion </e2> remained .
NO_RELATION	One month after <e1> steroid </e1> therapy , the <e2> pleural effusion </e2> disappeared , and PR3 - ANCA titer normalized 3 months later .
NO_RELATION	This case suggests that <e1> sulphasalazine </e1> can induce PR3 - ANCA - positive necrotizing <e2> glomerulonephritis </e2> .
NO_RELATION	Is <e1> phenytoin </e1> administration safe in a <e2> hypothermic </e2> child ?
NO_RELATION	Intravenous <e1> phenytoin </e1> was administered during the later part of the surgery for <e2> seizure </e2> prophylaxis .
CID	Following <e1> phenytoin </e1> administration , the patient developed acute severe <e2> bradycardia </e2> , refractory to atropine and adrenaline .
NO_RELATION	Following phenytoin administration , the patient developed acute severe <e2> bradycardia </e2> , refractory to <e1> atropine </e1> and adrenaline .
NO_RELATION	Following phenytoin administration , the patient developed acute severe <e2> bradycardia </e2> , refractory to atropine and <e1> adrenaline </e1> .
NO_RELATION	The cardiac depressant actions of <e1> phenytoin </e1> and <e2> hypothermia </e2> can be additive .
NO_RELATION	Administration of <e1> phenytoin </e1> in the presence of <e2> hypothermia </e2> may lead to an adverse cardiac event in children .
CID	<e1> Amisulpride </e1> related <e2> tic - like symptoms </e2> in an adolescent schizophrenic .
NO_RELATION	<e1> Amisulpride </e1> related tic - like symptoms in an adolescent <e2> schizophrenic </e2> .
NO_RELATION	<e2> Tic disorders </e2> can be effectively treated by atypical antipsychotics such as <e1> risperidone </e1> , olanzapine and ziprasidone .
NO_RELATION	<e2> Tic disorders </e2> can be effectively treated by atypical antipsychotics such as risperidone , <e1> olanzapine </e1> and ziprasidone .
NO_RELATION	<e2> Tic disorders </e2> can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and <e1> ziprasidone </e1> .
NO_RELATION	However , there are two case reports that show <e2> tic - like symptoms </e2> , including motor and phonic variants , occurring during treatment with <e1> quetiapine </e1> or clozapine .
NO_RELATION	However , there are two case reports that show <e2> tic - like symptoms </e2> , including motor and phonic variants , occurring during treatment with quetiapine or <e1> clozapine </e1> .
NO_RELATION	We present a 15 - year - old girl <e2> schizophrenic </e2> who developed frequent involuntary eye - blinking movements after 5 months of <e1> amisulpride </e1> treatment ( 1000 mg per day ) .
NO_RELATION	We present a 15 - year - old girl schizophrenic who developed frequent <e2> involuntary eye - blinking movements </e2> after 5 months of <e1> amisulpride </e1> treatment ( 1000 mg per day ) .
CID	The <e2> tic - like symptoms </e2> resolved completely after we reduced the dose of <e1> amisulpride </e1> down to 800 mg per day .
NO_RELATION	Together with previously reported cases , our patient suggests that <e2> tic - like symptoms </e2> might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as <e1> quetiapine </e1> , clozapine , or amisulpride .
NO_RELATION	Together with previously reported cases , our patient suggests that <e2> tic - like symptoms </e2> might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , <e1> clozapine </e1> , or amisulpride .
CID	Together with previously reported cases , our patient suggests that <e2> tic - like symptoms </e2> might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or <e1> amisulpride </e1> .
CID	<e1> Aspirin </e1> ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces <e2> developmental anomalies </e2> when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ .
CID	Aspirin ( <e1> acetylsalicylic acid </e1> [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces <e2> developmental anomalies </e2> when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ .
CID	Aspirin ( acetylsalicylic acid [ <e1> ASA </e1> ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces <e2> developmental anomalies </e2> when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ .
NO_RELATION	Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when <e1> ASA </e1> is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal <e2> gastrointestinal toxicity </e2> confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used .
CID	Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when <e1> ASA </e1> is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence <e2> malformations </e2> with ASA when a multiple dosing paradigm is used .
NO_RELATION	Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal <e2> gastrointestinal toxicity </e2> confounds the detection of low incidence malformations with <e1> ASA </e1> when a multiple dosing paradigm is used .
CID	Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence <e2> malformations </e2> with <e1> ASA </e1> when a multiple dosing paradigm is used .
CID	RESULTS : The literature evaluation suggested that NSAIDs induce <e2> ventricular septal defects </e2> ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence malformations .
CID	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( <e2> VSDs </e2> ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence malformations .
NO_RELATION	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and <e2> midline defects </e2> ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence malformations .
NO_RELATION	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( <e2> MDs </e2> ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence malformations .
CID	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and <e2> diaphragmatic hernia </e2> ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence malformations .
CID	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( <e2> DH </e2> ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence malformations .
NO_RELATION	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , <e2> MDs </e2> , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence malformations .
CID	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and <e2> VSDs </e2> in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence malformations .
CID	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these <e2> malformations </e2> , even though <e1> ASA </e1> induces several other low - incidence malformations .
CID	RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though <e1> ASA </e1> induces several other low - incidence <e2> malformations </e2> .
CID	Variations and <e2> malformations </e2> were similar when <e1> ASA </e1> was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .
CID	It was also evident that , by titrating the dose to achieve a maximum tolerated dose , <e2> malformations </e2> that normally occur at low incidence , as reported from previous single dose studies , could also be induced with <e1> ASA </e1> given at multiple doses .
CID	<e2> Torsade de pointes </e2> induced by <e1> metoclopramide </e1> in an elderly woman with preexisting complete left bundle branch block .
NO_RELATION	Torsade de pointes induced by <e1> metoclopramide </e1> in an elderly woman with preexisting complete <e2> left bundle branch block </e2> .
NO_RELATION	We report on a 92 - year - old woman with preexisting complete <e2> left bundle branch block </e2> who developed torsade de pointes after intravenous and oral administration of <e1> metoclopramide </e1> .
CID	We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed <e2> torsade de pointes </e2> after intravenous and oral administration of <e1> metoclopramide </e1> .
CID	This patient also developed <e2> torsade de pointes </e2> when <e1> cisapride </e1> and erythromycin were given simultaneously .
CID	This patient also developed <e2> torsade de pointes </e2> when cisapride and <e1> erythromycin </e1> were given simultaneously .
CID	This is the first documentation that <e1> metoclopramide </e1> provokes <e2> torsade de pointes </e2> clinically .
CID	<e1> Metoclopramide </e1> should be used cautiously in patients with a risk of <e2> torsade de pointes </e2> .
NO_RELATION	<e1> Apomorphine </e1> : an underutilized therapy for <e2> Parkinson ' s disease </e2> .
NO_RELATION	<e1> Apomorphine </e1> was the first dopaminergic drug ever used to treat symptoms of <e2> Parkinson ' s disease </e2> .
NO_RELATION	While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating <e2> Parkinson ' s disease </e2> by subcutaneous administration of <e1> apomorphine </e1> has only recently become the subject of systematic study .
NO_RELATION	In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous <e1> apomorphine </e1> infusions is associated with marked reductions of preexisting levodopa - induced <e2> dyskinesias </e2> .
CID	In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting <e1> levodopa </e1> - induced <e2> dyskinesias </e2> .
NO_RELATION	The main side effects of subcutaneous <e1> apomorphine </e1> treatment are related to cutaneous tolerability problems , whereas sedation and <e2> psychiatric </e2> complications play a lesser role .
NO_RELATION	Given the marked degree of efficacy of subcutaneous <e1> apomorphine </e1> treatment in fluctuating <e2> Parkinson ' s disease </e2> , this approach seems to deserve more widespread clinical use .
CID	Fatal excited <e2> delirium </e2> following <e1> cocaine </e1> use : epidemiologic findings provide new evidence for mechanisms of cocaine toxicity .
NO_RELATION	Fatal excited delirium following <e1> cocaine </e1> use : epidemiologic findings provide new evidence for mechanisms of cocaine <e2> toxicity </e2> .
CID	Fatal excited <e2> delirium </e2> following cocaine use : epidemiologic findings provide new evidence for mechanisms of <e1> cocaine </e1> toxicity .
NO_RELATION	Fatal excited delirium following cocaine use : epidemiologic findings provide new evidence for mechanisms of <e1> cocaine </e1> <e2> toxicity </e2> .
CID	We describe an outbreak of deaths from <e1> cocaine </e1> - induced excited <e2> delirium </e2> ( EDDs ) in Dade County , Florida between 1979 and 1990 .
CID	We describe an outbreak of deaths from <e1> cocaine </e1> - induced excited delirium ( <e2> EDDs </e2> ) in Dade County , Florida between 1979 and 1990 .
CID	From a registry of all <e1> cocaine </e1> - related deaths in Dade County , Florida , from 1969 - 1990 , 58 <e2> EDDs </e2> were compared with 125 victims of accidental cocaine overdose without excited delirium .
NO_RELATION	From a registry of all <e1> cocaine </e1> - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine <e2> overdose </e2> without excited delirium .
CID	From a registry of all <e1> cocaine </e1> - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited <e2> delirium </e2> .
CID	From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 <e2> EDDs </e2> were compared with 125 victims of accidental <e1> cocaine </e1> overdose without excited delirium .
NO_RELATION	From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental <e1> cocaine </e1> <e2> overdose </e2> without excited delirium .
CID	From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental <e1> cocaine </e1> overdose without excited <e2> delirium </e2> .
CID	<e2> EDDs </e2> had concentrations of <e1> cocaine </e1> and benzoylecgonine in autopsy blood that were similar to those for controls .
NO_RELATION	<e2> EDDs </e2> had concentrations of cocaine and <e1> benzoylecgonine </e1> in autopsy blood that were similar to those for controls .
NO_RELATION	The epidemiologic findings are most consistent with the hypothesis that chronic <e1> cocaine </e1> use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate <e2> agitation </e2> , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .
CID	The epidemiologic findings are most consistent with the hypothesis that chronic <e1> cocaine </e1> use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , <e2> delirium </e2> , aberrant thermoregulation , rhabdomyolysis , and sudden death .
CID	The epidemiologic findings are most consistent with the hypothesis that chronic <e1> cocaine </e1> use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , <e2> rhabdomyolysis </e2> , and sudden death .
CID	The epidemiologic findings are most consistent with the hypothesis that chronic <e1> cocaine </e1> use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and <e2> sudden death </e2> .
NO_RELATION	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent <e1> cocaine </e1> use , may precipitate <e2> agitation </e2> , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .
CID	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent <e1> cocaine </e1> use , may precipitate agitation , <e2> delirium </e2> , aberrant thermoregulation , rhabdomyolysis , and sudden death .
CID	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent <e1> cocaine </e1> use , may precipitate agitation , delirium , aberrant thermoregulation , <e2> rhabdomyolysis </e2> , and sudden death .
CID	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent <e1> cocaine </e1> use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and <e2> sudden death </e2> .
CID	<e1> Heparin </e1> - induced <e2> thrombocytopenia </e2> , thrombosis , and hemorrhage .
NO_RELATION	<e1> Heparin </e1> - induced thrombocytopenia , <e2> thrombosis </e2> , and hemorrhage .
CID	<e1> Heparin </e1> - induced thrombocytopenia , thrombosis , and <e2> hemorrhage </e2> .
CID	Sixty - two patients with a <e1> heparin </e1> - induced <e2> thrombocytopenia </e2> are reported .
CID	Clinical manifestations of this disorder include <e2> hemorrhage </e2> or , more frequently , thromboembolic events in patients receiving <e1> heparin </e1> .
CID	Clinical manifestations of this disorder include hemorrhage or , more frequently , <e2> thromboembolic </e2> events in patients receiving <e1> heparin </e1> .
NO_RELATION	Laboratory testing has revealed <e2> a falling platelet count </e2> , increased resistance to <e1> heparin </e1> , and aggregation of platelets by the patient ' s plasma when heparin is added .
NO_RELATION	Laboratory testing has revealed <e2> a falling platelet count </e2> , increased resistance to heparin , and aggregation of platelets by the patient ' s plasma when <e1> heparin </e1> is added .
NO_RELATION	If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving <e1> heparin </e1> , <e2> platelet aggregation </e2> testing , using the patient ' s plasma , is indicated .
NO_RELATION	<e2> Cardiac toxicity </e2> of <e1> 5 - fluorouracil </e1> .
NO_RELATION	We report a case of a patient with <e2> colon carcinoma </e2> and liver metastasis who presented chest pain after <e1> 5 - fluorouracil </e1> ( 5 - FU ) administration .
NO_RELATION	We report a case of a patient with colon carcinoma and liver <e2> metastasis </e2> who presented chest pain after <e1> 5 - fluorouracil </e1> ( 5 - FU ) administration .
CID	We report a case of a patient with colon carcinoma and liver metastasis who presented <e2> chest pain </e2> after <e1> 5 - fluorouracil </e1> ( 5 - FU ) administration .
NO_RELATION	We report a case of a patient with <e2> colon carcinoma </e2> and liver metastasis who presented chest pain after 5 - fluorouracil ( <e1> 5 - FU </e1> ) administration .
NO_RELATION	We report a case of a patient with colon carcinoma and liver <e2> metastasis </e2> who presented chest pain after 5 - fluorouracil ( <e1> 5 - FU </e1> ) administration .
CID	We report a case of a patient with colon carcinoma and liver metastasis who presented <e2> chest pain </e2> after 5 - fluorouracil ( <e1> 5 - FU </e1> ) administration .
NO_RELATION	Clinical electrocardiographic evolution was similar to that observed in <e2> Prinzmetal ' s angina </e2> , and chest pain promptly resolved with <e1> nifedipine </e1> .
NO_RELATION	Clinical electrocardiographic evolution was similar to that observed in Prinzmetal ' s angina , and <e2> chest pain </e2> promptly resolved with <e1> nifedipine </e1> .
NO_RELATION	These data suggest that <e2> coronary spasm </e2> may be the cause of cardiotoxicity due to <e1> 5 - FU </e1> , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .
NO_RELATION	These data suggest that coronary spasm may be the cause of <e2> cardiotoxicity </e2> due to <e1> 5 - FU </e1> , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .
NO_RELATION	These data suggest that coronary spasm may be the cause of cardiotoxicity due to <e1> 5 - FU </e1> , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU <e2> cardiotoxicity </e2> .
NO_RELATION	These data suggest that <e2> coronary spasm </e2> may be the cause of cardiotoxicity due to 5 - FU , and that <e1> calcium </e1> antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .
NO_RELATION	These data suggest that coronary spasm may be the cause of <e2> cardiotoxicity </e2> due to 5 - FU , and that <e1> calcium </e1> antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .
NO_RELATION	These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that <e1> calcium </e1> antagonists may probably be used in the prevention or treatment of 5 - FU <e2> cardiotoxicity </e2> .
NO_RELATION	These data suggest that <e2> coronary spasm </e2> may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of <e1> 5 - FU </e1> cardiotoxicity .
NO_RELATION	These data suggest that coronary spasm may be the cause of <e2> cardiotoxicity </e2> due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of <e1> 5 - FU </e1> cardiotoxicity .
NO_RELATION	These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of <e1> 5 - FU </e1> <e2> cardiotoxicity </e2> .
CID	A strong association has been found between <e2> nephritis </e2> and dermatitis due to <e1> Tiopronin </e1> ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .
CID	A strong association has been found between nephritis and <e2> dermatitis </e2> due to <e1> Tiopronin </e1> ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .
CID	A strong association has been found between nephritis and dermatitis due to <e1> Tiopronin </e1> ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between <e2> dermatitis </e2> due to gold thiosulphate and B35 .
NO_RELATION	A strong association has been found between <e2> nephritis </e2> and dermatitis due to Tiopronin ( a <e1> D - Penicillamine </e1> like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .
NO_RELATION	A strong association has been found between nephritis and <e2> dermatitis </e2> due to Tiopronin ( a <e1> D - Penicillamine </e1> like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .
NO_RELATION	A strong association has been found between nephritis and dermatitis due to Tiopronin ( a <e1> D - Penicillamine </e1> like compound ) and class I antigens B35 - Cw4 , and between <e2> dermatitis </e2> due to gold thiosulphate and B35 .
NO_RELATION	A strong association has been found between <e2> nephritis </e2> and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to <e1> gold </e1> thiosulphate and B35 .
CID	A strong association has been found between nephritis and <e2> dermatitis </e2> due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to <e1> gold </e1> thiosulphate and B35 .
CID	A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between <e2> dermatitis </e2> due to <e1> gold </e1> thiosulphate and B35 .
NO_RELATION	A strong association has been found between <e2> nephritis </e2> and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold <e1> thiosulphate </e1> and B35 .
NO_RELATION	A strong association has been found between nephritis and <e2> dermatitis </e2> due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold <e1> thiosulphate </e1> and B35 .
NO_RELATION	A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between <e2> dermatitis </e2> due to gold <e1> thiosulphate </e1> and B35 .
NO_RELATION	Compared to healthy controls a lower DR5 frequency was observed in patients with <e2> RA </e2> except for the <e1> Tiopronin </e1> related nephritis group .
CID	Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the <e1> Tiopronin </e1> related <e2> nephritis </e2> group .
CID	Transient <e2> hemiparesis </e2> : a rare manifestation of <e1> diphenylhydantoin </e1> toxicity .
NO_RELATION	Transient hemiparesis : a rare manifestation of <e1> diphenylhydantoin </e1> <e2> toxicity </e2> .
CID	Among the common side effects of <e1> diphenylhydantoin </e1> ( DPH ) <e2> overdose </e2> , the most frequently encountered neurological signs are those of cerebellar dysfunction .
CID	Among the common side effects of <e1> diphenylhydantoin </e1> ( DPH ) overdose , the most frequently encountered neurological signs are those of <e2> cerebellar dysfunction </e2> .
CID	Among the common side effects of diphenylhydantoin ( <e1> DPH </e1> ) <e2> overdose </e2> , the most frequently encountered neurological signs are those of cerebellar dysfunction .
CID	Among the common side effects of diphenylhydantoin ( <e1> DPH </e1> ) overdose , the most frequently encountered neurological signs are those of <e2> cerebellar dysfunction </e2> .
CID	Two patients are presented who suffered progressive <e2> hemiparesis </e2> due to <e1> DPH </e1> overdose .
CID	Two patients are presented who suffered progressive hemiparesis due to <e1> DPH </e1> <e2> overdose </e2> .
NO_RELATION	It is assumed that patients with some <e2> cerebral damage </e2> are liable to manifest <e1> DPH </e1> toxicity as focal neurological signs .
NO_RELATION	It is assumed that patients with some cerebral damage are liable to manifest <e1> DPH </e1> <e2> toxicity </e2> as focal neurological signs .
NO_RELATION	Nerve growth factor and <e1> prostaglandins </e1> in the urine of female patients with <e2> overactive bladder </e2> .
NO_RELATION	We investigated changes in urinary NGF and <e1> PGs </e1> in women with <e2> OAB </e2> .
NO_RELATION	In addition , correlations between urinary NGF and <e1> PG </e1> , and urodynamic parameters in patients with <e2> OAB </e2> were examined .
CID	RESULTS : Urinary NGF , <e1> PGE2 </e1> and PGF2alpha were significantly increased in patients with <e2> OAB </e2> compared with controls ( p < 0 . 05 ) .
CID	RESULTS : Urinary NGF , PGE2 and <e1> PGF2alpha </e1> were significantly increased in patients with <e2> OAB </e2> compared with controls ( p < 0 . 05 ) .
NO_RELATION	However , urinary <e1> PGI2 </e1> was not different between controls and patients with <e2> OAB </e2> .
CID	In patients with <e2> OAB </e2> urinary <e1> PGE2 </e1> positively correlated with volume at first desire to void and maximum cystometric capacity ( p < 0 . 05 ) .
CID	Urinary NGF , <e1> PGF2alpha </e1> and PGI2 did not correlate with urodynamic parameters in patients with <e2> OAB </e2> .
NO_RELATION	Urinary NGF , PGF2alpha and <e1> PGI2 </e1> did not correlate with urodynamic parameters in patients with <e2> OAB </e2> .
NO_RELATION	CONCLUSIONS : NGF and <e1> PGs </e1> have important roles in the development of <e2> OAB </e2> symptoms in female patients .
CID	Acute <e2> low back pain </e2> during intravenous administration of <e1> amiodarone </e1> : a report of two cases .
NO_RELATION	<e1> Amiodarone </e1> represents an effective antiarrhythmic drug for cardioversion of recent - onset <e2> atrial fibrillation </e2> ( AF ) and maintenance of sinus rhythm .
NO_RELATION	<e1> Amiodarone </e1> represents an effective antiarrhythmic drug for cardioversion of recent - onset atrial fibrillation ( <e2> AF </e2> ) and maintenance of sinus rhythm .
NO_RELATION	We briefly describe two patients suffering from recent - onset <e2> atrial fibrillation </e2> , who experienced an acute devastating low back pain a few minutes after initiation of intravenous <e1> amiodarone </e1> loading .
CID	We briefly describe two patients suffering from recent - onset atrial fibrillation , who experienced an acute devastating <e2> low back pain </e2> a few minutes after initiation of intravenous <e1> amiodarone </e1> loading .
CID	<e2> Postoperative myalgia </e2> after <e1> succinylcholine </e1> : no evidence for an inflammatory origin .
CID	A common side effect associated with <e1> succinylcholine </e1> is <e2> postoperative myalgia </e2> .
CID	The incidence and severity of <e1> succinylcholine </e1> - associated <e2> myalgia </e2> was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .
NO_RELATION	The incidence and severity of succinylcholine - associated <e2> myalgia </e2> was determined in 64 patients pretreated with saline or <e1> dexamethasone </e1> before succinylcholine ( n = 32 for each ) .
CID	The incidence and severity of succinylcholine - associated <e2> myalgia </e2> was determined in 64 patients pretreated with saline or dexamethasone before <e1> succinylcholine </e1> ( n = 32 for each ) .
NO_RELATION	Incidence and severity of <e2> myalgia </e2> did not differ significantly between the two groups : 15 patients in the <e1> dexamethasone </e1> group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .
NO_RELATION	Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the <e1> dexamethasone </e1> group complained of <e2> myalgia </e2> compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .
NO_RELATION	Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the <e1> dexamethasone </e1> group complained of myalgia compared with 18 patients in the saline group , and severe <e2> myalgia </e2> was reported by five patients and three patients , respectively ( not significant ) .
CID	In conclusion , there is no evidence for an inflammatory origin of <e1> succinylcholine </e1> - associated <e2> myalgia </e2> .
NO_RELATION	IMPLICATIONS : Administration of <e1> dexamethasone </e1> before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced <e2> postoperative myalgia </e2> .
CID	IMPLICATIONS : Administration of dexamethasone before <e1> succinylcholine </e1> was not effective in decreasing the incidence or the severity of succinylcholine - induced <e2> postoperative myalgia </e2> .
CID	IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of <e1> succinylcholine </e1> - induced <e2> postoperative myalgia </e2> .
NO_RELATION	Pretreatment with <e1> dexamethasone </e1> is not justified to prevent <e2> postoperative myalgia </e2> after succinylcholine .
CID	Pretreatment with dexamethasone is not justified to prevent <e2> postoperative myalgia </e2> after <e1> succinylcholine </e1> .
CID	<e1> Levodopa </e1> - induced oromandibular <e2> dystonia </e2> in progressive supranuclear palsy .
NO_RELATION	<e1> Levodopa </e1> - induced oromandibular dystonia in <e2> progressive supranuclear palsy </e2> .
NO_RELATION	<e1> Levodopa </e1> - induced <e2> dyskinesias </e2> have been reported in Parkinson ' s disease and multiple system atrophy .
NO_RELATION	<e1> Levodopa </e1> - induced dyskinesias have been reported in <e2> Parkinson ' s disease </e2> and multiple system atrophy .
NO_RELATION	<e1> Levodopa </e1> - induced dyskinesias have been reported in Parkinson ' s disease and <e2> multiple system atrophy </e2> .
NO_RELATION	In this report we describe an unusual case of reversible <e1> levodopa </e1> - induced <e2> Oromandibular dystonia </e2> ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .
NO_RELATION	In this report we describe an unusual case of reversible <e1> levodopa </e1> - induced Oromandibular dystonia ( <e2> OMD </e2> ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .
NO_RELATION	In this report we describe an unusual case of reversible <e1> levodopa </e1> - induced Oromandibular dystonia ( OMD ) in a <e2> PSP </e2> patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .
NO_RELATION	In this report we describe an unusual case of reversible <e1> levodopa </e1> - induced Oromandibular dystonia ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of <e2> PSP </e2> , and discuss the possible underlying pathophysiology .
NO_RELATION	Protective effect of <e1> edaravone </e1> against streptomycin - induced <e2> vestibulotoxicity </e2> in the guinea pig .
CID	Protective effect of edaravone against <e1> streptomycin </e1> - induced <e2> vestibulotoxicity </e2> in the guinea pig .
CID	This study investigated alleviation of <e1> streptomycin </e1> - induced <e2> vestibulotoxicity </e2> by edaravone in guinea pigs .
NO_RELATION	This study investigated alleviation of streptomycin - induced <e2> vestibulotoxicity </e2> by <e1> edaravone </e1> in guinea pigs .
NO_RELATION	<e1> Edaravone </e1> , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat <e2> cerebral infarction </e2> .
NO_RELATION	These results suggest that <e1> edaravone </e1> suppresses streptomycin - induced <e2> vestibulotoxicity </e2> .
CID	These results suggest that edaravone suppresses <e1> streptomycin </e1> - induced <e2> vestibulotoxicity </e2> .
NO_RELATION	<e1> Diazepam </e1> , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative <e2> hallucinations </e2> .
CID	Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to <e1> ketamine </e1> as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative <e2> hallucinations </e2> .
NO_RELATION	<e1> Steroid </e1> structure and pharmacological properties determine the anti - <e2> amnesic </e2> effects of pregnenolone sulphate in the passive avoidance task in rats .
NO_RELATION	Steroid structure and pharmacological properties determine the anti - <e2> amnesic </e2> effects of <e1> pregnenolone sulphate </e1> in the passive avoidance task in rats .
NO_RELATION	Moreover , <e1> PREGS </e1> is able to reverse the <e2> amnesic </e2> - like effects of NMDAR and GABA ( A ) R ligands .
NO_RELATION	Moreover , PREGS is able to reverse the <e2> amnesic </e2> - like effects of NMDAR and <e1> GABA </e1> ( A ) R ligands .
NO_RELATION	The memory - enhancing effects of <e1> PREGS </e1> and its analogs were tested in the passive avoidance task using the model of scopolamine - induced <e2> amnesia </e2> .
CID	The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of <e1> scopolamine </e1> - induced <e2> amnesia </e2> .
NO_RELATION	Moreover , enantioselectivity was demonstrated by the ability of natural <e1> PREGS </e1> to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced <e2> amnesia </e2> .
CID	Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing <e1> scopolamine </e1> - induced <e2> amnesia </e2> .
NO_RELATION	BACKGROUND : Preclinical studies of intrathecal <e1> adenosine </e1> suggest it may be effective in the treatment of <e2> acute and chronic pain </e2> in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .
NO_RELATION	BACKGROUND : Preclinical studies of intrathecal <e1> adenosine </e1> suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in <e2> hypersensitivity </e2> states but not with acute noxious stimulation .
NO_RELATION	BACKGROUND : Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of <e2> acute and chronic pain </e2> in humans , and preliminary studies in volunteers and patients with a Swedish formulation of <e1> adenosine </e1> suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .
NO_RELATION	BACKGROUND : Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of <e1> adenosine </e1> suggests it may be effective in <e2> hypersensitivity </e2> states but not with acute noxious stimulation .
NO_RELATION	The purpose of this study was to screen for efficacy of a different formulation of <e1> adenosine </e1> marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical <e2> hypersensitivity </e2> .
NO_RELATION	The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and <e1> capsaicin </e1> - evoked mechanical <e2> hypersensitivity </e2> .
NO_RELATION	Cerebrospinal fluid was obtained for pharmacokinetic analysis , and <e2> pain </e2> ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal <e1> capsaicin </e1> injection were determined .
CID	Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of <e2> mechanical hyperalgesia </e2> and allodynia after intradermal <e1> capsaicin </e1> injection were determined .
CID	Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and <e2> allodynia </e2> after intradermal <e1> capsaicin </e1> injection were determined .
NO_RELATION	RESULTS : <e1> Adenosine </e1> produced no effect on <e2> pain </e2> report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .
NO_RELATION	RESULTS : <e1> Adenosine </e1> produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced <e2> mechanical hyperalgesia </e2> and allodynia from intradermal capsaicin injection for at least 24 h .
NO_RELATION	RESULTS : <e1> Adenosine </e1> produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and <e2> allodynia </e2> from intradermal capsaicin injection for at least 24 h .
NO_RELATION	RESULTS : Adenosine produced no effect on <e2> pain </e2> report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal <e1> capsaicin </e1> injection for at least 24 h .
CID	RESULTS : Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced <e2> mechanical hyperalgesia </e2> and allodynia from intradermal <e1> capsaicin </e1> injection for at least 24 h .
CID	RESULTS : Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and <e2> allodynia </e2> from intradermal <e1> capsaicin </e1> injection for at least 24 h .
NO_RELATION	CONCLUSIONS : These results show selective inhibition by intrathecal <e1> adenosine </e1> of <e2> hypersensitivity </e2> , presumed to reflect central sensitization in humans after peripheral capsaicin injection .
NO_RELATION	CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of <e2> hypersensitivity </e2> , presumed to reflect central sensitization in humans after peripheral <e1> capsaicin </e1> injection .
NO_RELATION	The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic <e2> neuropathic pain </e2> and is not due to prolonged residence of <e1> adenosine </e1> in cerebrospinal fluid .
NO_RELATION	These were evaluated with respect to the duration of <e1> lithium </e1> therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with <e2> thyroid disease </e2> ) .
NO_RELATION	PATIENTS : One hundred and one patients ( 28 men and 73 women ) with <e2> bipolar disorder </e2> receiving <e1> lithium </e1> maintenance therapy ranging from 1 year ' s to 32 years ' duration .
NO_RELATION	All patients having first - degree relatives affected by <e2> thyroid illness </e2> had accelerated onset of hypothyroidism ( 3 . 7 years after onset of <e1> lithium </e1> therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .
CID	All patients having first - degree relatives affected by thyroid illness had accelerated onset of <e2> hypothyroidism </e2> ( 3 . 7 years after onset of <e1> lithium </e1> therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .
NO_RELATION	All patients having first - degree relatives affected by <e2> thyroid illness </e2> had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of <e1> lithium </e1> therapy ) .
CID	All patients having first - degree relatives affected by thyroid illness had accelerated onset of <e2> hypothyroidism </e2> ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of <e1> lithium </e1> therapy ) .
NO_RELATION	CONCLUSIONS : Familial <e2> thyroid illness </e2> is a risk factor for hypothyroidism and hypercalcemia during <e1> lithium </e1> therapy .
CID	CONCLUSIONS : Familial thyroid illness is a risk factor for <e2> hypothyroidism </e2> and hypercalcemia during <e1> lithium </e1> therapy .
NO_RELATION	CONCLUSIONS : Familial thyroid illness is a risk factor for hypothyroidism and <e2> hypercalcemia </e2> during <e1> lithium </e1> therapy .
NO_RELATION	Systemic <e2> toxicity </e2> following administration of <e1> sirolimus </e1> ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .
NO_RELATION	Systemic toxicity following administration of <e1> sirolimus </e1> ( formerly rapamycin ) for <e2> psoriasis </e2> : association of capillary leak syndrome with apoptosis of lesional lymphocytes .
CID	Systemic toxicity following administration of <e1> sirolimus </e1> ( formerly rapamycin ) for psoriasis : association of <e2> capillary leak syndrome </e2> with apoptosis of lesional lymphocytes .
NO_RELATION	Systemic <e2> toxicity </e2> following administration of sirolimus ( formerly <e1> rapamycin </e1> ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .
NO_RELATION	Systemic toxicity following administration of sirolimus ( formerly <e1> rapamycin </e1> ) for <e2> psoriasis </e2> : association of capillary leak syndrome with apoptosis of lesional lymphocytes .
CID	Systemic toxicity following administration of sirolimus ( formerly <e1> rapamycin </e1> ) for psoriasis : association of <e2> capillary leak syndrome </e2> with apoptosis of lesional lymphocytes .
NO_RELATION	After 2 individuals with <e2> psoriasis </e2> developed a capillary leak syndrome following treatment with oral <e1> sirolimus </e1> lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .
CID	After 2 individuals with psoriasis developed a <e2> capillary leak syndrome </e2> following treatment with oral <e1> sirolimus </e1> lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .
CID	OBSERVATIONS : A keratome skin specimen from 1 patient with <e1> sirolimus </e1> - induced <e2> capillary leak syndrome </e2> had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .
NO_RELATION	OBSERVATIONS : A keratome skin specimen from 1 patient with <e1> sirolimus </e1> - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with <e2> psoriasis </e2> ( 21 % ) .
CID	OBSERVATIONS : A keratome skin specimen from 1 patient with sirolimus - induced <e2> capillary leak syndrome </e2> had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected <e1> sirolimus </e1> - treated patient with psoriasis ( 21 % ) .
NO_RELATION	OBSERVATIONS : A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected <e1> sirolimus </e1> - treated patient with <e2> psoriasis </e2> ( 21 % ) .
NO_RELATION	Activated peripheral blood T cells from patients with <e2> psoriasis </e2> tended to exhibit greater spontaneous or <e1> dexamethasone </e1> - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .
NO_RELATION	Activated peripheral blood T cells from patients with <e2> psoriasis </e2> tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of <e1> sirolimus </e1> .
NO_RELATION	CONCLUSIONS : Severe adverse effects of <e1> sirolimus </e1> include <e2> fever </e2> , anemia , and capillary leak syndrome .
NO_RELATION	CONCLUSIONS : Severe adverse effects of <e1> sirolimus </e1> include fever , <e2> anemia </e2> , and capillary leak syndrome .
CID	CONCLUSIONS : Severe adverse effects of <e1> sirolimus </e1> include fever , anemia , and <e2> capillary leak syndrome </e2> .
CID	<e2> Muscle rigidity </e2> was induced by <e1> haloperidol </e1> ( 2 . 5 mg / kg i . p . ) .
NO_RELATION	<e1> 5 , 7 - dichlorokynurenic acid </e1> ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced <e2> muscle rigidity </e2> ( MMG ) and the enhanced electromyographic activity ( EMG ) .
NO_RELATION	5 , 7 - dichlorokynurenic acid ( <e1> 5 , 7 - DCKA </e1> ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced <e2> muscle rigidity </e2> ( MMG ) and the enhanced electromyographic activity ( EMG ) .
NO_RELATION	5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective <e1> glycine </e1> site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced <e2> muscle rigidity </e2> ( MMG ) and the enhanced electromyographic activity ( EMG ) .
CID	5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the <e1> haloperidol </e1> - induced <e2> muscle rigidity </e2> ( MMG ) and the enhanced electromyographic activity ( EMG ) .
NO_RELATION	Efficacy and tolerability of <e1> lovastatin </e1> in 3390 women with moderate <e2> hypercholesterolemia </e2> .
NO_RELATION	OBJECTIVE : To evaluate the efficacy and safety of <e1> lovastatin </e1> in women with moderate <e2> hypercholesterolemia </e2> .
NO_RELATION	<e2> Myopathy </e2> , defined as muscle symptoms with <e1> creatine </e1> kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .
CID	<e2> Myopathy </e2> , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of <e1> lovastatin </e1> ( 80 mg ) .
NO_RELATION	CONCLUSION : <e1> Lovastatin </e1> is highly effective and generally well tolerated as therapy for primary <e2> hypercholesterolemia </e2> in women .
NO_RELATION	The effects of <e2> REM sleep deprivation </e2> ( REMD ) on <e1> apomorphine </e1> - induced aggressiveness and quipazine - induced head twitches in rats were determined .
NO_RELATION	The effects of REM sleep deprivation ( <e2> REMD </e2> ) on <e1> apomorphine </e1> - induced aggressiveness and quipazine - induced head twitches in rats were determined .
CID	The effects of REM sleep deprivation ( REMD ) on <e1> apomorphine </e1> - induced <e2> aggressiveness </e2> and quipazine - induced head twitches in rats were determined .
NO_RELATION	The effects of REM sleep deprivation ( REMD ) on <e1> apomorphine </e1> - induced aggressiveness and quipazine - induced <e2> head twitches </e2> in rats were determined .
NO_RELATION	The effects of <e2> REM sleep deprivation </e2> ( REMD ) on apomorphine - induced aggressiveness and <e1> quipazine </e1> - induced head twitches in rats were determined .
NO_RELATION	The effects of REM sleep deprivation ( <e2> REMD </e2> ) on apomorphine - induced aggressiveness and <e1> quipazine </e1> - induced head twitches in rats were determined .
NO_RELATION	The effects of REM sleep deprivation ( REMD ) on apomorphine - induced <e2> aggressiveness </e2> and <e1> quipazine </e1> - induced head twitches in rats were determined .
CID	The effects of REM sleep deprivation ( REMD ) on apomorphine - induced aggressiveness and <e1> quipazine </e1> - induced <e2> head twitches </e2> in rats were determined .
NO_RELATION	Forty - eight hr of <e2> REMD </e2> increased <e1> apomorphine </e1> - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .
CID	Forty - eight hr of REMD increased <e1> apomorphine </e1> - induced <e2> aggressiveness </e2> , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .
NO_RELATION	Forty - eight hr of REMD increased <e1> apomorphine </e1> - induced aggressiveness , and reduced ( immediately after completing of <e2> REMD </e2> ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .
NO_RELATION	Forty - eight hr of REMD increased <e1> apomorphine </e1> - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of <e2> REMD </e2> ) quipazine - induced head twitches .
NO_RELATION	Forty - eight hr of REMD increased <e1> apomorphine </e1> - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced <e2> head twitches </e2> .
NO_RELATION	Forty - eight hr of <e2> REMD </e2> increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) <e1> quipazine </e1> - induced head twitches .
NO_RELATION	Forty - eight hr of REMD increased apomorphine - induced <e2> aggressiveness </e2> , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) <e1> quipazine </e1> - induced head twitches .
NO_RELATION	Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of <e2> REMD </e2> ) or increased ( 96 hr after completing of REMD ) <e1> quipazine </e1> - induced head twitches .
NO_RELATION	Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of <e2> REMD </e2> ) <e1> quipazine </e1> - induced head twitches .
CID	Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) <e1> quipazine </e1> - induced <e2> head twitches </e2> .
CID	The incidence of <e2> parkinsonism </e2> was higher at higher doses of <e1> haloperidol </e1> and in younger patients .
NO_RELATION	<e2> Akathisia </e2> was controlled by the <e1> benzodiazepine </e1> lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .
NO_RELATION	<e2> Akathisia </e2> was controlled by the benzodiazepine <e1> lorazepam </e1> in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .
CID	<e2> Hepatic veno - occlusive disease </e2> caused by <e1> 6 - thioguanine </e1> .
CID	Clinically reversible <e2> veno - occlusive disease of the liver </e2> developed in a 23 - year - old man with acute lymphocytic leukemia after 10 months of maintenance therapy with <e1> 6 - thioguanine </e1> .
NO_RELATION	Clinically reversible veno - occlusive disease of the liver developed in a 23 - year - old man with <e2> acute lymphocytic leukemia </e2> after 10 months of maintenance therapy with <e1> 6 - thioguanine </e1> .
CID	This case presented a unique opportunity to observe the histologic features of clinically reversible <e2> hepatic veno - occlusive disease </e2> over time , and may be the first case of veno - occlusive related solely to <e1> 6 - thioguanine </e1> .
CID	Treatment of <e1> ifosfamide </e1> - induced <e2> urothelial toxicity </e2> by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable lung cancer .
NO_RELATION	Treatment of <e1> ifosfamide </e1> - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable <e2> lung cancer </e2> .
NO_RELATION	Treatment of ifosfamide - induced <e2> urothelial toxicity </e2> by oral administration of <e1> sodium 2 - mercaptoethane sulphonate </e1> ( MESNA ) to patients with inoperable lung cancer .
NO_RELATION	Treatment of ifosfamide - induced urothelial toxicity by oral administration of <e1> sodium 2 - mercaptoethane sulphonate </e1> ( MESNA ) to patients with inoperable <e2> lung cancer </e2> .
NO_RELATION	Treatment of ifosfamide - induced <e2> urothelial toxicity </e2> by oral administration of sodium 2 - mercaptoethane sulphonate ( <e1> MESNA </e1> ) to patients with inoperable lung cancer .
NO_RELATION	Treatment of ifosfamide - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( <e1> MESNA </e1> ) to patients with inoperable <e2> lung cancer </e2> .
NO_RELATION	The protective effect of oral administration of the <e1> thiol </e1> compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against <e2> urothelial toxicity </e2> induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	The protective effect of oral administration of the <e1> thiol </e1> compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	The protective effect of oral administration of the thiol compound <e1> sodium 2 - mercaptoethane sulphonate </e1> ( MESNA ) against <e2> urothelial toxicity </e2> induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	The protective effect of oral administration of the thiol compound <e1> sodium 2 - mercaptoethane sulphonate </e1> ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( <e1> MESNA </e1> ) against <e2> urothelial toxicity </e2> induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( <e1> MESNA </e1> ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
CID	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against <e2> urothelial toxicity </e2> induced by <e1> ifosfamide </e1> ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by <e1> ifosfamide </e1> ( IF ) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
CID	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against <e2> urothelial toxicity </e2> induced by ifosfamide ( <e1> IF </e1> ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( <e1> IF </e1> ) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
CID	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against <e2> urothelial toxicity </e2> induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with <e1> IF </e1> ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable <e2> lung cancer </e2> under treatment with <e1> IF </e1> ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
NO_RELATION	There were no appreciable differences between the <e1> MESNA </e1> series and the conventional prophylaxis series with respect to either haematological or systemic <e2> toxicity </e2> of the cytostatic treatment .
CID	Production of autochthonous <e2> prostate cancer </e2> in Lobund - Wistar rats by treatments with <e1> N - nitroso - N - methylurea </e1> and testosterone .
NO_RELATION	Production of autochthonous <e2> prostate cancer </e2> in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and <e1> testosterone </e1> .
CID	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable <e2> prostate adenocarcinomas </e2> ( PAs ) following treatments with <e1> N - nitroso - N - methylurea </e1> ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .
CID	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( <e2> PAs </e2> ) following treatments with <e1> N - nitroso - N - methylurea </e1> ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .
NO_RELATION	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with <e1> N - nitroso - N - methylurea </e1> ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the <e2> tumor </e2> - bearing rats manifested metastatic lesions .
CID	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable <e2> prostate adenocarcinomas </e2> ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and <e1> testosterone propionate </e1> [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .
CID	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( <e2> PAs </e2> ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and <e1> testosterone propionate </e1> [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .
NO_RELATION	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and <e1> testosterone propionate </e1> [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the <e2> tumor </e2> - bearing rats manifested metastatic lesions .
CID	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable <e2> prostate adenocarcinomas </e2> ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( <e1> TP </e1> ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .
CID	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( <e2> PAs </e2> ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( <e1> TP </e1> ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .
NO_RELATION	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( <e1> TP </e1> ) CAS : 57 - 85 - 2 ] , and most of the <e2> tumor </e2> - bearing rats manifested metastatic lesions .
CID	Within the same timeframe , no L - W rat developed a similar palpable <e2> PA </e2> when treated only with <e1> TP </e1> .
NO_RELATION	In L - W rats , <e1> TP </e1> acted as a <e2> tumor </e2> enhancement agent , with primary emphasis on the development of prostate cancer .
CID	In L - W rats , <e1> TP </e1> acted as a tumor enhancement agent , with primary emphasis on the development of <e2> prostate cancer </e2> .
CID	A <e2> dystonia </e2> - like syndrome after neuropeptide ( <e1> MSH </e1> / ACTH ) stimulation of the rat locus ceruleus .
CID	A <e2> dystonia </e2> - like syndrome after neuropeptide ( MSH / <e1> ACTH </e1> ) stimulation of the rat locus ceruleus .
NO_RELATION	However , it is not certain as to the following : ( a ) what receptors were stimulated by the <e1> ACTH </e1> N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term <e2> depression </e2> at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the movement disorder ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .
NO_RELATION	However , it is not certain as to the following : ( a ) what receptors were stimulated by the <e1> ACTH </e1> N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term depression at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the <e2> movement disorder </e2> ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .
NO_RELATION	<e1> Dexmedetomidine </e1> , acting through central alpha - 2 adrenoceptors , prevents opiate - induced <e2> muscle rigidity </e2> in the rat .
NO_RELATION	The highly - selective alpha - 2 adrenergic agonist <e1> dexmedetomidine </e1> ( D - MED ) is capable of inducing <e2> muscle flaccidity </e2> and anesthesia in rats and dogs .
NO_RELATION	The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( <e1> D - MED </e1> ) is capable of inducing <e2> muscle flaccidity </e2> and anesthesia in rats and dogs .
NO_RELATION	In the present study , the authors determined if treatment with <e1> D - MED </e1> prevents the <e2> muscle rigidity </e2> caused by high - dose alfentanil anesthesia in the rat .
CID	In the present study , the authors determined if treatment with D - MED prevents the <e2> muscle rigidity </e2> caused by high - dose <e1> alfentanil </e1> anesthesia in the rat .
NO_RELATION	In contrast , <e1> D - MED </e1> prevented alfentanil - induced <e2> muscle rigidity </e2> in a dose - dependent fashion .
CID	In contrast , D - MED prevented <e1> alfentanil </e1> - induced <e2> muscle rigidity </e2> in a dose - dependent fashion .
NO_RELATION	The high - dose <e1> D - MED </e1> animals were flaccid , <e2> akinetic </e2> , and lacked a startle response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	The high - dose <e1> D - MED </e1> animals were flaccid , akinetic , and lacked a <e2> startle </e2> response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	<e2> Seizure </e2> activity with <e1> imipenem </e1> therapy : incidence and risk factors .
NO_RELATION	Two elderly patients with a history of either <e2> cerebral vascular accident </e2> ( CVA ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of <e1> imipenem / cilastatin </e1> .
NO_RELATION	Two elderly patients with a history of either cerebral vascular accident ( <e2> CVA </e2> ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of <e1> imipenem / cilastatin </e1> .
NO_RELATION	Two elderly patients with a history of either cerebral vascular accident ( CVA ) or <e2> head trauma </e2> and no evidence of renal disease developed seizures while receiving maximum doses of <e1> imipenem / cilastatin </e1> .
NO_RELATION	Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of <e2> renal disease </e2> developed seizures while receiving maximum doses of <e1> imipenem / cilastatin </e1> .
CID	Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of renal disease developed <e2> seizures </e2> while receiving maximum doses of <e1> imipenem / cilastatin </e1> .
NO_RELATION	All <e2> seizures </e2> were controlled with therapeutic doses of <e1> phenytoin </e1> .
NO_RELATION	Both patients had received maximum doses of other <e1> beta - lactam </e1> antibiotics without evidence of <e2> seizure </e2> activity .
CID	The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by <e1> streptozotocin </e1> - induced <e2> diabetes mellitus </e2> .
CID	The effects of insulin treatment on in vivo and in vitro urinary bladder function in <e1> streptozotocin </e1> - <e2> diabetic </e2> rats were investigated .
NO_RELATION	Insulin treatment also prevented the increases in contractile responses of bladder body strips from <e2> diabetic </e2> rats to nerve stimulation , <e1> ATP </e1> , and bethanechol .
NO_RELATION	Insulin treatment also prevented the increases in contractile responses of bladder body strips from <e2> diabetic </e2> rats to nerve stimulation , ATP , and <e1> bethanechol </e1> .
NO_RELATION	Insulin treatment reversed the increases in contractile responses of bladder body strips from <e2> diabetic </e2> rats to nerve stimulation , <e1> ATP </e1> , and bethanechol .
NO_RELATION	Insulin treatment reversed the increases in contractile responses of bladder body strips from <e2> diabetic </e2> rats to nerve stimulation , ATP , and <e1> bethanechol </e1> .
CID	The data indicate that the effects of <e1> streptozotocin </e1> - induced <e2> diabetes </e2> on urinary bladder function are both prevented and reversed by insulin treatment .
NO_RELATION	Under <e1> isoflurane </e1> anesthesia , the MCA of 14 spontaneously <e2> hypertensive </e2> rats was occluded .
NO_RELATION	The extent of <e2> neuronal injury </e2> was determined by <e1> 2 , 3 , 5 - triphenyltetrazolium </e1> staining .
CID	The data indicate that <e1> phenylephrine </e1> - induced <e2> hypertension </e2> instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .
NO_RELATION	The data indicate that <e1> phenylephrine </e1> - induced hypertension instituted 2 h after <e2> MCAO </e2> does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .
NO_RELATION	The data indicate that <e1> phenylephrine </e1> - induced hypertension instituted 2 h after MCAO does not aggravate <e2> edema </e2> in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .
NO_RELATION	The data indicate that <e1> phenylephrine </e1> - induced hypertension instituted 2 h after MCAO does not aggravate edema in the <e2> ischemic </e2> core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .
NO_RELATION	The data indicate that <e1> phenylephrine </e1> - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves <e2> edema </e2> in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .
NO_RELATION	The data indicate that <e1> phenylephrine </e1> - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the <e2> ischemic </e2> territory , and that it reduces the area of histochemical neuronal dysfunction .
NO_RELATION	The data indicate that <e1> phenylephrine </e1> - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical <e2> neuronal dysfunction </e2> .
NO_RELATION	<e1> Amiodarone </e1> <e2> pulmonary toxicity </e2> .
CID	<e1> Amiodarone </e1> is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being <e2> pneumonitis </e2> .
NO_RELATION	The <e2> pulmonary toxicity </e2> of <e1> amiodarone </e1> is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated hypersensitivity pneumonitis .
NO_RELATION	The pulmonary toxicity of <e1> amiodarone </e1> is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated <e2> hypersensitivity pneumonitis </e2> .
NO_RELATION	The clinical and radiographic features of <e1> amiodarone </e1> - induced <e2> pulmonary toxicity </e2> are characteristic but nonspecific .
CID	Light chain <e2> proteinuria </e2> and cellular mediated immunity in <e1> rifampin </e1> treated patients with tuberculosis .
NO_RELATION	Light chain proteinuria and cellular mediated immunity in <e1> rifampin </e1> treated patients with <e2> tuberculosis </e2> .
CID	Light chain <e2> proteinuria </e2> was found in 9 of 17 tuberculosis patients treated with <e1> rifampin </e1> .
NO_RELATION	Light chain proteinuria was found in 9 of 17 <e2> tuberculosis </e2> patients treated with <e1> rifampin </e1> .
NO_RELATION	Initial <e1> potassium </e1> loss and <e2> hypokalaemia </e2> during chlorthalidone administration in patients with essential hypertension : the influence of dietary sodium restriction .
NO_RELATION	Initial <e1> potassium </e1> loss and hypokalaemia during chlorthalidone administration in patients with essential <e2> hypertension </e2> : the influence of dietary sodium restriction .
CID	Initial potassium loss and <e2> hypokalaemia </e2> during <e1> chlorthalidone </e1> administration in patients with essential hypertension : the influence of dietary sodium restriction .
NO_RELATION	Initial potassium loss and hypokalaemia during <e1> chlorthalidone </e1> administration in patients with essential <e2> hypertension </e2> : the influence of dietary sodium restriction .
NO_RELATION	Initial potassium loss and <e2> hypokalaemia </e2> during chlorthalidone administration in patients with essential hypertension : the influence of dietary <e1> sodium </e1> restriction .
NO_RELATION	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential <e2> hypertension </e2> : the influence of dietary <e1> sodium </e1> restriction .
NO_RELATION	To investigate the initial <e1> potassium </e1> loss and development of <e2> hypokalaemia </e2> during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment .
NO_RELATION	To investigate the initial <e1> potassium </e1> loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential <e2> hypertension </e2> who had shown hypokalaemia under prior oral diuretic treatment .
NO_RELATION	To investigate the initial <e1> potassium </e1> loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown <e2> hypokalaemia </e2> under prior oral diuretic treatment .
CID	In this study we postulated that during <e2> acute renal failure </e2> induced by <e1> gentamicin </e1> the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .
CID	<e1> Oxytocin </e1> is a commonly used uterotonic that can cause significant and even fatal <e2> hypotension </e2> , particularly when given as a bolus .
CID	<e1> Oxytocin </e1> - induced <e2> hypotension </e2> at cesarean delivery may be incorrectly attributed to blood loss .
NO_RELATION	<e1> Oxytocin </e1> - induced hypotension at cesarean delivery may be incorrectly attributed to <e2> blood loss </e2> .
CID	<e2> Hypotension </e2> in response to <e1> oxytocin </e1> was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume , heart rate and cardiac output .
NO_RELATION	Hypotension in response to <e1> oxytocin </e1> was associated with a decrease in systemic vascular resistance and a compensatory increase in <e2> stroke </e2> volume , heart rate and cardiac output .
CID	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with <e1> cyclophosphamide </e1> ( CYP ) - induced <e2> cystitis </e2> .
CID	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( <e1> CYP </e1> ) - induced <e2> cystitis </e2> .
CID	VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after <e1> cyclophosphamide </e1> ( CYP ) - induced <e2> cystitis </e2> .
CID	VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( <e1> CYP </e1> ) - induced <e2> cystitis </e2> .
CID	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without <e1> CYP </e1> - induced <e2> cystitis </e2> ( 150 mg / kg ; i . p . ; 48 h ) .
NO_RELATION	The data suggest that in VIP ( - / - ) mice with <e2> bladder inflammation </e2> , inflammatory mediators are increased above that observed in WT with <e1> CYP </e1> .
NO_RELATION	Intraocular pressure in patients with <e2> uveitis </e2> treated with <e1> fluocinolone acetonide </e1> implants .
CID	OBJECTIVE : To report the incidence and management of <e2> elevated intraocular pressure </e2> ( IOP ) in patients with uveitis treated with the <e1> fluocinolone acetonide </e1> ( FA ) intravitreal implant .
NO_RELATION	OBJECTIVE : To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with <e2> uveitis </e2> treated with the <e1> fluocinolone acetonide </e1> ( FA ) intravitreal implant .
CID	OBJECTIVE : To report the incidence and management of <e2> elevated intraocular pressure </e2> ( IOP ) in patients with uveitis treated with the fluocinolone acetonide ( <e1> FA </e1> ) intravitreal implant .
NO_RELATION	OBJECTIVE : To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with <e2> uveitis </e2> treated with the fluocinolone acetonide ( <e1> FA </e1> ) intravitreal implant .
NO_RELATION	Pallidal stimulation improves <e2> bradykinesia </e2> and rigidity to a minor extent ; however , its strength seems to be in improving <e1> levodopa </e1> - induced dyskinesias .
NO_RELATION	Pallidal stimulation improves bradykinesia and <e2> rigidity </e2> to a minor extent ; however , its strength seems to be in improving <e1> levodopa </e1> - induced dyskinesias .
CID	Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving <e1> levodopa </e1> - induced <e2> dyskinesias </e2> .
CID	Case report : <e1> Dexatrim </e1> ( Phenylpropanolamine ) as a cause of <e2> myocardial infarction </e2> .
CID	Case report : Dexatrim ( <e1> Phenylpropanolamine </e1> ) as a cause of <e2> myocardial infarction </e2> .
NO_RELATION	Several reports have linked the abuse of <e1> PPA </e1> with <e2> myocardial injury </e2> , especially when overdose is involved .
NO_RELATION	Several reports have linked the abuse of <e1> PPA </e1> with myocardial injury , especially when <e2> overdose </e2> is involved .
NO_RELATION	We report here the first case of <e1> Dexatrim </e1> ( PPA ) - induced <e2> myocardial injury </e2> in a young woman who was using it at recommended doses for weight control .
NO_RELATION	We report here the first case of Dexatrim ( <e1> PPA </e1> ) - induced <e2> myocardial injury </e2> in a young woman who was using it at recommended doses for weight control .
NO_RELATION	In addition , we review the 7 other cases of <e1> PPA </e1> related <e2> myocardial injury </e2> that have been reported so far .
CID	<e1> Risperidone </e1> - associated , benign transient <e2> visual disturbances </e2> in schizophrenic patients with a past history of LSD abuse .
NO_RELATION	<e1> Risperidone </e1> - associated , benign transient visual disturbances in <e2> schizophrenic </e2> patients with a past history of LSD abuse .
NO_RELATION	Risperidone - associated , benign transient <e2> visual disturbances </e2> in schizophrenic patients with a past history of <e1> LSD </e1> abuse .
NO_RELATION	Risperidone - associated , benign transient visual disturbances in <e2> schizophrenic </e2> patients with a past history of <e1> LSD </e1> abuse .
NO_RELATION	Two <e2> schizophrenic </e2> patients , who had a prior history of <e1> LSD </e1> abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .
NO_RELATION	Two schizophrenic patients , who had a prior history of <e1> LSD </e1> abuse and who had previously developed <e2> EPS </e2> with classic antipsychotics , were successfully treated with risperidone .
NO_RELATION	Two <e2> schizophrenic </e2> patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with <e1> risperidone </e1> .
NO_RELATION	Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed <e2> EPS </e2> with classic antipsychotics , were successfully treated with <e1> risperidone </e1> .
CID	They both reported short episodes of transient <e2> visual disturbances </e2> , which appeared immediately after starting treatment with <e1> risperidone </e1> .
NO_RELATION	This imagery resembled <e2> visual disturbances </e2> previously experienced as " flashbacks " related to prior <e1> LSD </e1> consumption .
CID	<e1> Risperidone </e1> administration was continued and the <e2> visual disturbances </e2> gradually wore off .
NO_RELATION	Activation of <e1> poly ( ADP - ribose ) </e1> polymerase contributes to development of doxorubicin - induced <e2> heart failure </e2> .
CID	Activation of poly ( ADP - ribose ) polymerase contributes to development of <e1> doxorubicin </e1> - induced <e2> heart failure </e2> .
NO_RELATION	Increased oxidative stress is a major factor implicated in the <e2> cardiotoxicity </e2> of <e1> doxorubicin </e1> ( DOX ) , a widely used antitumor anthracycline antibiotic .
NO_RELATION	Increased oxidative stress is a major factor implicated in the <e2> cardiotoxicity </e2> of doxorubicin ( <e1> DOX </e1> ) , a widely used antitumor anthracycline antibiotic .
NO_RELATION	Increased oxidative stress is a major factor implicated in the <e2> cardiotoxicity </e2> of doxorubicin ( DOX ) , a widely used antitumor <e1> anthracycline </e1> antibiotic .
NO_RELATION	Thus , we hypothesized that the activation of PARP may contribute to the <e1> DOX </e1> - induced <e2> cardiotoxicity </e2> .
NO_RELATION	Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor <e1> PJ34 </e1> , we now demonstrate the role of PARP in the development of <e2> cardiac dysfunction </e2> induced by DOX .
NO_RELATION	Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of <e2> cardiac dysfunction </e2> induced by <e1> DOX </e1> .
NO_RELATION	Treatment with a <e1> PJ34 </e1> significantly improved <e2> cardiac dysfunction </e2> and increased the survival of the animals .
NO_RELATION	Thus , PARP activation contributes to the <e2> cardiotoxicity </e2> of <e1> DOX </e1> .
NO_RELATION	PARP inhibitors may exert protective effects against the development of severe <e2> cardiac complications </e2> associated with the <e1> DOX </e1> treatment .
CID	<e1> Fluconazole </e1> - induced <e2> torsade de pointes </e2> .
CID	OBJECTIVE : To present a case of <e1> fluconazole </e1> - associated <e2> torsade de pointes </e2> ( TDP ) and discuss fluconazole ' s role in causing TDP .
CID	OBJECTIVE : To present a case of <e1> fluconazole </e1> - associated torsade de pointes ( <e2> TDP </e2> ) and discuss fluconazole ' s role in causing TDP .
CID	OBJECTIVE : To present a case of <e1> fluconazole </e1> - associated torsade de pointes ( TDP ) and discuss fluconazole ' s role in causing <e2> TDP </e2> .
CID	OBJECTIVE : To present a case of fluconazole - associated <e2> torsade de pointes </e2> ( TDP ) and discuss <e1> fluconazole </e1> ' s role in causing TDP .
CID	OBJECTIVE : To present a case of fluconazole - associated torsade de pointes ( <e2> TDP </e2> ) and discuss <e1> fluconazole </e1> ' s role in causing TDP .
CID	OBJECTIVE : To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss <e1> fluconazole </e1> ' s role in causing <e2> TDP </e2> .
CID	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed <e2> TDP </e2> eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .
CID	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for <e2> TDP </e2> , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .
NO_RELATION	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP , including <e2> coronary artery disease </e2> , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .
NO_RELATION	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP , including coronary artery disease , <e2> cardiomyopathy </e2> , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .
NO_RELATION	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , <e2> congestive heart failure </e2> , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .
CID	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <e1> fluconazole </e1> The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and <e2> TDP </e2> .
CID	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed <e2> TDP </e2> eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> and TDP .
CID	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for <e2> TDP </e2> , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> and TDP .
NO_RELATION	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including <e2> coronary artery disease </e2> , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> and TDP .
NO_RELATION	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , <e2> cardiomyopathy </e2> , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> and TDP .
NO_RELATION	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , <e2> congestive heart failure </e2> , and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> and TDP .
CID	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of <e1> fluconazole </e1> and <e2> TDP </e2> .
CID	The <e2> TDP </e2> resolved when <e1> fluconazole </e1> was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .
NO_RELATION	The TDP resolved when <e1> fluconazole </e1> was discontinued ; however , the patient continued to have <e2> premature ventricular contractions </e2> and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .
NO_RELATION	The TDP resolved when <e1> fluconazole </e1> was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained <e2> ventricular tachycardia </e2> ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .
NO_RELATION	The TDP resolved when <e1> fluconazole </e1> was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( <e2> NSVT </e2> ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .
CID	The TDP resolved when <e1> fluconazole </e1> was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of <e2> TDP </e2> .
CID	The <e2> TDP </e2> resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> and the development of TDP .
NO_RELATION	The TDP resolved when fluconazole was discontinued ; however , the patient continued to have <e2> premature ventricular contractions </e2> and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> and the development of TDP .
NO_RELATION	The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained <e2> ventricular tachycardia </e2> ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> and the development of TDP .
NO_RELATION	The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( <e2> NSVT </e2> ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> and the development of TDP .
CID	The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of <e1> fluconazole </e1> and the development of <e2> TDP </e2> .
NO_RELATION	The possible mechanism is <e2> depression </e2> of rapidly activating delayed rectifier <e1> potassium </e1> currents .
NO_RELATION	In our patient , there was no other etiology identified that could explain <e2> QT prolongation </e2> or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <e1> fluconazole </e1> as the etiology .
CID	In our patient , there was no other etiology identified that could explain QT prolongation or <e2> TDP </e2> The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <e1> fluconazole </e1> as the etiology .
NO_RELATION	In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of <e2> NSVT </e2> and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <e1> fluconazole </e1> as the etiology .
NO_RELATION	In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and <e2> premature ventricular contractions </e2> followed by normalization of QT interval after the drug was stopped strongly suggests <e1> fluconazole </e1> as the etiology .
NO_RELATION	CONCLUSIONS : Clinicians should be aware that <e1> fluconazole </e1> , even at low doses , may cause <e2> prolongation of the QT interval </e2> , leading to TDP .
CID	CONCLUSIONS : Clinicians should be aware that <e1> fluconazole </e1> , even at low doses , may cause prolongation of the QT interval , leading to <e2> TDP </e2> .
NO_RELATION	Serial electrocardiographic monitoring may be considered when <e1> fluconazole </e1> is administered in patients who are at risk for <e2> ventricular arrhythmias </e2> .
NO_RELATION	High - dose <e1> methylprednisolone </e1> may do more harm for <e2> spinal cord injury </e2> .
NO_RELATION	Because of the National Acute <e2> Spinal Cord Injury </e2> Studies ( NASCIS ) , high - dose <e1> methylprednisolone </e1> became the standard of care for the acute spinal cord injury .
NO_RELATION	Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose <e1> methylprednisolone </e1> became the standard of care for the acute <e2> spinal cord injury </e2> .
NO_RELATION	In the NASCIS , there was no mention regarding the possibility of acute <e1> corticosteroid </e1> <e2> myopathy </e2> that high - dose methylprednisolone may cause .
CID	In the NASCIS , there was no mention regarding the possibility of acute corticosteroid <e2> myopathy </e2> that high - dose <e1> methylprednisolone </e1> may cause .
NO_RELATION	Further , <e1> steroid </e1> <e2> myopathy </e2> recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .
NO_RELATION	Further , <e1> steroid </e1> myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid <e2> myopathy </e2> , instead of any protection that methylprednisolone offers to the spinal cord injury .
NO_RELATION	Further , <e1> steroid </e1> myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the <e2> spinal cord injury </e2> .
NO_RELATION	Further , steroid <e2> myopathy </e2> recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the <e1> steroid </e1> myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .
NO_RELATION	Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the <e1> steroid </e1> <e2> myopathy </e2> , instead of any protection that methylprednisolone offers to the spinal cord injury .
NO_RELATION	Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the <e1> steroid </e1> myopathy , instead of any protection that methylprednisolone offers to the <e2> spinal cord injury </e2> .
CID	Further , steroid <e2> myopathy </e2> recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that <e1> methylprednisolone </e1> offers to the spinal cord injury .
CID	Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid <e2> myopathy </e2> , instead of any protection that <e1> methylprednisolone </e1> offers to the spinal cord injury .
NO_RELATION	Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that <e1> methylprednisolone </e1> offers to the <e2> spinal cord injury </e2> .
CID	To our knowledge , this is the first discussion considering the possibility that the <e1> methylprednisolone </e1> recommended by NASCIS may cause acute corticosteroid <e2> myopathy </e2> .
NO_RELATION	To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute <e1> corticosteroid </e1> <e2> myopathy </e2> .
NO_RELATION	OUTCOME MEASURES : Pupil size at time points after administration of <e1> tropicamide </e1> and pilocarpine ; scopolamine - induced <e2> impairment in word recall </e2> .
NO_RELATION	OUTCOME MEASURES : Pupil size at time points after administration of tropicamide and <e1> pilocarpine </e1> ; scopolamine - induced <e2> impairment in word recall </e2> .
CID	OUTCOME MEASURES : Pupil size at time points after administration of tropicamide and pilocarpine ; <e1> scopolamine </e1> - induced <e2> impairment in word recall </e2> .
CID	Compared with the young group , the elderly group had greater <e1> scopolamine </e1> - induced <e2> impairment in word recall </e2> 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .
CID	<e1> Acetazolamide </e1> - induced <e2> Gerstmann syndrome </e2> .
NO_RELATION	Acute <e2> confusion </e2> induced by <e1> acetazolamide </e1> is a well known adverse drug reaction in patients with renal impairment .
NO_RELATION	Acute confusion induced by <e1> acetazolamide </e1> is a well known adverse drug reaction in patients with <e2> renal impairment </e2> .
CID	We report a case of <e1> acetazolamide </e1> - induced <e2> Gerstmann syndrome </e2> in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .
CID	<e2> Hypomania </e2> - like syndrome induced by <e1> olanzapine </e1> .
NO_RELATION	We report a female patient with a diagnosis of a not otherwise specified <e2> psychotic disorder </e2> ( DSM - IV ) who developed hypomania shortly after the introduction of <e1> olanzapine </e1> treatment .
CID	We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed <e2> hypomania </e2> shortly after the introduction of <e1> olanzapine </e1> treatment .
NO_RELATION	Neutrophil <e1> superoxide </e1> and hydrogen peroxide production in patients with <e2> acute liver failure </e2> .
NO_RELATION	Neutrophil superoxide and <e1> hydrogen peroxide </e1> production in patients with <e2> acute liver failure </e2> .
NO_RELATION	Defects in <e1> superoxide </e1> and hydrogen peroxide production may be implicated in the high incidence of <e2> bacterial infections </e2> in patients with acute liver failure ( ALF ) .
NO_RELATION	Defects in <e1> superoxide </e1> and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with <e2> acute liver failure </e2> ( ALF ) .
NO_RELATION	Defects in <e1> superoxide </e1> and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( <e2> ALF </e2> ) .
NO_RELATION	Defects in superoxide and <e1> hydrogen peroxide </e1> production may be implicated in the high incidence of <e2> bacterial infections </e2> in patients with acute liver failure ( ALF ) .
NO_RELATION	Defects in superoxide and <e1> hydrogen peroxide </e1> production may be implicated in the high incidence of bacterial infections in patients with <e2> acute liver failure </e2> ( ALF ) .
NO_RELATION	Defects in superoxide and <e1> hydrogen peroxide </e1> production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( <e2> ALF </e2> ) .
NO_RELATION	In the present study , <e1> oxygen </e1> radical production in patients with <e2> ALF </e2> due to paracetamol overdose was compared with that of healthy volunteers .
NO_RELATION	In the present study , <e1> oxygen </e1> radical production in patients with ALF due to paracetamol <e2> overdose </e2> was compared with that of healthy volunteers .
CID	In the present study , oxygen radical production in patients with <e2> ALF </e2> due to <e1> paracetamol </e1> overdose was compared with that of healthy volunteers .
NO_RELATION	In the present study , oxygen radical production in patients with ALF due to <e1> paracetamol </e1> <e2> overdose </e2> was compared with that of healthy volunteers .
NO_RELATION	<e1> Superoxide </e1> and hydrogen peroxide production by <e2> ALF </e2> neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .
NO_RELATION	<e1> Superoxide </e1> and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with <e2> ALF </e2> serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .
NO_RELATION	Superoxide and <e1> hydrogen peroxide </e1> production by <e2> ALF </e2> neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .
NO_RELATION	Superoxide and <e1> hydrogen peroxide </e1> production by ALF neutrophils stimulated with zymosan opsonized with <e2> ALF </e2> serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .
NO_RELATION	<e1> Superoxide </e1> and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 <e2> ALF </e2> patients was unaffected compared with control neutrophils .
NO_RELATION	Superoxide and <e1> hydrogen peroxide </e1> production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 <e2> ALF </e2> patients was unaffected compared with control neutrophils .
NO_RELATION	Superoxide and hydrogen peroxide production in neutrophils stimulated with <e1> formyl - methionyl - leucyl - phenylalanine </e1> ( fMLP ) from a further 18 <e2> ALF </e2> patients was unaffected compared with control neutrophils .
NO_RELATION	Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( <e1> fMLP </e1> ) from a further 18 <e2> ALF </e2> patients was unaffected compared with control neutrophils .
CID	These results demonstrate a neutrophil defect in <e2> ALF </e2> due to <e1> paracetamol </e1> overdose , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .
NO_RELATION	These results demonstrate a neutrophil defect in ALF due to <e1> paracetamol </e1> <e2> overdose </e2> , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .
NO_RELATION	Absence of effect of <e1> sertraline </e1> on time - based sensitization of <e2> cognitive impairment </e2> with haloperidol .
CID	Absence of effect of sertraline on time - based sensitization of <e2> cognitive impairment </e2> with <e1> haloperidol </e1> .
CID	RESULTS : <e2> Impairment of cognitive function </e2> was observed 6 to 8 hours after administration of <e1> haloperidol </e1> on Day 2 but was not evident 23 hours after dosing .
CID	CONCLUSION : <e1> Haloperidol </e1> produced a clear profile of <e2> cognitive impairment </e2> that was not worsened by concomitant sertraline administration .
NO_RELATION	CONCLUSION : Haloperidol produced a clear profile of <e2> cognitive impairment </e2> that was not worsened by concomitant <e1> sertraline </e1> administration .
NO_RELATION	<e1> Ciprofloxacin </e1> - induced <e2> nephrotoxicity </e2> in patients with cancer .
NO_RELATION	<e1> Ciprofloxacin </e1> - induced nephrotoxicity in patients with <e2> cancer </e2> .
NO_RELATION	<e2> Nephrotoxicity </e2> associated with <e1> ciprofloxacin </e1> is uncommon .
NO_RELATION	Five patients with <e2> cancer </e2> who developed acute renal failure that followed treatment with <e1> ciprofloxacin </e1> are described and an additional 15 cases reported in the literature are reviewed .
CID	Five patients with cancer who developed <e2> acute renal failure </e2> that followed treatment with <e1> ciprofloxacin </e1> are described and an additional 15 cases reported in the literature are reviewed .
CID	An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of <e1> ciprofloxacin </e1> - induced <e2> acute renal failure </e2> .
NO_RELATION	Case report : <e1> pentamidine </e1> and polymorphic <e2> ventricular tachycardia </e2> revisited .
NO_RELATION	<e1> Pentamidine isethionate </e1> has been associated with <e2> ventricular tachyarrhythmias </e2> , including torsade de pointes .
CID	<e1> Pentamidine isethionate </e1> has been associated with ventricular tachyarrhythmias , including <e2> torsade de pointes </e2> .
CID	<e1> Pentamidine </e1> - induced <e2> torsade de pointes </e2> may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade .
NO_RELATION	<e1> Pentamidine </e1> - induced torsade de pointes may be related to serum magnesium levels and <e2> hypomagnesemia </e2> may synergistically induce torsade .
NO_RELATION	Pentamidine - induced <e2> torsade de pointes </e2> may be related to serum <e1> magnesium </e1> levels and hypomagnesemia may synergistically induce torsade .
NO_RELATION	Pentamidine - induced torsade de pointes may be related to serum <e1> magnesium </e1> levels and <e2> hypomagnesemia </e2> may synergistically induce torsade .
CID	<e2> Torsade de pointes </e2> occurred after an average of 10 days of treatment with <e1> pentamidine </e1> .
CID	<e2> Torsade de pointes </e2> can be treated when recognized early , possibly without discontinuation of <e1> pentamidine </e1> .
NO_RELATION	When <e2> QTc interval prolongation </e2> is observed , early <e1> magnesium </e1> supplementation is advocated .
CID	Time dependence of plasma <e1> malondialdehyde </e1> , oxypurines , and nucleosides during incomplete <e2> cerebral ischemia </e2> in the rat .
NO_RELATION	Time dependence of plasma malondialdehyde , <e1> oxypurines </e1> , and nucleosides during incomplete <e2> cerebral ischemia </e2> in the rat .
NO_RELATION	Time dependence of plasma malondialdehyde , oxypurines , and <e1> nucleosides </e1> during incomplete <e2> cerebral ischemia </e2> in the rat .
NO_RELATION	During <e2> ischemia </e2> , a time - dependent increase of plasma <e1> oxypurines </e1> and nucleosides was observed .
NO_RELATION	During <e2> ischemia </e2> , a time - dependent increase of plasma oxypurines and <e1> nucleosides </e1> was observed .
NO_RELATION	Plasma <e1> malondialdehyde </e1> , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of <e2> ischemia </e2> , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .
NO_RELATION	of the cyclooxygenase inhibitor <e1> acetylsalicylate </e1> intravenously immediately before <e2> ischemia </e2> , the other receiving 650 micrograms / kg b . w .
NO_RELATION	of the <e2> hypotensive </e2> drug <e1> nitroprusside </e1> at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group malondialdehyde was significantly higher .
NO_RELATION	of the hypotensive drug <e1> nitroprusside </e1> at a flow rate of 103 microliters / min intravenously during <e2> ischemia </e2> , although in this latter group malondialdehyde was significantly higher .
NO_RELATION	of the <e2> hypotensive </e2> drug nitroprusside at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group <e1> malondialdehyde </e1> was significantly higher .
NO_RELATION	of the hypotensive drug nitroprusside at a flow rate of 103 microliters / min intravenously during <e2> ischemia </e2> , although in this latter group <e1> malondialdehyde </e1> was significantly higher .
NO_RELATION	The present data indicate that the determination of <e1> malondialdehyde </e1> , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during <e2> ischemic </e2> phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	The present data indicate that the determination of malondialdehyde , <e1> oxypurines </e1> , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during <e2> ischemic </e2> phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	The present data indicate that the determination of malondialdehyde , oxypurines , and <e1> nucleosides </e1> in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during <e2> ischemic </e2> phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )
NO_RELATION	Cholinergic <e2> toxicity </e2> resulting from ocular instillation of <e1> echothiophate iodide </e1> eye drops .
CID	A patient developed a severe cholinergic syndrome from the use of <e1> echothiophate iodide </e1> ophthalmic drops , presented with profound <e2> muscle weakness </e2> and was initially given the diagnosis of myasthenia gravis .
NO_RELATION	A patient developed a severe cholinergic syndrome from the use of <e1> echothiophate iodide </e1> ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of <e2> myasthenia gravis </e2> .
CID	<e2> Acute renal failure </e2> in high dose <e1> carboplatin </e1> chemotherapy .
CID	<e1> Carboplatin </e1> has been reported to cause <e2> acute renal failure </e2> when administered in high doses to adult patients .
NO_RELATION	We report a 4 1 / 2 - year - old girl who was treated with high - dose <e1> carboplatin </e1> for metastatic parameningeal <e2> embryonal rhabdomyosarcoma </e2> .
NO_RELATION	She had <e2> ovarian failure </e2> after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous <e1> estrogens </e1> , a treatment implicated in the development of endometrial cancer in menopausal women .
NO_RELATION	She had ovarian failure after abdominal irradiation and chemotherapy for <e2> Hodgkin disease </e2> , and received exogenous <e1> estrogens </e1> , a treatment implicated in the development of endometrial cancer in menopausal women .
CID	She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous <e1> estrogens </e1> , a treatment implicated in the development of <e2> endometrial cancer </e2> in menopausal women .
NO_RELATION	Young women on replacement <e1> estrogens </e1> for <e2> ovarian failure </e2> after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .
NO_RELATION	Young women on replacement <e1> estrogens </e1> for ovarian failure after <e2> cancer </e2> therapy may also have increased risk of endometrial carcinoma and should be examined periodically .
CID	Young women on replacement <e1> estrogens </e1> for ovarian failure after cancer therapy may also have increased risk of <e2> endometrial carcinoma </e2> and should be examined periodically .
CID	Induction of the <e2> obstructive sleep apnea syndrome </e2> in a woman by exogenous <e1> androgen </e1> administration .
CID	We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the <e2> syndrome of obstructive sleep apnea </e2> while being administered exogenous <e1> androgens </e1> .
CID	A rechallenge with <e1> androgen </e1> produced symptoms of <e2> obstructive sleep apnea </e2> that abated upon withdrawal of the hormone .
NO_RELATION	Previous reports have favored a role of <e1> androgens </e1> in the pathogenesis of <e2> sleep apnea </e2> .
CID	Development of the <e2> obstructive sleep apnea syndrome </e2> must be considered a possible side effect of <e1> androgen </e1> therapy .
NO_RELATION	Effect of <e1> captopril </e1> on pre - existing and aminonucleoside - induced <e2> proteinuria </e2> in spontaneously hypertensive rats .
NO_RELATION	Effect of <e1> captopril </e1> on pre - existing and aminonucleoside - induced proteinuria in spontaneously <e2> hypertensive </e2> rats .
CID	Effect of captopril on pre - existing and <e1> aminonucleoside </e1> - induced <e2> proteinuria </e2> in spontaneously hypertensive rats .
NO_RELATION	Effect of captopril on pre - existing and <e1> aminonucleoside </e1> - induced proteinuria in spontaneously <e2> hypertensive </e2> rats .
NO_RELATION	<e2> Proteinuria </e2> is a side effect of <e1> captopril </e1> treatment in hypertensive patients .
NO_RELATION	Proteinuria is a side effect of <e1> captopril </e1> treatment in <e2> hypertensive </e2> patients .
NO_RELATION	The possibility of reproducing the same <e2> renal abnormality </e2> with <e1> captopril </e1> was examined in SHR .
NO_RELATION	Oral administration of <e1> captopril </e1> at 100 mg / kg for 14 days failed to aggravate <e2> proteinuria </e2> pre - existing in SHR .
NO_RELATION	Also , <e1> captopril </e1> treatment failed to potentiate or facilitate development of massive <e2> proteinuria </e2> invoked by puromycin aminonucleoside in SHR .
CID	Also , captopril treatment failed to potentiate or facilitate development of massive <e2> proteinuria </e2> invoked by <e1> puromycin aminonucleoside </e1> in SHR .
CID	In one patient , <e1> enflurane </e1> administered during a donor nephrectomy resulted in unexpected partial motor <e2> seizures </e2> .
NO_RELATION	<e2> Epileptic </e2> foci delineated and activated by <e1> enflurane </e1> were surgically ablated and the patients are now seizure - free .
CID	Epileptic foci delineated and activated by <e1> enflurane </e1> were surgically ablated and the patients are now <e2> seizure </e2> - free .
NO_RELATION	On the other hand , <e1> enflurane </e1> may prove to be a safe fast acting activator of <e2> epileptic </e2> foci during corticography or depth electrode intraoperative recordings .
CID	Reversible <e2> cerebral lesions </e2> associated with <e1> tiazofurin </e1> usage : MR demonstration .
CID	Enhanced stimulus - induced neurotransmitter overflow in <e1> epinephrine </e1> - induced <e2> hypertensive </e2> rats is not mediated by prejunctional beta - adrenoceptor activation .
NO_RELATION	Even after early detection and prompt treatment , 41 % of cases of <e2> uveitis </e2> did not respond to more than six months of intensive topical treatment with <e1> corticosteroids </e1> and mydriatics .
NO_RELATION	We used <e1> chloroquine </e1> or hydroxychloroquine in 173 of 210 cases and found only one case of <e2> chorioretinopathy </e2> attributable to these drugs .
CID	We used chloroquine or <e1> hydroxychloroquine </e1> in 173 of 210 cases and found only one case of <e2> chorioretinopathy </e2> attributable to these drugs .
NO_RELATION	Systemically administered <e1> corticosteroids </e1> were used in 75 of 210 cases ; a significant number of posterior subcapsular <e2> cataracts </e2> was found .
CID	<e2> Water intoxication </e2> associated with <e1> oxytocin </e1> administration during saline - induced abortion .
NO_RELATION	Water intoxication associated with <e1> oxytocin </e1> administration during saline - induced <e2> abortion </e2> .
CID	Four cases of <e2> water intoxication </e2> in connection with <e1> oxytocin </e1> administration during saline - induced abortions are described .
NO_RELATION	Four cases of water intoxication in connection with <e1> oxytocin </e1> administration during saline - induced <e2> abortions </e2> are described .
NO_RELATION	<e1> Oxytocin </e1> administration during midtrimester - induced <e2> abortions </e2> is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .
CID	<e1> Oxytocin </e1> administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of <e2> water intoxication </e2> and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .
NO_RELATION	<e1> Oxytocin </e1> administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as <e2> asthenia </e2> , muscular irritability , or headaches .
NO_RELATION	<e1> Oxytocin </e1> administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular <e2> irritability </e2> , or headaches .
NO_RELATION	<e1> Oxytocin </e1> administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or <e2> headaches </e2> .
